{"PMC7337415": [["IntroductionCoronavirus Disease 2019 (COVID-19) is a rapid, global spread virus,[1\u20134] which attacks people in almost all countries worldwide.[5\u20138] So far, only its transmission in China has been controlled.[9,10] The rate of its infections outside China is still rapidly increasing, especially in the United States, which accounts for almost one-third of all patients with COVID-19 globally.[11,12] Till May 25, 2020, about 5,586,715 cases of COVID-19 and 347,852 deaths have been reported.[12] A variety of studies reported that patients who received or even cured with this condition often experience psychological disorder (PD), including depression, and anxiety.[13\u201324] So the effective prevention and treatment of PD in patients with COVID-19 are very essential task.", [["COVID-19", "CHEMICAL", 38, 46], ["infections", "DISEASE", 229, 239], ["deaths", "DISEASE", 464, 470], ["psychological disorder", "DISEASE", 603, 625], ["PD", "DISEASE", 627, 629], ["depression", "DISEASE", 642, 652], ["anxiety", "DISEASE", 658, 665], ["PD", "DISEASE", 719, 721], ["COVID-19", "CHEMICAL", 739, 747], ["people", "ORGANISM", 100, 106], ["patients", "ORGANISM", 359, 367], ["patients", "ORGANISM", 530, 538], ["patients", "ORGANISM", 725, 733], ["people", "SPECIES", 100, 106], ["patients", "SPECIES", 359, 367], ["patients", "SPECIES", 530, 538], ["patients", "SPECIES", 725, 733], ["IntroductionCoronavirus Disease 2019 (COVID-19", "SPECIES", 0, 46], ["IntroductionCoronavirus Disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43], ["a rapid, global spread virus", "PROBLEM", 51, 79], ["its infections", "PROBLEM", 225, 239], ["COVID", "TEST", 373, 378], ["COVID", "TEST", 443, 448], ["psychological disorder", "PROBLEM", 603, 625], ["depression", "PROBLEM", 642, 652], ["anxiety", "PROBLEM", 658, 665], ["treatment", "TREATMENT", 706, 715], ["PD", "TREATMENT", 719, 721], ["COVID", "TEST", 739, 744], ["infections", "OBSERVATION", 229, 239], ["rapidly", "OBSERVATION_MODIFIER", 263, 270], ["increasing", "OBSERVATION_MODIFIER", 271, 281]]], ["Studies suggested that advanced nursing care (ANC) may benefit PD in patients with COVID-19.[25\u201328] However, no systematic review has investigated this issue.", [["PD", "DISEASE", 63, 65], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["advanced nursing care", "TREATMENT", 23, 44], ["COVID", "TEST", 83, 88]]], ["Therefore, this study will aim to assess the effect of ANC on managing PD in patients with COVID-19.Study registration ::: MethodsThis study was registered through PROSPERO (CRD42020187610).", [["PD", "DISEASE", 71, 73], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["this study", "TEST", 11, 21], ["ANC", "TREATMENT", 55, 58], ["managing PD", "TREATMENT", 62, 73], ["COVID", "TEST", 91, 96], ["Methods", "TREATMENT", 123, 130], ["This study", "TEST", 130, 140]]], ["It is reported in accordance with the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol statement.Study types ::: Eligibility criteria ::: MethodsThe present study will include randomized controlled trials (RCTs) on investigating the effect of ANC on PD in patients with COVID-19, irrespective language, and publication status.Intervention types ::: Eligibility criteria ::: MethodsIn the experimental group, all patients received ANC on PD in patients with COVID-19.Intervention types ::: Eligibility criteria ::: MethodsIn the control group, no restrictions related to the comparators are applied.", [["PD", "DISEASE", 291, 293], ["PD", "DISEASE", 478, 480], ["patients", "ORGANISM", 297, 305], ["patients", "ORGANISM", 453, 461], ["patients", "ORGANISM", 484, 492], ["patients", "SPECIES", 297, 305], ["patients", "SPECIES", 453, 461], ["patients", "SPECIES", 484, 492], ["Systematic Reviews", "TEST", 82, 100], ["Methods", "TREATMENT", 179, 186], ["The present study", "TEST", 186, 203], ["randomized controlled trials (RCTs", "TREATMENT", 217, 251], ["ANC", "TREATMENT", 284, 287], ["PD", "TREATMENT", 291, 293], ["COVID", "TEST", 311, 316], ["Methods", "TREATMENT", 415, 422], ["ANC", "TREATMENT", 471, 474], ["PD", "TREATMENT", 478, 480], ["COVID", "TEST", 498, 503], ["Methods", "TREATMENT", 555, 562]]], ["However, we will not consider any controls involved in ANC.Participant types ::: Eligibility criteria ::: MethodsThis study will include patients with COVID-19, who were diagnosed as PD, regardless sex, race, age, and severity of PD.Outcome measurements ::: Eligibility criteria ::: MethodsPrimary outcomes are depression and anxiety, as measured by any related scales reported in the primary trials.Outcome measurements ::: Eligibility criteria ::: MethodsSecondary outcomes are pressure, panic disorder, quality of life, and expected and unexpected adverse events.Search strategy ::: MethodsWe will search following electronic databases (Cochrane Library, PUBMED, EMBASE, PsycINFO, Web of Science, OpenGrey, Cumulative Index to Nursing and Allied Health Literature, CNKI and WANGFANG) up to June 30, 2020 without language and publication status restrictions.", [["PD", "DISEASE", 183, 185], ["PD", "DISEASE", 230, 232], ["depression", "DISEASE", 311, 321], ["anxiety", "DISEASE", 326, 333], ["panic disorder", "DISEASE", 490, 504], ["ANC", "CELL", 55, 58], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["ANC", "TEST", 55, 58], ["Methods", "TREATMENT", 106, 113], ["This study", "TEST", 113, 123], ["PD", "PROBLEM", 230, 232], ["depression", "PROBLEM", 311, 321], ["anxiety", "PROBLEM", 326, 333], ["panic disorder", "PROBLEM", 490, 504], ["unexpected adverse events", "PROBLEM", 540, 565], ["depression", "OBSERVATION", 311, 321], ["pressure", "OBSERVATION_MODIFIER", 480, 488]]], ["In addition, gray literatures will also be searched, including conference proceedings, reference lists of included studies, and websites of clinical trial registry.", [["studies", "TEST", 115, 122]]], ["All potential RCTs of ANC on PD in patients with COVID-19 will be considered.", [["PD", "DISEASE", 29, 31], ["COVID-19", "CHEMICAL", 49, 57], ["ANC", "CELL", 22, 25], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["ANC", "TEST", 22, 25], ["PD", "TREATMENT", 29, 31], ["COVID", "TEST", 49, 54]]], ["We will modify similar search strategies to the other electronic databases.Study selection ::: MethodsTwo authors will independently scan the retrieved records based on titles/abstracts; and unrelated studies will be excluded.", [["unrelated studies", "TEST", 191, 208]]], ["Then, we will read full articles of remaining studies in accordance with the full inclusion criteria.", [["remaining studies", "TEST", 36, 53]]], ["Each excluded study will be recorded with specific reason.", [["Each excluded study", "TEST", 0, 19]]], ["If any divergences occur, we will invite a third author to help solve them through discussion.Data collection and management ::: MethodsTwo authors will independently collect data from all eligible studies based on the data extraction form.", [["all eligible studies", "TEST", 185, 205], ["the data extraction", "TEST", 215, 234]]], ["It consists of following information: title, publication time, country, study design and setting, participant characteristics, eligible criteria, treatments and controls, outcomes, risk of bias, and other essential information.", [["treatments", "TREATMENT", 146, 156]]], ["Otherwise, we will analyze the available data if we cannot achieve them.Risk of bias assessment ::: MethodsWe will utilize Cochrane risk of bias tool to evaluate risk of bias for each included trial.", [["bias assessment", "TEST", 80, 95], ["Methods", "TREATMENT", 100, 107], ["bias tool", "TEST", 140, 149]]], ["We will solve disagreements by consulting a third author.Data synthesis ::: MethodsWe will use RevMan 5.3 software to perform statistical analysis.", [["statistical analysis", "TEST", 126, 146]]], ["All continuous data will be estimated as standardized mean difference and 95% confidence intervals (CIs), and all dichotomous data will be expressed as risk ratio and 95% CIs.", [["CIs", "TEST", 100, 103], ["all dichotomous data", "TEST", 110, 130], ["risk ratio", "TEST", 152, 162]]], ["All statistical heterogeneity is appraised by I2 test.", [["I2 test", "TEST", 46, 53], ["heterogeneity", "OBSERVATION", 16, 29]]], ["I2 \u226450% indicates minor heterogeneity, and a fixed-effect model will be applied.", [["I2", "TEST", 0, 2], ["minor heterogeneity", "PROBLEM", 18, 37], ["a fixed-effect model", "TREATMENT", 43, 63], ["minor", "OBSERVATION_MODIFIER", 18, 23], ["heterogeneity", "OBSERVATION", 24, 37]]], ["I2 \u226450% suggests obvious heterogeneity, and a random-effect model will be placed.", [["I2", "TEST", 0, 2], ["obvious heterogeneity", "PROBLEM", 17, 38], ["a random-effect model", "TREATMENT", 44, 65], ["obvious", "OBSERVATION_MODIFIER", 17, 24], ["heterogeneity", "OBSERVATION", 25, 38]]], ["If sufficient data are collected with minor heterogeneity, we will plan to conduct meta-analysis.", [["meta-analysis", "TEST", 83, 96]]], ["If remarkable heterogeneity is detected, we will carry out subgroup analysis to test its heterogeneity sources.", [["subgroup analysis", "TEST", 59, 76], ["remarkable", "OBSERVATION_MODIFIER", 3, 13], ["heterogeneity", "OBSERVATION", 14, 27]]], ["If necessary, we will report study results by narrative description.Subgroup analysis ::: MethodsWe will perform subgroup analysis according to the different details of interventions, study quality and outcome indicators.Sensitivity analysis ::: MethodsWe will undertake sensitivity analysis to examine the robustness and stability of synthesized results by eliminating low-quality studies.Reporting bias ::: MethodsWe will detect reporting bias using Funnel plot and Egger regression test if >10 eligible studies are included.Ethics and dissemination ::: MethodsNo ethics approval is required, since no individual patient data will be collected in this study.", [["patient", "ORGANISM", 615, 622], ["patient", "SPECIES", 615, 622], ["Methods", "TREATMENT", 90, 97], ["subgroup analysis", "TEST", 113, 130], ["interventions", "TREATMENT", 169, 182], ["study quality", "TEST", 184, 197], ["sensitivity analysis", "TEST", 271, 291], ["Funnel plot", "TEST", 452, 463], ["Egger regression test", "TEST", 468, 489], ["eligible studies", "TEST", 497, 513], ["Methods", "TREATMENT", 556, 563], ["this study", "TEST", 649, 659]]], ["We will publish this study at a peer-reviewed journal.DiscussionCOVID-19 is a globally spread disease, which attacks almost all countries.[1\u20134] Studies reported that patients who experience or cured with COVID-19 often have PD.", [["PD", "DISEASE", 224, 226], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["this study", "TEST", 16, 26], ["a globally spread disease", "PROBLEM", 76, 101], ["COVID", "TEST", 204, 209], ["PD", "PROBLEM", 224, 226], ["globally", "OBSERVATION_MODIFIER", 78, 86], ["spread", "OBSERVATION", 87, 93]]], ["Several studies reported that ANC can help patients with this disorder.", [["ANC", "SIMPLE_CHEMICAL", 30, 33], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["Several studies", "TEST", 0, 15], ["ANC", "TEST", 30, 33], ["this disorder", "PROBLEM", 57, 70]]], ["However, no systematic review assessed its effects.", [["systematic review", "TEST", 12, 29]]], ["Thus, this study is the first one to systematically and comprehensively appraise the effects of ANC on PD in patients with COVID-19.", [["PD", "DISEASE", 103, 105], ["ANC", "CELL", 96, 99], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["this study", "TEST", 6, 16], ["ANC", "TEST", 96, 99], ["PD", "TREATMENT", 103, 105], ["COVID", "TEST", 123, 128]]], ["The results of this study may provide evidence to determine whether ANC is effective for the treatment of PD following COVID-19.Author contributionsConceptualization: Wen-juan Fan, Xiao-ling Liu.Author contributionsData curation: Wen-juan Fan, Xiao-ling Liu.Author contributionsFormal analysis: Wen-juan Fan, Xiao-ling Liu.Author contributionsInvestigation: Xiao-ling Liu.Author contributionsMethodology: Wen-juan Fan.Author contributionsProject administration: Xiao-ling Liu.Author contributionsResources: Wen-juan Fan.Author contributionsSoftware: Wen-juan Fan.Author contributionsSupervision: Xiao-ling Liu.Author contributionsValidation: Wen-juan Fan, Xiao-ling Liu.Author contributionsVisualization: Wen-juan Fan, Xiao-ling Liu.Author contributionsWriting \u2013 original draft: Wen-juan Fan, Xiao-ling Liu.Author contributionsWriting \u2013 review & editing: Wen-juan Fan, Xiao-ling Liu.", [["PD", "DISEASE", 106, 108], ["COVID-19", "CHEMICAL", 119, 127], ["COVID-19", "CHEMICAL", 119, 127], ["this study", "TEST", 15, 25], ["ANC", "TEST", 68, 71], ["PD", "TREATMENT", 106, 108], ["COVID", "TEST", 119, 124], ["Wen-juan Fan", "TREATMENT", 167, 179], ["Xiao", "TREATMENT", 181, 185], ["Wen-juan Fan", "TREATMENT", 295, 307], ["Xiao", "TREATMENT", 309, 313], ["Wen-juan Fan", "TREATMENT", 405, 417], ["Xiao", "TREATMENT", 719, 723], ["Wen-juan Fan", "TREATMENT", 779, 791], ["Xiao", "TREATMENT", 793, 797]]]], "PMC7508154": [["Institute ethical clearance was obtained prior to the onset of the study.", [["the study", "TEST", 63, 72]]], ["Confirmed positive cases of COVID-19 by nasopharyngeal swab according to WHO standards with or without ocular symptoms were included in the study.[5] Suspect and probable cases and those patients who were critically ill were excluded.", [["nasopharyngeal swab", "ANATOMY", 40, 59], ["ocular", "ANATOMY", 103, 109], ["ocular symptoms", "DISEASE", 103, 118], ["critically ill", "DISEASE", 205, 219], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 40, 59], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["COVID", "TEST", 28, 33], ["nasopharyngeal swab", "TEST", 40, 59], ["ocular symptoms", "PROBLEM", 103, 118], ["the study", "TEST", 136, 145], ["critically ill", "PROBLEM", 205, 219], ["positive", "OBSERVATION_MODIFIER", 10, 18], ["nasopharyngeal", "ANATOMY", 40, 54]]], ["Signed consent was obtained for each sample collection from patients.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68]]], ["The conjunctival swab was collected by an ophthalmologist posted for COVID duty.", [["conjunctival swab", "ANATOMY", 4, 21], ["conjunctival swab", "ORGANISM_SUBSTANCE", 4, 21], ["The conjunctival swab", "TEST", 0, 21], ["conjunctival swab", "ANATOMY", 4, 21]]], ["Eyelids were everted and samples were obtained by sweeping the inferior fornices of either of the two eyes with sterile nylon flocked swabs without topical anesthesia.", [["samples", "ANATOMY", 25, 32], ["inferior fornices", "ANATOMY", 63, 80], ["eyes", "ANATOMY", 102, 106], ["swabs", "ANATOMY", 134, 139], ["eyes", "ORGAN", 102, 106], ["samples", "TEST", 25, 32], ["sterile nylon flocked swabs", "TREATMENT", 112, 139], ["topical anesthesia", "TREATMENT", 148, 166], ["inferior", "ANATOMY_MODIFIER", 63, 71], ["two eyes", "ANATOMY", 98, 106]]], ["The tips of the swab sticks were broken off and placed into a viral transport medium\u2014Hi media (HiMedia Laboratories Pvt. Ltd, Nashik, India.", [["swab", "ANATOMY", 16, 20], ["the swab sticks", "TREATMENT", 12, 27], ["a viral transport medium", "TREATMENT", 60, 84], ["tips", "OBSERVATION_MODIFIER", 4, 8], ["swab sticks", "OBSERVATION", 16, 27]]], ["Personal protection equipment was used and necessary precautions were used to minimize the risk of spread of infection from one patient to another.", [["infection", "DISEASE", 109, 118], ["patient", "ORGANISM", 128, 135], ["patient", "SPECIES", 128, 135], ["Personal protection equipment", "TREATMENT", 0, 29], ["necessary precautions", "TREATMENT", 43, 64], ["infection", "PROBLEM", 109, 118], ["infection", "OBSERVATION", 109, 118]]], ["Samples were transported to the specified lab facility maintaining the recommended cold chain.", [["the recommended cold chain", "TREATMENT", 67, 93]]], ["In the laboratory, samples were extracted using the magnetic bead extraction method (Thermo scientific viral isolation kit\u20145X MagMAX, Thermo Fischer scientific Baltics UAB, Vilnius, Lithuania) in Biomek 4000 platform as per the manufacturer's instructions.", [["samples", "ANATOMY", 19, 26], ["the magnetic bead extraction method", "TREATMENT", 48, 83]]], ["In eight-strip PCR tubes, 22.5 \u03bcL of the mixed reaction solution or master mix (SARS CoV-2 Detection kit; fortitude 2.0) was loaded.", [["eight-strip PCR tubes", "TREATMENT", 3, 24], ["the mixed reaction solution", "TREATMENT", 37, 64], ["SARS CoV", "TEST", 80, 88], ["Detection kit", "TEST", 91, 104], ["fortitude", "TEST", 106, 115]]], ["To this, 2.5 \u03bcL of the extracted nucleic acid was added to each well, covered and the PCR was performed using the CFX96 real-time PCR (Bio-Rad).", [["nucleic acid", "CHEMICAL", 33, 45], ["nucleic acid", "SIMPLE_CHEMICAL", 33, 45], ["Bio-Rad", "DNA", 135, 142], ["the extracted nucleic acid", "TREATMENT", 19, 45], ["the PCR", "TEST", 82, 89], ["the CFX96", "TEST", 110, 119]]], ["After the completion of the PCR run, the amplification curves were judged to decide if the results were negative or positive.", [["the PCR run", "TEST", 24, 35], ["the amplification curves", "TEST", 37, 61]]], ["A cutoff cycle threshold (Ct) value of 40 was considered as positive as per the manufacturer's instructions.ResultsOut of 45 patients, 35 (77.77%) were males and the rest were females.", [["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["A cutoff cycle threshold", "TEST", 0, 24], ["Ct) value", "TEST", 26, 35]]], ["Patients with a minimum age of 6 years and a maximum age of 75 years were present in the study.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["the study", "TEST", 85, 94]]], ["For our convenience, patients were divided into four age groups: less than 20 years (6); 21\u201340 years (29); 41\u201360 years (9), and more than 60 years (1).", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["None of the patients in our study had any ocular symptoms.ResultsOnly one (2.23%) out of 45 patients was positive with the Ct value of 33, for real-time RT-PCR SARS-CoV-2 in conjunctival swab as shown in Table 1.DiscussionNo reports were suggesting ocular transmission of COVID-19 initially.", [["ocular", "ANATOMY", 42, 48], ["conjunctival swab", "ANATOMY", 174, 191], ["ocular", "ANATOMY", 249, 255], ["ocular symptoms", "DISEASE", 42, 57], ["COVID-19", "CHEMICAL", 272, 280], ["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 92, 100], ["conjunctival swab", "PATHOLOGICAL_FORMATION", 174, 191], ["ocular", "ORGAN", 249, 255], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 92, 100], ["our study", "TEST", 24, 33], ["any ocular symptoms", "PROBLEM", 38, 57], ["the Ct value", "TEST", 119, 131], ["PCR SARS", "TEST", 156, 164], ["CoV", "TEST", 165, 168], ["conjunctival swab", "TEST", 174, 191], ["COVID", "TEST", 272, 277], ["conjunctival", "ANATOMY", 174, 186]]], ["Xia et al. evaluated the conjunctival secretions of 30 confirmed cases of COVID-19.[6] In one of these patients, both tear and conjunctival secretions tested positive for the virus by RT-PCR.", [["conjunctival secretions", "ANATOMY", 25, 48], ["tear", "ANATOMY", 118, 122], ["conjunctival secretions", "ANATOMY", 127, 150], ["patients", "ORGANISM", 103, 111], ["tear", "TISSUE", 118, 122], ["conjunctival secretions", "ORGANISM_SUBSTANCE", 127, 150], ["patients", "SPECIES", 103, 111], ["the conjunctival secretions", "TEST", 21, 48], ["COVID", "TEST", 74, 79], ["conjunctival secretions", "TEST", 127, 150], ["the virus", "PROBLEM", 171, 180], ["PCR", "TEST", 187, 190], ["conjunctival", "ANATOMY", 25, 37], ["secretions", "OBSERVATION", 38, 48], ["tear", "OBSERVATION", 118, 122], ["conjunctival", "ANATOMY", 127, 139], ["secretions", "OBSERVATION", 140, 150]]], ["There are numerous anecdotal reports suggesting conjunctivitis as the initial symptom before the onset of pneumonia, including that of Guangfa Wang, a national expert on the panel for pneumonia during the early investigations in Wuhan, China.[7]DiscussionSome studies reported the presence of SARS-CoV or Middle-East respiratory syndrome (MERS-CoV) in tears or conjunctival sac.[8] Another study by Chen et al. detected SARS-CoV-2 in the conjunctival sac of only three COVID-19 patients out of 67 positive cases.", [["tears", "ANATOMY", 352, 357], ["conjunctival sac", "ANATOMY", 361, 377], ["conjunctival sac", "ANATOMY", 438, 454], ["conjunctivitis", "DISEASE", 48, 62], ["pneumonia", "DISEASE", 106, 115], ["pneumonia", "DISEASE", 184, 193], ["SARS", "DISEASE", 293, 297], ["Middle-East respiratory syndrome", "DISEASE", 305, 337], ["SARS-CoV", "ORGANISM", 293, 301], ["tears", "TISSUE", 352, 357], ["conjunctival sac", "MULTI-TISSUE_STRUCTURE", 361, 377], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 420, 430], ["conjunctival sac", "MULTI-TISSUE_STRUCTURE", 438, 454], ["patients", "ORGANISM", 478, 486], ["patients", "SPECIES", 478, 486], ["SARS-CoV", "SPECIES", 293, 301], ["Middle-East respiratory syndrome (MERS-CoV", "SPECIES", 305, 347], ["SARS-CoV", "SPECIES", 420, 428], ["conjunctivitis", "PROBLEM", 48, 62], ["the initial symptom", "PROBLEM", 66, 85], ["pneumonia", "PROBLEM", 106, 115], ["the panel", "TEST", 170, 179], ["pneumonia", "PROBLEM", 184, 193], ["DiscussionSome studies", "TEST", 245, 267], ["SARS", "PROBLEM", 293, 297], ["CoV", "PROBLEM", 298, 301], ["Middle-East respiratory syndrome", "PROBLEM", 305, 337], ["tears", "PROBLEM", 352, 357], ["conjunctival sac", "PROBLEM", 361, 377], ["Another study", "TEST", 382, 395], ["SARS", "TEST", 420, 424], ["CoV", "TEST", 425, 428], ["suggesting", "UNCERTAINTY", 37, 47], ["conjunctivitis", "OBSERVATION", 48, 62], ["pneumonia", "OBSERVATION", 106, 115], ["pneumonia", "OBSERVATION", 184, 193], ["Middle", "ANATOMY_MODIFIER", 305, 311], ["respiratory syndrome", "OBSERVATION", 317, 337], ["conjunctival sac", "ANATOMY", 361, 377], ["SARS", "OBSERVATION", 420, 424], ["conjunctival sac", "ANATOMY", 438, 454]]], ["But these three patients did not have any ocular symptoms.[9] Sun et al. found that among 72 patients confirmed by laboratory diagnosis with SARS-CoV-2 RT-PCR assay, SARS-CoV-2 RNA fragments were found in ocular discharges belonging to one patient.[10] The above studies show that SARS-CoV-2 can be detected in conjunctival sac, in only a small percentage of COVID-19 positive patients.", [["ocular", "ANATOMY", 42, 48], ["ocular", "ANATOMY", 205, 211], ["conjunctival sac", "ANATOMY", 311, 327], ["ocular symptoms", "DISEASE", 42, 57], ["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 93, 101], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 166, 176], ["patient", "ORGANISM", 240, 247], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 281, 291], ["conjunctival sac", "MULTI-TISSUE_STRUCTURE", 311, 327], ["COVID-19", "CELL", 359, 367], ["patients", "ORGANISM", 377, 385], ["SARS-CoV-2 RT", "DNA", 141, 154], ["SARS-CoV-2 RNA fragments", "DNA", 166, 190], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 93, 101], ["patient", "SPECIES", 240, 247], ["patients", "SPECIES", 377, 385], ["SARS-CoV", "SPECIES", 166, 174], ["any ocular symptoms", "PROBLEM", 38, 57], ["SARS", "TEST", 141, 145], ["CoV", "TEST", 146, 149], ["PCR assay", "TEST", 155, 164], ["SARS", "PROBLEM", 166, 170], ["CoV", "TEST", 171, 174], ["2 RNA fragments", "PROBLEM", 175, 190], ["ocular discharges", "PROBLEM", 205, 222], ["The above studies", "TEST", 253, 270], ["SARS", "PROBLEM", 281, 285], ["CoV", "TEST", 286, 289], ["COVID", "TEST", 359, 364], ["ocular", "ANATOMY", 205, 211], ["conjunctival sac", "ANATOMY", 311, 327], ["small", "OBSERVATION_MODIFIER", 339, 344]]], ["Also, the risk of infection of SARS-CoV-2 through eye secretions remains uncertain.DiscussionOur study showed that only one (2.23%) out of 45 patients had detectable levels of SARS-CoV-2 in conjunctival swabs of COVID-19-positive patients using RT-PCR.", [["eye secretions", "ANATOMY", 50, 64], ["conjunctival swabs", "ANATOMY", 190, 208], ["infection", "DISEASE", 18, 27], ["SARS", "DISEASE", 31, 35], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 31, 41], ["eye", "ORGAN", 50, 53], ["patients", "ORGANISM", 142, 150], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 176, 186], ["conjunctival swabs", "ORGANISM_SUBSTANCE", 190, 208], ["COVID-19", "GENE_OR_GENE_PRODUCT", 212, 220], ["patients", "ORGANISM", 230, 238], ["patients", "SPECIES", 142, 150], ["patients", "SPECIES", 230, 238], ["SARS-CoV", "SPECIES", 31, 39], ["infection", "PROBLEM", 18, 27], ["SARS", "PROBLEM", 31, 35], ["CoV", "TEST", 36, 39], ["eye secretions", "PROBLEM", 50, 64], ["DiscussionOur study", "TEST", 83, 102], ["SARS", "TEST", 176, 180], ["CoV", "TEST", 181, 184], ["conjunctival swabs", "TEST", 190, 208], ["COVID", "TEST", 212, 217], ["RT-PCR", "TEST", 245, 251], ["infection", "OBSERVATION", 18, 27], ["eye", "ANATOMY", 50, 53], ["secretions", "OBSERVATION", 54, 64], ["conjunctival", "ANATOMY", 190, 202]]], ["Low level of viral detection can be due to various factors like the time for maximum replication of the virus, the timing of performing of sampling, time of presentation of the patient to the hospital and possibly less secretion of the virus through conjunctival secretion, and also low sensitivity of RT-PCR.[11] In a study done by Ziad and colleagues, tracheal aspirates yielded a higher SARS-CoV-2 load than a nasopharyngeal swab.[12] This suggests that viral concentration differs in different sites and secretions.", [["conjunctival", "ANATOMY", 250, 262], ["tracheal aspirates", "ANATOMY", 354, 372], ["nasopharyngeal swab", "ANATOMY", 413, 432], ["sites", "ANATOMY", 498, 503], ["secretions", "ANATOMY", 508, 518], ["patient", "ORGANISM", 177, 184], ["conjunctival", "ORGAN", 250, 262], ["tracheal aspirates", "MULTI-TISSUE_STRUCTURE", 354, 372], ["CoV-2", "GENE_OR_GENE_PRODUCT", 395, 400], ["nasopharyngeal swab", "CANCER", 413, 432], ["secretions", "ORGANISM_SUBSTANCE", 508, 518], ["patient", "SPECIES", 177, 184], ["Low level of viral detection", "PROBLEM", 0, 28], ["various factors", "PROBLEM", 43, 58], ["the virus", "PROBLEM", 100, 109], ["the virus through conjunctival secretion", "PROBLEM", 232, 272], ["RT-PCR", "TEST", 302, 308], ["a study", "TEST", 317, 324], ["tracheal aspirates", "TEST", 354, 372], ["a higher SARS", "PROBLEM", 381, 394], ["CoV", "TEST", 395, 398], ["a nasopharyngeal swab", "TEST", 411, 432], ["viral concentration", "PROBLEM", 457, 476], ["secretions", "PROBLEM", 508, 518], ["viral", "OBSERVATION", 13, 18], ["tracheal", "ANATOMY", 354, 362], ["nasopharyngeal", "ANATOMY", 413, 427], ["swab", "OBSERVATION", 428, 432], ["viral concentration", "OBSERVATION", 457, 476], ["secretions", "OBSERVATION", 508, 518]]], ["A study was done by de Wit et al. in the rhesus macaque model with MERS-CoV, which is another type of coronavirus.[13] They found out that MERS-CoV RNA could be detected in the conjunctiva well within 6 days of infection beyond which, it failed to detect the virus.", [["conjunctiva", "ANATOMY", 177, 188], ["coronavirus", "DISEASE", 102, 113], ["infection", "DISEASE", 211, 220], ["macaque", "ORGANISM", 48, 55], ["MERS-CoV", "ORGANISM", 67, 75], ["coronavirus", "ORGANISM", 102, 113], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 139, 147], ["conjunctiva", "ORGAN", 177, 188], ["MERS-CoV RNA", "RNA", 139, 151], ["rhesus macaque", "SPECIES", 41, 55], ["rhesus macaque", "SPECIES", 41, 55], ["MERS-CoV", "SPECIES", 67, 75], ["A study", "TEST", 0, 7], ["coronavirus", "PROBLEM", 102, 113], ["CoV RNA", "PROBLEM", 144, 151], ["infection", "PROBLEM", 211, 220], ["the virus", "PROBLEM", 255, 264], ["rhesus macaque", "ANATOMY", 41, 55], ["coronavirus", "OBSERVATION", 102, 113], ["conjunctiva", "ANATOMY", 177, 188], ["infection", "OBSERVATION", 211, 220]]], ["Since the majority of people infected with the SARS-CoV-2 virus are asymptomatic, it is difficult to determine the peak of virus load unless multiple samplings are done at varied intervals.DiscussionThere are several limitations to this study which include relatively small sample size, absence of detailed ocular examinations, sampling done only once from the eyes of each patient, which can increase the prevalence of false-negatives.Financial support and sponsorship ::: ConclusionNil.Conflicts of interest ::: ConclusionThere are no conflicts of interest.", [["ocular", "ANATOMY", 307, 313], ["eyes", "ANATOMY", 361, 365], ["SARS", "DISEASE", 47, 51], ["people", "ORGANISM", 22, 28], ["SARS-CoV-2 virus", "ORGANISM", 47, 63], ["eyes", "ORGAN", 361, 365], ["patient", "ORGANISM", 374, 381], ["people", "SPECIES", 22, 28], ["CoV-2 virus", "SPECIES", 52, 63], ["patient", "SPECIES", 374, 381], ["SARS-CoV-2 virus", "SPECIES", 47, 63], ["the SARS-CoV-2 virus", "PROBLEM", 43, 63], ["asymptomatic", "PROBLEM", 68, 80], ["multiple samplings", "TEST", 141, 159], ["this study", "TEST", 232, 242], ["detailed ocular examinations", "TEST", 298, 326], ["sampling", "TEST", 328, 336], ["small", "OBSERVATION_MODIFIER", 268, 273], ["size", "OBSERVATION_MODIFIER", 281, 285], ["no", "UNCERTAINTY", 534, 536], ["conflicts", "OBSERVATION", 537, 546]]]], "084c057974b2f90fa844d3b36fc01b5fe1204942": [[", which mimics the transition state of the hydrolysis reaction.", [["the hydrolysis reaction", "PROBLEM", 39, 62]]], ["PL250 inhibits APN with a K i of 1.5-2.2 nM and its three-dimensional structure in complex with E. coli APN showed its interaction with the S 1 , S 0 1 and S 0 2 subsites of the catalytic site.", [["PL250", "CHEMICAL", 0, 5], ["K", "CHEMICAL", 26, 27], ["PL250", "CHEMICAL", 0, 5], ["PL250", "SIMPLE_CHEMICAL", 0, 5], ["APN", "GENE_OR_GENE_PRODUCT", 15, 18], ["E. coli", "ORGANISM", 96, 103], ["APN", "GENE_OR_GENE_PRODUCT", 104, 107], ["APN", "PROTEIN", 15, 18], ["APN", "PROTEIN", 104, 107], ["S 1 , S 0 1 and S 0 2 subsites", "PROTEIN", 140, 170], ["catalytic site", "DNA", 178, 192], ["E. coli", "SPECIES", 96, 103], ["E. coli", "SPECIES", 96, 103], ["APN", "TEST", 15, 18], ["a K i", "TEST", 24, 29], ["E. coli APN", "TEST", 96, 107], ["the S", "TEST", 136, 141], ["E. coli", "OBSERVATION", 96, 103], ["catalytic site", "OBSERVATION", 178, 192]]], ["In this structure, the Zn ion was shown to be pentacoordinated by His297, His301 and Glu320 of APN and the two O atoms of the phosphinic moiety of PL250.", [["Zn", "CHEMICAL", 23, 25], ["His297", "CHEMICAL", 66, 72], ["His301", "CHEMICAL", 74, 80], ["Glu320", "CHEMICAL", 85, 91], ["PL250", "CHEMICAL", 147, 152], ["Zn", "CHEMICAL", 23, 25], ["His297", "CHEMICAL", 66, 72], ["His301", "CHEMICAL", 74, 80], ["Glu320", "CHEMICAL", 85, 91], ["O", "CHEMICAL", 111, 112], ["phosphinic", "CHEMICAL", 126, 136], ["PL250", "CHEMICAL", 147, 152], ["Zn ion", "SIMPLE_CHEMICAL", 23, 29], ["His297", "SIMPLE_CHEMICAL", 66, 72], ["His301", "SIMPLE_CHEMICAL", 74, 80], ["Glu320", "AMINO_ACID", 85, 91], ["APN", "GENE_OR_GENE_PRODUCT", 95, 98], ["phosphinic moiety", "SIMPLE_CHEMICAL", 126, 143], ["PL250", "SIMPLE_CHEMICAL", 147, 152], ["APN", "PROTEIN", 95, 98], ["O atoms", "PROTEIN", 111, 118], ["PL250", "PROTEIN", 147, 152], ["His301", "TEST", 74, 80], ["APN", "TEST", 95, 98], ["the phosphinic moiety of PL250", "TREATMENT", 122, 152]]], ["One of these O atoms is also involved in a hydrogen bond to Tyr381, supporting the proposed role of this amino acid in the stabilization of the transition state of the enzymatic process.", [["Tyr381", "CHEMICAL", 60, 66], ["amino acid", "CHEMICAL", 105, 115], ["O", "CHEMICAL", 13, 14], ["hydrogen", "CHEMICAL", 43, 51], ["Tyr381", "CHEMICAL", 60, 66], ["amino acid", "CHEMICAL", 105, 115], ["O atoms", "SIMPLE_CHEMICAL", 13, 20], ["Tyr381", "SIMPLE_CHEMICAL", 60, 66], ["amino acid", "AMINO_ACID", 105, 115], ["this amino acid", "TREATMENT", 100, 115], ["enzymatic process", "OBSERVATION", 168, 185]]], ["The strength of the phosphinic zinc binding and the occupancy of the S 0 2 subsite account for the 100-fold increase in affinity of PL250 compared with the dipeptide-derived inhibitor bestatin (K i = 4.1 \u00c2 10 \u00c06 M).", [["zinc", "CHEMICAL", 31, 35], ["PL250", "CHEMICAL", 132, 137], ["bestatin", "CHEMICAL", 184, 192], ["K", "CHEMICAL", 194, 195], ["zinc", "CHEMICAL", 31, 35], ["PL250", "CHEMICAL", 132, 137], ["dipeptide", "CHEMICAL", 156, 165], ["bestatin", "CHEMICAL", 184, 192], ["PL250", "SIMPLE_CHEMICAL", 132, 137], ["bestatin", "SIMPLE_CHEMICAL", 184, 192], ["S 0 2 subsite", "PROTEIN", 69, 82], ["the phosphinic zinc binding", "PROBLEM", 16, 43], ["affinity of PL250", "TREATMENT", 120, 137], ["the dipeptide-derived inhibitor bestatin", "TREATMENT", 152, 192], ["K i", "TEST", 194, 197]]], ["Accordingly, the removal of the C-terminal phenylalanine of PL250 resulted in a large decrease in affinity (K i = 2.17 \u00c2 10 \u00c07 M).", [["phenylalanine", "CHEMICAL", 43, 56], ["PL250", "CHEMICAL", 60, 65], ["C", "CHEMICAL", 32, 33], ["phenylalanine", "CHEMICAL", 43, 56], ["PL250", "CHEMICAL", 60, 65], ["C-terminal phenylalanine", "SIMPLE_CHEMICAL", 32, 56], ["PL250", "SIMPLE_CHEMICAL", 60, 65], ["the removal", "TREATMENT", 13, 24], ["the C-terminal phenylalanine of PL250", "TREATMENT", 28, 65], ["a large decrease in affinity", "PROBLEM", 78, 106], ["K i", "TEST", 108, 111], ["large", "OBSERVATION_MODIFIER", 80, 85], ["decrease", "OBSERVATION_MODIFIER", 86, 94]]], ["Furthermore, it was observed that the C-terminal carboxyl group of the inhibitor makes no direct interactions with the amino acids of the APN active site.", [["amino acids", "CHEMICAL", 119, 130], ["C", "CHEMICAL", 38, 39], ["carboxyl", "CHEMICAL", 49, 57], ["amino acids", "CHEMICAL", 119, 130], ["amino acids", "AMINO_ACID", 119, 130], ["APN", "GENE_OR_GENE_PRODUCT", 138, 141], ["C-terminal carboxyl group", "PROTEIN", 38, 63], ["APN active site", "PROTEIN", 138, 153], ["the C-terminal carboxyl group of the inhibitor", "TREATMENT", 34, 80], ["the amino acids", "TREATMENT", 115, 130]]], ["Interestingly, PL250 exhibits the same inhibitory potency for E. coli APN and for mammalian enzymes, suggesting that the structure of the complex could be used as a template for the rational design of various human APN inhibitors needed to study the role of this aminopeptidase in various pathologies.IntroductionAminopeptidase N (APN; EC 3.4.11.2) is a well conserved exopeptidase (Maroux et al., 1973) that is expressed in a broad spectrum of species (bacteria, plants, insects and mammals) in which it plays an important role in the final digestion of peptides.", [["PL250", "CHEMICAL", 15, 20], ["PL250", "CHEMICAL", 15, 20], ["PL250", "SIMPLE_CHEMICAL", 15, 20], ["E. coli", "ORGANISM", 62, 69], ["APN", "GENE_OR_GENE_PRODUCT", 70, 73], ["human", "ORGANISM", 209, 214], ["APN", "GENE_OR_GENE_PRODUCT", 215, 218], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 263, 277], ["Aminopeptidase N", "GENE_OR_GENE_PRODUCT", 313, 329], ["APN", "PROTEIN", 70, 73], ["mammalian enzymes", "PROTEIN", 82, 99], ["aminopeptidase", "PROTEIN", 263, 277], ["Aminopeptidase N", "PROTEIN", 313, 329], ["APN", "PROTEIN", 331, 334], ["E. coli", "SPECIES", 62, 69], ["human", "SPECIES", 209, 214], ["E. coli", "SPECIES", 62, 69], ["human", "SPECIES", 209, 214], ["E. coli APN", "PROBLEM", 62, 73], ["mammalian enzymes", "TEST", 82, 99], ["a template", "TREATMENT", 163, 173], ["various human APN inhibitors", "TREATMENT", 201, 229], ["this aminopeptidase in various pathologies", "PROBLEM", 258, 300], ["IntroductionAminopeptidase N (APN", "TREATMENT", 301, 334], ["EC", "TEST", 336, 338], ["species", "PROBLEM", 445, 452], ["bacteria", "PROBLEM", 454, 462]]], ["This type II membrane-bound zinc peptidase is also widely distributed in mammalian tissues, including the central nervous system (Hersh et al., 1987; Noble et al., 2001; Larrinaga et al., 2005) , and is particularly abundant in the kidney, the intestine and the lung (Maroux et al., 1973; Hersh et al., 1987) .", [["membrane", "ANATOMY", 13, 21], ["tissues", "ANATOMY", 83, 90], ["central nervous system", "ANATOMY", 106, 128], ["kidney", "ANATOMY", 232, 238], ["intestine", "ANATOMY", 244, 253], ["lung", "ANATOMY", 262, 266], ["zinc", "CHEMICAL", 28, 32], ["zinc", "CHEMICAL", 28, 32], ["type II", "GENE_OR_GENE_PRODUCT", 5, 12], ["membrane", "CELLULAR_COMPONENT", 13, 21], ["zinc peptidase", "GENE_OR_GENE_PRODUCT", 28, 42], ["mammalian tissues", "TISSUE", 73, 90], ["central nervous system", "ANATOMICAL_SYSTEM", 106, 128], ["kidney", "ORGAN", 232, 238], ["intestine", "ORGAN", 244, 253], ["lung", "ORGAN", 262, 266], ["zinc peptidase", "PROTEIN", 28, 42], ["This type II membrane-bound zinc peptidase", "PROBLEM", 0, 42], ["zinc peptidase", "OBSERVATION", 28, 42], ["widely", "OBSERVATION_MODIFIER", 51, 57], ["mammalian tissues", "OBSERVATION", 73, 90], ["central", "ANATOMY_MODIFIER", 106, 113], ["nervous system", "ANATOMY", 114, 128], ["kidney", "ANATOMY", 232, 238], ["intestine", "ANATOMY", 244, 253], ["lung", "ANATOMY", 262, 266]]], ["In vivo, this enzyme is involved in the catabolism of biologically active peptides such as angiotensin III (Zini et al., 1996) , nociceptin (Montiel et al., 1997) and enkephalins in association with neprilysin (Roques et al., 1993) in the brain and in peripheral organs.", [["brain", "ANATOMY", 239, 244], ["peripheral organs", "ANATOMY", 252, 269], ["angiotensin", "CHEMICAL", 91, 102], ["nociceptin", "CHEMICAL", 129, 139], ["angiotensin III", "GENE_OR_GENE_PRODUCT", 91, 106], ["nociceptin", "SIMPLE_CHEMICAL", 129, 139], ["enkephalins", "GENE_OR_GENE_PRODUCT", 167, 178], ["neprilysin", "GENE_OR_GENE_PRODUCT", 199, 209], ["brain", "ORGAN", 239, 244], ["peripheral organs", "MULTI-TISSUE_STRUCTURE", 252, 269], ["neprilysin", "PROTEIN", 199, 209], ["this enzyme", "TEST", 9, 20], ["biologically active peptides", "PROBLEM", 54, 82], ["nociceptin", "TREATMENT", 129, 139], ["enkephalins", "TREATMENT", 167, 178], ["neprilysin", "TREATMENT", 199, 209], ["brain", "ANATOMY", 239, 244], ["peripheral", "ANATOMY_MODIFIER", 252, 262], ["organs", "ANATOMY", 263, 269]]], ["Furthermore, APN is identical to the human lymphocyte surface cluster differentiation antigen CD13 (Look et al., 1989) and behaves as a receptor for coronaviruses TGEV and 229E in pigs and humans (Delmas et al., 1992; Yeager et al., 1992) .", [["lymphocyte surface", "ANATOMY", 43, 61], ["APN", "GENE_OR_GENE_PRODUCT", 13, 16], ["human", "ORGANISM", 37, 42], ["lymphocyte", "CELL", 43, 53], ["CD13", "GENE_OR_GENE_PRODUCT", 94, 98], ["coronaviruses TGEV", "ORGANISM", 149, 167], ["pigs", "ORGANISM", 180, 184], ["humans", "ORGANISM", 189, 195], ["APN", "PROTEIN", 13, 16], ["human lymphocyte surface cluster differentiation antigen CD13", "PROTEIN", 37, 98], ["human", "SPECIES", 37, 42], ["pigs", "SPECIES", 180, 184], ["humans", "SPECIES", 189, 195], ["human", "SPECIES", 37, 42], ["coronaviruses TGEV", "SPECIES", 149, 167], ["pigs", "SPECIES", 180, 184], ["humans", "SPECIES", 189, 195], ["coronaviruses TGEV", "PROBLEM", 149, 167]]], ["Moreover, APN has recently been shown to play an important role in the invasion of metastatic tumours (Saiki et al., 1993; Hashida et al., 2002) and in angiogenesis (Sato, 2004) .IntroductionOwing to the importance of APN in many physiological and pathological processes, there is a challenging interest in the development of potent and selective inhibitors of this enzyme for potential therapeutic applications.", [["metastatic tumours", "ANATOMY", 83, 101], ["tumours", "DISEASE", 94, 101], ["APN", "GENE_OR_GENE_PRODUCT", 10, 13], ["metastatic tumours", "CANCER", 83, 101], ["APN", "GENE_OR_GENE_PRODUCT", 218, 221], ["APN", "PROTEIN", 10, 13], ["APN", "PROTEIN", 218, 221], ["metastatic tumours", "PROBLEM", 83, 101], ["APN", "TREATMENT", 218, 221], ["this enzyme", "TREATMENT", 361, 372], ["potential therapeutic applications", "TREATMENT", 377, 411], ["metastatic", "OBSERVATION_MODIFIER", 83, 93], ["tumours", "OBSERVATION", 94, 101]]], ["Various families of inhibitors have been described (Fourni\u00e9 -Zaluski & Roques, 2002; Bauvois & Dauzonne, 2006) , most of which have inhibitory potencies in the micromolar range and low selectivity.", [["inhibitors", "TREATMENT", 20, 30], ["micromolar range", "OBSERVATION_MODIFIER", 160, 176], ["low selectivity", "OBSERVATION_MODIFIER", 181, 196]]], ["Consequently, to aid in the design of new potent and specific inhibitors of this enzyme, it seems important to determine the structural parameters which allow optimized recognition of the aminopeptidase N active site.IntroductionAPN belongs to the M1 family of zinc metallopeptidases (clan MA; Rawlings & Barrett, 1995) , which also contains leukotriene A4 hydrolase (LTA4H), aminopeptidase A (APA) and aminopeptidase B (APB) and is characterized by two consensus sequences: (i) the active-site sequence HEX-XH(X 18 )E, where the two histidine residues and the second glutamate are zinc ligands, with the first glutamate being involved in the catalytic process, and (ii) the sequence GXMEN containing the glutamate residue which ensures the aminopeptidase selectivity of this class of enzymes (Luciani et al., 1998; Vazeux et al., 1998) .IntroductionOnly three members of this family have been crystallized and their three-dimensional structures established by X-ray crystallography: human LTA4H (Thunnissen et al., 2001) , Escherichia coli APN Addlagatta et al., 2006; Nocek et al., 2008) and the archaeal tricorn interacting factor F3 (Kyrieleis et al., 2005) .", [["zinc", "CHEMICAL", 261, 265], ["leukotriene", "CHEMICAL", 342, 353], ["histidine", "CHEMICAL", 534, 543], ["glutamate", "CHEMICAL", 568, 577], ["zinc", "CHEMICAL", 582, 586], ["glutamate", "CHEMICAL", 611, 620], ["glutamate", "CHEMICAL", 705, 714], ["N", "CHEMICAL", 203, 204], ["zinc", "CHEMICAL", 261, 265], ["HEX-XH(X 18 )E", "CHEMICAL", 504, 518], ["histidine", "CHEMICAL", 534, 543], ["glutamate", "CHEMICAL", 568, 577], ["zinc", "CHEMICAL", 582, 586], ["glutamate", "CHEMICAL", 611, 620], ["glutamate", "CHEMICAL", 705, 714], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 188, 204], ["leukotriene A4 hydrolase", "GENE_OR_GENE_PRODUCT", 342, 366], ["LTA4H", "GENE_OR_GENE_PRODUCT", 368, 373], ["aminopeptidase A", "GENE_OR_GENE_PRODUCT", 376, 392], ["APA", "GENE_OR_GENE_PRODUCT", 394, 397], ["aminopeptidase B", "GENE_OR_GENE_PRODUCT", 403, 419], ["APB", "GENE_OR_GENE_PRODUCT", 421, 424], ["HEX-XH(X 18 )E", "GENE_OR_GENE_PRODUCT", 504, 518], ["glutamate", "SIMPLE_CHEMICAL", 568, 577], ["glutamate", "SIMPLE_CHEMICAL", 611, 620], ["GXMEN", "SIMPLE_CHEMICAL", 684, 689], ["glutamate", "SIMPLE_CHEMICAL", 705, 714], ["human", "ORGANISM", 984, 989], ["Escherichia coli", "ORGANISM", 1024, 1040], ["enzyme", "PROTEIN", 81, 87], ["aminopeptidase N active site", "PROTEIN", 188, 216], ["M1 family", "PROTEIN", 248, 257], ["zinc metallopeptidases", "PROTEIN", 261, 283], ["leukotriene A4 hydrolase", "PROTEIN", 342, 366], ["LTA4H", "PROTEIN", 368, 373], ["aminopeptidase A", "PROTEIN", 376, 392], ["APA", "PROTEIN", 394, 397], ["aminopeptidase B", "PROTEIN", 403, 419], ["APB", "PROTEIN", 421, 424], ["consensus sequences", "DNA", 454, 473], ["active-site sequence", "DNA", 483, 503], ["XH(X 18 )E", "DNA", 508, 518], ["GXMEN", "PROTEIN", 684, 689], ["aminopeptidase", "PROTEIN", 741, 755], ["enzymes", "PROTEIN", 785, 792], ["archaeal tricorn interacting factor F3", "PROTEIN", 1098, 1136], ["human", "SPECIES", 984, 989], ["Escherichia coli", "SPECIES", 1024, 1040], ["human", "SPECIES", 984, 989], ["Escherichia coli", "SPECIES", 1024, 1040], ["this enzyme", "TEST", 76, 87], ["the aminopeptidase N active site", "TREATMENT", 184, 216], ["leukotriene A4 hydrolase (LTA4H)", "TREATMENT", 342, 374], ["aminopeptidase A (APA)", "TREATMENT", 376, 398], ["aminopeptidase B (APB)", "TEST", 403, 425], ["the two histidine residues", "TREATMENT", 526, 552], ["zinc ligands", "PROBLEM", 582, 594], ["the first glutamate", "TREATMENT", 601, 620], ["the sequence GXMEN", "TREATMENT", 671, 689], ["the glutamate residue", "PROBLEM", 701, 722], ["Escherichia coli", "TEST", 1024, 1040]]], ["In spite of low primary sequence identities, these three peptidases show great similarities in their three-dimensional structure, particularly at the activesite level, and in their mechanism of action.", [["great", "OBSERVATION_MODIFIER", 73, 78]]], ["Thus, bestatin (Fig. 1) , a nonspecific aminopeptidase inhibitor, has been cocrystallized with both LTA4H (Thunnissen et al., 2001) and with E. coli APN Addlagatta et al., 2006) revealing very similar structural organizations of the complexes.IntroductionA large homology in primary sequence is observed between aminopeptidases N from various species (80% identity between different mammalian enzymes and 44.1% similarity between human and E. coli APN), suggesting that the structure of the bacterial enzyme could be used as a model of its human counterpart.IntroductionIn this paper, we describe the three-dimensional structure of PL250, the most potent aminopeptidase N inhibitor reported to date (Chen et al., 1999) , in the active site of E. coli APN.", [["bestatin", "CHEMICAL", 6, 14], ["PL250", "CHEMICAL", 632, 637], ["bestatin", "CHEMICAL", 6, 14], ["PL250", "CHEMICAL", 632, 637], ["bestatin", "SIMPLE_CHEMICAL", 6, 14], ["Fig. 1", "GENE_OR_GENE_PRODUCT", 16, 22], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 40, 54], ["aminopeptidases N", "GENE_OR_GENE_PRODUCT", 312, 329], ["human", "ORGANISM", 430, 435], ["E. coli APN", "ORGANISM", 440, 451], ["human", "ORGANISM", 540, 545], ["PL250", "SIMPLE_CHEMICAL", 632, 637], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 655, 671], ["E. coli", "ORGANISM", 743, 750], ["APN", "GENE_OR_GENE_PRODUCT", 751, 754], ["aminopeptidases N", "PROTEIN", 312, 329], ["mammalian enzymes", "PROTEIN", 383, 400], ["APN", "PROTEIN", 448, 451], ["bacterial enzyme", "PROTEIN", 491, 507], ["APN", "PROTEIN", 751, 754], ["E. coli", "SPECIES", 141, 148], ["human", "SPECIES", 430, 435], ["E. coli", "SPECIES", 440, 447], ["human", "SPECIES", 540, 545], ["E. coli", "SPECIES", 743, 750], ["E. coli", "SPECIES", 141, 148], ["human", "SPECIES", 430, 435], ["E. coli", "SPECIES", 440, 447], ["human", "SPECIES", 540, 545], ["E. coli", "SPECIES", 743, 750], ["a nonspecific aminopeptidase inhibitor", "TREATMENT", 26, 64], ["E. coli", "TEST", 141, 148], ["IntroductionA large homology in primary sequence", "PROBLEM", 243, 291], ["various species", "PROBLEM", 335, 350], ["different mammalian enzymes", "TEST", 373, 400], ["human and E. coli APN", "TREATMENT", 430, 451], ["the bacterial enzyme", "PROBLEM", 487, 507], ["the most potent aminopeptidase N inhibitor", "TREATMENT", 639, 681], ["E. coli APN", "PROBLEM", 743, 754], ["very", "OBSERVATION_MODIFIER", 188, 192], ["similar", "OBSERVATION_MODIFIER", 193, 200], ["structural organizations", "OBSERVATION", 201, 225], ["E. coli APN", "OBSERVATION", 743, 754]]], ["This phosphinic derivative,3-phenylpropanoate[H 3 N + -CH(CH 3 )-P(O)(OH)-CH 2 -CH (CH 2 Ph)-CONH-CH(CH 2 Ph)CO 2 H] (Fig. 1) , which mimics a tripeptide and could be considered to be a 'transition-state analogue', inhibits hog kidney APN with a potency in the nanomolar range and has been used to visualize this enzyme in rat and chick by autoradiography using its radiolabelled form (Jardinaud et al., 2004; Sihn et al., 2006) .3-phenylpropanoateComparison of the three-dimensional structures of the free APN of E. coli and of its complexes with bestatin Addlagatta et al., 2006) and PL250 (this study) allows the confirmation of the proposed role of Tyr381 in the stabilization of the transition state during the hydrolytic process and demonstrates that the highly potent inhibition of APN by PL250 arises from the additional C-terminal aminoacid interactions with the S 0 2 subsite.", [["kidney", "ANATOMY", 228, 234], ["3-phenylpropanoate", "CHEMICAL", 27, 45], ["H", "CHEMICAL", 46, 47], ["CH 2 Ph)-CONH-CH(CH 2 Ph)CO 2 H", "CHEMICAL", 84, 115], ["bestatin", "CHEMICAL", 548, 556], ["Tyr381", "CHEMICAL", 653, 659], ["PL250", "CHEMICAL", 796, 801], ["3-phenylpropanoate", "CHEMICAL", 27, 45], ["H 3 N + -CH(CH 3 )-P(O)(OH)-CH 2 -CH (CH 2 Ph)-CONH-CH(CH 2 Ph)CO 2 H", "CHEMICAL", 46, 115], ["tripeptide", "CHEMICAL", 143, 153], [".3-phenylpropanoateComparison", "CHEMICAL", 429, 458], ["bestatin", "CHEMICAL", 548, 556], ["PL250", "CHEMICAL", 586, 591], ["Tyr381", "CHEMICAL", 653, 659], ["PL250", "CHEMICAL", 796, 801], ["C", "CHEMICAL", 829, 830], ["aminoacid", "CHEMICAL", 840, 849], ["phosphinic derivative", "SIMPLE_CHEMICAL", 5, 26], ["3-phenylpropanoate", "SIMPLE_CHEMICAL", 27, 45], ["H 3 N + -CH(CH 3 )-P(O)(OH)-CH 2 -CH (CH 2 Ph)-CONH-CH(CH 2 Ph)CO 2 H]", "SIMPLE_CHEMICAL", 46, 116], ["Fig. 1)", "SIMPLE_CHEMICAL", 118, 125], ["hog", "ORGANISM", 224, 227], ["kidney", "ORGAN", 228, 234], ["APN", "GENE_OR_GENE_PRODUCT", 235, 238], ["rat", "ORGANISM", 323, 326], ["chick", "ORGANISM", 331, 336], [".3-phenylpropanoateComparison", "SIMPLE_CHEMICAL", 429, 458], ["APN", "GENE_OR_GENE_PRODUCT", 507, 510], ["E. coli", "ORGANISM", 514, 521], ["PL250", "SIMPLE_CHEMICAL", 586, 591], ["Tyr381", "GENE_OR_GENE_PRODUCT", 653, 659], ["APN", "GENE_OR_GENE_PRODUCT", 789, 792], ["PL250", "SIMPLE_CHEMICAL", 796, 801], ["hog kidney APN", "PROTEIN", 224, 238], ["enzyme", "PROTEIN", 313, 319], ["APN", "PROTEIN", 507, 510], ["Tyr381", "PROTEIN", 653, 659], ["APN", "PROTEIN", 789, 792], ["S 0 2 subsite", "PROTEIN", 872, 885], ["hog", "SPECIES", 224, 227], ["rat", "SPECIES", 323, 326], ["E. coli", "SPECIES", 514, 521], ["hog", "SPECIES", 224, 227], ["rat", "SPECIES", 323, 326], ["E. coli", "SPECIES", 514, 521], ["This phosphinic derivative", "TREATMENT", 0, 26], ["phenylpropanoate[H", "TREATMENT", 29, 47], ["CONH", "TEST", 93, 97], ["a tripeptide", "TREATMENT", 141, 153], ["a 'transition-state analogue'", "PROBLEM", 184, 213], ["hog kidney APN", "PROBLEM", 224, 238], ["this enzyme", "TEST", 308, 319], ["E. coli", "PROBLEM", 514, 521], ["this study", "TEST", 593, 603], ["the confirmation", "TEST", 612, 628], ["the additional C-terminal aminoacid interactions", "TREATMENT", 814, 862], ["kidney", "ANATOMY", 228, 234], ["E. coli", "OBSERVATION", 514, 521]]], ["The identical affinities of this phosphinic inhibitor for aminopeptidase N from E. coli and from hog kidney suggests that the same organization of the active site occurs in the bacterial and mammalian enzymes and supports the use of these structural data to rationally design various classes of potent human APN inhibitors.Experimental procedures 2.1.", [["kidney", "ANATOMY", 101, 107], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 58, 74], ["E. coli", "ORGANISM", 80, 87], ["hog", "ORGANISM", 97, 100], ["kidney", "ORGAN", 101, 107], ["human", "ORGANISM", 302, 307], ["APN", "GENE_OR_GENE_PRODUCT", 308, 311], ["aminopeptidase N", "PROTEIN", 58, 74], ["bacterial and mammalian enzymes", "PROTEIN", 177, 208], ["E. coli", "SPECIES", 80, 87], ["hog", "SPECIES", 97, 100], ["human", "SPECIES", 302, 307], ["E. coli", "SPECIES", 80, 87], ["hog", "SPECIES", 97, 100], ["human", "SPECIES", 302, 307], ["this phosphinic inhibitor", "TREATMENT", 28, 53], ["aminopeptidase N", "TREATMENT", 58, 74], ["E. coli", "PROBLEM", 80, 87], ["the active site", "PROBLEM", 147, 162], ["mammalian enzymes", "TEST", 191, 208], ["potent human APN inhibitors", "TREATMENT", 295, 322], ["Experimental procedures", "TEST", 323, 346], ["kidney", "ANATOMY", 101, 107], ["active site", "OBSERVATION", 151, 162]]], ["MaterialsAminopeptidase from E. coli was produced and purified as described previously .", [["Aminopeptidase", "GENE_OR_GENE_PRODUCT", 9, 23], ["E. coli", "ORGANISM", 29, 36], ["Aminopeptidase", "PROTEIN", 9, 23], ["E. coli", "SPECIES", 29, 36], ["E. coli", "SPECIES", 29, 36], ["E. coli", "PROBLEM", 29, 36], ["E. coli", "OBSERVATION", 29, 36]]], ["Aminopeptidase N from hog kidney (4.07 mg ml \u00c01 ; specific activity 5.41 U mg \u00c01 ) was purchased from Pierce Biotechnology and Ala--NA was purchased from Sigma.", [["kidney", "ANATOMY", 26, 32], ["Aminopeptidase N", "CHEMICAL", 0, 16], ["NA", "CHEMICAL", 132, 134], ["Ala", "CHEMICAL", 127, 130], ["Aminopeptidase N", "GENE_OR_GENE_PRODUCT", 0, 16], ["hog", "ORGANISM", 22, 25], ["kidney", "ORGAN", 26, 32], ["Ala--NA", "SIMPLE_CHEMICAL", 127, 134], ["hog", "SPECIES", 22, 25], ["hog", "SPECIES", 22, 25], ["Aminopeptidase N from hog kidney", "TREATMENT", 0, 32], ["kidney", "ANATOMY", 26, 32]]], ["The four phosphinic inhibitors were synthesized as described by Chen et al. (1999) .Crystallization and data collectionCrystallization was carried out as described previously Onohara et al., 2006) .", [["The four phosphinic inhibitors", "TREATMENT", 0, 30], ["Crystallization", "TREATMENT", 84, 99], ["data collectionCrystallization", "TEST", 104, 134]]], ["Crystals of the complex with PL250 inhibitor were obtained by soaking ligand-free crystals for 3 d in a prepared solution containing 300 mM PL250, 2.2 M ammonium sulfate and 100 mM MES buffer pH 6.4.", [["PL250", "CHEMICAL", 140, 145], ["ammonium sulfate", "CHEMICAL", 153, 169], ["PL250", "CHEMICAL", 29, 34], ["PL250", "CHEMICAL", 140, 145], ["ammonium sulfate", "CHEMICAL", 153, 169], ["PL250", "SIMPLE_CHEMICAL", 29, 34], ["PL250", "SIMPLE_CHEMICAL", 140, 145], ["ammonium sulfate", "SIMPLE_CHEMICAL", 153, 169], ["Crystals", "TEST", 0, 8], ["PL250 inhibitor", "TREATMENT", 29, 44], ["a prepared solution", "TREATMENT", 102, 121], ["2.2 M ammonium sulfate", "TREATMENT", 147, 169], ["mM MES buffer pH", "TEST", 178, 194]]], ["These crystals were isomorphous with ligand-free crystals, belonging to space group P3 1 21 with unit-cell parameters a = b = 120.7, c = 171.0 \u00c5 , = 120 .", [["space group P3 1 21", "PROTEIN", 72, 91], ["These crystals", "TEST", 0, 14], ["ligand-free crystals", "TEST", 37, 57], ["space group P3", "TEST", 72, 86], ["unit-cell parameters", "TEST", 97, 117], ["c", "TEST", 133, 134]]], ["Diffraction data were collected to 1.55 \u00c5 resolution at 100 K using a wavelength of 1.000 \u00c5 at the Photon Factory BL-17A station synchrotron-radiation source (Tsukuba, Japan).", [["Diffraction data", "TEST", 0, 16], ["a wavelength", "TEST", 68, 80]]], ["For data collection under cryogenic conditions, the crystals were soaked for 1 min in a prepared solution containing 30%(v/v) glycerol, 1.75 M ammonium sulfate and 100 mM MES buffer pH 6.4.", [["glycerol", "CHEMICAL", 126, 134], ["ammonium sulfate", "CHEMICAL", 143, 159], ["glycerol", "CHEMICAL", 126, 134], ["ammonium sulfate", "CHEMICAL", 143, 159], ["glycerol", "SIMPLE_CHEMICAL", 126, 134], ["ammonium sulfate", "SIMPLE_CHEMICAL", 143, 159], ["cryogenic conditions", "TREATMENT", 26, 46], ["the crystals", "TREATMENT", 48, 60], ["a prepared solution", "TREATMENT", 86, 105], ["glycerol", "TREATMENT", 126, 134], ["ammonium sulfate", "TREATMENT", 143, 159], ["mM MES buffer pH", "TEST", 168, 184], ["cryogenic conditions", "OBSERVATION", 26, 46]]], ["The crystal was mounted in a nylon loop and flash-cooled in a liquid-nitrogen stream at 100 K. These data were processed and scaled using HKL-2000 (Otwinowski & Minor, 1997) .", [["nitrogen", "CHEMICAL", 69, 77], ["a nylon loop", "TREATMENT", 27, 39], ["flash", "PROBLEM", 44, 49], ["a liquid-nitrogen stream", "TREATMENT", 60, 84], ["crystal", "OBSERVATION_MODIFIER", 4, 11], ["nylon loop", "OBSERVATION", 29, 39]]], ["The data-collection statistics are summarized in Table 1 .Structure determination and refinementScaling and reduction of the diffraction data was performed using the CCP4 program suite (Collaborative Computational Project, Number 4, 1994).", [["The data", "TEST", 0, 8], ["the diffraction data", "TEST", 121, 141], ["reduction", "OBSERVATION_MODIFIER", 108, 117]]], ["The structure of ligand-free APN (PDB code 2dq6) was used as the initial model.", [["APN", "PROTEIN", 29, 32], ["PDB code 2dq6", "PROTEIN", 34, 47], ["ligand", "ANATOMY", 17, 23]]], ["The structure of the APN-PL250 complex was refined by rigid-body refinement, simulated annealing and energy minimization with the program CNS (Br\u00fc nger et al., 1998) using the data from 20 to 1.55 \u00c5 resolution.", [["APN", "GENE_OR_GENE_PRODUCT", 21, 24], ["APN", "PROTEIN", 21, 24], ["PL250 complex", "PROTEIN", 25, 38], ["rigid-body refinement", "TREATMENT", 54, 75], ["the data", "TEST", 172, 180]]], ["The structure was scrutinized by inspecting the composite OMIT map using the program XtalView (McRee, 1999) .", [["composite OMIT map", "DNA", 48, 66]]], ["The difference Fourier map clearly displayed residual electron density corresponding to the inhibitor bound at the active site.", [["electron", "SIMPLE_CHEMICAL", 54, 62], ["The difference Fourier map", "TEST", 0, 26], ["residual electron density", "PROBLEM", 45, 70], ["the inhibitor bound", "PROBLEM", 88, 107], ["residual", "OBSERVATION_MODIFIER", 45, 53], ["electron density", "OBSERVATION", 54, 70], ["active site", "OBSERVATION", 115, 126]]], ["Refinement and model rebuilding were alternately carried out for several cycles using the programs REFMAC5 from the CCP4 program suite (Collaborative Computational Project, Number 4, 1994) and Coot (Emsley & Cowtan, 2004) ; water molecules were then picked out from the difference map on the basis of peak height and distance criteria.", [["Refinement and model rebuilding", "TREATMENT", 0, 31], ["peak height", "OBSERVATION", 301, 312]]], ["Water molecules whose thermal factors were above 50 \u00c5 2 after refinement were removed from the list.", [["thermal factors", "PROTEIN", 22, 37]]], ["Further model-building and refinement cycles resulted in an R factor of 17.8% and an R free of 19.5% using 196 426 reflections from 20 to 1.55 \u00c5 resolution.", [["refinement cycles", "TREATMENT", 27, 44], ["an R factor", "TEST", 57, 68], ["an R free", "TEST", 82, 91]]], ["The maximal thermal factor of the water molecules was 49 \u00c5 2 .Enzyme-activity assayThe enzyme activity was measured using Ala--NA as a substrate for both E. coli and hog kidney aminopeptidases N. Hog kidney aminopeptidase (0.2 mU ml \u00c01 , 40 mg ml \u00c01 ) in 50 mM Tris-HCl buffer pH 7.5 was preincubated with or without various concentrations of the tested inhibitors in a final volume of 100 ml in 96-well microplates for 10 min at 310 K. The substrate Ala--NA (K m = 50 mM for the hog kidney enzyme) was added to a final concentration of 50 mM and the emitted fluorescence was measured for 30 min ( ex = 340 nm, em = 405 nm) on a Berthold Twinkle LB 970 fluorimeter.", [["kidney", "ANATOMY", 170, 176], ["kidney", "ANATOMY", 484, 490], ["Ala--NA", "CHEMICAL", 122, 129], ["Tris-HCl", "CHEMICAL", 261, 269], ["Ala", "CHEMICAL", 451, 454], ["NA", "CHEMICAL", 456, 458], ["K", "CHEMICAL", 460, 461], ["Ala", "CHEMICAL", 122, 125], ["Tris-HCl", "CHEMICAL", 261, 269], ["Ala", "CHEMICAL", 451, 454], ["Ala--NA", "SIMPLE_CHEMICAL", 122, 129], ["E. coli", "ORGANISM", 154, 161], ["hog", "ORGANISM", 166, 169], ["kidney", "ORGAN", 170, 176], ["Hog kidney aminopeptidase", "GENE_OR_GENE_PRODUCT", 196, 221], ["Tris-HCl", "SIMPLE_CHEMICAL", 261, 269], ["Ala--NA", "SIMPLE_CHEMICAL", 451, 458], ["hog", "ORGANISM", 480, 483], ["kidney", "ORGAN", 484, 490], ["hog kidney enzyme", "PROTEIN", 480, 497], ["E. coli", "SPECIES", 154, 161], ["hog", "SPECIES", 166, 169], ["E. coli", "SPECIES", 154, 161], ["hog", "SPECIES", 166, 169], ["the water molecules", "TEST", 30, 49], ["Enzyme", "TEST", 62, 68], ["activity assay", "TEST", 69, 83], ["The enzyme activity", "TEST", 83, 102], ["Ala--NA", "TREATMENT", 122, 129], ["a substrate", "TREATMENT", 133, 144], ["both E. coli", "TREATMENT", 149, 161], ["hog kidney aminopeptidases", "TREATMENT", 166, 192], ["Hog kidney aminopeptidase", "TREATMENT", 196, 221], ["HCl buffer pH", "TEST", 266, 279], ["the tested inhibitors", "TREATMENT", 343, 364], ["The substrate Ala", "TEST", 437, 454], ["NA", "TEST", 456, 458], ["K m", "TEST", 460, 463], ["the hog kidney enzyme", "TEST", 476, 497], ["the emitted fluorescence", "TEST", 547, 571], ["activity", "OBSERVATION_MODIFIER", 94, 102], ["coli", "OBSERVATION", 157, 161], ["kidney", "ANATOMY", 170, 176], ["kidney", "ANATOMY", 200, 206], ["kidney", "ANATOMY", 484, 490]]], ["Blank values were obtained by measuring the fluorescence emitted by the same reagents in the presence of heat-denaturated enzyme.", [["heat-denaturated enzyme", "PROTEIN", 105, 128], ["Blank values", "TEST", 0, 12]]], ["Assuming competitive inhibition of APN by the four inhibitors, their K i values were calculated using the Cheng-Prusoff equationEnzyme-activity assayFor E. coli aminopeptidase N, the assay was performed as described by Ito et al. (2006) .", [["K", "CHEMICAL", 69, 70], ["APN", "GENE_OR_GENE_PRODUCT", 35, 38], ["K i", "GENE_OR_GENE_PRODUCT", 69, 72], ["E. coli aminopeptidase N", "GENE_OR_GENE_PRODUCT", 153, 177], ["APN", "PROTEIN", 35, 38], ["E. coli", "SPECIES", 153, 160], ["E. coli", "SPECIES", 153, 160], ["APN", "TREATMENT", 35, 38], ["their K i values", "TEST", 63, 79], ["the Cheng", "TEST", 102, 111], ["Prusoff equationEnzyme", "TEST", 112, 134], ["E. coli aminopeptidase N", "TREATMENT", 153, 177], ["the assay", "TEST", 179, 188]]], ["Briefly, the reaction mixture consisted of 0.8 ml 20 mM Tris-HCl buffer pH 7.0, 0.1 ml enzyme solution, 0.1 ml of a 3 mM solution of Ala--NA (K m = 300 mM for the E. coli enzyme) and various concentrations of inhibitor.", [["Tris-HCl", "CHEMICAL", 56, 64], ["Ala--NA", "CHEMICAL", 133, 140], ["K", "CHEMICAL", 142, 143], ["Tris-HCl", "CHEMICAL", 56, 64], ["Ala", "CHEMICAL", 133, 136], ["Tris-HCl", "SIMPLE_CHEMICAL", 56, 64], ["Ala--NA", "SIMPLE_CHEMICAL", 133, 140], ["E. coli", "SPECIES", 163, 170], ["E. coli", "SPECIES", 163, 170], ["the reaction mixture", "TREATMENT", 9, 29], ["pH", "TEST", 72, 74], ["a 3 mM solution of Ala", "TREATMENT", 114, 136], ["the E. coli enzyme", "TEST", 159, 177], ["various concentrations of inhibitor", "TREATMENT", 183, 218]]], ["After 10 min incubation at 310 K, the reaction was stopped by the addition of 0.5 ml Fast Garnet GBC solution (1 mg ml \u00c01 ) containing 10% Triton X-100 in 1 M sodium acetate buffer pH 4.0.", [["Garnet GBC", "CHEMICAL", 90, 100], ["Triton X-100", "CHEMICAL", 139, 151], ["sodium acetate", "CHEMICAL", 159, 173], ["sodium acetate", "CHEMICAL", 159, 173], ["Triton X-100", "SIMPLE_CHEMICAL", 139, 151], ["sodium acetate", "SIMPLE_CHEMICAL", 159, 173], ["the reaction", "PROBLEM", 34, 46], ["Fast Garnet GBC solution", "TREATMENT", 85, 109], ["sodium acetate buffer pH", "TREATMENT", 159, 183]]], ["The absorbance at 550 nm was measured after 20 min.Aminopeptidase inhibitionFour inhibitors (Fig. 1) were tested with the aim of potentially linking their respective potencies to their enzyme activesite occupancy.", [["Aminopeptidase", "SIMPLE_CHEMICAL", 51, 65], ["activesite", "SIMPLE_CHEMICAL", 192, 202], ["enzyme", "PROTEIN", 185, 191], ["The absorbance", "PROBLEM", 0, 14], ["Aminopeptidase inhibitionFour inhibitors", "TREATMENT", 51, 91], ["absorbance", "OBSERVATION_MODIFIER", 4, 14]]], ["The present results show that compound 3 binds the S 1 , S 0 1 and S 0 2 subsites (following the nomenclature of Schechter & Berger, 1967) and compound 4 is very likely to bind E. coli APN similarly, whereas we could assume that compound 2 recognizes the S 1 and S 0 1 subsites and that compound 1 only recognizes the S 1 subsite.Aminopeptidase inhibitionAs shown in Table 2 , a very significant increase in APN recognition was observed from compound 1 (K i = 8.4 mM) to 2 (K i = 0.2 mM) to 3 (K i = 2.2 nM) and 4 (K i = 2.3 nM).Aminopeptidase inhibitionMoreover, the inhibitory potency of compound 3 (PL250) is not significantly different when measured using the bacterial E. coli APN (K i = 1.5 nM) or the mammalian hog APN (K i = 2.2 nM).", [["K", "CHEMICAL", 454, 455], ["PL250", "CHEMICAL", 602, 607], ["K", "CHEMICAL", 687, 688], ["K", "CHEMICAL", 727, 728], ["PL250", "CHEMICAL", 602, 607], ["S 0 1", "GENE_OR_GENE_PRODUCT", 57, 62], ["E. coli", "ORGANISM", 177, 184], ["APN", "GENE_OR_GENE_PRODUCT", 185, 188], ["Aminopeptidase", "SIMPLE_CHEMICAL", 330, 344], ["APN", "GENE_OR_GENE_PRODUCT", 408, 411], ["Aminopeptidase", "GENE_OR_GENE_PRODUCT", 529, 543], ["compound 3", "GENE_OR_GENE_PRODUCT", 590, 600], ["PL250", "SIMPLE_CHEMICAL", 602, 607], ["E. coli", "ORGANISM", 674, 681], ["APN", "GENE_OR_GENE_PRODUCT", 682, 685], ["APN", "PROTEIN", 185, 188], ["S 1 and S 0 1 subsites", "PROTEIN", 255, 277], ["S 1 subsite", "PROTEIN", 318, 329], ["APN", "PROTEIN", 408, 411], ["APN", "PROTEIN", 682, 685], ["mammalian hog APN", "PROTEIN", 708, 725], ["E. coli", "SPECIES", 177, 184], ["E. coli", "SPECIES", 674, 681], ["hog", "SPECIES", 718, 721], ["E. coli", "SPECIES", 177, 184], ["E. coli", "SPECIES", 674, 681], ["hog", "SPECIES", 718, 721], ["E. coli APN", "PROBLEM", 177, 188], ["Aminopeptidase inhibitionAs", "TEST", 330, 357], ["APN recognition", "TEST", 408, 423], ["K i", "TEST", 454, 457], ["K i", "TEST", 474, 477], ["K i", "TEST", 494, 497], ["K i", "TEST", 515, 518], ["Aminopeptidase inhibitionMoreover", "TREATMENT", 529, 562], ["the bacterial E. coli APN", "TEST", 660, 685], ["K i", "TEST", 687, 690], ["the mammalian hog APN", "TEST", 704, 725], ["K i", "TEST", 727, 730], ["very likely", "UNCERTAINTY", 157, 168], ["coli", "OBSERVATION", 180, 184], ["very", "OBSERVATION_MODIFIER", 379, 383], ["significant", "OBSERVATION_MODIFIER", 384, 395], ["increase", "OBSERVATION_MODIFIER", 396, 404], ["significantly different", "OBSERVATION_MODIFIER", 616, 639]]], ["Conversely, for compound 4 the K i value is ten times better for hog APN (K i = 2.3 nM) than for E. coli APN (K i = 25 nM).Structure of the APN-PL250 complexThe refined model of the APN-PL250 complex comprised 866 residues, a zinc ion, the PL250 inhibitor, a sulfate anion, seven glycerol molecules and 1039 water molecules with an R factor of 17.8% at 1.55 \u00c5 resolution.", [["K", "CHEMICAL", 31, 32], ["K", "CHEMICAL", 74, 75], ["zinc", "CHEMICAL", 226, 230], ["sulfate anion", "CHEMICAL", 259, 272], ["glycerol", "CHEMICAL", 280, 288], ["zinc", "CHEMICAL", 226, 230], ["sulfate", "CHEMICAL", 259, 266], ["glycerol", "CHEMICAL", 280, 288], ["K i", "GENE_OR_GENE_PRODUCT", 31, 34], ["APN", "GENE_OR_GENE_PRODUCT", 69, 72], ["APN", "GENE_OR_GENE_PRODUCT", 140, 143], ["APN", "GENE_OR_GENE_PRODUCT", 182, 185], ["PL250", "GENE_OR_GENE_PRODUCT", 186, 191], ["zinc ion", "SIMPLE_CHEMICAL", 226, 234], ["PL250", "SIMPLE_CHEMICAL", 240, 245], ["sulfate anion", "SIMPLE_CHEMICAL", 259, 272], ["glycerol molecules", "SIMPLE_CHEMICAL", 280, 298], ["APN", "PROTEIN", 140, 143], ["PL250 complex", "PROTEIN", 144, 157], ["APN", "PROTEIN", 182, 185], ["PL250 complex", "PROTEIN", 186, 199], ["R factor", "PROTEIN", 332, 340], ["E. coli", "SPECIES", 97, 104], ["hog", "SPECIES", 65, 68], ["E. coli", "SPECIES", 97, 104], ["the K i value", "TEST", 27, 40], ["hog APN", "TEST", 65, 72], ["K i", "TEST", 74, 77], ["E. coli APN", "TEST", 97, 108], ["K i", "TEST", 110, 113], ["the APN", "TEST", 136, 143], ["a zinc ion", "TREATMENT", 224, 234], ["the PL250 inhibitor", "TREATMENT", 236, 255], ["a sulfate anion", "TREATMENT", 257, 272], ["seven glycerol molecules", "TREATMENT", 274, 298], ["an R factor", "TEST", 329, 340]]], ["The present structure shows Ala122 in the cis-peptide conformation as in the ligandfree form and in the APN-bestatin complex (PDB codes 2dq6 and 2dqm, respectively).", [["bestatin", "CHEMICAL", 108, 116], ["Ala122", "CHEMICAL", 28, 34], ["bestatin", "CHEMICAL", 108, 116], ["Ala122", "SIMPLE_CHEMICAL", 28, 34], ["APN-bestatin", "GENE_OR_GENE_PRODUCT", 104, 116], ["Ala122", "PROTEIN", 28, 34], ["cis-peptide conformation", "PROTEIN", 42, 66], ["ligandfree form", "PROTEIN", 77, 92], ["APN", "PROTEIN", 104, 107], ["bestatin complex", "PROTEIN", 108, 124], ["2dq6", "PROTEIN", 136, 140], ["2dqm", "PROTEIN", 145, 149], ["PDB codes", "TEST", 126, 135], ["Ala122", "OBSERVATION_MODIFIER", 28, 34]]], ["This model lacks the four N-terminal residues owing to a lack of interpretable electron density.", [["N", "CHEMICAL", 26, 27], ["electron", "SIMPLE_CHEMICAL", 79, 87], ["N-terminal residues", "PROTEIN", 26, 45], ["density", "OBSERVATION", 88, 95]]], ["From the Fourier map, alternative conformations of side chains were found for 28 residues.", [["the Fourier map", "TEST", 5, 20], ["alternative conformations of side chains", "TREATMENT", 22, 62]]], ["Most of these are located on the protein surface and two residues, Glu382 and Ser784, are located on the surface of the cavity that is formed inside the protein.", [["surface", "ANATOMY", 105, 112], ["Glu382", "CHEMICAL", 67, 73], ["Ser784", "CHEMICAL", 78, 84], ["surface", "CELLULAR_COMPONENT", 41, 48], ["Glu382", "GENE_OR_GENE_PRODUCT", 67, 73], ["Ser784", "AMINO_ACID", 78, 84], ["surface", "CELLULAR_COMPONENT", 105, 112], ["Ser784", "PROTEIN", 78, 84], ["Glu382", "TEST", 67, 73], ["two", "OBSERVATION_MODIFIER", 53, 56], ["residues", "OBSERVATION_MODIFIER", 57, 65], ["surface", "OBSERVATION_MODIFIER", 105, 112], ["cavity", "OBSERVATION", 120, 126]]], ["The average thermal factors of the main-chain atoms, side-chain atoms, inhibitor atoms, sulfate anion, glycerol molecules and water molecules were 15.", [["sulfate anion", "CHEMICAL", 88, 101], ["glycerol", "CHEMICAL", 103, 111], ["sulfate", "CHEMICAL", 88, 95], ["glycerol", "CHEMICAL", 103, 111], ["sulfate anion", "SIMPLE_CHEMICAL", 88, 101], ["glycerol molecules", "SIMPLE_CHEMICAL", 103, 121], ["water molecules", "SIMPLE_CHEMICAL", 126, 141], ["the main-chain atoms", "TREATMENT", 31, 51], ["side-chain atoms, inhibitor atoms", "TREATMENT", 53, 86], ["sulfate anion, glycerol molecules", "TREATMENT", 88, 121], ["average", "OBSERVATION_MODIFIER", 4, 11], ["thermal", "OBSERVATION_MODIFIER", 12, 19]]], ["Analysis of the stereochemistry with PROCHECK (Laskowski et al., 1993) showed that all the main-chain atoms fell within the allowed region of the Ramachandran plot, with 740 residues (93.7%) in the most favoured region and 50 residues (6.3%) in the additionally allowed region.", [["chain atoms", "PROBLEM", 96, 107], ["main", "OBSERVATION_MODIFIER", 91, 95], ["chain atoms", "OBSERVATION", 96, 107]]], ["This model was superimposed onto the structures of the ligand-free form and the APN-bestatin complex (PDB code 2dqm) using the least-squares method at C positions with r.m.s. deviations of 0.12 and 0.11 \u00c5 , respectively.", [["bestatin", "CHEMICAL", 84, 92], ["bestatin", "CHEMICAL", 84, 92], ["APN-bestatin", "GENE_OR_GENE_PRODUCT", 80, 92], ["APN", "PROTEIN", 80, 83], ["bestatin complex", "PROTEIN", 84, 100], ["PDB code 2dqm", "PROTEIN", 102, 115], ["the APN-bestatin complex", "TREATMENT", 76, 100], ["r.m.s. deviations", "TEST", 168, 185], ["ligand", "ANATOMY", 55, 61]]], ["The overall structure of the APN-PL250 complex was almost identical to those of the ligand-free form and the the APN-bestatin complex.Structure of the APN-PL250 complexIn wild-type E. coli APN, the consensus Zn-binding sequence is 297 HEYFH 301 (X) 18 E 320 , in which His297, His301 and Glu320, together with a water molecule, bind the zinc ion with a tetrahedral geometry and Glu298 functions as a catalytic base through activation of the water molecule (Wat 2) that The zinc ion is represented as a pink sphere and residues at the active site are shown as stick models.", [["bestatin", "CHEMICAL", 117, 125], ["Zn", "CHEMICAL", 208, 210], ["Glu320", "CHEMICAL", 288, 294], ["zinc", "CHEMICAL", 337, 341], ["Glu298", "CHEMICAL", 378, 384], ["zinc", "CHEMICAL", 473, 477], ["bestatin", "CHEMICAL", 117, 125], ["Zn", "CHEMICAL", 208, 210], ["His297", "CHEMICAL", 269, 275], ["His301", "CHEMICAL", 277, 283], ["Glu320", "CHEMICAL", 288, 294], ["zinc", "CHEMICAL", 337, 341], ["Glu298", "CHEMICAL", 378, 384], ["zinc", "CHEMICAL", 473, 477], ["APN", "GENE_OR_GENE_PRODUCT", 29, 32], ["PL250", "GENE_OR_GENE_PRODUCT", 33, 38], ["APN-bestatin", "GENE_OR_GENE_PRODUCT", 113, 125], ["APN", "GENE_OR_GENE_PRODUCT", 151, 154], ["E. coli", "ORGANISM", 181, 188], ["APN", "GENE_OR_GENE_PRODUCT", 189, 192], ["His297", "GENE_OR_GENE_PRODUCT", 269, 275], ["His301", "GENE_OR_GENE_PRODUCT", 277, 283], ["Glu320", "AMINO_ACID", 288, 294], ["zinc ion", "SIMPLE_CHEMICAL", 337, 345], ["Glu298", "SIMPLE_CHEMICAL", 378, 384], ["zinc ion", "SIMPLE_CHEMICAL", 473, 481], ["APN", "PROTEIN", 29, 32], ["PL250 complex", "PROTEIN", 33, 46], ["APN", "PROTEIN", 113, 116], ["bestatin complex", "PROTEIN", 117, 133], ["APN", "PROTEIN", 151, 154], ["PL250", "PROTEIN", 155, 160], ["APN", "PROTEIN", 189, 192], ["consensus Zn-binding sequence", "DNA", 198, 227], ["water molecule", "PROTEIN", 441, 455], ["Wat 2", "PROTEIN", 457, 462], ["E. coli", "SPECIES", 181, 188], ["E. coli", "SPECIES", 181, 188], ["the APN", "TEST", 147, 154], ["the consensus Zn-binding sequence", "TEST", 194, 227], ["HEYFH", "TEST", 235, 240], ["His301", "TEST", 277, 283], ["Glu320", "TEST", 288, 294], ["a water molecule", "PROBLEM", 310, 326], ["a tetrahedral geometry", "TEST", 351, 373], ["The zinc ion", "TREATMENT", 469, 481], ["a pink sphere", "PROBLEM", 500, 513], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["structure", "OBSERVATION_MODIFIER", 12, 21], ["APN", "ANATOMY", 151, 154], ["pink sphere", "OBSERVATION", 502, 513], ["active site", "OBSERVATION", 534, 545]]], ["This diagram was produced with the program POVScript+ (Fenn et al., 2003) and rendered with the program POV-Ray (http://www.povray.org/).Table 2Inhibitory potency of the phosphinic inhibitors ( Fig. 1) attacks the carbon of the amide bond to be cleaved Addlagatta et al., 2006) .", [["carbon", "CHEMICAL", 214, 220], ["amide", "CHEMICAL", 228, 233], ["the phosphinic inhibitors", "TREATMENT", 166, 191], ["the carbon of the amide bond", "TREATMENT", 210, 238]]], ["The PL250 inhibitor was tightly bound to the active site of E. coli APN (Figs.", [["PL250", "GENE_OR_GENE_PRODUCT", 4, 9], ["E. coli", "ORGANISM", 60, 67], ["APN", "GENE_OR_GENE_PRODUCT", 68, 71], ["APN", "PROTEIN", 68, 71], ["E. coli", "SPECIES", 60, 67], ["E. coli", "SPECIES", 60, 67], ["The PL250 inhibitor", "TREATMENT", 0, 19], ["E. coli APN", "PROBLEM", 60, 71], ["E. coli", "OBSERVATION", 60, 67]]], ["In the complex between E. coli APN and PL250, the water molecule acting as a zinc ligand (Wat 1) is replaced by the two O atoms of the phosphinic moiety, as expected for a transition-state analogue, leading to pentacoordination of the zinc ion [Zn\u00c1 \u00c1 \u00c1O1(P) = 2.01 \u00c5 and Zn\u00c1 \u00c1 \u00c1O2(P) = 2.94 \u00c5 ].", [["PL250", "CHEMICAL", 39, 44], ["zinc", "CHEMICAL", 77, 81], ["zinc", "CHEMICAL", 235, 239], ["zinc", "CHEMICAL", 77, 81], ["O", "CHEMICAL", 120, 121], ["phosphinic", "CHEMICAL", 135, 145], ["zinc", "CHEMICAL", 235, 239], ["Zn\u00c1 \u00c1 \u00c1O1(P)", "CHEMICAL", 245, 257], ["Zn\u00c1", "CHEMICAL", 271, 274], ["\u00c1O2", "CHEMICAL", 277, 280], ["P", "CHEMICAL", 281, 282], ["E. coli", "ORGANISM", 23, 30], ["APN", "GENE_OR_GENE_PRODUCT", 31, 34], ["PL250", "SIMPLE_CHEMICAL", 39, 44], ["phosphinic moiety", "SIMPLE_CHEMICAL", 135, 152], ["zinc ion", "SIMPLE_CHEMICAL", 235, 243], ["APN", "PROTEIN", 31, 34], ["Wat 1", "PROTEIN", 90, 95], ["O atoms", "PROTEIN", 120, 127], ["E. coli", "SPECIES", 23, 30], ["E. coli", "SPECIES", 23, 30], ["E. coli APN", "TREATMENT", 23, 34], ["PL250", "TREATMENT", 39, 44], ["the water molecule", "TREATMENT", 46, 64], ["a zinc ligand", "TREATMENT", 75, 88], ["the phosphinic moiety", "TREATMENT", 131, 152], ["the zinc ion", "TEST", 231, 243], ["Zn\u00c1", "TEST", 245, 248], ["Zn\u00c1", "TEST", 271, 274], ["coli APN", "OBSERVATION", 26, 34]]], ["The geometry of the zinc complex corresponds to a distorted trigonal bipyramid.", [["zinc", "CHEMICAL", 20, 24], ["zinc", "CHEMICAL", 20, 24], ["zinc complex", "PROTEIN", 20, 32], ["trigonal bipyramid", "PROTEIN", 60, 78], ["the zinc complex", "PROBLEM", 16, 32], ["a distorted trigonal bipyramid", "PROBLEM", 48, 78], ["geometry", "OBSERVATION_MODIFIER", 4, 12], ["zinc complex", "OBSERVATION", 20, 32], ["distorted", "OBSERVATION_MODIFIER", 50, 59], ["trigonal bipyramid", "OBSERVATION", 60, 78]]], ["The O atoms of the phosphinic moiety are also involved in hydrogen bonds to Glu298 (O2\u00c1 \u00c1 \u00c1Glu298 = 2.61 \u00c5 ), Glu320 (O1\u00c1 \u00c1 \u00c1Glu320 = 2.96 \u00c5 ) and Tyr381 (O1\u00c1 \u00c1 \u00c1HO Tyr381 = 2.69 \u00c5 ).Table 2The active site of uncomplexed E. coli APN is also characterized by the presence of a salt-bridge network associating three glutamate residues (Glu121, Glu264 and Glu320) and the \"-NH 3 + of Lys319 Addlagatta et al., 2006) .", [["glutamate", "CHEMICAL", 314, 323], ["O", "CHEMICAL", 4, 5], ["phosphinic", "CHEMICAL", 19, 29], ["hydrogen", "CHEMICAL", 58, 66], ["Glu298", "CHEMICAL", 76, 82], ["O2\u00c1", "CHEMICAL", 84, 87], ["\u00c1Glu298", "CHEMICAL", 90, 97], ["Glu320", "CHEMICAL", 110, 116], ["O1\u00c1", "CHEMICAL", 118, 121], ["\u00c1Glu320", "CHEMICAL", 124, 131], ["Tyr381", "CHEMICAL", 147, 153], ["O1\u00c1", "CHEMICAL", 155, 158], ["\u00c1HO", "CHEMICAL", 161, 164], ["glutamate", "CHEMICAL", 314, 323], ["Glu121", "CHEMICAL", 334, 340], ["Glu264", "CHEMICAL", 342, 348], ["Glu320", "CHEMICAL", 353, 359], ["NH", "CHEMICAL", 371, 373], ["Lys319", "CHEMICAL", 381, 387], ["O atoms", "SIMPLE_CHEMICAL", 4, 11], ["phosphinic moiety", "SIMPLE_CHEMICAL", 19, 36], ["hydrogen", "SIMPLE_CHEMICAL", 58, 66], ["Glu298", "SIMPLE_CHEMICAL", 76, 82], ["Glu320", "AMINO_ACID", 110, 116], ["Tyr381", "AMINO_ACID", 147, 153], ["E. coli", "ORGANISM", 221, 228], ["APN", "GENE_OR_GENE_PRODUCT", 229, 232], ["glutamate", "SIMPLE_CHEMICAL", 314, 323], ["Glu121", "SIMPLE_CHEMICAL", 334, 340], ["O1\u00c1", "PROTEIN", 155, 158], ["APN", "PROTEIN", 229, 232], ["salt-bridge network", "PROTEIN", 276, 295], ["E. coli", "SPECIES", 221, 228], ["E. coli", "SPECIES", 221, 228], ["the phosphinic moiety", "TREATMENT", 15, 36], ["hydrogen bonds", "TEST", 58, 72], ["Glu298", "TEST", 76, 82], ["O2\u00c1", "TEST", 84, 87], ["\u00c1Glu298", "TEST", 90, 97], ["Glu320", "TEST", 110, 116], ["O1\u00c1", "TEST", 118, 121], ["\u00c1Glu320", "TEST", 124, 131], ["\u00c1HO", "TEST", 161, 164], ["uncomplexed E. coli APN", "PROBLEM", 209, 232], ["Glu121", "TEST", 334, 340], ["Glu264", "TEST", 342, 348], ["Glu320", "TEST", 353, 359], ["active", "OBSERVATION_MODIFIER", 194, 200], ["site", "OBSERVATION_MODIFIER", 201, 205], ["uncomplexed", "OBSERVATION_MODIFIER", 209, 220], ["E. coli", "OBSERVATION", 221, 228], ["glutamate residues", "OBSERVATION", 314, 332]]], ["In the complex with PL250, the free amino group of the inhibitor participates in this network by hydrogen bonding to two of these glutamates, i.e. Glu264 (2.69 \u00c5 ) and Glu121 (2.78 \u00c5 ) (Fig. 3) .Table 2The inhibitor backbone is in an extended conformation antiparallel to the -strand of the 261 GAMEN 265 motif (Luciani et al., 1998; Vazeux et al., 1998) leading to various types of interactions: the carbonyl of the inhibitor amide bond forms hydrogen bonds to the NH group of Gly261 and the CO group of Ala262, which is in close vicinity of the CH 2 group of the phosphinic moiety.", [["PL250", "CHEMICAL", 20, 25], ["amino", "CHEMICAL", 36, 41], ["carbonyl", "CHEMICAL", 401, 409], ["NH", "CHEMICAL", 466, 468], ["Gly261", "CHEMICAL", 478, 484], ["Ala262", "CHEMICAL", 505, 511], ["PL250", "CHEMICAL", 20, 25], ["amino", "CHEMICAL", 36, 41], ["hydrogen", "CHEMICAL", 97, 105], ["glutamates", "CHEMICAL", 130, 140], ["Glu264", "CHEMICAL", 147, 153], ["Glu121", "CHEMICAL", 168, 174], ["carbonyl", "CHEMICAL", 401, 409], ["amide", "CHEMICAL", 427, 432], ["hydrogen", "CHEMICAL", 444, 452], ["NH", "CHEMICAL", 466, 468], ["Gly261", "CHEMICAL", 478, 484], ["CO", "CHEMICAL", 493, 495], ["Ala262", "CHEMICAL", 505, 511], ["CH", "CHEMICAL", 547, 549], ["phosphinic", "CHEMICAL", 565, 575], ["PL250", "SIMPLE_CHEMICAL", 20, 25], ["amino", "AMINO_ACID", 36, 41], ["hydrogen", "SIMPLE_CHEMICAL", 97, 105], ["glutamates", "SIMPLE_CHEMICAL", 130, 140], ["Glu264", "SIMPLE_CHEMICAL", 147, 153], ["Glu121", "AMINO_ACID", 168, 174], ["carbonyl", "SIMPLE_CHEMICAL", 401, 409], ["Gly261", "SIMPLE_CHEMICAL", 478, 484], ["Ala262", "SIMPLE_CHEMICAL", 505, 511], ["phosphinic moiety", "SIMPLE_CHEMICAL", 565, 582], ["PL250", "TREATMENT", 20, 25], ["the free amino group of the inhibitor", "TREATMENT", 27, 64], ["these glutamates", "TEST", 124, 140], ["Glu264", "TEST", 147, 153], ["Glu121", "TEST", 168, 174], ["The inhibitor backbone", "TREATMENT", 202, 224], ["the carbonyl of the inhibitor amide bond", "TREATMENT", 397, 437], ["the phosphinic moiety", "TREATMENT", 561, 582]]], ["This methylene corresponds to the NH of the amide group of bestatin, which forms a hydrogen bond to the carbonyl of Ala262 in its complex with E. coli APN Addlagatta et al., 2006) .Table 2The S 1 subsite of E. coli APN was shown to be lined by Glu121, Tyr376, Met263 and Met260, the side chains of which were found to limit the size of this subsite in the ligand-free form Addlagatta et al., 2006) .", [["methylene", "CHEMICAL", 5, 14], ["bestatin", "CHEMICAL", 59, 67], ["Ala262", "CHEMICAL", 116, 122], ["methylene", "CHEMICAL", 5, 14], ["NH", "CHEMICAL", 34, 36], ["amide", "CHEMICAL", 44, 49], ["bestatin", "CHEMICAL", 59, 67], ["hydrogen", "CHEMICAL", 83, 91], ["carbonyl", "CHEMICAL", 104, 112], ["Ala262", "CHEMICAL", 116, 122], ["Glu121", "CHEMICAL", 244, 250], ["Tyr376", "CHEMICAL", 252, 258], ["Met263", "CHEMICAL", 260, 266], ["Met260", "CHEMICAL", 271, 277], ["methylene", "SIMPLE_CHEMICAL", 5, 14], ["bestatin", "SIMPLE_CHEMICAL", 59, 67], ["carbonyl", "SIMPLE_CHEMICAL", 104, 112], ["Ala262", "SIMPLE_CHEMICAL", 116, 122], ["E. coli", "ORGANISM", 207, 214], ["APN", "GENE_OR_GENE_PRODUCT", 215, 218], ["Glu121", "GENE_OR_GENE_PRODUCT", 244, 250], ["Tyr376", "GENE_OR_GENE_PRODUCT", 252, 258], ["Met263", "GENE_OR_GENE_PRODUCT", 260, 266], ["Met260", "GENE_OR_GENE_PRODUCT", 271, 277], ["APN", "PROTEIN", 215, 218], ["Met260", "PROTEIN", 271, 277], ["E. coli", "SPECIES", 143, 150], ["E. coli", "SPECIES", 207, 214], ["E. coli", "SPECIES", 143, 150], ["E. coli", "SPECIES", 207, 214], ["This methylene", "TREATMENT", 0, 14], ["the amide group of bestatin", "TREATMENT", 40, 67], ["E. coli APN", "TEST", 207, 218]]], ["In the complex with PL250, the methyl side chain of the inhibitor binds within this subsite, leading to a small displacement of the lateral chain of Met260.Table 2The S 0 1 S 0 2 domain represents an open hydrophobic cleft in which the two benzylic rings of PL250 are located.", [["PL250", "CHEMICAL", 20, 25], ["methyl", "CHEMICAL", 31, 37], ["PL250", "CHEMICAL", 20, 25], ["methyl", "CHEMICAL", 31, 37], ["Met260", "CHEMICAL", 149, 155], ["PL250", "CHEMICAL", 258, 263], ["PL250", "SIMPLE_CHEMICAL", 20, 25], ["Met260", "GENE_OR_GENE_PRODUCT", 149, 155], ["PL250", "SIMPLE_CHEMICAL", 258, 263], ["lateral chain", "PROTEIN", 132, 145], ["Met260", "PROTEIN", 149, 155], ["S 0 1 S 0 2 domain", "DNA", 167, 185], ["PL250", "TREATMENT", 20, 25], ["the methyl side chain", "TREATMENT", 27, 48], ["the inhibitor binds", "TREATMENT", 52, 71], ["a small displacement of the lateral chain", "PROBLEM", 104, 145], ["an open hydrophobic cleft", "TREATMENT", 197, 222], ["the two benzylic rings of PL250", "TREATMENT", 232, 263], ["small", "OBSERVATION_MODIFIER", 106, 111], ["displacement", "OBSERVATION", 112, 124], ["lateral", "ANATOMY_MODIFIER", 132, 139], ["chain", "ANATOMY_MODIFIER", 140, 145], ["hydrophobic cleft", "OBSERVATION", 205, 222], ["benzylic rings", "OBSERVATION", 240, 254]]], ["The S 0 1 subsite was surrounded by Tyr275, Val294, His297, Val324, Asp327, Tyr381 and the side-chain C H 2 -C H 2 group of Arg293 (Fig. 4) .", [["Tyr275", "CHEMICAL", 36, 42], ["Val294", "CHEMICAL", 44, 50], ["His297", "CHEMICAL", 52, 58], ["Val324", "CHEMICAL", 60, 66], ["Asp327", "CHEMICAL", 68, 74], ["Tyr381", "CHEMICAL", 76, 82], ["C H 2 -C H", "CHEMICAL", 102, 112], ["Arg293", "CHEMICAL", 124, 130], ["S 0 1", "GENE_OR_GENE_PRODUCT", 4, 9], ["Tyr275", "GENE_OR_GENE_PRODUCT", 36, 42], ["Val294", "GENE_OR_GENE_PRODUCT", 44, 50], ["His297", "GENE_OR_GENE_PRODUCT", 52, 58], ["Val324", "GENE_OR_GENE_PRODUCT", 60, 66], ["Asp327", "AMINO_ACID", 68, 74], ["Tyr381", "AMINO_ACID", 76, 82], ["C H 2 -C H 2", "SIMPLE_CHEMICAL", 102, 114], ["Arg293", "SIMPLE_CHEMICAL", 124, 130], ["S 0 1 subsite", "PROTEIN", 4, 17], ["Val294", "TEST", 44, 50], ["Val324", "TEST", 60, 66], ["Asp327", "TEST", 68, 74], ["Tyr381", "TEST", 76, 82], ["C H", "TEST", 102, 105], ["C H", "TEST", 109, 112]]], ["The benzyl side chain of the phosphinic moiety is found in this essentially hydrophobic pocket with the centre of the aromatic ring at about 6 \u00c5 from these residues.", [["benzyl", "CHEMICAL", 4, 10], ["phosphinic", "CHEMICAL", 29, 39], ["benzyl", "CHEMICAL", 4, 10], ["phosphinic", "CHEMICAL", 29, 39], ["benzyl side chain", "SIMPLE_CHEMICAL", 4, 21], ["phosphinic moiety", "SIMPLE_CHEMICAL", 29, 46], ["The benzyl side chain", "TREATMENT", 0, 21], ["the phosphinic moiety", "TREATMENT", 25, 46], ["this essentially hydrophobic pocket", "PROBLEM", 59, 94], ["hydrophobic pocket", "OBSERVATION", 76, 94], ["aromatic ring", "OBSERVATION", 118, 131]]], ["This structural arrangement is almost identical to that found for the leucine side chain in the APN-bestatin complex.", [["leucine", "CHEMICAL", 70, 77], ["bestatin", "CHEMICAL", 100, 108], ["leucine", "CHEMICAL", 70, 77], ["bestatin", "CHEMICAL", 100, 108], ["APN-bestatin", "GENE_OR_GENE_PRODUCT", 96, 108], ["leucine side chain", "PROTEIN", 70, 88], ["APN", "PROTEIN", 96, 99], ["bestatin complex", "PROTEIN", 100, 116], ["the leucine side chain", "PROBLEM", 66, 88]]], ["The S 0 2 subsite, in which the C-terminal benzyl side chain of PL250 is bound, corresponds to a large domain formed by the Met260, Tyr376, Thr377 and Arg825 side chains (Fig. 4) .", [["benzyl", "CHEMICAL", 43, 49], ["PL250", "CHEMICAL", 64, 69], ["C", "CHEMICAL", 32, 33], ["benzyl", "CHEMICAL", 43, 49], ["PL250", "CHEMICAL", 64, 69], ["Met260", "CHEMICAL", 124, 130], ["Tyr376", "CHEMICAL", 132, 138], ["Thr", "CHEMICAL", 140, 143], ["Arg825", "CHEMICAL", 151, 157], ["PL250", "SIMPLE_CHEMICAL", 64, 69], ["Met260", "GENE_OR_GENE_PRODUCT", 124, 130], ["Tyr376", "AMINO_ACID", 132, 138], ["Thr377", "AMINO_ACID", 140, 146], ["S 0 2 subsite", "PROTEIN", 4, 17], ["C-terminal benzyl side chain", "PROTEIN", 32, 60], ["PL250", "PROTEIN", 64, 69], ["Met260", "PROTEIN", 124, 130], ["the C-terminal benzyl side chain", "TREATMENT", 28, 60], ["Thr", "TEST", 140, 143], ["terminal", "ANATOMY_MODIFIER", 34, 42], ["large", "OBSERVATION_MODIFIER", 97, 102]]], ["These residues form a hydrophobic pocket with their constituent atoms at about 6 \u00c5 from the centre of the C-terminal phenyl ring of the inhibitor.", [["C", "CHEMICAL", 106, 107], ["phenyl", "CHEMICAL", 117, 123], ["C-terminal phenyl ring", "PROTEIN", 106, 128], ["a hydrophobic pocket", "PROBLEM", 20, 40], ["the C-terminal phenyl ring of the inhibitor", "TREATMENT", 102, 145], ["hydrophobic pocket", "OBSERVATION", 22, 40], ["terminal", "ANATOMY_MODIFIER", 108, 116], ["phenyl ring", "OBSERVATION", 117, 128]]], ["The two benzyl groups in S 0 1 and S 0 2 are in an antiparallel orientation (with a distance of 5.8 \u00c5 between the rings) with the C-terminal benzyl moiety pointing towards the S 1 methyl group (distance 4.2 \u00c5 ).Table 2A bridge is formed between the carboxylate of PL250 and the -carboxylate of Glu382 via two water molecules.", [["benzyl", "CHEMICAL", 8, 14], ["benzyl", "CHEMICAL", 141, 147], ["S 1 methyl", "CHEMICAL", 176, 186], ["PL250", "CHEMICAL", 264, 269], ["the -carboxylate", "CHEMICAL", 274, 290], ["Glu382", "CHEMICAL", 294, 300], ["benzyl", "CHEMICAL", 8, 14], ["C", "CHEMICAL", 130, 131], ["benzyl", "CHEMICAL", 141, 147], ["methyl", "CHEMICAL", 180, 186], ["carboxylate", "CHEMICAL", 249, 260], ["PL250", "CHEMICAL", 264, 269], ["carboxylate", "CHEMICAL", 279, 290], ["Glu382", "CHEMICAL", 294, 300], ["S 0 2", "SIMPLE_CHEMICAL", 35, 40], ["C-terminal benzyl moiety", "SIMPLE_CHEMICAL", 130, 154], ["S 1 methyl", "SIMPLE_CHEMICAL", 176, 186], ["PL250", "SIMPLE_CHEMICAL", 264, 269], ["Glu382", "SIMPLE_CHEMICAL", 294, 300], ["S 1 methyl group", "PROTEIN", 176, 192], ["The two benzyl groups", "TREATMENT", 0, 21], ["the C-terminal benzyl moiety", "TREATMENT", 126, 154], ["the carboxylate of PL250", "TREATMENT", 245, 269], ["the -carboxylate of Glu382", "TREATMENT", 274, 300]]], ["Consistent with this relatively weak interaction, the carboxyl group of the inhibitor can be replaced by an uncharged group without loss of affinity (not shown).Table 2The minimal compound structure for the recognition of a zinc aminopeptidase consists of amino-acid derivatives bearing a zinc ligand such as -aminothiol, -aminohydroxamate, -aminophosphonate etc. (Fourni\u00e9 -Zaluski & Roques, 2002; Bauvois & Dauzonne, 2006) .", [["zinc", "CHEMICAL", 224, 228], ["amino-acid", "CHEMICAL", 256, 266], ["zinc", "CHEMICAL", 289, 293], ["-aminothiol", "CHEMICAL", 309, 320], ["-aminohydroxamate", "CHEMICAL", 322, 339], ["-aminophosphonate", "CHEMICAL", 341, 358], ["carboxyl", "CHEMICAL", 54, 62], ["zinc", "CHEMICAL", 224, 228], ["amino-acid", "CHEMICAL", 256, 266], ["zinc", "CHEMICAL", 289, 293], ["-aminothiol", "CHEMICAL", 309, 320], ["-aminohydroxamate", "CHEMICAL", 322, 339], ["-aminophosphonate", "CHEMICAL", 341, 358], ["zinc aminopeptidase", "SIMPLE_CHEMICAL", 224, 243], ["amino-acid derivatives", "SIMPLE_CHEMICAL", 256, 278], ["zinc ligand", "SIMPLE_CHEMICAL", 289, 300], ["-aminothiol", "SIMPLE_CHEMICAL", 309, 320], ["-aminohydroxamate", "SIMPLE_CHEMICAL", 322, 339], ["-aminophosphonate etc", "SIMPLE_CHEMICAL", 341, 362], ["zinc aminopeptidase", "PROTEIN", 224, 243], ["this relatively weak interaction", "PROBLEM", 16, 48], ["the carboxyl group of the inhibitor", "TREATMENT", 50, 85], ["loss of affinity", "PROBLEM", 132, 148], ["a zinc aminopeptidase", "TREATMENT", 222, 243], ["amino-acid derivatives", "TREATMENT", 256, 278], ["a zinc ligand", "TREATMENT", 287, 300], ["-aminothiol", "TREATMENT", 309, 320], ["-aminohydroxamate", "TREATMENT", 322, 339], ["-aminophosphonate etc", "TREATMENT", 341, 362], ["weak", "OBSERVATION_MODIFIER", 32, 36], ["interaction", "OBSERVATION", 37, 48], ["minimal", "OBSERVATION_MODIFIER", 172, 179], ["compound structure", "OBSERVATION", 180, 198]]], ["These compounds, which recognize only the S 1 subsite of the catalytic site, have inhibitory potencies from 10 \u00c05 to 10 \u00c08 M, depending on the zinc ligand moiety.", [["zinc", "CHEMICAL", 143, 147], ["zinc", "CHEMICAL", 143, 147], ["zinc ligand moiety", "SIMPLE_CHEMICAL", 143, 161], ["S 1 subsite", "PROTEIN", 42, 53], ["catalytic site", "PROTEIN", 61, 75], ["inhibitory potencies", "PROBLEM", 82, 102], ["the zinc ligand moiety", "TREATMENT", 139, 161]]], ["The commonly used but nonspecific inhibitor bestatin (Fig. 1) , a dipeptide analogue, inhibits aminopeptidase N with a K i value of 4 \u00c2 10 \u00c06 M (Rich et al., 1984) , suggesting that all the stabilizing interactions between the inhibitor and the enzyme are not completely satisfied.", [["bestatin", "CHEMICAL", 44, 52], ["K", "CHEMICAL", 119, 120], ["bestatin", "CHEMICAL", 44, 52], ["dipeptide", "CHEMICAL", 66, 75], ["bestatin", "SIMPLE_CHEMICAL", 44, 52], ["Fig. 1", "SIMPLE_CHEMICAL", 54, 60], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 95, 111], ["aminopeptidase N", "PROTEIN", 95, 111], ["enzyme", "PROTEIN", 245, 251], ["nonspecific inhibitor bestatin", "TREATMENT", 22, 52], ["a dipeptide analogue", "TREATMENT", 64, 84], ["aminopeptidase N", "TEST", 95, 111], ["a K i value", "TEST", 117, 128], ["the inhibitor", "TREATMENT", 223, 236], ["the enzyme", "TEST", 241, 251]]], ["In this chemical series, the best inhibitor of APN is amastatin (Fig. 1) , a tetrapeptide analogue of bestatin with a K i value of 2 \u00c2 10 \u00c08 M (Rich et al., 1984) .", [["amastatin", "CHEMICAL", 54, 63], ["bestatin", "CHEMICAL", 102, 110], ["K", "CHEMICAL", 118, 119], ["amastatin", "CHEMICAL", 54, 63], ["tetrapeptide", "CHEMICAL", 77, 89], ["bestatin", "CHEMICAL", 102, 110], ["APN", "GENE_OR_GENE_PRODUCT", 47, 50], ["amastatin", "SIMPLE_CHEMICAL", 54, 63], ["bestatin", "SIMPLE_CHEMICAL", 102, 110], ["APN", "PROTEIN", 47, 50], ["APN is amastatin", "TREATMENT", 47, 63], ["a tetrapeptide analogue of bestatin", "TREATMENT", 75, 110], ["a K i value", "TEST", 116, 127]]], ["This suggests that, in this latter case, some additional interactions are likely to occur within the S 0 2 subsite as in PL250 (see below).Table 2Using a homogenous series of -aminophosphinic inhibitors we have shown (Table 1 ) an improvement in the inhibitory potency by three orders of magnitude from the amino acid 1 to the pseudotripeptide 3 (PL250), with a K i value of about 2 nM.", [["amino acid", "CHEMICAL", 307, 317], ["K", "CHEMICAL", 362, 363], ["amino acid", "CHEMICAL", 307, 317], ["PL250", "CHEMICAL", 347, 352], ["amino acid", "AMINO_ACID", 307, 317], ["PL250", "SIMPLE_CHEMICAL", 347, 352], ["-aminophosphinic inhibitors", "TREATMENT", 175, 202], ["the amino acid", "TREATMENT", 303, 317], ["a K i value", "TEST", 360, 371]]], ["In research papers this series of inhibitors, a further extension of the peptide chain does not improve the inhibitory potency (not shown), indicating that PL250 optimally fits the APN active site.Table 2Comparison of the K i values of the aminophosphinic compounds 2 (K i = 2 \u00c2 10 \u00c07 M) and 3 (K i = 2 \u00c2 10 \u00c09 M) (Chen et al., 1999) reflects the important contribution of hydrophobic interactions inside the S 0 2 subsite to APN inhibition.", [["PL250", "CHEMICAL", 156, 161], ["K", "CHEMICAL", 222, 223], ["PL250", "CHEMICAL", 156, 161], ["aminophosphinic", "CHEMICAL", 240, 255], ["PL250", "SIMPLE_CHEMICAL", 156, 161], ["APN", "GENE_OR_GENE_PRODUCT", 181, 184], ["APN", "GENE_OR_GENE_PRODUCT", 426, 429], ["APN active site", "PROTEIN", 181, 196], ["APN", "PROTEIN", 426, 429], ["inhibitors", "TREATMENT", 34, 44], ["a further extension of the peptide chain", "PROBLEM", 46, 86], ["the APN active site", "PROBLEM", 177, 196], ["the K i values", "TEST", 218, 232], ["the aminophosphinic compounds", "TEST", 236, 265], ["K i", "TEST", 269, 272], ["K i", "TEST", 295, 298], ["hydrophobic interactions", "PROBLEM", 373, 397], ["active site", "OBSERVATION", 185, 196]]], ["Likewise, comparison of the K i values of bestatin (K i = 4 \u00c2 10 \u00c06 M) and compound 2 (K i = 2 \u00c2 10 \u00c07 M), which are expected to recognize the same APN subsites, shows a significant difference (a factor of 20) between their affinity for the enzyme that could be attributed at least partly to the better zinc-chelating properties of a phosphinic group compared with the hydroxyl amide ligand of bestatin.Structural comparison of E. coli APN-bestatin and E. coli APN-PL250 complexesLarge similarities were observed between the two complexes regarding their common domain of interaction.", [["K", "CHEMICAL", 28, 29], ["bestatin", "CHEMICAL", 42, 50], ["K", "CHEMICAL", 52, 53], ["zinc", "CHEMICAL", 303, 307], ["phosphinic", "CHEMICAL", 334, 344], ["hydroxyl", "CHEMICAL", 369, 377], ["bestatin", "CHEMICAL", 394, 402], ["bestatin", "CHEMICAL", 440, 448], ["bestatin", "CHEMICAL", 42, 50], ["zinc", "CHEMICAL", 303, 307], ["phosphinic", "CHEMICAL", 334, 344], ["hydroxyl amide", "CHEMICAL", 369, 383], ["bestatin", "CHEMICAL", 394, 402], ["bestatin", "SIMPLE_CHEMICAL", 42, 50], ["APN", "GENE_OR_GENE_PRODUCT", 148, 151], ["zinc", "SIMPLE_CHEMICAL", 303, 307], ["phosphinic", "SIMPLE_CHEMICAL", 334, 344], ["bestatin", "SIMPLE_CHEMICAL", 394, 402], ["E. coli", "ORGANISM", 428, 435], ["APN-bestatin", "GENE_OR_GENE_PRODUCT", 436, 448], ["E. coli", "ORGANISM", 453, 460], ["APN-PL250", "GENE_OR_GENE_PRODUCT", 461, 470], ["APN subsites", "PROTEIN", 148, 160], ["APN", "PROTEIN", 436, 439], ["APN", "PROTEIN", 461, 464], ["PL250 complexes", "PROTEIN", 465, 480], ["E. coli", "SPECIES", 428, 435], ["E. coli", "SPECIES", 453, 460], ["E. coli", "SPECIES", 428, 435], ["E. coli", "SPECIES", 453, 460], ["the K i values", "TEST", 24, 38], ["bestatin", "TEST", 42, 50], ["K i", "TEST", 52, 55], ["compound", "TEST", 75, 83], ["K i", "TEST", 87, 90], ["the enzyme", "TEST", 237, 247], ["a phosphinic group", "TREATMENT", 332, 350], ["the hydroxyl amide ligand", "TREATMENT", 365, 390], ["bestatin", "TREATMENT", 394, 402], ["E. coli APN", "TEST", 428, 439], ["bestatin", "TREATMENT", 440, 448], ["E. coli APN", "TEST", 453, 464], ["significant", "OBSERVATION_MODIFIER", 170, 181], ["difference", "OBSERVATION_MODIFIER", 182, 192], ["E. coli", "OBSERVATION_MODIFIER", 428, 435], ["E. coli", "OBSERVATION_MODIFIER", 453, 460]]], ["Thus, in the catalytic site both inhibitors act as bidentate ligands of the zinc ion (using two O atoms from either the phosphinic moiety in PL250 or the hydroxyl amide bond in bestatin), leading to a final stable pentacoordination of the metallic ion.", [["zinc", "CHEMICAL", 76, 80], ["PL250", "CHEMICAL", 141, 146], ["hydroxyl", "CHEMICAL", 154, 162], ["bestatin", "CHEMICAL", 177, 185], ["zinc", "CHEMICAL", 76, 80], ["O", "CHEMICAL", 96, 97], ["phosphinic", "CHEMICAL", 120, 130], ["PL250", "CHEMICAL", 141, 146], ["hydroxyl amide", "CHEMICAL", 154, 168], ["bestatin", "CHEMICAL", 177, 185], ["zinc ion", "SIMPLE_CHEMICAL", 76, 84], ["PL250", "SIMPLE_CHEMICAL", 141, 146], ["bestatin", "SIMPLE_CHEMICAL", 177, 185], ["catalytic site", "PROTEIN", 13, 27], ["the zinc ion", "TREATMENT", 72, 84], ["two O atoms", "TREATMENT", 92, 103], ["the phosphinic moiety", "TREATMENT", 116, 137], ["PL250", "TREATMENT", 141, 146], ["the hydroxyl amide bond in bestatin", "TREATMENT", 150, 185], ["the metallic ion", "TREATMENT", 235, 251], ["stable", "OBSERVATION_MODIFIER", 207, 213], ["pentacoordination", "OBSERVATION", 214, 231], ["metallic ion", "OBSERVATION", 239, 251]]], ["The relative distances between the Zn atom and the O atoms are similar, but the strength of the zinc coordination is likely to be higher for the phosphinic group.Structural comparison of E. coli APN-bestatin and E. coli APN-PL250 complexesIn the APN-PL250 complex, the free amino group of PL250 is hydrogen bonded to the -carboxylates of Glu121 and Glu264 located in the negatively charged pocket, which provides the exopeptidase specificity of APN.", [["Zn", "CHEMICAL", 35, 37], ["zinc", "CHEMICAL", 96, 100], ["bestatin", "CHEMICAL", 199, 207], ["amino", "CHEMICAL", 274, 279], ["PL250", "CHEMICAL", 289, 294], ["hydrogen", "CHEMICAL", 298, 306], ["Glu121", "CHEMICAL", 338, 344], ["Glu264", "CHEMICAL", 349, 355], ["Zn", "CHEMICAL", 35, 37], ["O", "CHEMICAL", 51, 52], ["zinc", "CHEMICAL", 96, 100], ["phosphinic", "CHEMICAL", 145, 155], ["amino", "CHEMICAL", 274, 279], ["PL250", "CHEMICAL", 289, 294], ["hydrogen", "CHEMICAL", 298, 306], ["carboxylates", "CHEMICAL", 322, 334], ["Glu121", "CHEMICAL", 338, 344], ["Glu264", "CHEMICAL", 349, 355], ["Zn atom", "SIMPLE_CHEMICAL", 35, 42], ["O atoms", "SIMPLE_CHEMICAL", 51, 58], ["zinc", "SIMPLE_CHEMICAL", 96, 100], ["phosphinic", "SIMPLE_CHEMICAL", 145, 155], ["E. coli", "ORGANISM", 187, 194], ["APN-bestatin", "GENE_OR_GENE_PRODUCT", 195, 207], ["E. coli", "ORGANISM", 212, 219], ["APN", "GENE_OR_GENE_PRODUCT", 246, 249], ["amino", "AMINO_ACID", 274, 279], ["PL250", "SIMPLE_CHEMICAL", 289, 294], ["Glu121", "SIMPLE_CHEMICAL", 338, 344], ["Glu264", "SIMPLE_CHEMICAL", 349, 355], ["APN", "GENE_OR_GENE_PRODUCT", 445, 448], ["APN", "PROTEIN", 195, 198], ["E. coli APN-PL250 complexes", "PROTEIN", 212, 239], ["APN", "PROTEIN", 246, 249], ["PL250 complex", "PROTEIN", 250, 263], ["exopeptidase", "PROTEIN", 417, 429], ["APN", "PROTEIN", 445, 448], ["E. coli", "SPECIES", 187, 194], ["E. coli", "SPECIES", 212, 219], ["E. coli", "SPECIES", 187, 194], ["E. coli", "SPECIES", 212, 219], ["the Zn atom", "TREATMENT", 31, 42], ["E. coli APN", "TEST", 187, 198], ["bestatin", "TREATMENT", 199, 207], ["E. coli", "PROBLEM", 212, 219], ["Glu121", "TEST", 338, 344], ["distances", "OBSERVATION_MODIFIER", 13, 22], ["Zn atom", "OBSERVATION", 35, 42], ["atoms", "ANATOMY_MODIFIER", 53, 58], ["similar", "OBSERVATION_MODIFIER", 63, 70], ["likely to be", "UNCERTAINTY", 117, 129], ["higher", "OBSERVATION_MODIFIER", 130, 136], ["E. coli", "OBSERVATION_MODIFIER", 187, 194], ["E. coli", "OBSERVATION", 212, 219], ["hydrogen bonded", "OBSERVATION", 298, 313], ["negatively", "OBSERVATION_MODIFIER", 371, 381], ["charged pocket", "OBSERVATION", 382, 396]]], ["5(a) and 5(b), the free amino group of PL250 was located at the same position as the amino group of bestatin in the APN-bestatin complex and the water molecule (Wat2) in the ligand-free APN structure Addlagatta et al., 2006) .", [["amino", "CHEMICAL", 24, 29], ["PL250", "CHEMICAL", 39, 44], ["bestatin", "CHEMICAL", 100, 108], ["bestatin", "CHEMICAL", 120, 128], ["amino", "CHEMICAL", 24, 29], ["PL250", "CHEMICAL", 39, 44], ["amino", "CHEMICAL", 85, 90], ["bestatin", "CHEMICAL", 100, 108], ["bestatin", "CHEMICAL", 120, 128], ["PL250", "SIMPLE_CHEMICAL", 39, 44], ["bestatin", "SIMPLE_CHEMICAL", 100, 108], ["APN-bestatin", "GENE_OR_GENE_PRODUCT", 116, 128], ["Wat2", "SIMPLE_CHEMICAL", 161, 165], ["APN", "PROTEIN", 116, 119], ["bestatin complex", "PROTEIN", 120, 136], ["water molecule", "PROTEIN", 145, 159], ["Wat2", "PROTEIN", 161, 165], ["the free amino group of PL250", "TREATMENT", 15, 44], ["bestatin", "TREATMENT", 100, 108], ["bestatin complex", "TREATMENT", 120, 136], ["ligand", "ANATOMY", 174, 180]]], ["In the APN-PL250 complex, the two O atoms of the phosphinic group take similar places to the carbonyl and hydroxyl Stereoview of the surface diagram at the active site in the APN-PL250 complex.", [["surface", "ANATOMY", 133, 140], ["carbonyl", "CHEMICAL", 93, 101], ["hydroxyl", "CHEMICAL", 106, 114], ["PL250", "CHEMICAL", 11, 16], ["O", "CHEMICAL", 34, 35], ["phosphinic", "CHEMICAL", 49, 59], ["carbonyl", "CHEMICAL", 93, 101], ["hydroxyl", "CHEMICAL", 106, 114], ["APN", "GENE_OR_GENE_PRODUCT", 7, 10], ["phosphinic", "SIMPLE_CHEMICAL", 49, 59], ["carbonyl", "SIMPLE_CHEMICAL", 93, 101], ["hydroxyl", "SIMPLE_CHEMICAL", 106, 114], ["APN-PL250 complex", "GENE_OR_GENE_PRODUCT", 175, 192], ["APN", "PROTEIN", 7, 10], ["PL250 complex", "PROTEIN", 11, 24], ["O atoms", "PROTEIN", 34, 41], ["phosphinic group", "PROTEIN", 49, 65], ["APN", "PROTEIN", 175, 178], ["PL250 complex", "PROTEIN", 179, 192], ["the phosphinic group", "TREATMENT", 45, 65], ["the carbonyl and hydroxyl Stereoview", "TREATMENT", 89, 125], ["the surface diagram", "TREATMENT", 129, 148], ["active site", "OBSERVATION", 156, 167]]], ["The S 1 , S 0 1 and S 0 2 subsites of E. coli APN are shown.", [["E. coli", "ORGANISM", 38, 45], ["APN", "GENE_OR_GENE_PRODUCT", 46, 49], ["APN", "PROTEIN", 46, 49], ["E. coli", "SPECIES", 38, 45], ["E. coli", "SPECIES", 38, 45], ["The S", "TEST", 0, 5], ["E. coli APN", "TEST", 38, 49], ["coli APN", "OBSERVATION", 41, 49]]], ["The zinc ion and main chain are shown as a pink sphere and a C trace, respectively.", [["zinc", "CHEMICAL", 4, 8], ["zinc", "CHEMICAL", 4, 8], ["zinc ion", "SIMPLE_CHEMICAL", 4, 12], ["zinc ion", "OBSERVATION", 4, 12], ["main", "OBSERVATION_MODIFIER", 17, 21], ["chain", "OBSERVATION_MODIFIER", 22, 27], ["pink sphere", "OBSERVATION", 43, 54], ["trace", "OBSERVATION_MODIFIER", 63, 68]]], ["The residues constituting these subsites are represented using stick models.", [["The residues constituting these subsites", "PROBLEM", 0, 40], ["stick models", "TEST", 63, 75]]], ["The PL250 stick model binding to the active site is in cyan.", [["PL250", "CHEMICAL", 4, 9], ["PL250", "SIMPLE_CHEMICAL", 4, 9], ["PL250", "PROTEIN", 4, 9], ["The PL250 stick model binding", "TREATMENT", 0, 29], ["active", "OBSERVATION_MODIFIER", 37, 43]]], ["This diagram was drawn and rendered with the program PyMOL (http://www.pymol.org/). groups of bestatin in the E. coli APN complex.", [["bestatin", "CHEMICAL", 94, 102], ["bestatin", "CHEMICAL", 94, 102], ["bestatin", "SIMPLE_CHEMICAL", 94, 102], ["E. coli", "ORGANISM", 110, 117], ["APN", "GENE_OR_GENE_PRODUCT", 118, 121], ["E. coli APN complex", "PROTEIN", 110, 129], ["E. coli", "SPECIES", 110, 117], ["E. coli", "SPECIES", 110, 117], ["This diagram", "TEST", 0, 12], ["bestatin", "TREATMENT", 94, 102], ["coli APN", "OBSERVATION_MODIFIER", 113, 121], ["complex", "OBSERVATION_MODIFIER", 122, 129]]], ["All these groups replace the water molecule Wat1 that is present in ligand-free APN Addlagatta et al., 2006) .", [["Wat1", "PROTEIN", 44, 48], ["the water molecule Wat1", "TREATMENT", 25, 48]]], ["The conformations of the amino-acid side chains around the zinc ion were almost identical in the ligand-free APN, APNbestatin and APN-PL250 complexes, with the exception of Glu298 (Fig. 5c) .", [["amino-acid", "CHEMICAL", 25, 35], ["zinc", "CHEMICAL", 59, 63], ["APNbestatin", "CHEMICAL", 114, 125], ["amino-acid", "CHEMICAL", 25, 35], ["zinc", "CHEMICAL", 59, 63], ["APNbestatin", "CHEMICAL", 114, 125], ["Glu298", "CHEMICAL", 173, 179], ["amino", "AMINO_ACID", 25, 30], ["APN", "GENE_OR_GENE_PRODUCT", 109, 112], ["APNbestatin", "SIMPLE_CHEMICAL", 114, 125], ["APN-PL250", "SIMPLE_CHEMICAL", 130, 139], ["Glu298", "SIMPLE_CHEMICAL", 173, 179], ["amino-acid side chains", "PROTEIN", 25, 47], ["APN", "PROTEIN", 109, 112], ["APNbestatin", "PROTEIN", 114, 125], ["APN", "PROTEIN", 130, 133], ["PL250 complexes", "PROTEIN", 134, 149], ["the amino-acid side chains", "TREATMENT", 21, 47], ["the zinc ion", "TEST", 55, 67], ["APNbestatin", "TREATMENT", 114, 125], ["APN-PL250 complexes", "TREATMENT", 130, 149], ["Glu298", "TEST", 173, 179]]], ["Indeed, in the APN-PL250 complex, Glu298, which functions as the catalytic base, was shifted by 0.66 \u00c5 from its corresponding position in the APN-bestatin complex.", [["Glu298", "CHEMICAL", 34, 40], ["bestatin", "CHEMICAL", 146, 154], ["Glu298", "CHEMICAL", 34, 40], ["bestatin", "CHEMICAL", 146, 154], ["APN", "GENE_OR_GENE_PRODUCT", 15, 18], ["PL250", "GENE_OR_GENE_PRODUCT", 19, 24], ["Glu298", "GENE_OR_GENE_PRODUCT", 34, 40], ["APN-bestatin", "GENE_OR_GENE_PRODUCT", 142, 154], ["APN", "PROTEIN", 15, 18], ["PL250 complex", "PROTEIN", 19, 32], ["Glu298", "PROTEIN", 34, 40], ["APN", "PROTEIN", 142, 145], ["bestatin complex", "PROTEIN", 146, 162], ["Glu298", "TEST", 34, 40], ["base", "ANATOMY_MODIFIER", 75, 79]]], ["This shift of Glu298 is related to the phosphinic group, in which the oxygen (P)O2 was found at 1.04 \u00c5 from the position of Wat1 in the free enzyme and at 0.73 \u00c5 from the hydroxyl group of bestatin in its complex with APN.", [["Glu298", "CHEMICAL", 14, 20], ["oxygen", "CHEMICAL", 70, 76], ["O2", "CHEMICAL", 80, 82], ["hydroxyl", "CHEMICAL", 171, 179], ["bestatin", "CHEMICAL", 189, 197], ["Glu298", "CHEMICAL", 14, 20], ["phosphinic", "CHEMICAL", 39, 49], ["oxygen", "CHEMICAL", 70, 76], ["P", "CHEMICAL", 78, 79], ["O2", "CHEMICAL", 80, 82], ["hydroxyl", "CHEMICAL", 171, 179], ["bestatin", "CHEMICAL", 189, 197], ["Glu298", "GENE_OR_GENE_PRODUCT", 14, 20], ["phosphinic", "SIMPLE_CHEMICAL", 39, 49], ["oxygen (P)O2", "SIMPLE_CHEMICAL", 70, 82], ["Wat1", "GENE_OR_GENE_PRODUCT", 124, 128], ["hydroxyl", "SIMPLE_CHEMICAL", 171, 179], ["bestatin", "SIMPLE_CHEMICAL", 189, 197], ["APN", "GENE_OR_GENE_PRODUCT", 218, 221], ["Wat1", "PROTEIN", 124, 128], ["APN", "PROTEIN", 218, 221], ["the oxygen (P)O2", "TREATMENT", 66, 82], ["the free enzyme", "TEST", 132, 147], ["the hydroxyl group of bestatin", "TREATMENT", 167, 197]]], ["In the Michaelis complex, the NH amide group in the P 0 1 position of the substrate was expected to form hydrogen bonds to the carbonyl group of Ala262 and the carboxyl group of Glu298 .", [["NH amide", "CHEMICAL", 30, 38], ["carbonyl", "CHEMICAL", 127, 135], ["Ala262", "CHEMICAL", 145, 151], ["Glu298", "CHEMICAL", 178, 184], ["NH amide", "CHEMICAL", 30, 38], ["hydrogen", "CHEMICAL", 105, 113], ["carbonyl", "CHEMICAL", 127, 135], ["Ala262", "CHEMICAL", 145, 151], ["carboxyl", "CHEMICAL", 160, 168], ["Glu298", "CHEMICAL", 178, 184], ["NH amide", "SIMPLE_CHEMICAL", 30, 38], ["carbonyl", "SIMPLE_CHEMICAL", 127, 135], ["Ala262", "SIMPLE_CHEMICAL", 145, 151], ["Glu298", "SIMPLE_CHEMICAL", 178, 184], ["Michaelis complex", "PROTEIN", 7, 24], ["P 0 1 position", "PROTEIN", 52, 66], ["the carboxyl group of Glu298", "TEST", 156, 184]]], ["It was also expected that these hydrogen bonds would be conserved in the tetrahedral transition state mimicked by the phosphinic inhibitor.", [["hydrogen", "CHEMICAL", 32, 40], ["phosphinic", "SIMPLE_CHEMICAL", 118, 128], ["these hydrogen bonds", "PROBLEM", 26, 46], ["the phosphinic inhibitor", "TREATMENT", 114, 138], ["hydrogen bonds", "OBSERVATION", 32, 46]]], ["Consistent with this hypothesis, the CH 2 group of the phosphinic moiety, which corresponds to the NH group in the P 0 1 position, was in close contact (3.17 \u00c5 ) with the carbonyl group of Ala262 and was separated from Glu298 by 4.06 \u00c5 .Structural comparison of E. coli APN-bestatin and E. coli APN-PL250 complexesThe catalytic process of zinc-dependent metalloproteases requires the involvement of residues in the stabilization of the transition state, although the organization can vary depending on the protease family.", [["phosphinic", "CHEMICAL", 55, 65], ["NH", "CHEMICAL", 99, 101], ["carbonyl", "CHEMICAL", 171, 179], ["Ala262", "CHEMICAL", 189, 195], ["bestatin", "CHEMICAL", 274, 282], ["zinc", "CHEMICAL", 339, 343], ["CH 2", "CHEMICAL", 37, 41], ["phosphinic", "CHEMICAL", 55, 65], ["NH", "CHEMICAL", 99, 101], ["carbonyl", "CHEMICAL", 171, 179], ["Ala262", "CHEMICAL", 189, 195], ["Glu298", "CHEMICAL", 219, 225], ["zinc", "CHEMICAL", 339, 343], ["phosphinic moiety", "SIMPLE_CHEMICAL", 55, 72], ["Ala262", "SIMPLE_CHEMICAL", 189, 195], ["Glu298", "SIMPLE_CHEMICAL", 219, 225], ["E. coli", "ORGANISM", 262, 269], ["APN-bestatin", "GENE_OR_GENE_PRODUCT", 270, 282], ["E. coli", "ORGANISM", 287, 294], ["zinc", "SIMPLE_CHEMICAL", 339, 343], ["NH group", "PROTEIN", 99, 107], ["P 0 1 position", "DNA", 115, 129], ["APN", "PROTEIN", 270, 273], ["E. coli APN-PL250 complexes", "PROTEIN", 287, 314], ["zinc-dependent metalloproteases", "PROTEIN", 339, 370], ["protease family", "PROTEIN", 506, 521], ["E. coli", "SPECIES", 262, 269], ["E. coli", "SPECIES", 287, 294], ["E. coli", "SPECIES", 262, 269], ["E. coli", "SPECIES", 287, 294], ["this hypothesis", "PROBLEM", 16, 31], ["the phosphinic moiety", "TREATMENT", 51, 72], ["E. coli APN", "TEST", 262, 273], ["bestatin", "TREATMENT", 274, 282], ["E. coli", "PROBLEM", 287, 294], ["zinc-dependent metalloproteases", "TREATMENT", 339, 370], ["phosphinic moiety", "OBSERVATION", 55, 72], ["E. coli", "OBSERVATION_MODIFIER", 262, 269], ["E. coli", "OBSERVATION", 287, 294], ["zinc", "OBSERVATION_MODIFIER", 339, 343], ["dependent", "OBSERVATION_MODIFIER", 344, 353], ["metalloproteases", "OBSERVATION", 354, 370], ["stabilization", "OBSERVATION_MODIFIER", 415, 428], ["transition state", "OBSERVATION", 436, 452]]], ["For example, in the M4 family the transition state is stabilized by a tyrosine residue and a histidine residue (Tyr157 and His231 for thermolysin TLN; Matthews, 1988; Beaumont et al., 1995) , whereas in the neprilysin family (M13 family) only one histidine is involved (His711; Dion et al., 1993; Marie-Claire et al., 1998; Schultz et al., 2009) in the same process.", [["tyrosine", "CHEMICAL", 70, 78], ["histidine", "CHEMICAL", 93, 102], ["histidine", "CHEMICAL", 247, 256], ["tyrosine", "CHEMICAL", 70, 78], ["histidine", "CHEMICAL", 93, 102], ["Tyr157", "CHEMICAL", 112, 118], ["His", "CHEMICAL", 123, 126], ["histidine", "CHEMICAL", 247, 256], ["tyrosine", "AMINO_ACID", 70, 78], ["histidine", "AMINO_ACID", 93, 102], ["neprilysin", "GENE_OR_GENE_PRODUCT", 207, 217], ["histidine", "AMINO_ACID", 247, 256], ["M4 family", "PROTEIN", 20, 29], ["neprilysin family", "PROTEIN", 207, 224], ["M13 family", "PROTEIN", 226, 236], ["a tyrosine residue", "PROBLEM", 68, 86], ["a histidine residue", "PROBLEM", 91, 110]]], ["Furthermore, the involvement of a tyrosine in the transition-state stabilization is not restricted to peptidases of the MA clan, since Tyr149 was shown to play this role in astacin (family M12 clan MB; Grams et al., 1996) .", [["tyrosine", "CHEMICAL", 34, 42], ["Tyr149", "CHEMICAL", 135, 141], ["tyrosine", "CHEMICAL", 34, 42], ["tyrosine", "AMINO_ACID", 34, 42], ["MA", "GENE_OR_GENE_PRODUCT", 120, 122], ["Tyr149", "GENE_OR_GENE_PRODUCT", 135, 141], ["astacin", "GENE_OR_GENE_PRODUCT", 173, 180], ["peptidases", "PROTEIN", 102, 112], ["MA clan", "PROTEIN", 120, 127], ["Tyr149", "PROTEIN", 135, 141], ["a tyrosine", "TREATMENT", 32, 42]]], ["In the APN-bestatin complex, the formation of a hydrogen bond between the hydroxyl group of Tyr381 and the O atom of the amide group (2.64 \u00c5 ) of the inhibitor was proposed to mimic the stabilization of the tetrahedral transition state that occurs during the enzymatic process Addlagatta et al., 2006; Figs.", [["bestatin", "CHEMICAL", 11, 19], ["hydroxyl", "CHEMICAL", 74, 82], ["Tyr381", "CHEMICAL", 92, 98], ["bestatin", "CHEMICAL", 11, 19], ["hydrogen", "CHEMICAL", 48, 56], ["hydroxyl", "CHEMICAL", 74, 82], ["Tyr381", "CHEMICAL", 92, 98], ["O", "CHEMICAL", 107, 108], ["amide", "CHEMICAL", 121, 126], ["APN-bestatin", "GENE_OR_GENE_PRODUCT", 7, 19], ["hydroxyl", "SIMPLE_CHEMICAL", 74, 82], ["Tyr381", "SIMPLE_CHEMICAL", 92, 98], ["APN", "PROTEIN", 7, 10], ["bestatin complex", "PROTEIN", 11, 27], ["the inhibitor", "TREATMENT", 146, 159], ["the tetrahedral transition state", "PROBLEM", 203, 235], ["hydrogen bond", "OBSERVATION", 48, 61], ["tetrahedral transition", "OBSERVATION", 207, 229]]], ["This was confirmed in this study with PL250, which corresponds to a true transition-state analogue.", [["PL250", "CHEMICAL", 38, 43], ["PL250", "CHEMICAL", 38, 43], ["PL250", "SIMPLE_CHEMICAL", 38, 43], ["this study", "TEST", 22, 32]]], ["In this case, one of the P-(O) O atoms forms a hydrogen bond to Tyr381 OH (2.66 \u00c5 ).", [["Tyr381 OH", "CHEMICAL", 64, 73], ["P-(O) O", "CHEMICAL", 25, 32], ["hydrogen", "CHEMICAL", 47, 55], ["Tyr381 OH", "CHEMICAL", 64, 73], ["P-(O) O atoms", "SIMPLE_CHEMICAL", 25, 38], ["Tyr381 OH", "SIMPLE_CHEMICAL", 64, 73], ["P-(O) O atoms", "PROTEIN", 25, 38], ["a hydrogen bond", "TEST", 45, 60]]], ["Interestingly, this tyrosine is well conserved in the M1 peptidase family, suggesting that this amino acid plays the same stabilizing role in all these enzymes.Structural comparison of E. coli APN-bestatin and E. coli APN-PL250 complexesThe isobutyl side chain of bestatin at the P 0 1 position was reported to be surrounded by Tyr275, Val294, His297, Val324, Tyr381 and the lateral face of the guanidinium group of Arg293 (Addlagatta et al., 2006) .", [["tyrosine", "CHEMICAL", 20, 28], ["amino acid", "CHEMICAL", 96, 106], ["bestatin", "CHEMICAL", 197, 205], ["isobutyl side", "CHEMICAL", 241, 254], ["bestatin", "CHEMICAL", 264, 272], ["guanidinium", "CHEMICAL", 395, 406], ["Arg293", "CHEMICAL", 416, 422], ["tyrosine", "CHEMICAL", 20, 28], ["amino acid", "CHEMICAL", 96, 106], ["isobutyl", "CHEMICAL", 241, 249], ["bestatin", "CHEMICAL", 264, 272], ["Tyr275", "CHEMICAL", 328, 334], ["Val294", "CHEMICAL", 336, 342], ["His", "CHEMICAL", 344, 347], ["Val324", "CHEMICAL", 352, 358], ["Tyr381", "CHEMICAL", 360, 366], ["guanidinium", "CHEMICAL", 395, 406], ["Arg293", "CHEMICAL", 416, 422], ["tyrosine", "AMINO_ACID", 20, 28], ["M1 peptidase", "GENE_OR_GENE_PRODUCT", 54, 66], ["amino acid", "AMINO_ACID", 96, 106], ["E. coli", "ORGANISM", 185, 192], ["APN-bestatin", "GENE_OR_GENE_PRODUCT", 193, 205], ["E. coli", "ORGANISM", 210, 217], ["bestatin", "SIMPLE_CHEMICAL", 264, 272], ["Tyr275", "GENE_OR_GENE_PRODUCT", 328, 334], ["Val294", "GENE_OR_GENE_PRODUCT", 336, 342], ["His297", "GENE_OR_GENE_PRODUCT", 344, 350], ["Val324", "GENE_OR_GENE_PRODUCT", 352, 358], ["Tyr381", "AMINO_ACID", 360, 366], ["Arg293", "SIMPLE_CHEMICAL", 416, 422], ["M1 peptidase family", "PROTEIN", 54, 73], ["enzymes", "PROTEIN", 152, 159], ["APN", "PROTEIN", 193, 196], ["E. coli APN-PL250 complexes", "PROTEIN", 210, 237], ["P 0 1 position", "DNA", 280, 294], ["E. coli", "SPECIES", 185, 192], ["E. coli", "SPECIES", 210, 217], ["E. coli", "SPECIES", 185, 192], ["E. coli", "SPECIES", 210, 217], ["this amino acid", "TEST", 91, 106], ["all these enzymes", "TEST", 142, 159], ["E. coli APN", "TEST", 185, 196], ["bestatin", "TREATMENT", 197, 205], ["E. coli", "PROBLEM", 210, 217], ["The isobutyl side chain", "TREATMENT", 237, 260], ["bestatin", "TREATMENT", 264, 272], ["Val294", "TEST", 336, 342], ["Val324", "TEST", 352, 358], ["E. coli", "OBSERVATION_MODIFIER", 185, 192], ["E. coli", "OBSERVATION", 210, 217], ["lateral", "ANATOMY_MODIFIER", 375, 382]]], ["The benzyl group of PL250 at the P 0 1 position is bound to the same open hydrophobic cleft as the isobutyl group in the APN-bestatin complex (Figs.", [["benzyl", "CHEMICAL", 4, 10], ["PL250", "CHEMICAL", 20, 25], ["isobutyl", "CHEMICAL", 99, 107], ["bestatin", "CHEMICAL", 125, 133], ["benzyl", "CHEMICAL", 4, 10], ["PL250", "CHEMICAL", 20, 25], ["isobutyl", "CHEMICAL", 99, 107], ["bestatin", "CHEMICAL", 125, 133], ["benzyl", "SIMPLE_CHEMICAL", 4, 10], ["PL250", "SIMPLE_CHEMICAL", 20, 25], ["isobutyl", "SIMPLE_CHEMICAL", 99, 107], ["APN-bestatin", "GENE_OR_GENE_PRODUCT", 121, 133], ["P 0 1 position", "DNA", 33, 47], ["APN", "PROTEIN", 121, 124], ["bestatin complex", "PROTEIN", 125, 141], ["The benzyl group of PL250", "TREATMENT", 0, 25], ["the isobutyl group", "TREATMENT", 95, 113], ["cleft", "OBSERVATION", 86, 91]]], ["This phenyl ring is oriented almost perpendicularly to Tyr275, with a distance of 5.59 \u00c5 between the centres of the aromatic rings.", [["phenyl", "CHEMICAL", 5, 11], ["phenyl", "CHEMICAL", 5, 11], ["Tyr275", "CHEMICAL", 55, 61], ["phenyl ring", "SIMPLE_CHEMICAL", 5, 16], ["Tyr275", "SIMPLE_CHEMICAL", 55, 61], ["This phenyl ring", "TREATMENT", 0, 16], ["phenyl ring", "OBSERVATION", 5, 16], ["oriented", "OBSERVATION_MODIFIER", 20, 28], ["almost", "OBSERVATION_MODIFIER", 29, 35], ["perpendicularly", "OBSERVATION_MODIFIER", 36, 51], ["aromatic rings", "OBSERVATION", 116, 130]]], ["One of the carboxyl O atoms of Asp327, located in the S 0 1 subsite at a distance of 4.00 \u00c5 from the benzyl group of PL250, is involved in a hydrogen bond (2.78 \u00c5 ) to His297, a ligand of the zinc ion.", [["Asp327", "CHEMICAL", 31, 37], ["benzyl", "CHEMICAL", 101, 107], ["PL250", "CHEMICAL", 117, 122], ["His297", "CHEMICAL", 168, 174], ["zinc", "CHEMICAL", 192, 196], ["carboxyl", "CHEMICAL", 11, 19], ["O", "CHEMICAL", 20, 21], ["Asp327", "CHEMICAL", 31, 37], ["benzyl", "CHEMICAL", 101, 107], ["PL250", "CHEMICAL", 117, 122], ["hydrogen", "CHEMICAL", 141, 149], ["His297", "CHEMICAL", 168, 174], ["zinc", "CHEMICAL", 192, 196], ["Asp327", "AMINO_ACID", 31, 37], ["PL250", "SIMPLE_CHEMICAL", 117, 122], ["His297", "SIMPLE_CHEMICAL", 168, 174], ["zinc ion", "SIMPLE_CHEMICAL", 192, 200], ["carboxyl O atoms", "PROTEIN", 11, 27], ["S 0 1 subsite", "PROTEIN", 54, 67], ["Asp327", "TREATMENT", 31, 37]]], ["These various interactions are hypothesized to stabilize the inhibitor inside the active site.Structural comparison of E. coli APN-bestatin and E. coli APN-PL250 complexesAlthough APN seems to exhibit a preference for hydrophobic moieties in the P 0 1 position (Kenny et al., 1987) , some peptides with hydrophilic or even charged residues can be found in this position.", [["bestatin", "CHEMICAL", 131, 139], ["E. coli", "ORGANISM", 119, 126], ["APN-bestatin", "GENE_OR_GENE_PRODUCT", 127, 139], ["E. coli", "ORGANISM", 144, 151], ["APN", "GENE_OR_GENE_PRODUCT", 180, 183], ["APN", "PROTEIN", 127, 130], ["E. coli APN-PL250 complexes", "PROTEIN", 144, 171], ["APN", "PROTEIN", 180, 183], ["E. coli", "SPECIES", 119, 126], ["E. coli", "SPECIES", 144, 151], ["E. coli", "SPECIES", 119, 126], ["E. coli", "SPECIES", 144, 151], ["the inhibitor", "TREATMENT", 57, 70], ["E. coli APN", "TEST", 119, 130], ["bestatin", "TREATMENT", 131, 139], ["E. coli", "PROBLEM", 144, 151], ["hydrophilic or even charged residues", "PROBLEM", 303, 339], ["active site", "OBSERVATION", 82, 93], ["E. coli", "OBSERVATION_MODIFIER", 119, 126], ["E. coli", "OBSERVATION", 144, 151]]], ["In this case, stabilization of the complex could be ensured by interactions with APN hydrophilic amino acids located in the S 0 1 subsite, such as Asp327 in E. coli APN.", [["amino acids", "CHEMICAL", 97, 108], ["amino acids", "CHEMICAL", 97, 108], ["APN", "GENE_OR_GENE_PRODUCT", 81, 84], ["amino acids", "AMINO_ACID", 97, 108], ["Asp327", "GENE_OR_GENE_PRODUCT", 147, 153], ["E. coli", "ORGANISM", 157, 164], ["APN", "GENE_OR_GENE_PRODUCT", 165, 168], ["APN", "PROTEIN", 81, 84], ["S 0 1 subsite", "PROTEIN", 124, 137], ["Asp327", "PROTEIN", 147, 153], ["APN", "PROTEIN", 165, 168], ["E. coli", "SPECIES", 157, 164], ["E. coli", "SPECIES", 157, 164], ["APN hydrophilic amino acids", "TEST", 81, 108], ["coli APN", "OBSERVATION", 160, 168]]], ["The importance of this residue is confirmed by its isosteric replacement by Glu413 in hog APN and Glu418 in human APN.", [["Glu413", "CHEMICAL", 76, 82], ["Glu418", "CHEMICAL", 98, 104], ["Glu413", "SIMPLE_CHEMICAL", 76, 82], ["hog", "ORGANISM", 86, 89], ["APN", "GENE_OR_GENE_PRODUCT", 90, 93], ["Glu418", "GENE_OR_GENE_PRODUCT", 98, 104], ["human", "ORGANISM", 108, 113], ["APN", "GENE_OR_GENE_PRODUCT", 114, 117], ["hog APN", "PROTEIN", 86, 93], ["Glu418", "PROTEIN", 98, 104], ["human APN", "PROTEIN", 108, 117], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 108, 113], ["this residue", "PROBLEM", 18, 30], ["its isosteric replacement", "TREATMENT", 47, 72], ["hog APN", "TREATMENT", 86, 93], ["isosteric replacement", "OBSERVATION", 51, 72]]], ["This suggests that the acidic residue conserved in this subsite may be able to interact with a P 0 1 side chain containing positively charged groups through hydrogen bonding.", [["hydrogen", "CHEMICAL", 157, 165], ["hydrogen", "SIMPLE_CHEMICAL", 157, 165], ["P 0 1 side chain", "PROTEIN", 95, 111], ["the acidic residue", "PROBLEM", 19, 37], ["a P 0 1 side chain", "TREATMENT", 93, 111], ["acidic residue", "OBSERVATION", 23, 37]]], ["In accordance with this assumption, peptides with a lysine or an arginine residue in the P 0 1 position, such as thymopentin, somatostatin and neurokinin A, were shown to be cleaved by APN (Noren et al., 1997) .Structural comparison of E. coli APN-bestatin and E. coli APN-PL250 complexesMoreover, another important parameter which could explain the binding of non-aromatic side chains is the high flexibility of the Arg293 side chain, which is nicely demonstrated by comparison of its positions in the ligand-free APN, the APN-bestatin complex and the APN-PL250 complex (Fig. 5b) .Structural comparison of E. coli APN-bestatin and E. coli APN-PL250 complexesAnother interesting point is the flexibility of the Met260 side chain located at the bottom of the S 1 subsite.", [["lysine", "CHEMICAL", 52, 58], ["arginine", "CHEMICAL", 65, 73], ["thymopentin", "CHEMICAL", 113, 124], ["bestatin", "CHEMICAL", 248, 256], ["bestatin", "CHEMICAL", 528, 536], ["bestatin", "CHEMICAL", 619, 627], ["Met260", "CHEMICAL", 711, 717], ["lysine", "CHEMICAL", 52, 58], ["arginine", "CHEMICAL", 65, 73], ["thymopentin", "CHEMICAL", 113, 124], ["somatostatin", "CHEMICAL", 126, 138], ["Arg293", "CHEMICAL", 417, 423], ["bestatin", "CHEMICAL", 528, 536], ["Met260", "CHEMICAL", 711, 717], ["lysine", "AMINO_ACID", 52, 58], ["arginine", "AMINO_ACID", 65, 73], ["thymopentin", "GENE_OR_GENE_PRODUCT", 113, 124], ["somatostatin", "GENE_OR_GENE_PRODUCT", 126, 138], ["neurokinin A", "GENE_OR_GENE_PRODUCT", 143, 155], ["APN", "GENE_OR_GENE_PRODUCT", 185, 188], ["E. coli", "ORGANISM", 236, 243], ["APN-bestatin", "GENE_OR_GENE_PRODUCT", 244, 256], ["E. coli", "ORGANISM", 261, 268], ["APN-PL250", "GENE_OR_GENE_PRODUCT", 269, 278], ["APN", "GENE_OR_GENE_PRODUCT", 515, 518], ["APN-bestatin", "GENE_OR_GENE_PRODUCT", 524, 536], ["APN-PL250", "GENE_OR_GENE_PRODUCT", 553, 562], ["E. coli", "ORGANISM", 607, 614], ["APN-bestatin", "GENE_OR_GENE_PRODUCT", 615, 627], ["E. coli", "ORGANISM", 632, 639], ["P 0 1 position", "DNA", 89, 103], ["thymopentin", "PROTEIN", 113, 124], ["APN", "PROTEIN", 185, 188], ["APN", "PROTEIN", 244, 247], ["APN", "PROTEIN", 269, 272], ["PL250 complexes", "PROTEIN", 273, 288], ["Arg293 side chain", "PROTEIN", 417, 434], ["APN", "PROTEIN", 515, 518], ["APN", "PROTEIN", 524, 527], ["bestatin complex", "PROTEIN", 528, 544], ["APN", "PROTEIN", 553, 556], ["PL250 complex", "PROTEIN", 557, 570], ["Fig. 5b", "PROTEIN", 572, 579], ["APN", "PROTEIN", 615, 618], ["E. coli APN-PL250 complexes", "PROTEIN", 632, 659], ["Met260 side chain", "PROTEIN", 711, 728], ["S 1 subsite", "PROTEIN", 758, 769], ["E. coli", "SPECIES", 236, 243], ["E. coli", "SPECIES", 261, 268], ["E. coli", "SPECIES", 607, 614], ["E. coli", "SPECIES", 632, 639], ["E. coli", "SPECIES", 236, 243], ["E. coli", "SPECIES", 261, 268], ["E. coli", "SPECIES", 607, 614], ["E. coli", "SPECIES", 632, 639], ["a lysine", "TREATMENT", 50, 58], ["an arginine residue", "PROBLEM", 62, 81], ["thymopentin", "TREATMENT", 113, 124], ["somatostatin", "TREATMENT", 126, 138], ["neurokinin A", "TREATMENT", 143, 155], ["E. coli APN", "TEST", 236, 247], ["bestatin", "TREATMENT", 248, 256], ["E. coli APN", "TEST", 261, 272], ["the binding of non-aromatic side chains", "PROBLEM", 346, 385], ["the APN", "TEST", 520, 527], ["bestatin complex", "PROBLEM", 528, 544], ["the APN", "TEST", 549, 556], ["E. coli APN", "TEST", 607, 618], ["bestatin", "TREATMENT", 619, 627], ["E. coli", "PROBLEM", 632, 639], ["the Met260 side chain", "TREATMENT", 707, 728], ["arginine residue", "OBSERVATION", 65, 81], ["E. coli", "OBSERVATION_MODIFIER", 236, 243], ["E. coli", "OBSERVATION_MODIFIER", 261, 268], ["high flexibility", "OBSERVATION_MODIFIER", 393, 409], ["E. coli", "OBSERVATION_MODIFIER", 607, 614], ["E. coli", "OBSERVATION", 632, 639], ["bottom", "ANATOMY_MODIFIER", 744, 750]]], ["In the bestatin-APN complex, the displacement of this side chain has been explained by the size of the S 1 benzyl moiety of the inhibitor Addlagatta et al., 2006) .", [["bestatin", "CHEMICAL", 7, 15], ["S 1 benzyl", "CHEMICAL", 103, 113], ["bestatin", "CHEMICAL", 7, 15], ["benzyl", "CHEMICAL", 107, 113], ["bestatin-APN", "GENE_OR_GENE_PRODUCT", 7, 19], ["bestatin-APN complex", "PROTEIN", 7, 27], ["the bestatin-APN complex", "TREATMENT", 3, 27], ["the displacement of this side chain", "PROBLEM", 29, 64], ["displacement", "OBSERVATION_MODIFIER", 33, 45], ["size", "OBSERVATION_MODIFIER", 91, 95]]], ["In the PL250-APN complex, despite the smaller size of the P 1 methyl group of PL250, the Met260 side chain is also displaced from its position in free APN, which is likely to be a consequence of the proximity of the phenylalanine in the P 0 2 position of PL250 (Fig. 5c) .Structural comparison of E. coli APN-bestatin and E. coli APN-PL250 complexesFinally, the carboxylate group of bestatin shows a two-point interaction with the enzyme: one O atom is hydrogen bonded to Gly261 NH and Ala262 NH, while the other O atom interacts with the guanidinium groups of Arg783 and Arg825 through two water molecules (Addlagatta et al., 2006) .", [["PL250", "CHEMICAL", 7, 12], ["P 1 methyl", "CHEMICAL", 58, 68], ["PL250", "CHEMICAL", 78, 83], ["Met260", "CHEMICAL", 89, 95], ["phenylalanine", "CHEMICAL", 216, 229], ["bestatin", "CHEMICAL", 309, 317], ["carboxylate", "CHEMICAL", 362, 373], ["bestatin", "CHEMICAL", 383, 391], ["Gly261 NH", "CHEMICAL", 472, 481], ["Ala262 NH", "CHEMICAL", 486, 495], ["guanidinium", "CHEMICAL", 539, 550], ["Arg783", "CHEMICAL", 561, 567], ["Arg825", "CHEMICAL", 572, 578], ["methyl", "CHEMICAL", 62, 68], ["PL250", "CHEMICAL", 78, 83], ["Met260", "CHEMICAL", 89, 95], ["phenylalanine", "CHEMICAL", 216, 229], ["PL250", "CHEMICAL", 255, 260], ["carboxylate", "CHEMICAL", 362, 373], ["bestatin", "CHEMICAL", 383, 391], ["O", "CHEMICAL", 443, 444], ["hydrogen", "CHEMICAL", 453, 461], ["Gly261", "CHEMICAL", 472, 478], ["NH", "CHEMICAL", 479, 481], ["Ala", "CHEMICAL", 486, 489], ["NH", "CHEMICAL", 493, 495], ["O", "CHEMICAL", 513, 514], ["guanidinium", "CHEMICAL", 539, 550], ["Arg783", "CHEMICAL", 561, 567], ["Arg825", "CHEMICAL", 572, 578], ["PL250-APN", "GENE_OR_GENE_PRODUCT", 7, 16], ["PL250", "SIMPLE_CHEMICAL", 78, 83], ["APN", "GENE_OR_GENE_PRODUCT", 151, 154], ["phenylalanine", "AMINO_ACID", 216, 229], ["PL250", "SIMPLE_CHEMICAL", 255, 260], ["E. coli", "ORGANISM", 297, 304], ["APN-bestatin", "GENE_OR_GENE_PRODUCT", 305, 317], ["E. coli", "ORGANISM", 322, 329], ["APN-PL250", "GENE_OR_GENE_PRODUCT", 330, 339], ["bestatin", "SIMPLE_CHEMICAL", 383, 391], ["O atom", "SIMPLE_CHEMICAL", 443, 449], ["hydrogen", "SIMPLE_CHEMICAL", 453, 461], ["Gly261 NH", "SIMPLE_CHEMICAL", 472, 481], ["Ala262 NH", "SIMPLE_CHEMICAL", 486, 495], ["O atom", "SIMPLE_CHEMICAL", 513, 519], ["Arg783", "SIMPLE_CHEMICAL", 561, 567], ["Arg825", "SIMPLE_CHEMICAL", 572, 578], ["PL250", "PROTEIN", 7, 12], ["APN complex", "PROTEIN", 13, 24], ["PL250", "PROTEIN", 78, 83], ["Met260 side chain", "PROTEIN", 89, 106], ["APN", "PROTEIN", 151, 154], ["P 0 2 position", "PROTEIN", 237, 251], ["PL250", "PROTEIN", 255, 260], ["APN", "PROTEIN", 305, 308], ["APN", "PROTEIN", 330, 333], ["PL250 complexes", "PROTEIN", 334, 349], ["E. coli", "SPECIES", 297, 304], ["E. coli", "SPECIES", 322, 329], ["E. coli", "SPECIES", 297, 304], ["E. coli", "SPECIES", 322, 329], ["the P 1 methyl group of PL250", "TREATMENT", 54, 83], ["the Met260 side chain", "TREATMENT", 85, 106], ["the phenylalanine in the P 0 2 position of PL250 (Fig.", "TREATMENT", 212, 266], ["E. coli APN", "TEST", 297, 308], ["bestatin", "TREATMENT", 309, 317], ["E. coli APN", "TEST", 322, 333], ["the carboxylate group of bestatin", "TREATMENT", 358, 391], ["the enzyme", "TEST", 427, 437], ["the guanidinium groups", "TREATMENT", 535, 557], ["smaller", "OBSERVATION_MODIFIER", 38, 45], ["size", "OBSERVATION_MODIFIER", 46, 50], ["displaced", "OBSERVATION_MODIFIER", 115, 124], ["position", "OBSERVATION_MODIFIER", 134, 142], ["free APN", "OBSERVATION_MODIFIER", 146, 154], ["likely to be", "UNCERTAINTY", 165, 177], ["E. coli", "OBSERVATION_MODIFIER", 297, 304], ["E. coli", "OBSERVATION_MODIFIER", 322, 329], ["hydrogen bonded", "OBSERVATION", 453, 468]]], ["In the complex with PL250, the hydrogen bond between Gly261 NH and the CO of the amide bond is also observed, but owing to the presence of a P 0 2 moiety the interaction with the two arginine residues is lacking.", [["PL250", "CHEMICAL", 20, 25], ["Gly261 NH", "CHEMICAL", 53, 62], ["arginine", "CHEMICAL", 183, 191], ["PL250", "CHEMICAL", 20, 25], ["hydrogen", "CHEMICAL", 31, 39], ["Gly", "CHEMICAL", 53, 56], ["NH", "CHEMICAL", 60, 62], ["CO", "CHEMICAL", 71, 73], ["amide", "CHEMICAL", 81, 86], ["arginine", "CHEMICAL", 183, 191], ["PL250", "SIMPLE_CHEMICAL", 20, 25], ["Gly261 NH", "AMINO_ACID", 53, 62], ["the two arginine residues", "TREATMENT", 175, 200]]], ["In this conformation, Arg825 actually lines the S 0 2 subsite along with Thr377, Tyr376 and Met260 and all these residues are close to the centre of the aromatic ring of the C-terminal Phe (Fig. 3) .", [["Arg825", "CHEMICAL", 22, 28], ["Thr377", "CHEMICAL", 73, 79], ["Tyr376", "CHEMICAL", 81, 87], ["Met260", "CHEMICAL", 92, 98], ["Phe", "CHEMICAL", 185, 188], ["Arg825", "GENE_OR_GENE_PRODUCT", 22, 28], ["Thr377", "GENE_OR_GENE_PRODUCT", 73, 79], ["Tyr376", "AMINO_ACID", 81, 87], ["Met260", "AMINO_ACID", 92, 98], ["S 0 2 subsite", "PROTEIN", 48, 61], ["Thr377", "PROTEIN", 73, 79], ["aromatic ring", "OBSERVATION", 153, 166], ["C-terminal Phe", "OBSERVATION", 174, 188]]], ["One O atom of the carboxylate group of PL250 interacts through two water molecules with the -carboxylate of Glu382, which adopts two different positions (a and b) in the crystal (Fig. 3) .Structural homologies between E. coli APN and mammalian APNBased on sequence alignment, the main differences between the active sites of human and E. coli APN seem to research papers be associated with the anionic site and the S 1 pocket, as previously outlined .Structural homologies between E. coli APN and mammalian APNIn the anionic site of E. coli APN, a network involving three glutamates (Glu121, Glu264 and Glu320, which is also a zinc ligand) and the lysine residue Lys319 forms a negatively charged cavity which seems to be relatively well conserved in bacterial and insect aminopeptidases.", [["carboxylate", "CHEMICAL", 18, 29], ["PL250", "CHEMICAL", 39, 44], ["Glu382", "CHEMICAL", 108, 114], ["Glu121", "CHEMICAL", 584, 590], ["lysine", "CHEMICAL", 648, 654], ["Lys319", "CHEMICAL", 663, 669], ["O", "CHEMICAL", 4, 5], ["carboxylate", "CHEMICAL", 18, 29], ["PL250", "CHEMICAL", 39, 44], ["carboxylate", "CHEMICAL", 93, 104], ["Glu382", "CHEMICAL", 108, 114], ["glutamates", "CHEMICAL", 572, 582], ["Glu121", "CHEMICAL", 584, 590], ["Glu264", "CHEMICAL", 592, 598], ["Glu320", "CHEMICAL", 603, 609], ["zinc", "CHEMICAL", 627, 631], ["lysine", "CHEMICAL", 648, 654], ["Lys319", "CHEMICAL", 663, 669], ["O atom", "SIMPLE_CHEMICAL", 4, 10], ["PL250", "SIMPLE_CHEMICAL", 39, 44], ["Glu382", "SIMPLE_CHEMICAL", 108, 114], ["E. coli", "ORGANISM", 218, 225], ["APN", "GENE_OR_GENE_PRODUCT", 226, 229], ["human", "ORGANISM", 325, 330], ["E. coli", "ORGANISM", 335, 342], ["APN", "GENE_OR_GENE_PRODUCT", 343, 346], ["E. coli", "ORGANISM", 481, 488], ["APN", "GENE_OR_GENE_PRODUCT", 489, 492], ["E. coli APN", "GENE_OR_GENE_PRODUCT", 533, 544], ["glutamates", "SIMPLE_CHEMICAL", 572, 582], ["Glu121", "SIMPLE_CHEMICAL", 584, 590], ["Glu264", "GENE_OR_GENE_PRODUCT", 592, 598], ["Glu320", "GENE_OR_GENE_PRODUCT", 603, 609], ["Lys319", "AMINO_ACID", 663, 669], ["APN", "PROTEIN", 226, 229], ["mammalian APNBased", "PROTEIN", 234, 252], ["APN", "PROTEIN", 343, 346], ["S 1 pocket", "DNA", 415, 425], ["APN", "PROTEIN", 489, 492], ["mammalian APNIn the anionic site", "DNA", 497, 529], ["APN", "PROTEIN", 541, 544], ["bacterial and insect aminopeptidases", "PROTEIN", 751, 787], ["E. coli", "SPECIES", 218, 225], ["human", "SPECIES", 325, 330], ["E. coli", "SPECIES", 335, 342], ["E. coli", "SPECIES", 481, 488], ["E. coli", "SPECIES", 533, 540], ["E. coli", "SPECIES", 218, 225], ["human", "SPECIES", 325, 330], ["E. coli", "SPECIES", 335, 342], ["E. coli", "SPECIES", 481, 488], ["E. coli", "SPECIES", 533, 540], ["the carboxylate group of PL250", "TREATMENT", 14, 44], ["the -carboxylate of Glu382", "TREATMENT", 88, 114], ["E. coli APN", "TEST", 218, 229], ["mammalian APNBased on sequence alignment", "PROBLEM", 234, 274], ["E. coli APN", "PROBLEM", 335, 346], ["the S 1 pocket", "PROBLEM", 411, 425], ["E. coli APN", "PROBLEM", 481, 492], ["E. coli APN", "PROBLEM", 533, 544], ["Glu121", "TEST", 584, 590], ["Glu264", "TEST", 592, 598], ["Glu320", "TEST", 603, 609], ["a zinc ligand", "TEST", 625, 638], ["the lysine residue", "TEST", 644, 662], ["a negatively charged cavity", "PROBLEM", 676, 703], ["coli APN", "OBSERVATION", 221, 229], ["main", "OBSERVATION_MODIFIER", 280, 284], ["active", "OBSERVATION_MODIFIER", 309, 315], ["coli APN", "OBSERVATION", 484, 492], ["E. coli APN", "OBSERVATION", 533, 544], ["bacterial", "OBSERVATION_MODIFIER", 751, 760]]], ["In mammalian APN, however, this network is not as conserved; in human APN the analogue of Lys319 is Asn410 and Glu121 is replaced by Gln213.", [["Asn410", "CHEMICAL", 100, 106], ["Glu121", "CHEMICAL", 111, 117], ["Gln213", "CHEMICAL", 133, 139], ["APN", "GENE_OR_GENE_PRODUCT", 13, 16], ["human", "ORGANISM", 64, 69], ["APN", "GENE_OR_GENE_PRODUCT", 70, 73], ["Lys319", "GENE_OR_GENE_PRODUCT", 90, 96], ["Asn410", "GENE_OR_GENE_PRODUCT", 100, 106], ["Glu121", "GENE_OR_GENE_PRODUCT", 111, 117], ["Gln213", "GENE_OR_GENE_PRODUCT", 133, 139], ["mammalian APN", "PROTEIN", 3, 16], ["human APN", "PROTEIN", 64, 73], ["Glu121", "PROTEIN", 111, 117], ["Gln213", "PROTEIN", 133, 139], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69]]], ["Moreover, Gln136, Glu271, Glu318 and Asn317 in human LTA4H, which belongs to the same M1 family, replace the Glu121, Glu264, Glu320 and Lys319 residues of E. coli APN, respectively.", [["Gln136", "CHEMICAL", 10, 16], ["Glu271", "CHEMICAL", 18, 24], ["Glu318", "CHEMICAL", 26, 32], ["Asn317", "CHEMICAL", 37, 43], ["Glu121", "CHEMICAL", 109, 115], ["Glu264", "CHEMICAL", 117, 123], ["Glu320", "CHEMICAL", 125, 131], ["Lys319", "CHEMICAL", 136, 142], ["Gln136", "GENE_OR_GENE_PRODUCT", 10, 16], ["Glu271", "GENE_OR_GENE_PRODUCT", 18, 24], ["Glu318", "GENE_OR_GENE_PRODUCT", 26, 32], ["Asn317", "GENE_OR_GENE_PRODUCT", 37, 43], ["human", "ORGANISM", 47, 52], ["LTA4H", "GENE_OR_GENE_PRODUCT", 53, 58], ["M1", "GENE_OR_GENE_PRODUCT", 86, 88], ["Glu121", "GENE_OR_GENE_PRODUCT", 109, 115], ["Glu264", "GENE_OR_GENE_PRODUCT", 117, 123], ["Glu320", "GENE_OR_GENE_PRODUCT", 125, 131], ["Lys319", "AMINO_ACID", 136, 142], ["E. coli", "ORGANISM", 155, 162], ["APN", "GENE_OR_GENE_PRODUCT", 163, 166], ["Gln136", "PROTEIN", 10, 16], ["Asn317", "PROTEIN", 37, 43], ["human LTA4H", "PROTEIN", 47, 58], ["M1 family", "PROTEIN", 86, 95], ["Glu121, Glu264, Glu320 and Lys319 residues", "PROTEIN", 109, 151], ["APN", "PROTEIN", 163, 166], ["human", "SPECIES", 47, 52], ["E. coli", "SPECIES", 155, 162], ["human", "SPECIES", 47, 52], ["E. coli", "SPECIES", 155, 162], ["Moreover", "TEST", 0, 8], ["Gln136", "TEST", 10, 16], ["Glu271", "TEST", 18, 24], ["Glu318", "TEST", 26, 32], ["human LTA4H", "TEST", 47, 58], ["the Glu121", "TEST", 105, 115], ["Glu264", "TEST", 117, 123], ["Glu320", "TEST", 125, 131], ["E. coli APN", "PROBLEM", 155, 166], ["E. coli", "OBSERVATION", 155, 162]]], ["These residues are identical in human LTA4H and in human APN.", [["human", "ORGANISM", 32, 37], ["LTA4H", "CELL", 38, 43], ["human", "ORGANISM", 51, 56], ["APN", "GENE_OR_GENE_PRODUCT", 57, 60], ["human LTA4H", "PROTEIN", 32, 43], ["human APN", "PROTEIN", 51, 60], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 51, 56]]], ["In the LTA4H-bestatin complex (PDB code 1hs6; Thunnissen et al., 2001) , a water molecule is located at the corresponding position to an \"-amino group of Lys319 in E. coli APN and the hydrogen-bonding network is formed through this water molecule.", [["LTA4H", "CHEMICAL", 7, 12], ["bestatin", "CHEMICAL", 13, 21], ["Lys319", "CHEMICAL", 154, 160], ["bestatin", "CHEMICAL", 13, 21], ["amino", "CHEMICAL", 139, 144], ["Lys319", "CHEMICAL", 154, 160], ["hydrogen", "CHEMICAL", 184, 192], ["LTA4H-bestatin", "GENE_OR_GENE_PRODUCT", 7, 21], ["Lys319", "SIMPLE_CHEMICAL", 154, 160], ["E. coli APN", "GENE_OR_GENE_PRODUCT", 164, 175], ["LTA4H", "PROTEIN", 7, 12], ["bestatin complex", "PROTEIN", 13, 29], ["APN", "PROTEIN", 172, 175], ["E. coli", "SPECIES", 164, 171], ["E. coli", "SPECIES", 164, 171], ["a water molecule", "PROBLEM", 73, 89], ["E. coli APN", "TREATMENT", 164, 175], ["the hydrogen-bonding network", "TREATMENT", 180, 208]]], ["The sequence homology between human LTA4H and APN suggest that a similar network may occur in human APN.Structural homologies between E. coli APN and mammalian APNThe S 1 subsite of E. coli APN is limited by the side chain of Met260, leading to a subsite cavity that is well adapted to small residues such as Ala.", [["Met260", "CHEMICAL", 226, 232], ["Met260", "CHEMICAL", 226, 232], ["Ala", "CHEMICAL", 309, 312], ["human", "ORGANISM", 30, 35], ["LTA4H", "GENE_OR_GENE_PRODUCT", 36, 41], ["APN", "GENE_OR_GENE_PRODUCT", 46, 49], ["human", "ORGANISM", 94, 99], ["APN", "GENE_OR_GENE_PRODUCT", 100, 103], ["E. coli APN", "ORGANISM", 134, 145], ["E. coli", "ORGANISM", 182, 189], ["APN", "GENE_OR_GENE_PRODUCT", 190, 193], ["Met260", "GENE_OR_GENE_PRODUCT", 226, 232], ["Ala", "AMINO_ACID", 309, 312], ["human LTA4H", "PROTEIN", 30, 41], ["APN", "PROTEIN", 46, 49], ["human APN", "PROTEIN", 94, 103], ["APN", "PROTEIN", 142, 145], ["mammalian APN", "PROTEIN", 150, 163], ["S 1 subsite", "PROTEIN", 167, 178], ["APN", "PROTEIN", 190, 193], ["Met260", "PROTEIN", 226, 232], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 94, 99], ["E. coli", "SPECIES", 134, 141], ["E. coli", "SPECIES", 182, 189], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 94, 99], ["E. coli", "SPECIES", 134, 141], ["E. coli", "SPECIES", 182, 189], ["human LTA4H", "TREATMENT", 30, 41], ["E. coli APN", "TREATMENT", 134, 145], ["mammalian APN", "TREATMENT", 150, 163], ["E. coli APN", "TEST", 182, 193], ["a subsite cavity", "PROBLEM", 245, 261], ["small residues", "PROBLEM", 286, 300], ["E. coli", "OBSERVATION_MODIFIER", 182, 189], ["cavity", "OBSERVATION", 255, 261], ["small", "OBSERVATION_MODIFIER", 286, 291], ["residues", "OBSERVATION", 292, 300]]], ["However, the structure of the APNbestatin complex showed that the side chain of Met260 is able to move in order to facilitate the interaction of larger residues (such as the benzyl side chain of bestatin) inside this pocket Addlagatta et al., 2006) .", [["APNbestatin", "CHEMICAL", 30, 41], ["Met260", "CHEMICAL", 80, 86], ["benzyl", "CHEMICAL", 174, 180], ["bestatin", "CHEMICAL", 195, 203], ["APNbestatin", "CHEMICAL", 30, 41], ["Met260", "CHEMICAL", 80, 86], ["benzyl", "CHEMICAL", 174, 180], ["bestatin", "CHEMICAL", 195, 203], ["APNbestatin", "GENE_OR_GENE_PRODUCT", 30, 41], ["Met260", "SIMPLE_CHEMICAL", 80, 86], ["bestatin", "SIMPLE_CHEMICAL", 195, 203], ["APNbestatin complex", "PROTEIN", 30, 49], ["Met260", "PROTEIN", 80, 86], ["the APNbestatin complex", "TEST", 26, 49], ["larger residues", "PROBLEM", 145, 160], ["the benzyl side chain of bestatin", "TREATMENT", 170, 203]]], ["In mammalian APN, Met260 is replaced by an alanine residue (Ala351 in human enzyme), leading to an extended cavity which could accept large side chains, such as a phenethyl group, without a requirement for side-chain transconformation.", [["Met260", "CHEMICAL", 18, 24], ["alanine", "CHEMICAL", 43, 50], ["phenethyl", "CHEMICAL", 163, 172], ["alanine", "CHEMICAL", 43, 50], ["phenethyl", "CHEMICAL", 163, 172], ["APN", "GENE_OR_GENE_PRODUCT", 13, 16], ["Met260", "GENE_OR_GENE_PRODUCT", 18, 24], ["alanine", "AMINO_ACID", 43, 50], ["Ala351", "AMINO_ACID", 60, 66], ["human", "ORGANISM", 70, 75], ["phenethyl", "SIMPLE_CHEMICAL", 163, 172], ["mammalian APN", "PROTEIN", 3, 16], ["Met260", "PROTEIN", 18, 24], ["human enzyme", "PROTEIN", 70, 82], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["an alanine residue", "PROBLEM", 40, 58], ["human enzyme", "TEST", 70, 82], ["an extended cavity", "PROBLEM", 96, 114], ["large side chains", "PROBLEM", 134, 151], ["a phenethyl group", "TREATMENT", 161, 178], ["side-chain transconformation", "PROBLEM", 206, 234], ["cavity", "OBSERVATION", 108, 114], ["large", "OBSERVATION_MODIFIER", 134, 139], ["side chains", "OBSERVATION_MODIFIER", 140, 151]]], ["This accounts for the identical inhibitory potency of various aminophosphinic derivatives, such as compounds 3 and 4 (Table 2) , towards hog APN, whatever the size of the S 1 -interacting side chain (Chen et al., 1999) .", [["aminophosphinic", "CHEMICAL", 62, 77], ["aminophosphinic", "CHEMICAL", 62, 77], ["aminophosphinic derivatives", "SIMPLE_CHEMICAL", 62, 89], ["hog", "ORGANISM", 137, 140], ["APN", "GENE_OR_GENE_PRODUCT", 141, 144], ["hog APN", "PROTEIN", 137, 144], ["S 1 -interacting side chain", "PROTEIN", 171, 198], ["various aminophosphinic derivatives", "TREATMENT", 54, 89], ["aminophosphinic derivatives", "OBSERVATION", 62, 89], ["size", "OBSERVATION_MODIFIER", 159, 163]]], ["Interestingly, this is different for E. coli APN inhibition, where the K i values of compounds 3 and 4 are 1.5 and 25 nM, respectively.", [["K", "CHEMICAL", 71, 72], ["E. coli", "ORGANISM", 37, 44], ["APN", "GENE_OR_GENE_PRODUCT", 45, 48], ["E. coli", "SPECIES", 37, 44], ["E. coli", "SPECIES", 37, 44], ["E. coli APN inhibition", "PROBLEM", 37, 59], ["the K i values", "TEST", 67, 81], ["compounds", "TEST", 85, 94], ["different", "OBSERVATION_MODIFIER", 23, 32], ["E. coli", "OBSERVATION_MODIFIER", 37, 44]]], ["This tenfold decrease in affinity could result from an energetically consuming transconformational process involving the side chain of Met260.Structural homologies between E. coli APN and mammalian APNConsistent with the high homology in the active site of all these aminopeptidases N, we have found that the K i values of PL250 for E. coli APN (K i = 1.5 \u00c2 10 \u00c09 M) and hog kidney APN (K i = 2.2 \u00c2 10 \u00c09 M) were almost identical.", [["kidney", "ANATOMY", 375, 381], ["Met260", "CHEMICAL", 135, 141], ["Met260", "CHEMICAL", 135, 141], ["Met260", "GENE_OR_GENE_PRODUCT", 135, 141], ["E. coli", "ORGANISM", 172, 179], ["APN", "GENE_OR_GENE_PRODUCT", 180, 183], ["aminopeptidases N", "GENE_OR_GENE_PRODUCT", 267, 284], ["K i", "GENE_OR_GENE_PRODUCT", 309, 312], ["E. coli", "ORGANISM", 333, 340], ["APN", "GENE_OR_GENE_PRODUCT", 341, 344], ["kidney", "ORGAN", 375, 381], ["Met260", "PROTEIN", 135, 141], ["APN", "PROTEIN", 180, 183], ["aminopeptidases N", "PROTEIN", 267, 284], ["APN", "PROTEIN", 341, 344], ["E. coli", "SPECIES", 172, 179], ["E. coli", "SPECIES", 333, 340], ["hog", "SPECIES", 371, 374], ["E. coli", "SPECIES", 172, 179], ["E. coli", "SPECIES", 333, 340], ["hog", "SPECIES", 371, 374], ["This tenfold decrease in affinity", "PROBLEM", 0, 33], ["an energetically consuming transconformational process", "PROBLEM", 52, 106], ["E. coli APN", "PROBLEM", 172, 183], ["the K i values", "TEST", 305, 319], ["PL250", "TEST", 323, 328], ["E. coli APN", "TEST", 333, 344], ["K i", "TEST", 346, 349], ["hog kidney APN", "TEST", 371, 385], ["K i", "TEST", 387, 390], ["decrease", "OBSERVATION_MODIFIER", 13, 21], ["coli APN", "OBSERVATION", 175, 183], ["kidney", "ANATOMY", 375, 381]]], ["As the sequence identity between the mammalian APNs are around 90%, the results obtained with the hog enzyme could very likely be extended to human APN.Structural homologies between E. coli APN and mammalian APNOne of the peculiarities of APN is the complete occlusion of the active site by the C-terminal domain of the enzyme (domain IV; Ito et al., 2006; Addlagatta et al., 2006) .", [["C", "CHEMICAL", 295, 296], ["APNs", "GENE_OR_GENE_PRODUCT", 47, 51], ["hog", "ORGANISM", 98, 101], ["human", "ORGANISM", 142, 147], ["APN", "GENE_OR_GENE_PRODUCT", 148, 151], ["E. coli", "ORGANISM", 182, 189], ["APN", "GENE_OR_GENE_PRODUCT", 190, 193], ["APN", "GENE_OR_GENE_PRODUCT", 239, 242], ["mammalian APNs", "DNA", 37, 51], ["hog enzyme", "PROTEIN", 98, 108], ["human APN", "PROTEIN", 142, 151], ["APN", "PROTEIN", 190, 193], ["mammalian APNOne", "PROTEIN", 198, 214], ["APN", "PROTEIN", 239, 242], ["C-terminal domain", "PROTEIN", 295, 312], ["enzyme", "PROTEIN", 320, 326], ["domain IV", "PROTEIN", 328, 337], ["human", "SPECIES", 142, 147], ["E. coli", "SPECIES", 182, 189], ["human", "SPECIES", 142, 147], ["E. coli", "SPECIES", 182, 189], ["the hog enzyme", "TEST", 94, 108], ["E. coli APN", "TREATMENT", 182, 193], ["the complete occlusion of the active site", "PROBLEM", 246, 287], ["coli APN", "OBSERVATION", 185, 193], ["complete", "OBSERVATION_MODIFIER", 250, 258], ["occlusion", "OBSERVATION", 259, 268], ["active", "OBSERVATION_MODIFIER", 276, 282], ["site", "OBSERVATION_MODIFIER", 283, 287]]], ["Two mechanisms have been proposed to account for the binding step of substrates into the active site.", [["active", "OBSERVATION", 89, 95]]], ["Large transconformational changes could occur, either constitutively or induced by the substrate, allowing the introduction of the substrate into the catalytic site Addlagatta et al., 2006) .", [["Large transconformational changes", "PROBLEM", 0, 33], ["transconformational", "OBSERVATION", 6, 25]]], ["The peptide could also enter through the small cavity (10 \u00c5 ) present in the C-terminal -domain of the enzyme (domain IV).Structural homologies between E. coli APN and mammalian APNA superimposition of the three-dimensional structure of domain IV in the complexes of E. coli APN with bestatin and PL250 does not show any differences at the level of the hole; the increased size of PL250 compared with bestatin is not sufficient to discriminate between these two proposed mechanisms.Structural homologies between E. coli APN and mammalian APNIn conclusion, the present study demonstrates the importance of S 0 2 subsite binding for the optimization of APN inhibitors.", [["bestatin", "CHEMICAL", 284, 292], ["PL250", "CHEMICAL", 381, 386], ["bestatin", "CHEMICAL", 401, 409], ["C", "CHEMICAL", 77, 78], ["bestatin", "CHEMICAL", 284, 292], ["PL250", "CHEMICAL", 297, 302], ["PL250", "CHEMICAL", 381, 386], ["bestatin", "CHEMICAL", 401, 409], ["E. coli", "ORGANISM", 152, 159], ["APN", "GENE_OR_GENE_PRODUCT", 160, 163], ["E. coli", "ORGANISM", 267, 274], ["APN", "GENE_OR_GENE_PRODUCT", 275, 278], ["bestatin", "SIMPLE_CHEMICAL", 284, 292], ["PL250", "SIMPLE_CHEMICAL", 297, 302], ["PL250", "SIMPLE_CHEMICAL", 381, 386], ["bestatin", "SIMPLE_CHEMICAL", 401, 409], ["E. coli", "ORGANISM", 512, 519], ["APN", "GENE_OR_GENE_PRODUCT", 520, 523], ["APN", "GENE_OR_GENE_PRODUCT", 651, 654], ["C-terminal -domain", "PROTEIN", 77, 95], ["enzyme", "PROTEIN", 103, 109], ["domain IV", "PROTEIN", 111, 120], ["APN", "PROTEIN", 160, 163], ["mammalian APNA", "PROTEIN", 168, 182], ["domain IV", "PROTEIN", 237, 246], ["APN", "PROTEIN", 275, 278], ["APN", "PROTEIN", 520, 523], ["APN", "PROTEIN", 651, 654], ["E. coli", "SPECIES", 152, 159], ["E. coli", "SPECIES", 267, 274], ["E. coli", "SPECIES", 512, 519], ["E. coli", "SPECIES", 152, 159], ["E. coli", "SPECIES", 267, 274], ["E. coli", "SPECIES", 512, 519], ["The peptide", "TREATMENT", 0, 11], ["the enzyme (domain IV", "TREATMENT", 99, 120], ["E. coli APN", "PROBLEM", 152, 163], ["mammalian APNA superimposition", "PROBLEM", 168, 198], ["domain IV", "TREATMENT", 237, 246], ["E. coli APN", "TREATMENT", 267, 278], ["bestatin", "TREATMENT", 284, 292], ["bestatin", "TREATMENT", 401, 409], ["E. coli APN", "TREATMENT", 512, 523], ["the present study", "TEST", 556, 573], ["APN inhibitors", "TREATMENT", 651, 665], ["small", "OBSERVATION_MODIFIER", 41, 46], ["cavity", "OBSERVATION", 47, 53], ["coli APN", "OBSERVATION", 155, 163], ["mammalian APNA", "OBSERVATION", 168, 182], ["E. coli", "OBSERVATION", 267, 274], ["hole", "OBSERVATION", 353, 357], ["increased", "OBSERVATION_MODIFIER", 363, 372], ["size", "OBSERVATION_MODIFIER", 373, 377], ["E. coli", "OBSERVATION", 512, 519]]], ["This subsite is large, essentially hydrophobic and can accept bulky side chains.", [["essentially hydrophobic", "PROBLEM", 23, 46], ["large", "OBSERVATION_MODIFIER", 16, 21], ["essentially", "OBSERVATION_MODIFIER", 23, 34], ["hydrophobic", "OBSERVATION_MODIFIER", 35, 46], ["bulky", "OBSERVATION_MODIFIER", 62, 67]]], ["However, the optimal size of these chains remains to be determined, since the steric hindrance arising from the domain IV hole could behave as a restrictive factor in the absence of conformational modifications.Structural homologies between E. coli APN and mammalian APNWe thank Tanja Ouimet for critical reading of the manuscript.", [["E. coli", "ORGANISM", 241, 248], ["APN", "GENE_OR_GENE_PRODUCT", 249, 252], ["domain IV hole", "PROTEIN", 112, 126], ["restrictive factor", "PROTEIN", 145, 163], ["APN", "PROTEIN", 249, 252], ["E. coli", "SPECIES", 241, 248], ["E. coli", "SPECIES", 241, 248], ["the steric hindrance", "PROBLEM", 74, 94], ["the domain IV hole", "TREATMENT", 108, 126], ["a restrictive factor", "PROBLEM", 143, 163], ["E. coli APN", "TREATMENT", 241, 252], ["optimal", "OBSERVATION_MODIFIER", 13, 20], ["size", "OBSERVATION_MODIFIER", 21, 25], ["chains", "OBSERVATION_MODIFIER", 35, 41], ["steric hindrance", "OBSERVATION", 78, 94], ["restrictive", "OBSERVATION_MODIFIER", 145, 156], ["conformational modifications", "OBSERVATION", 182, 210]]]], "4b2439a916d724e156482c6c071394c93b974f0e": [["45The SARS-CoV-2 virus outbreak that began in late 2019 in Wuhan, has a mortality rate of approximately 46 6.1% worldwide [1] [2] [3] .", [["SARS-CoV-2 virus", "ORGANISM", 6, 22], ["CoV-2 virus", "SPECIES", 11, 22], ["SARS-CoV-2 virus", "SPECIES", 6, 22], ["The SARS", "TEST", 2, 10], ["a mortality rate", "TEST", 70, 86]]], ["Diagnostic testing is necessary for identifying and isolating infected individuals to 47 limit spread of disease.", [["Diagnostic testing", "TEST", 0, 18], ["isolating infected individuals", "PROBLEM", 52, 82], ["disease", "PROBLEM", 105, 112], ["infected", "OBSERVATION", 62, 70], ["disease", "OBSERVATION", 105, 112]]], ["Molecular testing such as reverse-transcriptase polymerase chain reaction (rtPCR) 48 detects active infection; and serology testing helps identify those who were previously infected (including 49 asymptomatic infections) and have recovered [4, 5] .", [["active infection", "DISEASE", 93, 109], ["infections", "DISEASE", 209, 219], ["reverse-transcriptase", "PROTEIN", 26, 47], ["Molecular testing", "TEST", 0, 17], ["reverse-transcriptase polymerase chain reaction", "PROBLEM", 26, 73], ["active infection", "PROBLEM", 93, 109], ["serology testing", "TEST", 115, 131], ["49 asymptomatic infections", "PROBLEM", 193, 219], ["active", "OBSERVATION_MODIFIER", 93, 99], ["infection", "OBSERVATION", 100, 109]]], ["Nucleic acid detection using rtPCR has become the 50 confirmation test, due to its 99% specificity and 60-90% sensitivity within 7 days of exposure [6] but is 51 faced with numerous supply challenges [7] .", [["Nucleic acid", "CHEMICAL", 0, 12], ["rtPCR", "PROTEIN", 29, 34], ["Nucleic acid detection", "TEST", 0, 22], ["rtPCR", "TEST", 29, 34]]], ["The United States Food and Drug Administration (FDA) 5245issued an Emergency Use Authorization (EUA) approval for antibody testing as complementary to rtPCR, 5345leading to an explosion of new antibody methods, including rapid diagnostic test (RDT), enzyme-linked 54 immunosorbent assay (ELISA), virus neutralization assay (VNA), and chemiluminescent immunoassay 5545One hundred and fifty-two serum samples were from patients who tested negative by rtPCR, 134 of these 80 were collected on same day as rtPCR testing.", [["serum samples", "ANATOMY", 393, 406], ["serum samples", "ORGANISM_SUBSTANCE", 393, 406], ["patients", "ORGANISM", 417, 425], ["patients", "SPECIES", 417, 425], ["antibody testing", "TEST", 114, 130], ["rtPCR", "TEST", 151, 156], ["new antibody methods", "PROBLEM", 189, 209], ["rapid diagnostic test", "TEST", 221, 242], ["RDT", "TEST", 244, 247], ["enzyme", "TEST", 250, 256], ["immunosorbent assay", "TEST", 267, 286], ["ELISA", "TEST", 288, 293], ["virus neutralization assay", "TEST", 296, 322], ["chemiluminescent immunoassay", "TEST", 334, 362], ["two serum samples", "TEST", 389, 406], ["rtPCR", "TEST", 449, 454], ["rtPCR testing", "TEST", 502, 515]]], ["For the remaining 18 samples, the interval between rtPCR 81 and sample collection ranged from 1-48 days.", [["samples", "ANATOMY", 21, 28], ["sample", "ANATOMY", 64, 70], ["rtPCR", "TEST", 51, 56], ["sample collection", "TEST", 64, 81]]], ["To avoid degradation, the specimens were tested by four 82 methodologies within 12-20 h of each other.", [["specimens", "ANATOMY", 26, 35], ["the specimens", "TEST", 22, 35]]], ["Only samples having sufficient serum volume and rtPCR test 83 results were included in the evaluation project.", [["samples", "ANATOMY", 5, 12], ["serum", "ANATOMY", 31, 36], ["samples", "CANCER", 5, 12], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["serum volume", "TEST", 31, 43], ["rtPCR test", "TEST", 48, 58], ["the evaluation", "TEST", 87, 101]]], ["84Instrumentation and analysis85 Table 1 summarizes the characteristics of the four serologic assays we investigated.", [["the four serologic assays", "TEST", 75, 100]]], ["86 peroxidase.", [["peroxidase", "GENE_OR_GENE_PRODUCT", 3, 13], ["86 peroxidase", "PROTEIN", 0, 13]]], ["After a second incubation and washing step, the wells are incubated with the substrate 97 tetramethylbenzidine (TMB) chromogen solution to induce color change.", [["97 tetramethylbenzidine", "CHEMICAL", 87, 110], ["TMB", "CHEMICAL", 112, 115], ["tetramethylbenzidine", "CHEMICAL", 90, 110], ["TMB", "CHEMICAL", 112, 115], ["chromogen", "CHEMICAL", 117, 126], ["97 tetramethylbenzidine", "SIMPLE_CHEMICAL", 87, 110], ["TMB", "SIMPLE_CHEMICAL", 112, 115], ["a second incubation", "TREATMENT", 6, 25], ["the substrate 97 tetramethylbenzidine (TMB) chromogen solution", "TREATMENT", 73, 135], ["color change", "PROBLEM", 146, 158]]], ["An acidic stopping solution is 98 All rights reserved.", [["An acidic stopping solution", "TREATMENT", 0, 27], ["acidic", "OBSERVATION_MODIFIER", 3, 9]]], ["No reuse allowed without permission.Instrumentation and analysiswas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Instrumentation and analysisThe copyright holder for this preprint (which this version posted July 8, 2020 . . https://doi.org/10.1101 added and the degree of enzymatic turnover of the substrate is determined by wavelength absorbance 99 measurement, with 450 nm as the primary filter and 630 nm as the reference filter.", [["https://doi.org/10.1101", "CHEMICAL", 303, 326], ["Instrumentation", "TREATMENT", 36, 51], ["Instrumentation", "TREATMENT", 192, 207], ["analysis", "TEST", 212, 220], ["The copyright holder", "TREATMENT", 220, 240], ["the primary filter", "TREATMENT", 457, 475], ["the reference filter", "TREATMENT", 490, 510], ["med", "ANATOMY", 136, 139], ["enzymatic turnover", "OBSERVATION", 351, 369]]], ["The intensity of color 100 change corresponds to arbitrary units of antibody-antigen complex concentration present in the specimen.", [["specimen", "ANATOMY", 122, 130], ["antibody-antigen complex", "GENE_OR_GENE_PRODUCT", 68, 92], ["antibody-antigen complex", "PROTEIN", 68, 92], ["color", "TEST", 17, 22], ["antibody", "TEST", 68, 76], ["intensity", "OBSERVATION_MODIFIER", 4, 13]]], ["101Instrumentation and analysisThe analyzer calculates antibody concentration in arbitrary concentration units (AU/mL).", [["analysis", "TEST", 23, 31], ["The analyzer calculates antibody concentration in arbitrary concentration units (AU/mL)", "TREATMENT", 31, 118]]], ["Samples with 102 AU/mL of >12, 10-12, and <10 are considered positive, indeterminate and negative for IgG respectively.", [["Samples", "ANATOMY", 0, 7], ["IgG", "GENE_OR_GENE_PRODUCT", 102, 105], ["IgG", "PROTEIN", 102, 105], ["Samples", "TEST", 0, 7], ["AU/mL", "TEST", 17, 22], ["IgG", "TEST", 102, 105], ["indeterminate", "OBSERVATION_MODIFIER", 71, 84]]], ["103Instrumentation and analysisIt is the only test that uses a three-point calibration curve.", [["analysis", "TEST", 23, 31]]], ["The sensitivity and specificity are 95.0% and 104Instrumentation and analysis98.3% respectively [11] .", [["The sensitivity", "TEST", 0, 15], ["specificity", "TEST", 20, 31], ["104Instrumentation", "TEST", 46, 64], ["analysis", "TEST", 69, 77]]], ["105Instrumentation and analysisThe Abbott SARS-CoV-2 IgG assay was run on the Abbott Architect i2000SR analyzer that measures 106Instrumentation and analysisIgG antibodies to the nucleocapsid protein.", [["IgG", "PROTEIN", 53, 56], ["analysisIgG antibodies", "PROTEIN", 149, 171], ["nucleocapsid protein", "PROTEIN", 179, 199], ["SARS-CoV", "SPECIES", 42, 50], ["analysis", "TEST", 23, 31], ["The Abbott SARS", "TEST", 31, 46], ["CoV", "TEST", 47, 50], ["IgG assay", "TEST", 53, 62], ["analysisIgG antibodies", "TEST", 149, 171]]], ["The automated, two-step immunoassay uses 107 chemiluminescent microparticle immunoassay (CMIA) technology for qualitative detection of IgG 108Instrumentation and analysisantibodies in human serum.", [["serum", "ANATOMY", 190, 195], ["IgG 108Instrumentation", "SIMPLE_CHEMICAL", 135, 157], ["human", "ORGANISM", 184, 189], ["serum", "ORGANISM_SUBSTANCE", 190, 195], ["IgG 108Instrumentation", "PROTEIN", 135, 157], ["human", "SPECIES", 184, 189], ["human", "SPECIES", 184, 189], ["two-step immunoassay", "TEST", 15, 35], ["chemiluminescent microparticle immunoassay", "TEST", 45, 87], ["qualitative detection", "TEST", 110, 131], ["IgG 108Instrumentation", "TEST", 135, 157], ["analysisantibodies in human serum", "TEST", 162, 195]]], ["The sample, SARS-CoV-2 antigen-coated paramagnetic microparticles, and 109 diluent are combined and incubated.", [["sample", "ANATOMY", 4, 10], ["SARS-CoV-2 antigen", "CHEMICAL", 12, 30], ["SARS-CoV", "SPECIES", 12, 20], ["The sample", "TEST", 0, 10], ["SARS", "TEST", 12, 16], ["CoV", "TEST", 17, 20], ["coated paramagnetic microparticles", "TREATMENT", 31, 65]]], ["The antibodies bind to the antigen-coated microparticles.", [["antibodies", "PROTEIN", 4, 14], ["The antibodies bind", "TREATMENT", 0, 19], ["coated microparticles", "OBSERVATION", 35, 56]]], ["The 110 mixture is washed and anti-human IgG acridinium-labeled conjugate is added.", [["acridinium", "CHEMICAL", 45, 55], ["acridinium", "CHEMICAL", 45, 55], ["acridinium", "SIMPLE_CHEMICAL", 45, 55], ["anti-human IgG acridinium-labeled conjugate", "PROTEIN", 30, 73], ["The 110 mixture", "TREATMENT", 0, 15], ["anti-human IgG acridinium-labeled conjugate", "TREATMENT", 30, 73]]], ["The resulting chemiluminescent reaction is measured as a relative light unit (RLU).", [["The resulting chemiluminescent reaction", "PROBLEM", 0, 39], ["chemiluminescent reaction", "OBSERVATION", 14, 39]]], ["112Instrumentation and analysisThe presence or absence of IgG antibodies is determined by dividing the sample RLU by the stored 113 calibrator RLU to find the IgG assay index (S/C), with a positive cutoff of \u22651.4.", [["sample", "ANATOMY", 103, 109], ["IgG antibodies", "PROTEIN", 58, 72], ["IgG", "PROTEIN", 159, 162], ["analysis", "TEST", 23, 31], ["IgG antibodies", "PROBLEM", 58, 72], ["the IgG assay index", "TEST", 155, 174], ["a positive cutoff of \u2265", "PROBLEM", 187, 209], ["IgG antibodies", "OBSERVATION", 58, 72]]], ["The sensitivity and 114 specificity are 100% and 99.63% respectively at \u2265 14 days post onset of symptoms [12] .", [["The sensitivity", "TEST", 0, 15], ["specificity", "TEST", 24, 35], ["symptoms", "PROBLEM", 96, 104]]], ["115Instrumentation and analysisThe LIAISON SARS-Cov-2 S1/S2 IgG is a chemiluminescent immunoassay (CLIA) for detection of anti-116 S1 and anti-S2 spike glycoprotein specific to SARS-CoV-2 in human serum or plasma on the DiaSorin 117 XL analyzer (Stillwater, MN).", [["serum", "ANATOMY", 197, 202], ["plasma", "ANATOMY", 206, 212], ["anti-116 S1", "GENE_OR_GENE_PRODUCT", 122, 133], ["anti-S2", "GENE_OR_GENE_PRODUCT", 138, 145], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 177, 187], ["human", "ORGANISM", 191, 196], ["serum", "ORGANISM_SUBSTANCE", 197, 202], ["plasma", "ORGANISM_SUBSTANCE", 206, 212], ["LIAISON SARS-Cov-2 S1/S2 IgG", "PROTEIN", 35, 63], ["anti-116 S1", "PROTEIN", 122, 133], ["anti-S2 spike glycoprotein", "PROTEIN", 138, 164], ["human", "SPECIES", 191, 196], ["SARS-CoV", "SPECIES", 177, 185], ["human", "SPECIES", 191, 196], ["Instrumentation", "TEST", 3, 18], ["analysis", "TEST", 23, 31], ["The LIAISON SARS", "TEST", 31, 47], ["Cov", "TEST", 48, 51], ["a chemiluminescent immunoassay", "TEST", 67, 97], ["detection", "TEST", 109, 118], ["anti", "TEST", 122, 126], ["SARS", "TEST", 177, 181], ["CoV", "TEST", 182, 185], ["human serum", "TEST", 191, 202], ["the DiaSorin", "TREATMENT", 216, 228]]], ["Specimen, calibrator, control, coated magnetic particles and diluent are 118 incubated in reaction cuvettes.", [["Specimen", "TEST", 0, 8], ["calibrator, control, coated magnetic particles", "TREATMENT", 10, 56]]], ["The antibodies bind to the solid phase through the recombinant S1 and S2 119 antigens.", [["S2 119 antigens", "GENE_OR_GENE_PRODUCT", 70, 85], ["antibodies", "PROTEIN", 4, 14], ["recombinant S1 and S2 119 antigens", "PROTEIN", 51, 85], ["The antibodies", "TEST", 0, 14], ["solid phase", "OBSERVATION_MODIFIER", 27, 38], ["S1", "ANATOMY", 63, 65]]], ["A second incubation links recombinant S1 and S2 antigens to an isoluminol-antibody conjugate.", [["isoluminol", "CHEMICAL", 63, 73], ["isoluminol", "CHEMICAL", 63, 73], ["S2 antigens", "GENE_OR_GENE_PRODUCT", 45, 56], ["isoluminol", "SIMPLE_CHEMICAL", 63, 73], ["recombinant S1 and S2 antigens", "PROTEIN", 26, 56], ["isoluminol-antibody conjugate", "PROTEIN", 63, 92], ["an isoluminol-antibody conjugate", "TEST", 60, 92]]], ["120Instrumentation and analysisThe starter reagents are then added, and a flash chemiluminescence reaction induced.", [["analysis", "TEST", 23, 31], ["The starter reagents", "TREATMENT", 31, 51], ["a flash chemiluminescence reaction", "PROBLEM", 72, 106]]], ["The light signal, and 121Instrumentation and analysishence the amount of isoluminol-antibody conjugate, is measured by a photomultiplier and result 122 converted to arbitrary concentration, AU/mL.", [["isoluminol", "CHEMICAL", 73, 83], ["isoluminol", "CHEMICAL", 73, 83], ["isoluminol", "SIMPLE_CHEMICAL", 73, 83], ["isoluminol", "PROTEIN", 73, 83], ["antibody conjugate", "PROTEIN", 84, 102], ["The light signal", "TEST", 0, 16], ["isoluminol-antibody conjugate", "TREATMENT", 73, 102], ["a photomultiplier", "TEST", 119, 136]]], ["Samples with AU/mL of \u226515 are considered positive for 123 All rights reserved.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["AU/mL", "TEST", 13, 18]]], ["No reuse allowed without permission.Instrumentation and analysiswas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Instrumentation and analysisThe copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.06.20145938 doi: medRxiv preprint IgG antibodies.", [["doi: medRxiv preprint IgG antibodies", "PROTEIN", 346, 382], ["Instrumentation", "TREATMENT", 36, 51], ["Instrumentation", "TREATMENT", 192, 207], ["analysis", "TEST", 212, 220], ["The copyright holder", "TREATMENT", 220, 240], ["medRxiv preprint IgG antibodies", "TREATMENT", 351, 382], ["med", "ANATOMY", 136, 139]]], ["The sensitivity and specificity are 90-97% and 98% respectively \u2265 14 days post onset of 124 symptoms [13] .", [["The sensitivity", "TEST", 0, 15], ["specificity", "TEST", 20, 31], ["124 symptoms", "PROBLEM", 88, 100]]], ["125Instrumentation and analysisThe Elecsys Anti-SARS-CoV-2 assay is performed on the Roche cobas e601 analyzer for total antibodies 126 specific for IgG, IgM and IgA which target nucleocapsid protein, in human serum or plasma.", [["serum", "ANATOMY", 210, 215], ["plasma", "ANATOMY", 219, 225], ["IgG", "GENE_OR_GENE_PRODUCT", 149, 152], ["IgM", "GENE_OR_GENE_PRODUCT", 154, 157], ["IgA", "GENE_OR_GENE_PRODUCT", 162, 165], ["human", "ORGANISM", 204, 209], ["serum", "ORGANISM_SUBSTANCE", 210, 215], ["plasma", "ORGANISM_SUBSTANCE", 219, 225], ["total antibodies 126", "PROTEIN", 115, 135], ["IgG", "PROTEIN", 149, 152], ["IgM", "PROTEIN", 154, 157], ["IgA", "PROTEIN", 162, 165], ["nucleocapsid protein", "PROTEIN", 179, 199], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 204, 209], ["analysis", "TEST", 23, 31], ["The Elecsys", "TEST", 31, 42], ["Anti-SARS", "TEST", 43, 52], ["CoV", "TEST", 53, 56], ["the Roche cobas", "TEST", 81, 96], ["total antibodies", "TEST", 115, 131], ["IgG", "TEST", 149, 152], ["IgM", "TEST", 154, 157], ["IgA", "TEST", 162, 165], ["nucleocapsid protein", "TEST", 179, 199], ["human serum", "TEST", 204, 215]]], ["In order to rule out non-specific binding, samples that tested positive by ELISA assay were diluted using 144 sample diluent provided in the AnshLabs assay kit.", [["samples", "ANATOMY", 43, 50], ["non-specific binding", "PROBLEM", 21, 41], ["ELISA assay", "TEST", 75, 86]]], ["We made and reran samples for a 1:2, 1:3 and 1:4 145 dilution, and calculated percent recovery.", [["percent recovery", "OBSERVATION", 78, 94]]], ["No reuse allowed without permission.Instrumentation and analysiswas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Instrumentation and analysisThe copyright holder for this preprint (which this version posted July 8, 2020.155The specificities of the validated in-house AnshLabs SARS-CoV-2-IgG and IgM are listed in Table 2 .", [["CoV-2", "ORGANISM", 360, 365], ["IgG", "GENE_OR_GENE_PRODUCT", 366, 369], ["IgM", "GENE_OR_GENE_PRODUCT", 374, 377], ["IgG", "PROTEIN", 366, 369], ["IgM", "PROTEIN", 374, 377], ["Instrumentation", "TREATMENT", 36, 51], ["Instrumentation", "TREATMENT", 192, 207], ["analysis", "TEST", 212, 220], ["CoV", "TEST", 360, 363], ["med", "ANATOMY", 136, 139]]], ["156155The cross reactivity to anti-influenza B IgG (5 samples), anti-respiratory syncytial virus IgG (5 samples were positive for these analytes.", [["samples", "ANATOMY", 54, 61], ["samples", "ANATOMY", 104, 111], ["anti-influenza B IgG", "GENE_OR_GENE_PRODUCT", 30, 50], ["5", "ORGANISM", 52, 53], ["samples", "CANCER", 54, 61], ["anti-respiratory syncytial virus IgG", "ORGANISM", 64, 100], ["samples", "CANCER", 104, 111], ["anti-influenza B IgG", "PROTEIN", 30, 50], ["IgG", "PROTEIN", 97, 100], ["anti-respiratory syncytial virus", "SPECIES", 64, 96], ["anti-influenza B", "SPECIES", 30, 46], ["anti-respiratory syncytial virus", "SPECIES", 64, 96], ["The cross reactivity", "TEST", 6, 26], ["anti-influenza B IgG", "TEST", 30, 50], ["anti-respiratory syncytial virus IgG", "TEST", 64, 100], ["these analytes", "TEST", 130, 144]]], ["No cross-reactivity was noted for either SARS-CoV-2-IgG or IgM.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 41, 51], ["IgG", "GENE_OR_GENE_PRODUCT", 52, 55], ["IgM.", "SIMPLE_CHEMICAL", 59, 63], ["IgG", "PROTEIN", 52, 55], ["cross-reactivity", "PROBLEM", 3, 19], ["SARS", "TEST", 41, 45], ["CoV", "TEST", 46, 49], ["cross-reactivity", "OBSERVATION", 3, 19]]], ["The 161 clinical sensitivity and specificity using rtPCR results as the gold standard were found to be 86.7and 162 91.2% respectively.", [["rtPCR", "TEST", 51, 56]]], ["All samples used for the sensitivity and specificity evaluation were collected from 163 symptomatic patients, either hospitalized inpatients or treated in Emergency Department.", [["samples", "ANATOMY", 4, 11], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["All samples", "TEST", 0, 11], ["the sensitivity", "TEST", 21, 36], ["specificity evaluation", "TEST", 41, 63]]], ["The interval 164 between rtPCR confirmation and serology testing ranged from 2-12 days.", [["The interval", "TEST", 0, 12], ["rtPCR confirmation", "TEST", 25, 43], ["serology testing", "TEST", 48, 64]]], ["The specificity toward common 165 cold coronavirus is shown in Table 3 .", [["common 165 cold coronavirus", "PROBLEM", 23, 50]]], ["Three of 100 prepandemic samples tested positive for IgG by 166 ELISA and none tested positive by RAIA methods, thereby giving a calculated specificity of 97% and 167 100% for ELISA and RAIA respectively.", [["samples", "ANATOMY", 25, 32], ["samples", "CANCER", 25, 32], ["IgG", "GENE_OR_GENE_PRODUCT", 53, 56], ["IgG", "PROTEIN", 53, 56], ["100 prepandemic samples", "TEST", 9, 32], ["IgG", "TEST", 53, 56], ["ELISA", "TEST", 64, 69], ["a calculated specificity", "TEST", 127, 151], ["ELISA", "TEST", 176, 181]]], ["No reuse allowed without permission.155was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.155The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.06.20145938 doi: medRxiv preprint Table 4 shows the concordance between ELISA and RAIA results for samples that were confirmed 174 positive for SARS-CoV-2 by rtPCR.", [["samples", "ANATOMY", 383, 390], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 428, 438], ["rtPCR", "PROTEIN", 442, 447], ["SARS-CoV", "SPECIES", 428, 436], ["ELISA", "TEST", 356, 361], ["samples", "TEST", 383, 390], ["SARS", "TEST", 428, 432], ["CoV", "TEST", 433, 436], ["med", "ANATOMY", 111, 114]]], ["These samples were collected from symptomatic patients > 13 days 175 post rtPCR confirmation.", [["samples", "ANATOMY", 6, 13], ["samples", "CANCER", 6, 13], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["These samples", "TEST", 0, 13], ["rtPCR confirmation", "TEST", 74, 92]]], ["ELISA assay correlated best with Total Antibody assay on Roche Elecsys e601 176155analyzer.", [["ELISA assay", "TEST", 0, 11], ["Total Antibody assay", "TEST", 33, 53], ["Roche Elecsys", "TEST", 57, 70], ["analyzer", "TEST", 82, 90]]], ["This could possibly be attributed to the measurement of IgG antibodies directed towards 177 multiple antigenic proteins (nucleocapsid & spike) by ELISA or measurement of total antibodies (IgG, 178155IgM, and IgA) on Roche Elecsys e601 analyzer.", [["IgG antibodies", "GENE_OR_GENE_PRODUCT", 56, 70], ["nucleocapsid", "GENE_OR_GENE_PRODUCT", 121, 133], ["IgG, 178155IgM", "GENE_OR_GENE_PRODUCT", 188, 202], ["IgA", "GENE_OR_GENE_PRODUCT", 208, 211], ["IgG antibodies", "PROTEIN", 56, 70], ["177 multiple antigenic proteins", "PROTEIN", 88, 119], ["nucleocapsid", "PROTEIN", 121, 133], ["total antibodies", "PROTEIN", 170, 186], ["IgG", "PROTEIN", 188, 191], ["178155IgM", "PROTEIN", 193, 202], ["IgA", "PROTEIN", 208, 211], ["IgG antibodies", "TEST", 56, 70], ["multiple antigenic proteins (nucleocapsid & spike", "PROBLEM", 92, 141], ["ELISA", "TEST", 146, 151], ["total antibodies", "TEST", 170, 186], ["IgG", "TEST", 188, 191], ["IgM", "TEST", 199, 202], ["IgA", "TEST", 208, 211], ["could possibly be attributed to", "UNCERTAINTY", 5, 36]]], ["Concordance of 15 rtPCR positive samples between a) ELISA and RAIA systems and b) among 180 three RAIA platforms 181Concordance Between ELISA and RAIA for samples from rtPCR positive patients (N = 15)AnshLabs IgG vs Architect i2000 93.3% AnshLabs IgG vs Elecsys e601 100% All rights reserved.", [["samples", "ANATOMY", 33, 40], ["samples", "ANATOMY", 155, 162], ["patients", "ORGANISM", 183, 191], ["AnshLabs", "ORGANISM", 200, 208], ["IgG", "ORGANISM", 209, 212], ["rtPCR", "PROTEIN", 18, 23], ["IgG", "PROTEIN", 209, 212], ["IgG", "PROTEIN", 247, 250], ["patients", "SPECIES", 183, 191], ["Concordance", "TEST", 0, 11], ["rtPCR", "TEST", 18, 23], ["a) ELISA and RAIA systems", "TEST", 49, 74], ["RAIA platforms", "TEST", 98, 112], ["ELISA", "TEST", 136, 141], ["samples", "TEST", 155, 162], ["rtPCR", "TEST", 168, 173], ["N", "TEST", 193, 194], ["AnshLabs", "TEST", 200, 208], ["IgG", "TEST", 209, 212], ["Architect", "TEST", 216, 225], ["AnshLabs", "TEST", 238, 246], ["IgG", "TEST", 247, 250], ["Elecsys", "TEST", 254, 261], ["e601", "TEST", 262, 266]]], ["No reuse allowed without permission.Concordance Between ELISA and RAIA for samples from rtPCR positive patients (N = 15)was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Concordance Between ELISA and RAIA for samples from rtPCR positive patients (N = 15)The copyright holder for this preprint (which this version posted July 8, 2020.", [["samples", "ANATOMY", 75, 82], ["samples", "ANATOMY", 287, 294], ["patients", "ORGANISM", 103, 111], ["patients", "ORGANISM", 315, 323], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 315, 323], ["Concordance", "TEST", 36, 47], ["ELISA", "TEST", 56, 61], ["samples", "TEST", 75, 82], ["rtPCR", "TEST", 88, 93], ["Concordance", "TEST", 248, 259], ["ELISA", "TEST", 268, 273], ["samples", "TEST", 287, 294], ["rtPCR", "TEST", 300, 305], ["The copyright holder", "TREATMENT", 332, 352], ["med", "ANATOMY", 192, 195]]], ["The concordance of ELISA and RAIA results with rtPCR is shown in Table 6 .", [["RAIA", "PROTEIN", 29, 33], ["rtPCR", "PROTEIN", 47, 52], ["ELISA", "TEST", 19, 24], ["rtPCR", "TEST", 47, 52]]], ["All patient tested positive 193 by rtPCR also tested positive by ELISA and Elecsys e601 total antibody.", [["patient", "ORGANISM", 4, 11], ["rtPCR", "GENE_OR_GENE_PRODUCT", 35, 40], ["rtPCR", "PROTEIN", 35, 40], ["Elecsys e601 total antibody", "PROTEIN", 75, 102], ["patient", "SPECIES", 4, 11], ["All patient tested", "TEST", 0, 18], ["rtPCR", "TEST", 35, 40], ["ELISA", "TEST", 65, 70], ["Elecsys", "TEST", 75, 82], ["total antibody", "TEST", 88, 102]]], ["Architect i2000 IgG and Liaison XL were unable to detect antibodies in one sample.", [["IgG", "GENE_OR_GENE_PRODUCT", 16, 19], ["Architect i2000 IgG", "PROTEIN", 0, 19], ["antibodies", "PROTEIN", 57, 67], ["Architect", "TEST", 0, 9], ["Liaison XL", "TREATMENT", 24, 34], ["antibodies", "TEST", 57, 67]]], ["All RAIA methodologies showed 195 high correlation with nucleic acid test for patient samples that tested negative by rtPCR, with 196 All rights reserved.", [["samples", "ANATOMY", 86, 93], ["nucleic acid", "CHEMICAL", 56, 68], ["patient", "ORGANISM", 78, 85], ["patient", "SPECIES", 78, 85], ["All RAIA methodologies", "TEST", 0, 22], ["nucleic acid test", "TEST", 56, 73], ["patient samples", "TEST", 78, 93], ["rtPCR", "TEST", 118, 123]]], ["No reuse allowed without permission.Concordance Between ELISA and RAIA for samples from rtPCR positive patients (N = 15)was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Concordance Between ELISA and RAIA for samples from rtPCR positive patients (N = 15)The copyright holder for this preprint (which this version posted July 8, 2020.", [["samples", "ANATOMY", 75, 82], ["samples", "ANATOMY", 287, 294], ["patients", "ORGANISM", 103, 111], ["patients", "ORGANISM", 315, 323], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 315, 323], ["Concordance", "TEST", 36, 47], ["ELISA", "TEST", 56, 61], ["samples", "TEST", 75, 82], ["rtPCR", "TEST", 88, 93], ["Concordance", "TEST", 248, 259], ["ELISA", "TEST", 268, 273], ["samples", "TEST", 287, 294], ["rtPCR", "TEST", 300, 305], ["The copyright holder", "TREATMENT", 332, 352], ["med", "ANATOMY", 192, 195]]], ["The non-specific binding dilution data of the AnshLabs assay showed five samples with various 202 concentration levels of IgG were serial diluted to 1:2, 1:4: 1:8 and 1:16.", [["samples", "ANATOMY", 73, 80], ["IgG", "GENE_OR_GENE_PRODUCT", 122, 125], ["AnshLabs", "PROTEIN", 46, 54], ["IgG", "PROTEIN", 122, 125], ["The non-specific binding dilution data", "TEST", 0, 38], ["the AnshLabs assay", "TEST", 42, 60], ["IgG", "TEST", 122, 125]]], ["All samples gave a consistent 203 dilution pattern and expected 90-100% recovery of neat sample in AU/mL units (Fig 1) .", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11]]], ["204 205206All RAIA methods correlated well with ELISA and rtPCR for samples collected >13 days post rtPCR 207206confirmation.", [["samples", "ANATOMY", 68, 75], ["rtPCR 207206", "CHEMICAL", 100, 112], ["ELISA", "TEST", 48, 53], ["rtPCR", "TEST", 58, 63], ["samples", "TEST", 68, 75], ["rtPCR", "TEST", 100, 105]]], ["There were no significant differences among the methods which tested for IgG targeted to 208 one or both nucleocapsid and spike proteins, or tested for total antibodies.", [["IgG", "GENE_OR_GENE_PRODUCT", 73, 76], ["IgG", "PROTEIN", 73, 76], ["nucleocapsid and spike proteins", "PROTEIN", 105, 136], ["total antibodies", "PROTEIN", 152, 168], ["significant differences", "PROBLEM", 14, 37], ["the methods", "TEST", 44, 55], ["IgG", "TEST", 73, 76], ["spike proteins", "TEST", 122, 136], ["total antibodies", "TEST", 152, 168], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25]]], ["209 ELISA detected higher sero-prevalence in rtPCR negative samples than the RAIA methods.", [["samples", "ANATOMY", 60, 67], ["ELISA", "TEST", 4, 9], ["sero-prevalence", "TEST", 26, 41], ["rtPCR", "TEST", 45, 50]]], ["This may be 210 due to i) higher analytical sensitivity or a lower cutoff by ELISA, which triggered more positive results; 211206ii) cross reactivity to other coronavirus; iii) non-specific binding of other antibodies, for example 212 autoimmune antibodies or deposition of detection antibody on the microtiter well which led to increased 213 absorbance causing false positives 214 All rights reserved.", [["antibodies", "PROTEIN", 207, 217], ["autoimmune antibodies", "PROTEIN", 235, 256], ["detection antibody", "PROTEIN", 274, 292], ["higher analytical sensitivity", "PROBLEM", 26, 55], ["a lower cutoff", "PROBLEM", 59, 73], ["ELISA", "TEST", 77, 82], ["cross reactivity to other coronavirus", "PROBLEM", 133, 170], ["non-specific binding of other antibodies", "PROBLEM", 177, 217], ["autoimmune antibodies", "PROBLEM", 235, 256], ["detection antibody", "TEST", 274, 292], ["the microtiter", "TEST", 296, 310], ["increased 213 absorbance", "PROBLEM", 329, 353], ["false positives", "TEST", 362, 377]]], ["No reuse allowed without permission.206was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.206The copyright holder for this preprint (which this version posted July 8, 2020 . . https://doi.org/10.1101 ELISA assays are generally known for low detection limits in sub ng/mL to low pg/mL because of their 215 increased incubation time thereby allowing antigen-antibody to reach reaction equilibrium and extra 216 washing steps [15, 16] .", [["https://doi.org/10.1101", "CHEMICAL", 253, 276], ["antigen-antibody", "GENE_OR_GENE_PRODUCT", 425, 441], ["antigen-antibody", "PROTEIN", 425, 441], ["The copyright holder", "TREATMENT", 170, 190], ["ELISA assays", "TEST", 277, 289], ["antigen", "TEST", 425, 432], ["med", "ANATOMY", 111, 114]]], ["The Dynex DSX analyzer used for ELISA assay provided optimization flexibility 217 and automation, which is not available on RAIA due to throughput constraint.", [["DSX", "PROTEIN", 10, 13], ["The Dynex DSX analyzer", "TEST", 0, 22], ["ELISA assay", "TEST", 32, 43], ["optimization flexibility", "TEST", 53, 77], ["automation", "TEST", 86, 96]]], ["Cross-reactivity to other 218 coronavirus was evaluated by testing 100 prepandemic samples and found to be 3% and 0% for ELISA 219 and RAIA respectively.", [["samples", "ANATOMY", 83, 90], ["coronavirus", "ORGANISM", 30, 41], ["coronavirus", "PROBLEM", 30, 41], ["ELISA", "TEST", 121, 126]]], ["The differences in cross-reactivity may account for one or two false positive 220 results, but not for all 34 and 15 positives picked up by ELISA.", [["may account for", "UNCERTAINTY", 36, 51]]], ["Non-specific deposition of other 221 antibodies in patient samples or detection antibody was ruled out by dilution studies for ELISA.", [["samples", "ANATOMY", 59, 66], ["patient", "ORGANISM", 51, 58], ["221 antibodies", "PROTEIN", 33, 47], ["patient", "SPECIES", 51, 58], ["Non-specific deposition of other 221 antibodies", "PROBLEM", 0, 47], ["patient samples", "TEST", 51, 66], ["detection antibody", "TEST", 70, 88], ["dilution studies", "TEST", 106, 122], ["ELISA", "TEST", 127, 132], ["deposition", "OBSERVATION_MODIFIER", 13, 23]]], ["Recovery 222 of 90-110% ruled out non-specific binding as a possible cause for false positives (Fig 1) .", [["Recovery", "TEST", 0, 8], ["non-specific binding", "PROBLEM", 34, 54], ["false positives", "PROBLEM", 79, 94]]], ["The difference 223206in results for positive and negative samples by RAIA methods may also be due to a higher threshold for 224 positivity.", [["samples", "ANATOMY", 58, 65], ["RAIA methods", "TEST", 69, 81]]], ["The rtPCR assay is used as the gold standard in maximizing analytical sensitivity and 225 specificity during method development which is the most accurate in the early days of the infection when 226 antibody development is low and results in the reported sensitivity of 10-60% on samples collected <14 227 days post rtPCR confirmation [17] [18] [19] .", [["samples", "ANATOMY", 280, 287], ["infection", "DISEASE", 180, 189], ["rtPCR", "PROTEIN", 4, 9], ["The rtPCR assay", "TEST", 0, 15], ["the infection", "PROBLEM", 176, 189], ["antibody development", "TEST", 199, 219], ["samples", "TEST", 280, 287], ["rtPCR confirmation", "TEST", 316, 334], ["infection", "OBSERVATION", 180, 189]]], ["228206We believe that higher rate of positivity observed for ELISA i.e. 34 versus 1 by Architect, 7 by Liaison was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.206The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.", [["ELISA", "TEST", 61, 66], ["The copyright holder", "TREATMENT", 242, 262], ["med", "ANATOMY", 183, 186]]], ["1101 Our quality assurance project has some notable limitations.", [["notable", "OBSERVATION_MODIFIER", 44, 51]]], ["At this stage of the disease, true clinical 238 sensitivity and specificity for different methodologies is difficult to determine because of our limited 239 understanding of the disease process and kinetics.", [["the disease", "PROBLEM", 17, 28], ["the disease process", "PROBLEM", 174, 193], ["disease", "OBSERVATION", 21, 28]]], ["Secondly, our assumption that ELISA has better limits 240 of detection is based on circumstantial evidence, as certified standards quantifying limits of detection on 241 different platforms are not available.", [["ELISA", "TEST", 30, 35]]], ["Establishing laboratory specific cut-off is akin to 243 establishing reference ranges, which is highly dependent on prevalence of disease in local population.", [["disease", "PROBLEM", 130, 137], ["highly dependent", "OBSERVATION_MODIFIER", 96, 112], ["disease", "OBSERVATION", 130, 137]]], ["244 245246All of the assays we investigated would work well for epidemiological sero-prevalence studies.", [["244 245246", "CHEMICAL", 0, 10], ["the assays", "TEST", 17, 27], ["epidemiological sero-prevalence studies", "TEST", 64, 103]]], ["Among 247 rtPCR negative patients, ELISA gave higher estimates of sero-prevalence in our dataset and would 248 probably do so in population-based epidemiological surveys using serological testing.", [["rtPCR", "CANCER", 10, 15], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["rtPCR", "TEST", 10, 15], ["ELISA", "TEST", 35, 40], ["serological testing", "TEST", 176, 195]]], ["RAIA methods 249 could however offer other advantages over ELISA which includes i) faster turnaround time; ii) random 250 access to allow immediate testing; iii) longer calibration stability, obviating the need to perform daily 251 calibration as required by ELISA; iv) the ability to perform other immunoassay testing concurrently; and 252 v) higher test throughput and walk away capabilities.", [["immediate testing", "TEST", 138, 155], ["other immunoassay testing", "TEST", 293, 318], ["higher test", "TEST", 344, 355]]], ["However in conclusion, no serological method 253 tested has sensitivity and specificity greater than or equal to 99% for one to 5 days post exposure, limiting 254 their use in early diagnosis.", [["serological method", "TEST", 26, 44], ["sensitivity", "TEST", 60, 71], ["specificity", "TEST", 76, 87], ["no", "UNCERTAINTY", 23, 25]]], ["255256The authors would like to thank Ms. Briget Da Graca for editorial comments and manuscript revision.", [["255256", "CHEMICAL", 0, 6], ["255256", "SPECIES", 0, 6], ["manuscript revision", "TREATMENT", 85, 104], ["revision", "OBSERVATION", 96, 104]]], ["We 257 also acknowledge Ms. Laura Gonazales and her team from Health Texas Provider Network (Dallas, TX) 258 for correlation of AnshLabs results using Siemens Centaur total antibody assay.", [["Siemens Centaur total antibody assay", "TEST", 151, 187]]], ["No reuse allowed without permission.256was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.256The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.06.20145938 doi: medRxiv preprint non-specific binding in AnshLabs ELISA assay 320 All rights reserved.", [["medRxiv preprint non-specific binding", "PROBLEM", 301, 338], ["ELISA assay", "TEST", 351, 362], ["med", "ANATOMY", 111, 114]]], ["No reuse allowed without permission.Figure Legendwas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Figure LegendThe copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.06.20145938 doi: medRxiv preprint", [["medRxiv", "TREATMENT", 321, 328], ["med", "ANATOMY", 121, 124]]]], "02e34b2fe0968cb8a46313fe767858da7e2691b1": [["BackgroundOverlapping genes (whereby the same nucleotide sequence codes for two or more proteins in different reading frames) are particularly common in RNA viruses, where they may serve as mechanisms to optimize the coding potential of compact genomes, regulate gene expression, or circumvent the host cell's canonical -though not ubiquitous -rule of 'one functional protein per mRNA'.", [["cell", "ANATOMY", 303, 307], ["nucleotide", "CHEMICAL", 46, 56], ["host cell", "CELL", 298, 307], ["nucleotide sequence", "DNA", 46, 65], ["compact genomes", "DNA", 237, 252], ["mRNA", "RNA", 380, 384], ["RNA viruses", "PROBLEM", 153, 164], ["the host cell's canonical", "TEST", 294, 319], ["RNA viruses", "OBSERVATION", 153, 164]]], ["However, such genes can be difficult to detect using conventional gene-finding software.BackgroundMLOGD is a gene-finding program which was designed specifically for identifying overlapping coding sequences (CDSs) through the incorporation of explicit models for sequence evolution in multiply-coding regions [1] [2] [3] .", [["BackgroundMLOGD", "DNA", 88, 103], ["overlapping coding sequences", "DNA", 178, 206], ["CDSs", "DNA", 208, 212], ["sequence evolution", "TEST", 263, 281]]], ["One caveat is that de novo overlapping CDSs are often considerably less conserved than the ancestral genes that they overlap (the ancestral gene is usually the known gene as it tends to be the longer of the two, while the de novo gene is often very short).", [["CDSs", "DNA", 39, 43], ["de novo gene", "DNA", 222, 234]]], ["The explicit 'coding signal' of such a CDS may be swamped by the 'coding signal' of the ancestral CDS.", [["CDS", "DNA", 39, 42], ["ancestral CDS", "DNA", 88, 101]]], ["Thus there are a number of known overlapping CDSs which MLOGD fails to detect.", [["CDSs", "DNA", 45, 49], ["MLOGD", "DNA", 56, 61], ["known overlapping CDSs", "PROBLEM", 27, 49], ["overlapping CDSs", "OBSERVATION", 33, 49]]], ["Another caveat of MLOGD is that, if an overlapping CDS is very short and highly conserved (e.g. due to coding in two different reading frames and perhaps also harbouring an RNA secondary structure for stimulating ribosomal frameshifting into the overlapping CDS; [4] ), then there may be too few base variations to obtain a useful signal (either coding or non-coding).", [["ribosomal", "ANATOMY", 213, 222], ["MLOGD", "GENE_OR_GENE_PRODUCT", 18, 23], ["ribosomal", "CELLULAR_COMPONENT", 213, 222], ["MLOGD", "DNA", 18, 23], ["CDS", "DNA", 51, 54], ["reading frames", "DNA", 127, 141], ["overlapping CDS", "DNA", 246, 261], ["an overlapping CDS", "PROBLEM", 36, 54], ["an RNA secondary structure", "PROBLEM", 170, 196], ["stimulating ribosomal frameshifting", "PROBLEM", 201, 236], ["too few base variations", "PROBLEM", 288, 311], ["ribosomal frameshifting", "OBSERVATION", 213, 236]]], ["On the other hand, for overlapping CDSs that are subject to a reasonable degree of purifying selection and that are not too short, MLOGD can provide a robust detection with just two input sequences provided that they are sufficiently divergent.BackgroundA sometimes more sensitive, but generally less specific, approach involves analysis of conservation at synonymous sites within known CDSs.", [["overlapping CDSs", "DNA", 23, 39], ["MLOGD", "DNA", 131, 136], ["CDSs", "DNA", 387, 391], ["overlapping CDSs", "TEST", 23, 39], ["conservation at synonymous sites", "TREATMENT", 341, 373], ["purifying selection", "OBSERVATION", 83, 102]]], ["This method is particularly useful when a large and diverse input sequence alignment is available [5, 6] .", [["a large and diverse input sequence alignment", "PROBLEM", 40, 84]]], ["Enhanced conservation may be associated with overlapping functional elements.", [["overlapping functional elements", "DNA", 45, 76], ["may be associated with", "UNCERTAINTY", 22, 44], ["functional elements", "OBSERVATION", 57, 76]]], ["However such elements may be either coding or non-coding, so additional evidence (e.g. conservation of an overlapping open reading frame and a potential translation mechanism over a sufficiently divergent sequence alignment) is required in order to use this method to identify overlapping CDSs.", [["overlapping open reading frame", "DNA", 106, 136], ["CDSs", "DNA", 289, 293], ["an overlapping open reading frame", "TREATMENT", 103, 136], ["this method", "TREATMENT", 253, 264], ["may be", "UNCERTAINTY", 22, 28]]], ["Care also needs to be taken to discriminate dual-coding sequences from regions of enhanced conservation that may arise from recombination.BackgroundOver the past few years we have engaged in a systematic survey of viral genomes for previously undetected overlapping genes.", [["dual-coding sequences", "DNA", 44, 65], ["viral genomes", "DNA", 214, 227], ["overlapping genes", "DNA", 254, 271], ["enhanced conservation", "TREATMENT", 82, 103], ["viral genomes", "PROBLEM", 214, 227], ["viral genomes", "OBSERVATION", 214, 227]]], ["While many of these merit detailed analysis and experimental follow-up (either because they are in important and well-studied viruses or because they involve novel non-canonical translation mechanisms), there remain a miscellany of promising candidate new overlapping genes that we are not currently in a position to follow up experimentally but, nonetheless, may be of interest to the community.", [["detailed analysis", "TEST", 26, 43]]], ["The purpose of this article is to communicate five of these candidates.Results and DiscussionCandidate new overlapping CDSs were identified using either MLOGD or analysis of conservation at synonymous sites within known CDSs.", [["overlapping CDSs", "DNA", 107, 123], ["MLOGD", "DNA", 153, 158], ["synonymous sites", "DNA", 190, 206], ["CDSs", "DNA", 220, 224], ["new overlapping CDSs", "PROBLEM", 103, 123], ["conservation at synonymous sites", "TREATMENT", 174, 206]]], ["Some candidates were detected by both methods, while others were only detected by one (candidates only detected by MLOGD are typically those for which only a small number of relevant sequences were available; candidates only detected by synonymous site conservation are typically those for which the overlapping CDS is subject to fairly weak constraints at the amino acid level).", [["amino acid", "CHEMICAL", 361, 371], ["amino acid", "CHEMICAL", 361, 371], ["amino acid", "AMINO_ACID", 361, 371], ["overlapping CDS", "DNA", 300, 315], ["fairly weak constraints", "PROBLEM", 330, 353], ["the amino acid level", "TEST", 357, 377]]], ["In all cases, candidates were closely inspected for a potential translation mechanism in the context of current knowledge of the gene expression strategy of the virus in question.", [["the virus", "PROBLEM", 157, 166]]], ["Coding potential graphs and nucleotide sequence alignments showing the initiation contexts for each candidate are presented in the figures.", [["nucleotide", "CHEMICAL", 28, 38], ["Coding potential graphs", "TEST", 0, 23], ["nucleotide sequence alignments", "TEST", 28, 58]]], ["It is interesting to note that all five candidates are in the +1 reading frame relative to the annotated, and most likely ancestral, CDS.", [["+1 reading frame", "DNA", 62, 78], ["CDS", "DNA", 133, 136], ["most likely", "UNCERTAINTY", 110, 121]]], ["In fact the preference for the evolution of de novo overlapping genes in the +1 frame, as opposed to the +2 frame, has been previously noted and appears to be related to codon (or dicodon) usage in the ancestral CDS [7] .", [["overlapping genes", "DNA", 52, 69], ["+1 frame", "DNA", 77, 85], ["+2 frame", "DNA", 105, 113], ["codon (or dicodon)", "PROBLEM", 170, 188], ["+1 frame", "OBSERVATION", 77, 85], ["appears to be related to", "UNCERTAINTY", 145, 169], ["codon", "OBSERVATION", 170, 175]]], ["Note that, in the following, the name 'ORFX' will be used repeatedly to refer to each candidate overlapping CDS.Mamastrovirus (human, porcine, feline astrovirus clade)Astroviruses have monopartite positive-sense ssRNA genomes and are associated with gastroenteritis and viral diarrhoea in humans and other vertebrates.", [["Mamastrovirus", "CHEMICAL", 112, 125], ["gastroenteritis", "DISEASE", 250, 265], ["viral diarrhoea", "DISEASE", 270, 285], ["human", "ORGANISM", 127, 132], ["porcine,", "ORGANISM", 134, 142], ["feline astrovirus", "ORGANISM", 143, 160], ["Astroviruses", "GENE_OR_GENE_PRODUCT", 167, 179], ["humans", "ORGANISM", 289, 295], ["CDS", "DNA", 108, 111], ["monopartite positive-sense ssRNA genomes", "DNA", 185, 225], ["human", "SPECIES", 127, 132], ["porcine", "SPECIES", 134, 141], ["feline astrovirus", "SPECIES", 143, 160], ["humans", "SPECIES", 289, 295], ["human", "SPECIES", 127, 132], ["humans", "SPECIES", 289, 295], ["Mamastrovirus (human, porcine, feline astrovirus clade", "TREATMENT", 112, 166], ["Astroviruses", "PROBLEM", 167, 179], ["monopartite positive", "PROBLEM", 185, 205], ["sense ssRNA genomes", "PROBLEM", 206, 225], ["gastroenteritis", "PROBLEM", 250, 265], ["viral diarrhoea in humans and other vertebrates", "PROBLEM", 270, 317], ["gastroenteritis", "OBSERVATION", 250, 265], ["viral diarrhoea", "OBSERVATION", 270, 285]]], ["The non-structural polyprotein (ORF1a and, via ribosomal frameshifting, an ORF1a-ORF1b fusion) are translated from the genomic RNA (gRNA) while the structural polyprotein (ORF2) is translated from a sub-genomic RNA (sgRNA) [8, 9] .", [["ribosomal", "ANATOMY", 47, 56], ["ORF1a", "GENE_OR_GENE_PRODUCT", 32, 37], ["ribosomal", "CELLULAR_COMPONENT", 47, 56], ["ORF1a", "GENE_OR_GENE_PRODUCT", 75, 80], ["ORF1b", "GENE_OR_GENE_PRODUCT", 81, 86], ["ORF2", "GENE_OR_GENE_PRODUCT", 172, 176], ["non-structural polyprotein", "PROTEIN", 4, 30], ["ORF1a", "PROTEIN", 32, 37], ["ORF1a", "DNA", 75, 80], ["ORF1b fusion", "DNA", 81, 93], ["genomic RNA", "RNA", 119, 130], ["gRNA", "RNA", 132, 136], ["structural polyprotein", "DNA", 148, 170], ["ORF2", "DNA", 172, 176], ["The non-structural polyprotein (ORF1a", "TREATMENT", 0, 37], ["ribosomal frameshifting", "TREATMENT", 47, 70], ["an ORF1a-ORF1b fusion", "TREATMENT", 72, 93], ["the structural polyprotein (ORF2", "PROBLEM", 144, 176], ["a sub-genomic RNA (sgRNA)", "PROBLEM", 197, 222], ["non-structural polyprotein", "OBSERVATION", 4, 30], ["ribosomal frameshifting", "OBSERVATION", 47, 70], ["genomic RNA", "OBSERVATION", 119, 130], ["sub", "OBSERVATION_MODIFIER", 199, 202], ["genomic RNA", "OBSERVATION", 203, 214]]], ["ORFX overlaps the 5' end of ORF2 in the +1 reading frame.", [["ORFX", "GENE_OR_GENE_PRODUCT", 0, 4], ["ORF2", "GENE_OR_GENE_PRODUCT", 28, 32], ["ORFX", "DNA", 0, 4], ["5' end", "DNA", 18, 24], ["ORF2", "DNA", 28, 32], ["+1 reading frame", "DNA", 40, 56], ["ORF2", "TREATMENT", 28, 32]]], ["A 112-codon AUG-initiated +1 frame ORF is present in nearly all human astrovirus sequences in GenBank with complete or partial coverage of the ORFX region (~780 sequences;~150 with full coverage of ORFX; 25 Oct 2009).", [["human", "ORGANISM", 64, 69], ["112-codon AUG", "DNA", 2, 15], ["+1 frame ORF", "DNA", 26, 38], ["human astrovirus sequences", "DNA", 64, 90], ["ORFX region", "DNA", 143, 154], ["~780 sequences", "DNA", 156, 170], ["ORFX", "DNA", 198, 202], ["human", "SPECIES", 64, 69], ["human astrovirus", "SPECIES", 64, 80], ["A 112-codon AUG", "TREATMENT", 0, 15], ["+1 frame ORF", "PROBLEM", 26, 38], ["ORFX", "TEST", 198, 202]]], ["Just a very small number of sequences are ORFX-defective: one partial sequence contains a premature termination codon, one sequence contains a 16-codon 3' extension, and three sequences have a CUG codon (which may, nonetheless, allow a low level of initiation [10] ) instead of an AUG codon at the proposed ORFX initiation site.Mamastrovirus (human, porcine, feline astrovirus clade)An AUG-initiated ORF of similar length (91-122 codons) is present in those feline, porcine, dolphin, sea lion and dog astroviruses that cluster with the HAstV human astrovirus clade (see Refs.", [["Mamastrovirus", "CHEMICAL", 328, 341], ["ORFX", "GENE_OR_GENE_PRODUCT", 42, 46], ["ORFX", "GENE_OR_GENE_PRODUCT", 307, 311], ["human", "ORGANISM", 343, 348], ["porcine,", "ORGANISM", 350, 358], ["feline astrovirus", "ORGANISM", 359, 376], ["feline", "ORGANISM", 458, 464], ["porcine", "ORGANISM", 466, 473], ["dolphin", "ORGANISM", 475, 482], ["sea lion", "ORGANISM", 484, 492], ["dog", "ORGANISM", 497, 500], ["astroviruses", "ORGANISM", 501, 513], ["HAstV", "ORGANISM", 536, 541], ["human", "ORGANISM", 542, 547], ["ORFX", "PROTEIN", 42, 46], ["premature termination codon", "DNA", 90, 117], ["16-codon 3' extension", "DNA", 143, 164], ["CUG codon", "DNA", 193, 202], ["AUG codon", "DNA", 281, 290], ["ORFX initiation site", "DNA", 307, 327], ["AUG", "DNA", 386, 389], ["ORF", "DNA", 400, 403], ["human", "SPECIES", 343, 348], ["porcine", "SPECIES", 350, 357], ["feline astrovirus", "SPECIES", 359, 376], ["feline", "SPECIES", 458, 464], ["porcine", "SPECIES", 466, 473], ["sea lion", "SPECIES", 484, 492], ["dog", "SPECIES", 497, 500], ["human", "SPECIES", 542, 547], ["astrovirus", "SPECIES", 548, 558], ["human", "SPECIES", 343, 348], ["HAstV human astrovirus", "SPECIES", 536, 558], ["one partial sequence", "TEST", 58, 78], ["a premature termination codon", "PROBLEM", 88, 117], ["a 16-codon 3' extension", "TREATMENT", 141, 164], ["a CUG codon", "PROBLEM", 191, 202], ["an AUG codon", "TREATMENT", 278, 290], ["Mamastrovirus (human, porcine, feline astrovirus clade", "TREATMENT", 328, 382], ["An AUG", "TREATMENT", 383, 389], ["dog astroviruses", "PROBLEM", 497, 513], ["the HAstV human astrovirus clade", "TREATMENT", 532, 564], ["very", "OBSERVATION_MODIFIER", 7, 11], ["small", "OBSERVATION_MODIFIER", 12, 17]]], ["[11] [12] [13] [14] for recent phylogenetic trees).", [["[11] [12] [13] [14]", "SIMPLE_CHEMICAL", 0, 19]]], ["The ORF coincides with a region of enhanced conservation at ORF2-frame synonymous sites ( Figure 1 ).", [["ORF", "DNA", 4, 7], ["ORF2-frame synonymous sites", "DNA", 60, 87], ["The ORF", "PROBLEM", 0, 7], ["enhanced conservation", "TREATMENT", 35, 56], ["enhanced", "OBSERVATION_MODIFIER", 35, 43], ["conservation", "OBSERVATION", 44, 56]]], ["This region of enhanced conservation is not present in the avian astroviruses, which also lack a conserved +1 frame ORF in this region.", [["astroviruses", "ANATOMY", 65, 77], ["avian", "ORGANISM", 59, 64], ["astroviruses", "CANCER", 65, 77], ["+1 frame ORF", "DNA", 107, 119], ["enhanced", "OBSERVATION_MODIFIER", 15, 23], ["conservation", "OBSERVATION", 24, 36], ["not present", "UNCERTAINTY", 40, 51], ["astroviruses", "OBSERVATION", 65, 77], ["+1 frame", "OBSERVATION", 107, 115]]], ["There is also little evidence for ORFX in other mammalian astrovirus clades (ovine, mink, bat and certain human astroviruses that cluster outside of the classic human-porcine-feline astrovirus clade) -an equivalent of ORFX may be present in some but certainly not all of these astroviruses.Mamastrovirus (human, porcine, feline astrovirus clade)ORFX appears amenable to translation via leaky scanning ( Figure 2 ).", [["ORFX", "CHEMICAL", 34, 38], ["astrovirus", "DISEASE", 58, 68], ["astroviruses", "DISEASE", 277, 289], ["Mamastrovirus", "CHEMICAL", 290, 303], ["ORFX", "GENE_OR_GENE_PRODUCT", 34, 38], ["mammalian astrovirus", "ORGANISM", 48, 68], ["ovine", "ORGANISM", 77, 82], ["mink", "ORGANISM", 84, 88], ["bat", "ORGANISM", 90, 93], ["human", "ORGANISM", 106, 111], ["astroviruses", "CANCER", 112, 124], ["human", "ORGANISM", 161, 166], ["porcine-feline astrovirus", "ORGANISM", 167, 192], ["ORFX", "GENE_OR_GENE_PRODUCT", 218, 222], ["astroviruses", "CANCER", 277, 289], ["human", "ORGANISM", 305, 310], ["porcine", "ORGANISM", 312, 319], ["feline astrovirus", "ORGANISM", 321, 338], ["ORFX", "GENE_OR_GENE_PRODUCT", 345, 349], ["ORFX", "PROTEIN", 34, 38], ["ORFX", "PROTEIN", 218, 222], ["ovine", "SPECIES", 77, 82], ["mink", "SPECIES", 84, 88], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 161, 166], ["porcine-feline astrovirus", "SPECIES", 167, 192], ["human", "SPECIES", 305, 310], ["porcine", "SPECIES", 312, 319], ["feline astrovirus", "SPECIES", 321, 338], ["mink", "SPECIES", 84, 88], ["human", "SPECIES", 106, 111], ["human-porcine-feline astrovirus", "SPECIES", 161, 192], ["human", "SPECIES", 305, 310], ["ORFX in other mammalian astrovirus clades (ovine, mink, bat and certain human astroviruses", "PROBLEM", 34, 124], ["porcine-feline astrovirus clade", "TREATMENT", 167, 198], ["these astroviruses", "PROBLEM", 271, 289], ["Mamastrovirus (human, porcine, feline astrovirus clade", "TREATMENT", 290, 344], ["leaky scanning", "TEST", 386, 400], ["little evidence for", "UNCERTAINTY", 14, 33], ["ORFX", "OBSERVATION", 34, 38], ["mammalian astrovirus clades", "OBSERVATION", 48, 75], ["astroviruses", "OBSERVATION", 277, 289]]], ["Although the ORF2 AUG initiation codon generally has a 'G' at -3 and a 'G' at +4 (strong though not optimal Kozak context), it also appears to be positioned very close to the 5' end of the sgRNA (e.g. 12 nt in human astrovirus; [15] ), and it has been shown that efficient leaky scanning can occur irrespective of Kozak context when an AUG codon is positioned within approximately 12 nt of the 5' end of an mRNA [16, 17] .", [["ORF2", "GENE_OR_GENE_PRODUCT", 13, 17], ["G' at -3", "GENE_OR_GENE_PRODUCT", 56, 64], ["sgRNA", "GENE_OR_GENE_PRODUCT", 189, 194], ["human", "ORGANISM", 210, 215], ["ORF2 AUG initiation codon", "DNA", 13, 38], ["5' end", "DNA", 175, 181], ["sgRNA", "DNA", 189, 194], ["Kozak", "DNA", 314, 319], ["AUG codon", "DNA", 336, 345], ["5' end", "DNA", 394, 400], ["mRNA", "RNA", 407, 411], ["human", "SPECIES", 210, 215], ["human astrovirus", "SPECIES", 210, 226], ["the sgRNA (e.g. 12 nt in human astrovirus", "PROBLEM", 185, 226], ["efficient leaky scanning", "PROBLEM", 263, 287], ["an AUG codon", "TREATMENT", 333, 345]]], ["The ORFX AUG codon is typically 41 to 50 nt downstream and has an 'A' at -3 and a 'G' at +4 (strong Kozak context; conserved in 149 out of 152 human astrovirus sequences with coverage of both the ORF2 and ORFX AUG codons).", [["ORFX", "GENE_OR_GENE_PRODUCT", 4, 8], ["A' at -3", "GENE_OR_GENE_PRODUCT", 67, 75], ["human", "ORGANISM", 143, 148], ["ORFX AUG codon", "DNA", 4, 18], ["41 to 50 nt downstream", "DNA", 32, 54], ["human astrovirus sequences", "DNA", 143, 169], ["ORF2", "DNA", 196, 200], ["ORFX AUG codons", "DNA", 205, 220], ["human", "SPECIES", 143, 148], ["human astrovirus", "SPECIES", 143, 159], ["a 'G'", "TEST", 80, 85], ["human astrovirus sequences", "TREATMENT", 143, 169], ["coverage", "TREATMENT", 175, 183], ["the ORF2", "TREATMENT", 192, 200], ["AUG codon", "OBSERVATION", 9, 18]]], ["In the porcine, dog and dolphin astrovirus sequences, the ORFX AUG codon is just 20 nt downstream of the ORF2 AUG codon but has an 'A' at -3 and a 'U' at +4 (medium context).", [["porcine", "ORGANISM", 7, 14], ["dog", "ORGANISM", 16, 19], ["dolphin astrovirus", "ORGANISM", 24, 42], ["ORFX", "GENE_OR_GENE_PRODUCT", 58, 62], ["porcine, dog and dolphin astrovirus sequences", "DNA", 7, 52], ["ORFX AUG codon", "DNA", 58, 72], ["20 nt downstream", "DNA", 81, 97], ["ORF2 AUG codon", "DNA", 105, 119], ["porcine", "SPECIES", 7, 14], ["dog", "SPECIES", 16, 19], ["dolphin astrovirus", "SPECIES", 24, 42], ["dolphin astrovirus", "SPECIES", 24, 42], ["dolphin astrovirus sequences", "TEST", 24, 52]]], ["In all cases, there are no intervening AUG codons in any frame.", [["AUG codons", "DNA", 39, 49], ["intervening AUG codons", "PROBLEM", 27, 49], ["no", "UNCERTAINTY", 24, 26], ["AUG codons", "OBSERVATION", 39, 49]]], ["Interestingly, a product of the predicted size (12 kDa in human astrovirus) was observed when sequence corresponding to the sgRNA was translated in vitro [18] .Mamastrovirus (human, porcine, feline astrovirus clade)The infectivity of a mutant astrovirus in which ORFX expression was inadvertently abolished was reduced by only 50% relative to wild-type virus [19] (a reduction which may be due to amino acid changes in the polyprotein frame besides the absence of ORFX product), thus demonstrating that the putative ORFX product is non-essential -at least for replication in cell culture.", [["cell culture", "ANATOMY", 575, 587], ["Mamastrovirus", "CHEMICAL", 160, 173], ["astrovirus", "DISEASE", 243, 253], ["amino acid", "CHEMICAL", 397, 407], ["amino acid", "CHEMICAL", 397, 407], ["human", "ORGANISM", 58, 63], ["astrovirus", "ORGANISM", 64, 74], ["sgRNA", "GENE_OR_GENE_PRODUCT", 124, 129], ["human", "ORGANISM", 175, 180], ["porcine", "ORGANISM", 182, 189], ["feline astrovirus", "ORGANISM", 191, 208], ["mutant astrovirus", "ORGANISM", 236, 253], ["ORFX", "GENE_OR_GENE_PRODUCT", 263, 267], ["wild-type virus", "ORGANISM", 343, 358], ["amino acid", "AMINO_ACID", 397, 407], ["ORFX", "GENE_OR_GENE_PRODUCT", 464, 468], ["ORFX", "GENE_OR_GENE_PRODUCT", 516, 520], ["cell culture", "CELL", 575, 587], ["sgRNA", "PROTEIN", 124, 129], ["ORFX", "PROTEIN", 263, 267], ["polyprotein frame", "DNA", 423, 440], ["ORFX product", "PROTEIN", 464, 476], ["ORFX product", "PROTEIN", 516, 528], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 175, 180], ["porcine", "SPECIES", 182, 189], ["feline astrovirus", "SPECIES", 191, 208], ["human astrovirus", "SPECIES", 58, 74], ["human", "SPECIES", 175, 180], ["12 kDa in human astrovirus", "PROBLEM", 48, 74], ["the sgRNA", "PROBLEM", 120, 129], ["Mamastrovirus (human, porcine, feline astrovirus clade", "TREATMENT", 160, 214], ["a mutant astrovirus", "PROBLEM", 234, 253], ["type virus", "PROBLEM", 348, 358], ["a reduction", "TREATMENT", 365, 376], ["amino acid changes", "PROBLEM", 397, 415], ["the polyprotein frame", "TREATMENT", 419, 440], ["replication in cell culture", "TEST", 560, 587], ["size", "OBSERVATION_MODIFIER", 42, 46], ["infectivity", "OBSERVATION_MODIFIER", 219, 230]]], ["However, this does not imply that ORFX is not a CDS since the conditions or functions for which the presumed ORFX product is important may not have been directly tested (e.g. for comparison, the infectivity of a mutant alphavirus in which expression of the experimentally verified TF protein was abolished was also reduced by only~50% [4] ).Seadornavirus segment 7The seadornaviruses (family Reoviridae) are dsRNA viruses with 12 genome segments, all of which have so far been presumed to be monocistronic.", [["alphavirus", "DISEASE", 219, 229], ["ORFX", "GENE_OR_GENE_PRODUCT", 34, 38], ["ORFX", "GENE_OR_GENE_PRODUCT", 109, 113], ["mutant alphavirus", "ORGANISM", 212, 229], ["TF", "GENE_OR_GENE_PRODUCT", 281, 283], ["Seadornavirus segment 7", "ORGANISM", 341, 364], ["seadornaviruses", "GENE_OR_GENE_PRODUCT", 368, 383], ["Reoviridae", "GENE_OR_GENE_PRODUCT", 392, 402], ["ORFX", "PROTEIN", 34, 38], ["ORFX product", "PROTEIN", 109, 121], ["TF protein", "PROTEIN", 281, 291], ["monocistronic", "DNA", 492, 505], ["a CDS", "PROBLEM", 46, 51], ["a mutant alphavirus", "PROBLEM", 210, 229], ["TF protein", "TEST", 281, 291], ["Seadornavirus segment", "TREATMENT", 341, 362], ["The seadornaviruses (family Reoviridae", "TREATMENT", 364, 402], ["dsRNA viruses", "PROBLEM", 408, 421], ["dsRNA viruses", "OBSERVATION", 408, 421], ["presumed to be", "UNCERTAINTY", 477, 491], ["monocistronic", "OBSERVATION", 492, 505]]], ["These viruses are transmitted by mosquitoes and the type species, Banna virus (BAV), has been associated with fever, flulike symptoms and encephalitis in infected humans [20, 21] .", [["fever", "DISEASE", 110, 115], ["flulike symptoms", "DISEASE", 117, 133], ["encephalitis", "DISEASE", 138, 150], ["Banna virus", "ORGANISM", 66, 77], ["humans", "ORGANISM", 163, 169], ["Banna virus", "SPECIES", 66, 77], ["humans", "SPECIES", 163, 169], ["Banna virus", "SPECIES", 66, 77], ["humans", "SPECIES", 163, 169], ["These viruses", "PROBLEM", 0, 13], ["the type species", "PROBLEM", 48, 64], ["Banna virus", "PROBLEM", 66, 77], ["fever", "PROBLEM", 110, 115], ["flulike symptoms", "PROBLEM", 117, 133], ["encephalitis in infected humans", "PROBLEM", 138, 169], ["viruses", "OBSERVATION", 6, 13], ["encephalitis", "OBSERVATION", 138, 150]]], ["ORFX overlaps the 5'-terminal region of the major CDS of segment 7 (which encodes VP7, a nonstructural protein of uncertain function [22, 23] ) in the +1 reading frame.", [["ORFX", "GENE_OR_GENE_PRODUCT", 0, 4], ["segment 7", "CELLULAR_COMPONENT", 57, 66], ["VP7", "GENE_OR_GENE_PRODUCT", 82, 85], ["ORFX", "DNA", 0, 4], ["5'-terminal region", "DNA", 18, 36], ["major CDS", "DNA", 44, 53], ["segment 7", "DNA", 57, 66], ["VP7", "PROTEIN", 82, 85], ["nonstructural protein", "PROTEIN", 89, 110], ["+1 reading frame", "DNA", 151, 167], ["VP7", "TEST", 82, 85], ["a nonstructural protein", "TEST", 87, 110], ["5'", "ANATOMY_MODIFIER", 18, 20], ["terminal", "ANATOMY_MODIFIER", 21, 29], ["region", "ANATOMY_MODIFIER", 30, 36], ["segment 7", "ANATOMY_MODIFIER", 57, 66], ["nonstructural protein", "OBSERVATION_MODIFIER", 89, 110]]], ["A 52-codon AUG-initiated +1 frame ORF is present in all available BAV sequences with complete coverage of the VP7 CDS (six sequences; two additional sequences have only partial coverage of ORFX; 16 Nov 2009).", [["VP7", "GENE_OR_GENE_PRODUCT", 110, 113], ["52-codon AUG", "DNA", 2, 14], ["+1 frame ORF", "DNA", 25, 37], ["BAV sequences", "DNA", 66, 79], ["VP7 CDS", "DNA", 110, 117], ["A 52-codon AUG", "TREATMENT", 0, 14], ["the VP7 CDS", "TEST", 106, 117], ["six sequences", "TEST", 119, 132], ["two additional sequences", "TEST", 134, 158]]], ["Application of MLOGD to the ORF reveals a strong coding signal ( Figure 3) .", [["MLOGD", "DNA", 15, 20], ["ORF", "DNA", 28, 31], ["the ORF", "TEST", 24, 31]]], ["Similarly, there is greatly enhanced conservation at VP7-frame synonymous sites within the ORFX region ( Figure 3 ).", [["VP7", "GENE_OR_GENE_PRODUCT", 53, 56], ["VP7-frame synonymous sites", "DNA", 53, 79], ["ORFX region", "DNA", 91, 102], ["greatly enhanced conservation", "PROBLEM", 20, 49], ["greatly", "OBSERVATION_MODIFIER", 20, 27], ["enhanced", "OBSERVATION_MODIFIER", 28, 36], ["conservation", "OBSERVATION_MODIFIER", 37, 49], ["VP7-frame", "OBSERVATION_MODIFIER", 53, 62], ["synonymous sites", "OBSERVATION", 63, 79], ["ORFX", "ANATOMY", 91, 95], ["region", "ANATOMY_MODIFIER", 96, 102]]], ["Although there is also enhanced conservation at the 5' end of other seadornavirus segments, the 3'-extent of the conservation is much greater in segment 7 than other segments.", [["seadornavirus segments", "MULTI-TISSUE_STRUCTURE", 68, 90], ["5' end", "DNA", 52, 58], ["seadornavirus segments", "DNA", 68, 90], ["enhanced", "OBSERVATION_MODIFIER", 23, 31], ["conservation", "OBSERVATION", 32, 44], ["seadornavirus", "ANATOMY_MODIFIER", 68, 81], ["segments", "ANATOMY_MODIFIER", 82, 90], ["extent", "OBSERVATION_MODIFIER", 99, 105], ["conservation", "OBSERVATION", 113, 125], ["much", "OBSERVATION_MODIFIER", 129, 133], ["greater", "OBSERVATION_MODIFIER", 134, 141], ["segment 7", "ANATOMY_MODIFIER", 145, 154], ["segments", "ANATOMY_MODIFIER", 166, 174]]], ["In all cases, the VP7 CDS utilizes the first AUG codon, which has a poor Kozak context ('U' at -3, 'A' at +4), while ORFX utilizes the second AUG codon, which is separated from the first AUG codon by just 4 nt and has a strong Kozak context ('A' at -3, 'G' at +4; Figure 4 ).", [["VP7", "GENE_OR_GENE_PRODUCT", 18, 21], ["ORFX", "GENE_OR_GENE_PRODUCT", 117, 121], ["VP7 CDS", "DNA", 18, 25], ["AUG codon", "DNA", 45, 54], ["Kozak", "DNA", 73, 78], ["ORFX", "DNA", 117, 121], ["AUG codon", "DNA", 142, 151], ["first AUG codon", "DNA", 181, 196], ["the VP7 CDS", "TEST", 14, 25], ["a poor Kozak context", "PROBLEM", 66, 86]]], ["Thus ORFX is amenable to translation via leaky scanning.", [["ORFX", "GENE_OR_GENE_PRODUCT", 5, 9], ["ORFX", "PROTEIN", 5, 9], ["translation via leaky scanning", "TEST", 25, 55]]], ["Moreover, the close proximity of the ORFX AUG codon to the VP7 AUG codon may further enhance initiation at the latter, via the translation initiation coupling mechanism described in Ref.", [["ORFX", "GENE_OR_GENE_PRODUCT", 37, 41], ["VP7", "GENE_OR_GENE_PRODUCT", 59, 62], ["ORFX AUG codon", "DNA", 37, 51], ["VP7 AUG codon", "DNA", 59, 72], ["Ref", "PROTEIN", 182, 185], ["the ORFX AUG codon", "TREATMENT", 33, 51], ["the VP7 AUG codon", "TREATMENT", 55, 72]]], ["[24] .Seadornavirus segment 7There are currently two other seadornavirus species with sequence coverage of the ORFX region -Kadipiro virus (KDV; 1 sequence), and Liao ning virus (LNV; 2 sequences) [20, 25] .", [["ORFX", "GENE_OR_GENE_PRODUCT", 111, 115], ["Kadipiro virus", "ORGANISM", 124, 138], ["Liao ning virus", "ORGANISM", 162, 177], ["ORFX region", "DNA", 111, 122], ["Kadipiro virus", "SPECIES", 124, 138], ["Liao ning virus", "SPECIES", 162, 177], ["Kadipiro virus", "SPECIES", 124, 138], ["KDV", "SPECIES", 140, 143], ["Liao ning virus", "SPECIES", 162, 177], ["two other seadornavirus species", "PROBLEM", 49, 80], ["sequence coverage", "TREATMENT", 86, 103], ["the ORFX region", "TREATMENT", 107, 122], ["Kadipiro virus (KDV", "TREATMENT", 124, 143], ["Liao ning virus", "TREATMENT", 162, 177]]], ["When MLOGD was applied to an alignment of the three species BAV, KDV and LNV, the results were ambiguous due to the high divergence between the different sequences.", [["MLOGD", "PROTEIN", 5, 10], ["KDV", "DNA", 65, 68], ["LNV", "DNA", 73, 76], ["KDV", "SPECIES", 65, 68], ["the high divergence between the different sequences", "PROBLEM", 112, 163]]], ["However, there is the potential, at least, for a functional ORFX in KDV, and possibly also LNV.", [["ORFX", "GENE_OR_GENE_PRODUCT", 60, 64], ["KDV", "CANCER", 68, 71], ["ORFX", "PROTEIN", 60, 64], ["LNV", "PROTEIN", 91, 94], ["KDV", "SPECIES", 68, 71], ["a functional ORFX in KDV", "PROBLEM", 47, 71]]], ["In KDV, the VP7 CDS utilizes the first AUG codon, which has a weak Kozak context, while the second AUG (separated from the first AUG by 16 nt) is in the +1 reading frame and heads a 65codon potential ORFX ( Figure 4 ).", [["VP7", "GENE_OR_GENE_PRODUCT", 12, 15], ["KDV", "DNA", 3, 6], ["VP7 CDS", "DNA", 12, 19], ["AUG codon", "DNA", 39, 48], ["Kozak context", "DNA", 67, 80], ["AUG", "DNA", 99, 102], ["AUG", "DNA", 129, 132], ["+1 reading frame", "DNA", 153, 169], ["KDV", "SPECIES", 3, 6], ["the VP7 CDS", "TEST", 8, 19], ["weak", "OBSERVATION_MODIFIER", 62, 66]]], ["In LNV, however, the VP7 CDS has two closely spaced AUG codons in one sequence, and a medium Kozak context in both sequences ('G' at +4), so is sub-optimal for leaky scanning.", [["LNV", "CANCER", 3, 6], ["VP7", "GENE_OR_GENE_PRODUCT", 21, 24], ["LNV", "DNA", 3, 6], ["VP7 CDS", "DNA", 21, 28], ["AUG codons", "DNA", 52, 62], ["medium Kozak context", "DNA", 86, 106], ["the VP7 CDS", "TEST", 17, 28], ["a medium Kozak context", "PROBLEM", 84, 106], ["leaky scanning", "TEST", 160, 174]]], ["Moreover, although the next AUG codon is in the +1 reading frame, it is 64 nt downstream and only heads a 42-codon ORF.", [["AUG codon", "DNA", 28, 37], ["+1 reading frame", "DNA", 48, 64], ["64 nt downstream", "DNA", 72, 88], ["42-codon ORF", "DNA", 106, 118]]], ["Thus, although there is a very strong case for a coding ORFX in BAV, whether or not this ORF is also present in KDV, and especially in LNV, can not be reliably assessed with the currently available sequence data.Cytorhabdovirus (Lettuce necrotic yellows and Lettuce yellow mottle viruses)The cytorhabdoviruses comprise a genus within the family Rhabdoviridae, members of which have monopartite negative-sense ssRNA genomes.", [["Cytorhabdovirus", "CHEMICAL", 212, 227], ["necrotic yellows", "DISEASE", 237, 253], ["ORFX", "GENE_OR_GENE_PRODUCT", 56, 60], ["KDV", "CANCER", 112, 115], ["LNV", "CANCER", 135, 138], ["Lettuce necrotic yellows", "ORGANISM", 229, 253], ["Lettuce yellow mottle viruses", "ORGANISM", 258, 287], ["cytorhabdoviruses", "GENE_OR_GENE_PRODUCT", 292, 309], ["Rhabdoviridae", "GENE_OR_GENE_PRODUCT", 345, 358], ["ORFX", "DNA", 56, 60], ["ORF", "DNA", 89, 92], ["monopartite negative-sense ssRNA genomes", "DNA", 382, 422], ["yellow mottle", "SPECIES", 266, 279], ["KDV", "SPECIES", 112, 115], ["Lettuce yellow mottle viruses", "SPECIES", 258, 287], ["a coding ORFX in BAV", "PROBLEM", 47, 67], ["this ORF", "PROBLEM", 84, 92], ["the currently available sequence data", "TEST", 174, 211], ["Cytorhabdovirus (Lettuce necrotic yellows", "PROBLEM", 212, 253], ["Lettuce yellow mottle viruses", "PROBLEM", 258, 287], ["sense ssRNA genomes", "PROBLEM", 403, 422], ["BAV", "ANATOMY", 64, 67], ["necrotic", "OBSERVATION_MODIFIER", 237, 245], ["mottle viruses", "OBSERVATION", 273, 287], ["ssRNA genomes", "OBSERVATION", 409, 422]]], ["Species include Lettuce necrotic yellows virus (LNYV), Lettuce yellow mottle virus (LYMoV) and Northern cereal mosaic virus (NCMV).", [["necrotic yellows", "DISEASE", 24, 40], ["Lettuce necrotic yellows virus", "ORGANISM", 16, 46], ["LNYV", "ORGANISM", 48, 52], ["Lettuce yellow mottle virus", "ORGANISM", 55, 82], ["LYMoV", "ORGANISM", 84, 89], ["Northern cereal mosaic virus", "ORGANISM", 95, 123], ["Lettuce necrotic yellows virus", "SPECIES", 16, 46], ["Lettuce", "SPECIES", 55, 62], ["yellow mottle virus", "SPECIES", 63, 82], ["cereal mosaic virus", "SPECIES", 104, 123], ["Lettuce necrotic yellows virus", "SPECIES", 16, 46], ["LNYV", "SPECIES", 48, 52], ["Lettuce yellow mottle virus", "SPECIES", 55, 82], ["LYMoV", "SPECIES", 84, 89], ["Northern cereal mosaic virus", "SPECIES", 95, 123], ["NCMV", "SPECIES", 125, 129], ["Species", "TREATMENT", 0, 7], ["Lettuce necrotic yellows virus", "PROBLEM", 16, 46], ["Lettuce yellow mottle virus", "PROBLEM", 55, 82], ["Lettuce", "OBSERVATION_MODIFIER", 16, 23], ["necrotic", "OBSERVATION_MODIFIER", 24, 32], ["yellows virus", "OBSERVATION", 33, 46], ["yellow", "OBSERVATION_MODIFIER", 63, 69], ["mottle virus", "OBSERVATION", 70, 82], ["mosaic virus", "OBSERVATION", 111, 123]]], ["The genomes of LNYV and LYMoV contain at least six CDSs (N, P, putative movement protein, M, G, L) while the genome of the much more distantly related NCMV contains additional ORFs inserted upstream of M [26] [27] [28] .", [["LNYV", "GENE_OR_GENE_PRODUCT", 15, 19], ["LYMoV", "GENE_OR_GENE_PRODUCT", 24, 29], ["M, G, L", "GENE_OR_GENE_PRODUCT", 90, 97], ["NCMV", "CANCER", 151, 155], ["LNYV", "DNA", 15, 19], ["LYMoV", "DNA", 24, 29], ["CDSs", "DNA", 51, 55], ["N, P, putative movement protein", "DNA", 57, 88], ["NCMV", "DNA", 151, 155], ["ORFs", "DNA", 176, 180], ["putative movement protein", "TEST", 63, 88], ["M", "TEST", 90, 91], ["G", "TEST", 93, 94]]], ["The 97-102 codon ORFX overlaps the 5' end of the P (phosphoprotein) CDS in the +1 reading frame and is present in LNYV and LYMoV but apparently not in NCMV ( Figure 5 ).", [["ORFX", "GENE_OR_GENE_PRODUCT", 17, 21], ["LNYV", "CANCER", 114, 118], ["97-102 codon ORFX", "DNA", 4, 21], ["5' end", "DNA", 35, 41], ["P (phosphoprotein) CDS", "DNA", 49, 71], ["+1 reading frame", "DNA", 79, 95], ["apparently not", "UNCERTAINTY", 133, 147]]], ["In fact these two sequences are the only two distinct sequences with coverage of ORFX currently available in GenBank (2 Nov 2009).", [["ORFX", "GENE_OR_GENE_PRODUCT", 81, 85], ["ORFX", "DNA", 81, 85]]], ["The mean nucleotide identity between the two sequences within the ORFX region is only~50%, which is below the ideal range for MLOGD (substitution saturation at high divergences makes it more difficult for MLOGD to distinguish between the single-and dual-coding models and causes a high-divergence 'turnover' in the MLOGD score [1] ).", [["nucleotide", "CHEMICAL", 9, 19], ["nucleotide", "CHEMICAL", 9, 19], ["ORFX region", "DNA", 66, 77], ["MLOGD", "DNA", 126, 131], ["MLOGD (substitution saturation", "TREATMENT", 126, 156], ["a high-divergence 'turnover", "PROBLEM", 279, 306], ["ORFX", "ANATOMY_MODIFIER", 66, 70], ["region", "ANATOMY_MODIFIER", 71, 77]]], ["Nonetheless, and notwithstanding the very limited sequence data, there is a good coding signal for ORFX ( Figure 5 ).", [["ORFX", "PROTEIN", 99, 103]]], ["In fact the presence of this ORF has already been noted in both viruses [27, 28] (and designated P' by Ref.", [["ORF", "DNA", 29, 32], ["this ORF", "PROBLEM", 24, 32]]], ["[28] ) though, so far as we are aware, this is the first evidence (apart from its conserved presence) that it is likely to be coding.Cytorhabdovirus (Lettuce necrotic yellows and Lettuce yellow mottle viruses)CDSs in the Rhabdoviridae are translated from a series of mRNA transcripts produced via a transcription termination-reinitiation mechanism, with conserved junction sequences containing the transcription stop and start signals located between consecutive CDSs so that mRNAs are generally monocistronic [26, 28, 29] .", [["Cytorhabdovirus", "CHEMICAL", 133, 148], ["necrotic yellows", "DISEASE", 158, 174], ["Cytorhabdovirus", "ORGANISM", 133, 148], ["Lettuce necrotic yellows", "ORGANISM", 150, 174], ["Lettuce yellow mottle viruses", "ORGANISM", 179, 208], ["Rhabdoviridae", "GENE_OR_GENE_PRODUCT", 221, 234], ["mRNA transcripts", "RNA", 267, 283], ["conserved junction sequences", "DNA", 354, 382], ["transcription stop", "DNA", 398, 416], ["CDSs", "DNA", 463, 467], ["mRNAs", "RNA", 476, 481], ["yellow mottle viruses", "SPECIES", 187, 208], ["Lettuce yellow mottle viruses", "SPECIES", 179, 208], ["Cytorhabdovirus (Lettuce necrotic yellows", "PROBLEM", 133, 174], ["Lettuce yellow mottle viruses", "PROBLEM", 179, 208], ["CDSs", "TREATMENT", 209, 213], ["mRNA transcripts", "TREATMENT", 267, 283], ["a transcription termination", "TREATMENT", 297, 324], ["conserved junction sequences", "TREATMENT", 354, 382], ["the transcription", "TREATMENT", 394, 411], ["consecutive CDSs", "TREATMENT", 451, 467], ["likely to be", "UNCERTAINTY", 113, 125], ["necrotic", "OBSERVATION_MODIFIER", 158, 166], ["yellows", "OBSERVATION_MODIFIER", 167, 174]]], ["In the case of the P mRNA of LNYV and LYMoV, the P CDS utilizes the second AUG codon on the mRNA while the first AUG codon is in the correct frame for ORFX translation ( Figure 6 ).", [["LNYV", "GENE_OR_GENE_PRODUCT", 29, 33], ["LYMoV", "GENE_OR_GENE_PRODUCT", 38, 43], ["P mRNA", "RNA", 19, 25], ["LNYV", "DNA", 29, 33], ["LYMoV", "DNA", 38, 43], ["P CDS", "DNA", 49, 54], ["AUG codon", "DNA", 75, 84], ["mRNA", "RNA", 92, 96], ["AUG codon", "DNA", 113, 122], ["ORFX", "PROTEIN", 151, 155]]], ["However, the ORFX AUG codon has poor Kozak context ('U' at -3, 'A' or 'C' at +4; cf. [30] ), which presumably allows a significant proportion of ribosomes to translate the P CDS via leaky scanning.", [["ORFX", "GENE_OR_GENE_PRODUCT", 13, 17], ["ribosomes", "CELLULAR_COMPONENT", 145, 154], ["ORFX AUG codon", "DNA", 13, 27], ["P CDS", "DNA", 172, 177], ["poor Kozak context", "PROBLEM", 32, 50], ["leaky scanning", "TEST", 182, 196]]], ["A similarly positioned overlapping CDS (generally referred to as 'C' and generally initiating downstream rather than upstream of the P initation site) occurs in certain paramyxovirus genera (e.g. Morbillivirus, Respirovirus) besides Vesicular stomatitis virus (Vesiculovirus, family Rhabdoviridae), though the C gene is likely to have arisen independently in the two families [31] .", [["Vesicular stomatitis", "DISEASE", 233, 253], ["Respirovirus", "GENE_OR_GENE_PRODUCT", 211, 223], ["Vesicular stomatitis virus", "ORGANISM", 233, 259], ["Vesiculovirus", "GENE_OR_GENE_PRODUCT", 261, 274], ["Rhabdoviridae", "GENE_OR_GENE_PRODUCT", 283, 296], ["C", "GENE_OR_GENE_PRODUCT", 310, 311], ["overlapping CDS", "DNA", 23, 38], ["C'", "DNA", 66, 68], ["P initation site", "DNA", 133, 149], ["C gene", "DNA", 310, 316], ["Vesicular stomatitis virus", "SPECIES", 233, 259], ["Vesicular stomatitis virus", "SPECIES", 233, 259], ["A similarly positioned overlapping CDS", "PROBLEM", 0, 38], ["the P initation site", "TREATMENT", 129, 149], ["certain paramyxovirus genera", "PROBLEM", 161, 189], ["Morbillivirus", "PROBLEM", 196, 209], ["Vesicular stomatitis virus", "PROBLEM", 233, 259], ["overlapping", "OBSERVATION_MODIFIER", 23, 34], ["CDS", "OBSERVATION", 35, 38], ["paramyxovirus genera", "OBSERVATION", 169, 189], ["Vesicular stomatitis", "ANATOMY", 233, 253]]], ["It has been suggested that the highly variable nature of the P protein facilitates the evolution of novel genes overlapping its N-terminal regions and, in the absence of discernable sequence homology, it cannot be assumed that the resulting proteins have similar functions [31, 32] .CoronavirusesCoronaviruses (family Coronaviridae) belong to the order Nidovirales.", [["N", "CHEMICAL", 128, 129], ["CoronavirusesCoronaviruses", "GENE_OR_GENE_PRODUCT", 283, 309], ["P protein", "PROTEIN", 61, 70], ["novel genes", "DNA", 100, 111], ["N-terminal regions", "DNA", 128, 146], ["the P protein", "PROBLEM", 57, 70], ["novel genes", "PROBLEM", 100, 111], ["highly", "OBSERVATION_MODIFIER", 31, 37], ["variable", "OBSERVATION_MODIFIER", 38, 46]]], ["At 26-32 kb, coronavirus genomes are among the largest of all RNA viruses.", [["coronavirus", "ORGANISM", 13, 24], ["coronavirus genomes", "DNA", 13, 32], ["coronavirus genomes", "PROBLEM", 13, 32], ["coronavirus genomes", "OBSERVATION", 13, 32], ["largest", "OBSERVATION_MODIFIER", 47, 54], ["RNA viruses", "OBSERVATION", 62, 73]]], ["As with other members of the order, these viruses have a monopartite positive-sense ssRNA genome encoding a large replicase polyprotein that is expressed from the genomic RNA (ORF1a and, via ribosomal frameshifting, an ORF1a-ORF1b fusion product), and a number of other proteins which are translated from a nested set of 3'-coterminal sgRNAs [33, 34] .", [["ribosomal", "ANATOMY", 191, 200], ["ORF1a", "GENE_OR_GENE_PRODUCT", 176, 181], ["ribosomal", "CELLULAR_COMPONENT", 191, 200], ["ORF1a", "GENE_OR_GENE_PRODUCT", 219, 224], ["ORF1b", "GENE_OR_GENE_PRODUCT", 225, 230], ["monopartite positive-sense ssRNA genome", "DNA", 57, 96], ["genomic RNA", "RNA", 163, 174], ["ORF1a", "PROTEIN", 176, 181], ["ORF1a", "PROTEIN", 219, 224], ["ORF1b fusion product", "PROTEIN", 225, 245], ["these viruses", "PROBLEM", 36, 49], ["a monopartite positive", "PROBLEM", 55, 77], ["sense ssRNA genome", "PROBLEM", 78, 96], ["a large replicase polyprotein", "PROBLEM", 106, 135], ["ribosomal frameshifting", "TREATMENT", 191, 214], ["an ORF1a-ORF1b fusion product", "TREATMENT", 216, 245], ["ssRNA genome", "OBSERVATION", 84, 96], ["large", "OBSERVATION_MODIFIER", 108, 113], ["replicase polyprotein", "OBSERVATION", 114, 135], ["genomic RNA", "OBSERVATION", 163, 174], ["ribosomal frameshifting", "OBSERVATION", 191, 214]]], ["The coronaviruses are currently classified into three main groups (recently elevated to genera) which are further divided into subgroups, though there are also a large number of species that await formal classification.", [["coronaviruses", "ORGANISM", 4, 17], ["a large number of species", "PROBLEM", 160, 185], ["coronaviruses", "OBSERVATION", 4, 17], ["large", "OBSERVATION_MODIFIER", 162, 167], ["number", "OBSERVATION_MODIFIER", 168, 174]]], ["Although a core set of sgRNA-encoded structural proteins (S, E, M, N) are conserved throughout all groups, a variable number of auxilliary proteins are also encoded by sgRNAs -including a number of known overlapping CDSs (e.g. the I CDS that overlaps the N CDS of some Group 2 coronaviruses [35] ).", [["sgRNA", "GENE_OR_GENE_PRODUCT", 23, 28], ["sgRNAs", "GENE_OR_GENE_PRODUCT", 168, 174], ["sgRNA", "PROTEIN", 23, 28], ["structural proteins", "PROTEIN", 37, 56], ["S", "PROTEIN", 58, 59], ["E", "PROTEIN", 61, 62], ["N", "PROTEIN", 67, 68], ["auxilliary proteins", "PROTEIN", 128, 147], ["sgRNAs", "PROTEIN", 168, 174], ["CDSs", "DNA", 216, 220], ["I CDS", "DNA", 231, 236], ["N CDS", "DNA", 255, 260], ["sgRNA", "TEST", 23, 28], ["auxilliary proteins", "PROBLEM", 128, 147], ["sgRNAs", "TEST", 168, 174], ["known overlapping CDSs", "PROBLEM", 198, 220], ["the I CDS", "PROBLEM", 227, 236], ["some Group 2 coronaviruses", "PROBLEM", 264, 290], ["sgRNA", "OBSERVATION", 23, 28], ["variable", "OBSERVATION_MODIFIER", 109, 117], ["number", "OBSERVATION_MODIFIER", 118, 124], ["auxilliary proteins", "OBSERVATION", 128, 147], ["overlapping CDSs", "OBSERVATION", 204, 220]]], ["We have identified two new candidates -one in Group 3 coronaviruses of the proposed subgroup 3c [36] , and one in certain Group 1b coronaviruses.", [["coronaviruses", "ORGANISM", 131, 144], ["new", "OBSERVATION_MODIFIER", 23, 26], ["1b coronaviruses", "OBSERVATION", 128, 144]]], ["(Note that, while the evidence for the coding status of the preceding three candidates is very strong, the evidence for these two candidates is less certain but should become clearer as more sequence data become available.)Coronavirus Group 3cIn the subgroup 3c coronaviruses, ORFX overlaps the NS6 CDS (between M and N) in the +1 reading frame.", [["coronaviruses", "ORGANISM", 262, 275], ["ORFX", "GENE_OR_GENE_PRODUCT", 277, 281], ["ORFX", "DNA", 277, 281], ["NS6 CDS", "DNA", 295, 302], ["+1 reading frame", "DNA", 328, 344], ["more sequence data", "TEST", 186, 204]]], ["ORFX appears to be present in all available (8 Nov 2009 ) subgroup 3c sequences with coverage of the NS6 region: Thrush coronavirus (ThCoV), Bulbul coronavirus (BuCoV; 2 sequences), Munia coronavirus (MuCoV) and Asian leopard cat coronavirus (Figure 7 ) [36, 37] .", [["Bulbul coronavirus", "DISEASE", 141, 159], ["Munia coronavirus", "DISEASE", 182, 199], ["ORFX", "GENE_OR_GENE_PRODUCT", 0, 4], ["Thrush coronavirus", "ORGANISM", 113, 131], ["ThCoV", "GENE_OR_GENE_PRODUCT", 133, 138], ["Bulbul coronavirus", "ORGANISM", 141, 159], ["Munia coronavirus", "ORGANISM", 182, 199], ["leopard cat coronavirus", "ORGANISM", 218, 241], ["ORFX", "PROTEIN", 0, 4], ["NS6 region", "DNA", 101, 111], ["Bulbul coronavirus", "SPECIES", 141, 159], ["Munia coronavirus", "SPECIES", 182, 199], ["leopard cat coronavirus", "SPECIES", 218, 241], ["Thrush coronavirus", "SPECIES", 113, 131], ["ThCoV", "SPECIES", 133, 138], ["Bulbul coronavirus", "SPECIES", 141, 159], ["Munia coronavirus", "SPECIES", 182, 199], ["Asian leopard cat coronavirus", "SPECIES", 212, 241], ["subgroup 3c sequences", "TEST", 58, 79], ["coverage of the NS6 region", "TEST", 85, 111], ["Thrush coronavirus", "PROBLEM", 113, 131], ["Bulbul coronavirus", "PROBLEM", 141, 159], ["Munia coronavirus", "TEST", 182, 199], ["Asian leopard cat coronavirus", "TEST", 212, 241], ["Thrush coronavirus", "ANATOMY", 113, 131]]], ["ORFX has length 69-89 codons and covers 73-81% of NS6 (91-108 codons).", [["ORFX", "CHEMICAL", 0, 4], ["ORFX", "GENE_OR_GENE_PRODUCT", 0, 4], ["NS6", "GENE_OR_GENE_PRODUCT", 50, 53], ["ORFX", "DNA", 0, 4], ["length 69-89 codons", "DNA", 9, 28], ["length", "TEST", 9, 15], ["codons", "TEST", 22, 28], ["NS6", "TEST", 50, 53], ["length", "OBSERVATION_MODIFIER", 9, 15]]], ["Note the unusually high conservation within the ORFX region.", [["ORFX", "GENE_OR_GENE_PRODUCT", 48, 52], ["ORFX region", "DNA", 48, 59], ["unusually", "OBSERVATION_MODIFIER", 9, 18], ["high conservation", "OBSERVATION", 19, 36], ["ORFX", "ANATOMY", 48, 52], ["region", "ANATOMY_MODIFIER", 53, 59]]], ["The null model is that the sequence in the ORFX region is only coding in the +0 (VP7 CDS) frame, while the alternative model is that the ORFX region is coding in both the +0 and the +1 (ORFX) reading frames.", [["ORFX", "GENE_OR_GENE_PRODUCT", 43, 47], ["ORFX", "GENE_OR_GENE_PRODUCT", 137, 141], ["ORFX region", "DNA", 43, 54], ["+0 (VP7 CDS) frame", "DNA", 77, 95], ["ORFX region", "DNA", 137, 148], ["+0 and the +1 (ORFX) reading frames", "DNA", 171, 206], ["the ORFX region", "PROBLEM", 133, 148], ["null model", "OBSERVATION", 4, 14], ["both", "ANATOMY_MODIFIER", 162, 166]]], ["MLOGD coding potential scores are produced for each alignment column and averaged over a 21 nt sliding window for clarity.", [["MLOGD", "DNA", 0, 5], ["a 21 nt sliding window", "TREATMENT", 87, 109]]], ["The predominantly positive scores indicate that ORFX is likely to be a coding sequence.", [["ORFX", "GENE_OR_GENE_PRODUCT", 48, 52], ["ORFX", "DNA", 48, 52], ["coding sequence", "DNA", 71, 86], ["a coding sequence", "PROBLEM", 69, 86], ["predominantly", "OBSERVATION_MODIFIER", 4, 17], ["positive", "OBSERVATION", 18, 26], ["ORFX", "OBSERVATION", 48, 52], ["is likely to be", "UNCERTAINTY", 53, 68]]], ["ORFX appears amenable to translation via leaky scanning from the same sgRNA as NS6 since the NS6 AUG initiation codon has a 'G', 'A' or 'C' at -3 (depending on species) and a 'U' at +4 for a medium or weak Kozak context ( Figure 8 ) and there are no intervening AUG codons in any frame between the NS6 AUG codon and the ORFX AUG codon.", [["ORFX", "CHEMICAL", 0, 4], ["ORFX", "GENE_OR_GENE_PRODUCT", 0, 4], ["sgRNA", "GENE_OR_GENE_PRODUCT", 70, 75], ["NS6", "GENE_OR_GENE_PRODUCT", 79, 82], ["NS6", "GENE_OR_GENE_PRODUCT", 93, 96], ["C' at -3", "GENE_OR_GENE_PRODUCT", 137, 145], ["ORFX", "PROTEIN", 0, 4], ["sgRNA", "DNA", 70, 75], ["NS6", "DNA", 79, 82], ["NS6 AUG initiation codon", "DNA", 93, 117], ["AUG codons", "DNA", 262, 272], ["NS6 AUG codon", "DNA", 298, 311], ["ORFX AUG codon", "DNA", 320, 334], ["leaky scanning", "TEST", 41, 55], ["the NS6 AUG initiation codon", "TREATMENT", 89, 117], ["a 'G'", "TREATMENT", 122, 127], ["a medium or weak Kozak context", "PROBLEM", 189, 219], ["intervening AUG codons", "PROBLEM", 250, 272], ["leaky", "OBSERVATION", 41, 46], ["no", "UNCERTAINTY", 247, 249], ["AUG codons", "OBSERVATION", 262, 272], ["AUG codon", "OBSERVATION", 325, 334]]], ["However, ORFX translation may be a little more complex since Ref.", [["ORFX", "GENE_OR_GENE_PRODUCT", 9, 13], ["ORFX", "PROTEIN", 9, 13]]], ["[36] were unable to identify a transcription regulatory sequence (TRS; ACACCA in these viruses) for production of an NS6 sgRNA, which may mean that NS6 is translated via some non-canonical mechanism (such as reinitiation on the M sgRNA; cf. [38] ; in fact the UAA termination codon of the M CDS overlaps the AUG initiation codon of the NS6 CDS as UAAUG; Figure 8 ).", [["NS6", "GENE_OR_GENE_PRODUCT", 117, 120], ["NS6", "GENE_OR_GENE_PRODUCT", 148, 151], ["transcription regulatory sequence", "DNA", 31, 64], ["TRS", "DNA", 66, 69], ["ACACCA", "DNA", 71, 77], ["NS6 sgRNA", "DNA", 117, 126], ["NS6", "PROTEIN", 148, 151], ["M sgRNA", "DNA", 228, 235], ["UAA termination codon", "DNA", 260, 281], ["M CDS", "DNA", 289, 294], ["AUG initiation codon", "DNA", 308, 328], ["NS6 CDS", "DNA", 336, 343], ["UAAUG", "DNA", 347, 352], ["a transcription regulatory sequence", "TEST", 29, 64], ["an NS6 sgRNA", "PROBLEM", 114, 126], ["the M sgRNA", "TREATMENT", 224, 235], ["the UAA termination codon", "TREATMENT", 256, 281], ["the M CDS", "PROBLEM", 285, 294], ["NS6 sgRNA", "OBSERVATION", 117, 126]]], ["Potential, albeit imperfect, TRSs between the NS6 and ORFX initiation codons ( Figure 8 ) may mean that a separate sgRNA is produced for ORFX.", [["NS6", "GENE_OR_GENE_PRODUCT", 46, 49], ["sgRNA", "GENE_OR_GENE_PRODUCT", 115, 120], ["ORFX", "GENE_OR_GENE_PRODUCT", 137, 141], ["NS6 and ORFX initiation codons", "DNA", 46, 76], ["sgRNA", "DNA", 115, 120], ["ORFX", "PROTEIN", 137, 141], ["the NS6", "TREATMENT", 42, 49], ["ORFX initiation codons", "TREATMENT", 54, 76], ["a separate sgRNA", "PROBLEM", 104, 120], ["ORFX", "PROBLEM", 137, 141]]], ["[36] were unsure about the coding status of NS6 itself (due to the apparent absence of a TRS, and a relatively high K a /K s ratio), our MLOGD analysis suggests that NS6 is coding and is subject to significantly stronger functional constraints than ORFX (Figure 7 , panel 5).Coronavirus Group 3cBat coronaviruses 1A, 1B, HKU8Coronavirus Group 3cHere, ORFX overlaps ORF3 (between S and E) in the +1 reading frame (Figure 9 ).", [["NS6", "GENE_OR_GENE_PRODUCT", 44, 47], ["NS6", "GENE_OR_GENE_PRODUCT", 166, 169], ["Coronavirus Group 3cBat coronaviruses 1A", "ORGANISM", 275, 315], ["ORFX", "GENE_OR_GENE_PRODUCT", 351, 355], ["ORF3", "GENE_OR_GENE_PRODUCT", 365, 369], ["NS6", "PROTEIN", 44, 47], ["NS6", "DNA", 166, 169], ["ORFX", "PROTEIN", 249, 253], ["ORFX", "DNA", 351, 355], ["ORF3", "DNA", 365, 369], ["+1 reading frame", "DNA", 395, 411], ["Coronavirus Group 3cBat coronaviruses", "SPECIES", 275, 312], ["a TRS", "PROBLEM", 87, 92], ["a /K s ratio", "TEST", 118, 130], ["our MLOGD analysis", "TEST", 133, 151], ["Coronavirus Group", "TEST", 275, 292]]], ["ORFX appears to be present in bat coronavirus 1B (BtCoV 1B), bat coronavirus 1A (BtCoV 1A), and bat coronavirus HKU8 (BtCoV HKU8) [39] (just three sequences available), but does not appear to have a wider phylogenetic distribution among sequences currently available in GenBank (15 Nov Figure 3 for details).", [["ORFX", "CHEMICAL", 0, 4], ["ORFX", "GENE_OR_GENE_PRODUCT", 0, 4], ["bat coronavirus 1B", "ORGANISM", 30, 48], ["BtCoV 1B", "ORGANISM", 50, 58], ["bat coronavirus 1A", "ORGANISM", 61, 79], ["BtCoV 1A", "ORGANISM", 81, 89], ["bat coronavirus", "ORGANISM", 96, 111], ["HKU8", "GENE_OR_GENE_PRODUCT", 112, 116], ["BtCoV HKU8", "GENE_OR_GENE_PRODUCT", 118, 128], ["ORFX", "PROTEIN", 0, 4], ["BtCoV 1A", "PROTEIN", 81, 89], ["bat coronavirus", "SPECIES", 30, 45], ["bat coronavirus", "SPECIES", 61, 76], ["bat coronavirus", "SPECIES", 96, 111], ["bat coronavirus 1B", "SPECIES", 30, 48], ["BtCoV", "SPECIES", 50, 55], ["bat coronavirus 1A", "SPECIES", 61, 79], ["BtCoV", "SPECIES", 81, 86], ["bat coronavirus", "SPECIES", 96, 111], ["bat coronavirus", "TEST", 30, 45], ["bat coronavirus 1A", "TEST", 61, 79], ["bat coronavirus HKU8", "TEST", 96, 116], ["a wider phylogenetic distribution among sequences", "PROBLEM", 197, 246], ["appears to be", "UNCERTAINTY", 5, 18]]], ["The predominantly positive scores indicate that ORFX is likely to be a coding sequence.", [["ORFX", "GENE_OR_GENE_PRODUCT", 48, 52], ["ORFX", "DNA", 48, 52], ["coding sequence", "DNA", 71, 86], ["a coding sequence", "PROBLEM", 69, 86], ["predominantly", "OBSERVATION_MODIFIER", 4, 17], ["positive", "OBSERVATION", 18, 26], ["ORFX", "OBSERVATION", 48, 52], ["is likely to be", "UNCERTAINTY", 53, 68]]], ["The predominantly positive scores indicate that ORFX is likely to be a coding sequence, but is subject to significantly weaker purifying selection than NS6.", [["ORFX", "GENE_OR_GENE_PRODUCT", 48, 52], ["NS6", "GENE_OR_GENE_PRODUCT", 152, 155], ["ORFX", "DNA", 48, 52], ["coding sequence", "DNA", 71, 86], ["NS6", "DNA", 152, 155], ["a coding sequence", "PROBLEM", 69, 86], ["predominantly", "OBSERVATION_MODIFIER", 4, 17], ["positive", "OBSERVATION", 18, 26], ["is likely to be", "UNCERTAINTY", 53, 68]]], ["The negative scores at the 3' end of ORFX indicate that the C-terminal region of the putative product is not subject to strong functional constraints.", [["C", "CHEMICAL", 60, 61], ["ORFX", "GENE_OR_GENE_PRODUCT", 37, 41], ["3' end", "DNA", 27, 33], ["ORFX", "PROTEIN", 37, 41], ["C-terminal region", "DNA", 60, 77], ["the C-terminal region", "PROBLEM", 56, 77], ["negative", "OBSERVATION", 4, 12], ["terminal", "ANATOMY_MODIFIER", 62, 70]]], ["ORFX appears amenable to translation via leaky scanning from the same sgRNA as ORF3 since the ORF3 AUG initiation codon has a 'G' at -3 and a 'U' at +4 for a medium to weak Kozak context, and there are no intervening AUG codons in any frame between the ORF3 AUG codon and the ORFX AUG codon ( Figure 10 ).", [["ORFX", "CHEMICAL", 0, 4], ["ORFX", "GENE_OR_GENE_PRODUCT", 0, 4], ["sgRNA", "GENE_OR_GENE_PRODUCT", 70, 75], ["ORF3", "GENE_OR_GENE_PRODUCT", 79, 83], ["ORF3", "GENE_OR_GENE_PRODUCT", 94, 98], ["G' at -3", "GENE_OR_GENE_PRODUCT", 127, 135], ["ORFX", "PROTEIN", 0, 4], ["sgRNA", "DNA", 70, 75], ["ORF3", "DNA", 79, 83], ["ORF3 AUG initiation codon", "DNA", 94, 119], ["AUG codons", "DNA", 217, 227], ["ORF3 AUG codon", "DNA", 253, 267], ["ORFX AUG codon", "DNA", 276, 290], ["leaky scanning", "TEST", 41, 55], ["the ORF3 AUG", "TREATMENT", 90, 102], ["a 'G'", "TREATMENT", 124, 129], ["intervening AUG codons", "PROBLEM", 205, 227], ["leaky", "OBSERVATION", 41, 46], ["no", "UNCERTAINTY", 202, 204], ["AUG codons", "OBSERVATION", 217, 227], ["AUG codon", "OBSERVATION", 258, 267]]], ["ORFX has length 91-95 codons.", [["ORFX", "CHEMICAL", 0, 4], ["ORFX", "GENE_OR_GENE_PRODUCT", 0, 4], ["ORFX", "DNA", 0, 4], ["length 91-95 codons", "DNA", 9, 28], ["length", "TEST", 9, 15]]], ["As with Group 3c coronavirus NS6, our MLOGD analysis also confirmed the probable coding status of ORF3, and showed that ORF3 is subject to significantly stronger functional constraints than ORFX (Figure 9 , panel 5).ConclusionsOverlapping genes are difficult to identify and are often overlooked.", [["ORF3", "GENE_OR_GENE_PRODUCT", 98, 102], ["ORF3", "GENE_OR_GENE_PRODUCT", 120, 124], ["MLOGD", "DNA", 38, 43], ["ORF3", "DNA", 98, 102], ["ORF3", "DNA", 120, 124], ["ORFX", "PROTEIN", 190, 194], ["Group 3c coronavirus", "SPECIES", 8, 28], ["our MLOGD analysis", "TEST", 34, 52], ["coding status of ORF3", "PROBLEM", 81, 102], ["ORF3", "PROBLEM", 120, 124], ["panel", "TEST", 207, 212]]], ["However, it is important to be aware of such genes as early as possible in order to avoid confusion (otherwise functions of the overlapping gene may be wrongly ascribed to the gene they overlap), and also so that the functions of the overlapping gene may be investigated in their own right.", [["confusion", "DISEASE", 90, 99], ["overlapping gene", "DNA", 128, 144], ["overlapping gene", "DNA", 234, 250], ["confusion", "PROBLEM", 90, 99], ["right", "ANATOMY_MODIFIER", 284, 289]]], ["Computational analysis of sequence data is a time-and cost-efficient way to find such genes and help direct experimental follow-up.ConclusionsThe list of new candidate overlapping genes presented here is by no means complete as we have omitted several candidates that we are currently following up experimentally, and a number of candidates that are less certain -for example candidates where a conserved potential translation mechanism has not been identified, or candidates where a significant fraction of isolates contain premature termination codons, or candidates with too little phylogenetic support within the currently available sequence databases.", [["overlapping genes", "DNA", 168, 185], ["Computational analysis", "TEST", 0, 22], ["sequence data", "TEST", 26, 39], ["a significant fraction of isolates", "PROBLEM", 482, 516], ["premature termination codons", "PROBLEM", 525, 553]]], ["To the best of our knowledge (except as noted for cytorhabdovirus) these candiates have not previously been described or annotated elsewhere, and we apologize if we have accidently omitted any previous references to any of these candidates.MethodsVirus sequences were downloaded from GenBank and alignments were generated using standard bioinformatics software (blast [40] , clustal [41] and EMBOSS [42] ).", [["candiates", "CANCER", 73, 82], ["MethodsVirus sequences", "DNA", 240, 262], ["MethodsVirus sequences", "TEST", 240, 262]]], ["Candidate overlapping CDSs were identified using either MLOGD or analysis of conservation at Figure 3 for details).", [["overlapping CDSs", "DNA", 10, 26], ["MLOGD", "DNA", 56, 61], ["overlapping CDSs", "TREATMENT", 10, 26]]], ["The predominantly positive scores indicate that ORFX is likely to be a coding sequence, but is subject to significantly weaker purifying selection than ORF3.", [["ORFX", "GENE_OR_GENE_PRODUCT", 48, 52], ["ORF3", "GENE_OR_GENE_PRODUCT", 152, 156], ["ORFX", "DNA", 48, 52], ["coding sequence", "DNA", 71, 86], ["ORF3", "DNA", 152, 156], ["a coding sequence", "PROBLEM", 69, 86], ["predominantly", "OBSERVATION_MODIFIER", 4, 17], ["positive", "OBSERVATION", 18, 26], ["is likely to be", "UNCERTAINTY", 53, 68]]], ["The negative scores at the 3' end of ORFX indicate that the C-terminal region of the putative product is not subject to strong functional constraints.", [["C", "CHEMICAL", 60, 61], ["ORFX", "GENE_OR_GENE_PRODUCT", 37, 41], ["3' end", "DNA", 27, 33], ["ORFX", "PROTEIN", 37, 41], ["C-terminal region", "DNA", 60, 77], ["the C-terminal region", "PROBLEM", 56, 77], ["negative", "OBSERVATION", 4, 12], ["terminal", "ANATOMY_MODIFIER", 62, 70]]]], "228c9e9b4e528922098e47847ccaab2806245d5b": [["IntroductionThe coronavirus disease 2019 (COVID-19) is transmitted from the release of droplets when an infected person coughs or exhales.", [["coronavirus disease", "DISEASE", 16, 35], ["COVID-19", "CHEMICAL", 42, 50], ["coronavirus", "ORGANISM", 16, 27], ["person", "SPECIES", 113, 119], ["coronavirus disease 2019 (COVID-19", "SPECIES", 16, 50], ["The coronavirus disease", "PROBLEM", 12, 35], ["COVID", "TEST", 42, 47], ["exhales", "PROBLEM", 130, 137], ["coronavirus disease", "OBSERVATION", 16, 35], ["infected", "OBSERVATION", 104, 112]]], ["Then, the released droplets will fall on the nearby objects and surfaces, thus contaminating them.", [["the released droplets", "PROBLEM", 6, 27], ["surfaces", "OBSERVATION_MODIFIER", 64, 72]]], ["A nearby person can be infected by touching fomites, and then touching their mouth and nose [1] .", [["mouth", "ANATOMY", 77, 82], ["mouth", "ORGANISM_SUBDIVISION", 77, 82], ["person", "SPECIES", 9, 15], ["mouth", "ANATOMY", 77, 82]]], ["Moreover, the virus itself has the potential for viral entry from the human eyes [2] .", [["eyes", "ANATOMY", 76, 80], ["human", "ORGANISM", 70, 75], ["eyes", "ORGAN", 76, 80], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["virus", "OBSERVATION", 14, 19], ["human eyes", "ANATOMY", 70, 80]]], ["The common symptoms of COVID-19 are mild fever, dry cough, shortness of breath and muscle pain [3] .", [["muscle", "ANATOMY", 83, 89], ["COVID", "DISEASE", 23, 28], ["fever", "DISEASE", 41, 46], ["dry cough", "DISEASE", 48, 57], ["shortness of breath", "DISEASE", 59, 78], ["muscle pain", "DISEASE", 83, 94], ["muscle", "ORGAN", 83, 89], ["The common symptoms", "PROBLEM", 0, 19], ["COVID", "TEST", 23, 28], ["mild fever", "PROBLEM", 36, 46], ["dry cough", "PROBLEM", 48, 57], ["shortness of breath", "PROBLEM", 59, 78], ["muscle pain", "PROBLEM", 83, 94], ["mild", "OBSERVATION_MODIFIER", 36, 40], ["fever", "OBSERVATION", 41, 46], ["dry", "OBSERVATION_MODIFIER", 48, 51], ["cough", "OBSERVATION", 52, 57], ["muscle", "ANATOMY", 83, 89], ["pain", "OBSERVATION", 90, 94]]], ["However, severe symptoms such as high fever, pneumonia and acute kidney failure can be observed in the older persons and persons with comorbidities [4] .", [["kidney", "ANATOMY", 65, 71], ["fever", "DISEASE", 38, 43], ["pneumonia", "DISEASE", 45, 54], ["acute kidney failure", "DISEASE", 59, 79], ["kidney", "ORGAN", 65, 71], ["persons", "ORGANISM", 109, 116], ["persons", "SPECIES", 109, 116], ["persons", "SPECIES", 121, 128], ["severe symptoms", "PROBLEM", 9, 24], ["high fever", "PROBLEM", 33, 43], ["pneumonia", "PROBLEM", 45, 54], ["acute kidney failure", "PROBLEM", 59, 79], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["pneumonia", "OBSERVATION", 45, 54], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["kidney", "ANATOMY", 65, 71], ["failure", "OBSERVATION", 72, 79]]], ["Bear in mind that anyone could be in contact with COVID-19.", [["COVID-19", "CHEMICAL", 50, 58]]], ["Furthermore, this virus can cause severe complications to a high-risk group such as children, older persons, persons with comorbidities, persons with a weak immune system, pregnant women, and disabled persons [5] .", [["children", "ORGANISM", 84, 92], ["persons", "ORGANISM", 109, 116], ["women", "ORGANISM", 181, 186], ["persons", "ORGANISM", 201, 208], ["children", "SPECIES", 84, 92], ["persons", "SPECIES", 100, 107], ["persons", "SPECIES", 109, 116], ["persons", "SPECIES", 137, 144], ["women", "SPECIES", 181, 186], ["persons", "SPECIES", 201, 208], ["this virus", "PROBLEM", 13, 23], ["severe complications", "PROBLEM", 34, 54]]], ["Because of that, vulnerable people must be protected at all costs as the disease can be deadly to them.", [["people", "ORGANISM", 28, 34], ["people", "SPECIES", 28, 34], ["the disease", "PROBLEM", 69, 80]]], ["In addition, most of the COVID-19 patients show no symptoms [6, 7] .", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["the COVID", "TEST", 21, 30], ["symptoms", "PROBLEM", 51, 59], ["no", "UNCERTAINTY", 48, 50]]], ["COVID-19 patient with no symptoms is known as silent spreader [8, 9] and can spread the disease unknowingly through physical contact and close conversation.IntroductionThere are three ways to stop the spreading of COVID-19 [10] .", [["COVID-19", "CHEMICAL", 214, 222], ["patient", "ORGANISM", 9, 16], ["patient", "SPECIES", 9, 16], ["COVID", "TEST", 0, 5], ["symptoms", "PROBLEM", 25, 33], ["the disease", "PROBLEM", 84, 95], ["COVID", "TEST", 214, 219], ["disease", "OBSERVATION", 88, 95]]], ["One involves the movement restriction on social and economic sectors.", [["movement", "OBSERVATION_MODIFIER", 17, 25]]], ["Secondly, an efficient vaccine is developed, which may take at least 12 to 18 months for clinical trials and mass production [11] .", [["an efficient vaccine", "TREATMENT", 10, 30], ["mass production", "PROBLEM", 109, 124]]], ["The third way is to stop the COVID-19 outbreak naturally with herd immunity [10] .IntroductionCountries such as Taiwan, South Korea and Sweden are not implementing movement restriction, as they are relying on a high level of self-regulation and self-discipline among their citizens.", [["herd", "ORGANISM_SUBDIVISION", 62, 66]]], ["The citizens have been engaged and empowered to do their parts in preventing the spread of COVID-19.", [["COVID-19", "CHEMICAL", 91, 99], ["COVID", "TEST", 91, 96]]], ["Meanwhile, Malaysia and Singapore implement both movement restriction and self-regulation approaches.", [["movement restriction", "TREATMENT", 49, 69], ["self-regulation approaches", "TREATMENT", 74, 100]]], ["In Malaysia, movement restriction is implemented in the first few weeks to contain the outbreak.", [["movement restriction", "TREATMENT", 13, 33], ["the outbreak", "PROBLEM", 83, 95]]], ["Once the COVID-19 infection curve has been flattened, the self-regulation and self-discipline approaches are implemented to restart and recover the social and economic sectors.IntroductionMovement restriction puts a lot of pressure on the population's physical, mental, health, social and economy.", [["infection", "DISEASE", 18, 27], ["physical, mental, health, social and economy", "DISEASE", 252, 296], ["the COVID", "TEST", 5, 14], ["infection curve", "TEST", 18, 33], ["IntroductionMovement restriction", "TREATMENT", 176, 208], ["flattened", "OBSERVATION_MODIFIER", 43, 52]]], ["Moreover, global economies are hardly hit by the COVID-19 outbreak [12] .", [["the COVID", "TEST", 45, 54], ["global", "OBSERVATION_MODIFIER", 10, 16], ["economies", "OBSERVATION", 17, 26]]], ["Hence, there is an increasing pressure to restart and resurrect the social and economic sectors, and to allow people to get back to work.", [["people", "ORGANISM", 110, 116], ["people", "SPECIES", 110, 116], ["an increasing pressure", "PROBLEM", 16, 38], ["increasing", "OBSERVATION_MODIFIER", 19, 29], ["pressure", "OBSERVATION", 30, 38]]], ["The developed procedures should find the right balance between economic resurrection and COVID-19 prevention [13] .", [["COVID-19", "CHEMICAL", 89, 97], ["procedures", "TREATMENT", 14, 24], ["economic resurrection", "TREATMENT", 63, 84], ["COVID", "TREATMENT", 89, 94], ["right", "ANATOMY_MODIFIER", 41, 46]]], ["The social and economic sectors must open in phases by emphasising safety and health than an economic recovery.IntroductionHence, this paper reviews and recommends new normals and procedures for daily activities and work-lives to protect people's safety and health.", [["people", "ORGANISM", 238, 244], ["people", "SPECIES", 238, 244]]], ["Medical possibilities are not considered while compiling these new normals and procedures.", [["not considered", "UNCERTAINTY", 26, 40]]], ["No ethical approval required in this study.ResponsibilityThe World Health Organization (WHO) has recommended six criteria for countries that consider lifting the movement restriction.", [["ethical approval", "TREATMENT", 3, 19], ["this study", "TEST", 32, 42], ["the movement restriction", "TREATMENT", 158, 182], ["ethical", "OBSERVATION", 3, 10]]], ["Social distancing or physical distancing is a safe distance between individuals to prevent respiratory droplet transmission while working and social interactions [15] .", [["respiratory droplet", "ANATOMY", 91, 110], ["respiratory droplet transmission", "PROBLEM", 91, 123], ["respiratory droplet", "OBSERVATION", 91, 110]]], ["Meanwhile, personal hygiene is a good hand-washing practice as in [16] .", [["hand", "ANATOMY", 38, 42]]], ["Moreover, a facemask is recommended to be used if the mass gatherings and crowded places are unavoidable [17, 18] .", [["a facemask", "TREATMENT", 10, 20], ["the mass", "PROBLEM", 50, 58], ["mass", "OBSERVATION", 54, 58]]], ["A study reported that the cotton or cloth mask could prevent the spread of viral load up to 96% [19] .", [["cotton", "SPECIES", 26, 32], ["A study", "TEST", 0, 7], ["the cotton or cloth mask", "TREATMENT", 22, 46], ["viral load", "TEST", 75, 85]]], ["The economic sectors open in phases, by prioritising the most essential businesses.", [["economic", "OBSERVATION_MODIFIER", 4, 12], ["sectors", "OBSERVATION_MODIFIER", 13, 20], ["businesses", "OBSERVATION", 72, 82]]], ["Besides, the government should consider developing contact tracing and geofencing systems.", [["geofencing systems", "PROBLEM", 71, 89]]], ["Contact tracing is a system to trace people who have physical contact and close conversation for a prolonged period with an infected person.", [["people", "ORGANISM", 37, 43], ["people", "SPECIES", 37, 43], ["person", "SPECIES", 133, 139], ["infected", "OBSERVATION", 124, 132]]], ["Geofencing refers to the use of application to establish a virtual fence that limits the movement of an infected person, hence alarming the authority if the virtual fence is disregarded.", [["person", "SPECIES", 113, 119], ["application", "TREATMENT", 32, 43], ["infected", "OBSERVATION", 104, 112]]], ["This system requires active monitoring using location-based applications J o u r n a l P r e -p r o o f tied with the bearer.", [["active monitoring", "TREATMENT", 21, 38], ["active", "OBSERVATION_MODIFIER", 21, 27]]], ["Moreover, the close contacts of the suspected person can be traced, thus isolation and diagnostic testing can be done on them.", [["person", "SPECIES", 46, 52], ["diagnostic testing", "TEST", 87, 105]]], ["Close contact is being closer than 1 metre apart for more than 15 minutes with an infected person [18] .", [["person", "SPECIES", 91, 97]]], ["Furthermore, the government should consider enforcing a strict law for those who are violating COVID-19 preventive measures [21] .ResponsibilityThe procedures introduced by the government must be enforced by the local authorities to ensure the safety and health of the people.", [["people", "ORGANISM", 269, 275], ["people", "SPECIES", 269, 275], ["COVID", "TEST", 95, 100]]], ["The authorities can also prepare a list of dos and don'ts to help the people from contacting this coronavirus.", [["coronavirus", "DISEASE", 98, 109], ["people", "ORGANISM", 70, 76], ["coronavirus", "ORGANISM", 98, 109], ["people", "SPECIES", 70, 76], ["this coronavirus", "PROBLEM", 93, 109]]], ["Moreover, the local authorities should disinfect high-risk areas such as public parks and public transports.", [["high-risk areas", "PROBLEM", 49, 64]]], ["COVID-19 cleaning and disinfecting practices are referred to [22] .ResponsibilityOccupational safety and health (OSH) professionals can help and advise their employers regarding the COVID-19 issues to maintain the right balance between health and business operations.", [["COVID", "TEST", 0, 5], ["disinfecting practices", "TREATMENT", 22, 44], ["business operations", "TREATMENT", 247, 266], ["right", "ANATOMY_MODIFIER", 214, 219]]], ["They can also plan and enforce the COVID-19 safety measures in their workplaces.ResponsibilityMeanwhile, the employers must ascertain the essential and non-essential works in their operations.", [["the COVID-19 safety measures", "TREATMENT", 31, 59]]], ["After that, an adequate number of workers for essential operations can be organised.", [["essential operations", "TREATMENT", 46, 66]]], ["Moreover, the employers should adapt and embrace the industry 4.0 technologies such as artificial intelligence, internet of things, big data, virtual reality, halography, cloud computing, autonomous robot, 3D scanning, 3D printing and biosensor which can reduce contacts among their employees [23] .ResponsibilityOther than that, people must be responsible for themselves and their families.", [["people", "ORGANISM", 330, 336], ["people", "SPECIES", 330, 336], ["3D scanning", "TEST", 206, 217], ["3D printing and biosensor", "TREATMENT", 219, 244]]], ["A person should go out or travel only when it is necessary such as to get medical treatment, groceries, foods, necessities, essential works and emergency situations [24] , and must return home promptly.", [["person", "SPECIES", 2, 8], ["medical treatment", "TREATMENT", 74, 91]]], ["It is well recommended that only one person is allowed to go out at a time.", [["person", "SPECIES", 37, 43]]], ["The person should disinfect his or her shoes or leave them outside before entering their houses, as the coronavirus could be present on the floor surfaces.", [["floor surfaces", "ANATOMY", 140, 154], ["coronavirus", "DISEASE", 104, 115], ["coronavirus", "ORGANISM", 104, 115], ["person", "SPECIES", 4, 10], ["the coronavirus", "PROBLEM", 100, 115], ["coronavirus", "OBSERVATION", 104, 115]]], ["Then, a person should go straight to the bathroom to take a bath with water and soap, before touching their family members.", [["person", "SPECIES", 8, 14]]], ["Clothes must be changed and washed upon returning home.New normals and proceduresRapid diagnostic, drug and vaccine are not the only COVID-19 exit strategy.", [["Clothes", "TREATMENT", 0, 7], ["drug and vaccine", "TREATMENT", 99, 115], ["normals", "OBSERVATION", 59, 66]]], ["Selfregulation and self-discipline are equally important to prevent the virus from reappearing in the future [25] .", [["Selfregulation", "TREATMENT", 0, 14], ["the virus", "PROBLEM", 68, 77]]], ["The people must regulate themselves by following procedures provided by the government and authorities.", [["people", "ORGANISM", 4, 10], ["people", "SPECIES", 4, 10]]], ["Besides, people must discipline themselves to avoid violating the procedures.", [["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15], ["the procedures", "TREATMENT", 62, 76]]], ["Temperature checking will become a new normal or routine as an initial measure for COVID-19 detection [26, 27] .", [["Temperature checking", "TEST", 0, 20], ["COVID", "TEST", 83, 88]]], ["The persons with 37.5 o C or above temperature will be denied entry, and must seek medical attention immediately.New normals and proceduresThe other normal is the organisers, workers, visitors and participants at the meetings, events and gatherings must provide their contact details such as their name, telephone number, email and home address.", [["persons", "ORGANISM", 4, 11], ["persons", "SPECIES", 4, 11], ["participants", "SPECIES", 197, 209], ["normals", "OBSERVATION", 117, 124], ["normal", "OBSERVATION", 149, 155]]], ["These pieces of information will be shared with the health authorities if COVID-19 infection happens in the respective places.New normals and proceduresHowever, if COVID-19 infection happens, the respective workplaces, premises and buildings must be shut down immediately and all operations are suspended.", [["COVID-19", "CHEMICAL", 74, 82], ["infection", "DISEASE", 83, 92], ["infection", "DISEASE", 173, 182], ["COVID-19", "ORGANISM", 74, 82], ["COVID", "TEST", 74, 79], ["infection", "PROBLEM", 83, 92], ["COVID", "TEST", 164, 169], ["infection", "PROBLEM", 173, 182], ["all operations", "TREATMENT", 276, 290], ["infection", "OBSERVATION", 83, 92], ["normals", "OBSERVATION", 130, 137], ["infection", "OBSERVATION", 173, 182]]], ["Then, the diagnostic test is implemented on all workers and visitors.", [["the diagnostic test", "TEST", 6, 25]]], ["A person must self-isolate, be treated, and not be allowed to come to work after being infected.", [["person", "SPECIES", 2, 8], ["infected", "OBSERVATION", 87, 95]]], ["The infected person can come to work after at least 11 days of self-isolation.", [["person", "ORGANISM", 13, 19], ["person", "SPECIES", 13, 19], ["self-isolation", "TREATMENT", 63, 77], ["infected", "OBSERVATION", 4, 12]]], ["This is because the infected J o u r n a l P r e -p r o o f person is no longer infectious after 11 days of getting sick [28] .", [["person", "SPECIES", 60, 66], ["no longer", "UNCERTAINTY", 70, 79]]], ["Moreover, working from home can prevent workers from contacting the COVID-19 infection outside of their homes.", [["infection", "DISEASE", 77, 86]]], ["Breathing in fresh air has many advantages such as improving heart rate and blood pressure, giving sharper mind, cleaning lungs and providing energy.Working from homeA dedicated workspace must be prepared for working from home.", [["heart", "ANATOMY", 61, 66], ["blood", "ANATOMY", 76, 81], ["lungs", "ANATOMY", 122, 127], ["heart", "ORGAN", 61, 66], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["lungs", "ORGAN", 122, 127], ["blood pressure", "TEST", 76, 90], ["fresh air", "OBSERVATION", 13, 22], ["lungs", "ANATOMY", 122, 127]]], ["The workspace must be comfortable, quiet, has mild temperature and good lighting.", [["mild temperature", "PROBLEM", 46, 62], ["mild", "OBSERVATION_MODIFIER", 46, 50]]], ["Some workers might experience anxiety and stress when starting to work from home.", [["anxiety", "DISEASE", 30, 37], ["anxiety", "PROBLEM", 30, 37], ["stress", "PROBLEM", 42, 48]]], ["However, productivity can be improved over time.", [["improved", "OBSERVATION_MODIFIER", 29, 37]]], ["This is to ensure the workers commitment towards their tasks.Working from homeRecently, there is increasing evidence that domestic animals such as cats can spread the virus to the other cats [30] [31] [32] and show no symptoms [33] .", [["cats", "ORGANISM", 147, 151], ["cats", "SPECIES", 147, 151], ["cats", "SPECIES", 186, 190], ["symptoms", "PROBLEM", 218, 226], ["no", "UNCERTAINTY", 215, 217]]], ["Previously, the SARS-CoV-2 virus is originated from bats and transmitted from animals to humans [34] .", [["SARS-CoV-2 virus", "ORGANISM", 16, 32], ["bats", "ORGANISM", 52, 56], ["humans", "ORGANISM", 89, 95], ["CoV-2 virus", "SPECIES", 21, 32], ["humans", "SPECIES", 89, 95], ["SARS-CoV-2 virus", "SPECIES", 16, 32], ["humans", "SPECIES", 89, 95], ["the SARS-CoV-2 virus", "PROBLEM", 12, 32]]], ["Therefore, precautions must be taken to prevent transmission from pets to humans.", [["humans", "ORGANISM", 74, 80], ["humans", "SPECIES", 74, 80], ["humans", "SPECIES", 74, 80], ["precautions", "TREATMENT", 11, 22]]], ["This can prevent a large presence of workers in the workplace, thus can reduce physical contact among them.", [["large", "OBSERVATION_MODIFIER", 19, 24]]], ["Flexible working and business hours are recommended to avoid a large crowd in public transports during peak hours.", [["large", "OBSERVATION_MODIFIER", 63, 68], ["crowd", "OBSERVATION", 69, 74]]], ["Furthermore, a four-day workweek has been encouraged in New Zealand and Japan to boost the struggling economy and increase productivity [35] .", [["New Zealand", "TREATMENT", 56, 67]]], ["Therefore, this will allow people to travel during their off days and boost the local economy.Workforce and workplaceThe employers must promote and enforce social distancing, personal hygiene and personal protective equipment (PPE) among their workers.", [["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33], ["the local economy", "TREATMENT", 76, 93]]], ["Moreover, the hand-washing facilities can be accessed by workers, contractors and visitors.", [["hand", "ANATOMY", 14, 18]]], ["Hand sanitisers must be provided at all entrance points.", [["Hand sanitisers", "TREATMENT", 0, 15]]], ["On the J o u r n a l P r e -p r o o f other hand, a good cough etiquette is emphasised if a face mask is unavailable.", [["cough", "DISEASE", 57, 62], ["a l P r e -p r o o f other hand", "TEST", 17, 48], ["a face mask", "TREATMENT", 90, 101], ["hand", "ANATOMY", 44, 48], ["cough", "OBSERVATION", 57, 62]]], ["Besides, the geofencing system can be used to ensure social distancing is observed by the workers.", [["the geofencing system", "TREATMENT", 9, 30]]], ["On the other hand, handshaking is not encouraged to avoid close contact.Workforce and workplaceThe workers must clean and disinfect their workplace to prevent the spreading of COVID-19.", [["COVID-19", "CHEMICAL", 176, 184], ["COVID", "TEST", 176, 181]]], ["The virus itself can be transmitted through fomites such as handle, doorknob, tabletop, lift button, lamp switch, fan switch and rail.", [["virus", "OBSERVATION", 4, 9]]], ["The virus can remain infectious on these surfaces up to 9 days [36] .", [["The virus", "PROBLEM", 0, 9], ["infectious", "PROBLEM", 21, 31], ["virus", "OBSERVATION", 4, 9], ["infectious", "OBSERVATION", 21, 31]]], ["However, these fomites can be insulated with copper as the virus is not viable on its surface [37] .", [["surface", "ANATOMY", 86, 93], ["copper", "CHEMICAL", 45, 51], ["copper", "CHEMICAL", 45, 51], ["copper", "SIMPLE_CHEMICAL", 45, 51], ["the virus", "PROBLEM", 55, 64], ["virus", "OBSERVATION", 59, 64]]], ["The floor should be disinfected too as there were cases where the virus is detected on the shoes of the health care workers [38] .", [["the virus", "PROBLEM", 62, 71]]], ["Furthermore, toilet equipment such as tap, sink, door, hand rail, toilet seat and toilet cover must be disinfected regularly.", [["hand", "ANATOMY", 55, 59], ["toilet equipment", "TREATMENT", 13, 29], ["tap", "TREATMENT", 38, 41], ["toilet seat and toilet cover", "TREATMENT", 66, 94]]], ["Preventive maintenance on the ventilation system must be carried out periodically.", [["the ventilation system", "TREATMENT", 26, 48]]], ["The ventilator filter must be replaced to prevent cross contamination from bacteria and viruses.", [["The ventilator filter", "TREATMENT", 0, 21], ["cross contamination", "PROBLEM", 50, 69], ["bacteria", "PROBLEM", 75, 83], ["viruses", "PROBLEM", 88, 95], ["ventilator filter", "OBSERVATION", 4, 21]]], ["In fact, the previous coronavirus outbreak (SARS) was transmitted through an airborne transmission from the toilet flush and an exhaust fan of the plumbing system [39] .", [["coronavirus", "DISEASE", 22, 33], ["SARS", "DISEASE", 44, 48], ["coronavirus", "ORGANISM", 22, 33], ["the previous coronavirus outbreak (SARS", "PROBLEM", 9, 48], ["an airborne transmission", "TREATMENT", 74, 98], ["the toilet flush", "TREATMENT", 104, 120], ["coronavirus", "OBSERVATION_MODIFIER", 22, 33], ["toilet flush", "OBSERVATION", 108, 120]]], ["Because of that, efficient air circulation and ventilation must be maintained to ensure people's safety.", [["people", "ORGANISM", 88, 94], ["people", "SPECIES", 88, 94], ["efficient air circulation", "PROBLEM", 17, 42], ["ventilation", "TREATMENT", 47, 58], ["air circulation", "OBSERVATION", 27, 42]]], ["The workers can order their meals for takeaway and enjoy their lunch at their desks.Workforce and workplaceOn the other hand, workers with COVID-19 symptoms must stay at home and notify their employers.", [["hand", "ORGANISM_SUBDIVISION", 120, 124], ["symptoms", "PROBLEM", 148, 156]]], ["Furthermore, an emergency plan must be carried out when the worker shows COVID-19 symptoms during the working hours.", [["COVID-19 symptoms", "PROBLEM", 73, 90]]], ["Specific procedures must be taken to transfer the suspected worker from the workplace to the hospital.", [["Specific procedures", "TREATMENT", 0, 19]]], ["If the worker is infected, the whole household members must self-isolate.", [["infected", "OBSERVATION", 17, 25]]], ["Then, the health authority will conduct a diagnostic test for household members.", [["a diagnostic test", "TEST", 40, 57]]], ["The household members are not allowed to leave the house until the result is obtained.Manufacturing, construction and machineryIn the manufacturing and construction industries, the employers through their OSH professionals can promote COVID-19 awareness such as the method of spreading, protection, and prevention from the infection.", [["infection", "DISEASE", 323, 332], ["protection", "TREATMENT", 287, 297], ["the infection", "PROBLEM", 319, 332], ["infection", "OBSERVATION", 323, 332]]], ["Moreover, the OSH professionals must identify the high-risk workers that can get severe complications from the COVID-19 infection.", [["infection", "DISEASE", 120, 129], ["severe complications", "PROBLEM", 81, 101], ["the COVID-19 infection", "PROBLEM", 107, 129], ["infection", "OBSERVATION", 120, 129]]], ["The common contact surfaces such as table, chair, doorknob, handrail, lift button, handle and hand tool, need to be cleaned regularly.", [["hand", "ANATOMY", 94, 98], ["doorknob", "TREATMENT", 50, 58], ["handrail", "TREATMENT", 60, 68], ["handle and hand tool", "PROBLEM", 83, 103], ["common", "OBSERVATION_MODIFIER", 4, 10], ["contact surfaces", "OBSERVATION", 11, 27], ["hand", "ANATOMY", 94, 98]]], ["Based on the hierarchy of controls, engineering control is more effective than the administrative control and PPE control.", [["engineering control", "TREATMENT", 36, 55], ["the administrative control", "TREATMENT", 79, 105], ["PPE control", "TREATMENT", 110, 121], ["more effective", "OBSERVATION_MODIFIER", 59, 73]]], ["The engineering control includes; installing high-efficiency air filters, increasing ventilation rates in the workplace and installing physical barriers.", [["The engineering control", "TREATMENT", 0, 23], ["high-efficiency air filters", "TREATMENT", 45, 72], ["increasing ventilation rates", "TREATMENT", 74, 102], ["air filters", "OBSERVATION", 61, 72], ["increasing", "OBSERVATION_MODIFIER", 74, 84], ["ventilation rates", "OBSERVATION", 85, 102]]], ["Furthermore, high humidity and high temperature can reduce the transmission rate of COVID-19 [40] .", [["COVID-19", "CHEMICAL", 84, 92], ["high humidity", "PROBLEM", 13, 26], ["high temperature", "PROBLEM", 31, 47], ["COVID", "TEST", 84, 89], ["high", "OBSERVATION_MODIFIER", 13, 17], ["humidity", "OBSERVATION_MODIFIER", 18, 26]]], ["Hence, the humidity level of 40% -70% must be implemented in the workplace.Manufacturing, construction and machineryIn the manufacturing industry, employers and OSH professionals must ensure the safety of the workers by implementing COVID-19 control measures.", [["the humidity level", "TEST", 7, 25], ["COVID-19 control measures", "TREATMENT", 233, 258]]], ["Upon arrival at the workplace, the body temperature of the workers must be checked at the entrance facility.", [["body", "ANATOMY", 35, 39], ["body", "ORGANISM_SUBDIVISION", 35, 39]]], ["The number of access points can be increased to reduce congestion during the temperature check.", [["congestion", "DISEASE", 55, 65], ["access points", "TREATMENT", 14, 27], ["congestion", "PROBLEM", 55, 65], ["the temperature check", "TEST", 73, 94], ["congestion", "OBSERVATION", 55, 65]]], ["Then, each worker is required to clean their hands with hand sanitiser upon leaving the entrance facility.", [["hand", "ANATOMY", 56, 60]]], ["According to [38] , an elevated concentration of COVID-19 is measured in the confined space.", [["COVID-19", "CHEMICAL", 49, 57], ["COVID-19", "CHEMICAL", 49, 57], ["an elevated concentration of COVID", "PROBLEM", 20, 54], ["elevated", "OBSERVATION", 23, 31]]], ["Hence, adequate ventilation must be provided in confined spaces and rooms, at least 4 times per day.", [["adequate ventilation", "TREATMENT", 7, 27], ["adequate ventilation", "OBSERVATION", 7, 27]]], ["Moreover, the workers must be provided with PPEs such as the face masks and hand gloves, correspond to the OSH regulation.", [["hand", "ANATOMY", 76, 80], ["PPEs", "TREATMENT", 44, 48], ["the face masks", "TREATMENT", 57, 71], ["hand gloves", "TREATMENT", 76, 87], ["the OSH regulation", "TEST", 103, 121]]], ["If not possible, acrylic panels can be installed on the tables to separate the workers.", [["acrylic panels", "TEST", 17, 31], ["not possible", "UNCERTAINTY", 3, 15]]], ["Furthermore, a shift start time can be delayed for the cleaning and disinfection of equipment.", [["the cleaning", "TREATMENT", 51, 63], ["disinfection of equipment", "TREATMENT", 68, 93]]], ["If not possible, equipment sharing must be reduced to a minimum.", [["not possible", "UNCERTAINTY", 3, 15]]], ["The shift swapping is not allowed to reduce COVID-19 transmission.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 44, 52], ["COVID", "PROTEIN", 44, 49], ["The shift swapping", "TREATMENT", 0, 18], ["COVID", "TEST", 44, 49]]], ["Furthermore, the foreign workers must be screened as the infection within them can contribute to a major outbreak [41] .Manufacturing, construction and machineryThe construction industry is one of the largest and dangerous industries in the world, especially in the United States (US) [42] .", [["infection", "DISEASE", 57, 66], ["the infection", "PROBLEM", 53, 66], ["largest", "OBSERVATION_MODIFIER", 201, 208], ["dangerous", "OBSERVATION_MODIFIER", 213, 222], ["industries", "OBSERVATION", 223, 233]]], ["Because of that, more control measures should be taken at the construction sites to prevent the spreading of COVID-19.", [["COVID-19", "CHEMICAL", 109, 117], ["COVID-19", "DNA", 109, 117], ["COVID", "TEST", 109, 114]]], ["The safety and health officers (SHO) and safety site supervisors (SSS) are responsible to ensure the workers adhere to OSH regulations and COVID-19 procedures.", [["COVID-19 procedures", "TREATMENT", 139, 158]]], ["This will allow the employer to control and manage the large crowd in the construction site.", [["the large crowd in the construction site", "PROBLEM", 51, 91], ["large", "OBSERVATION_MODIFIER", 55, 60], ["crowd", "OBSERVATION", 61, 66]]], ["The temperature gun or scanner can be installed at each site entrance to measure the body temperature of the workers.", [["body", "ANATOMY", 85, 89], ["body", "ORGANISM_SUBDIVISION", 85, 89]]], ["Workers with COVID-19 symptoms will be denied entry and must seek medical attention immediately.", [["symptoms", "PROBLEM", 22, 30]]], ["The number of site entrances could be increased to reduce congestion during the temperature check.", [["congestion", "DISEASE", 58, 68], ["congestion", "PROBLEM", 58, 68], ["the temperature check", "TEST", 76, 97], ["site", "OBSERVATION_MODIFIER", 14, 18], ["entrances", "OBSERVATION", 19, 28], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["reduce", "OBSERVATION_MODIFIER", 51, 57], ["congestion", "OBSERVATION", 58, 68]]], ["The skin-to-skin works should not be carried out during the outbreak [43] .", [["skin", "ANATOMY", 4, 8], ["skin", "ANATOMY", 12, 16], ["skin", "ORGAN", 4, 8], ["skin", "ORGAN", 12, 16], ["skin", "ANATOMY", 4, 8], ["skin", "ANATOMY", 12, 16]]], ["If not possible, the exposure time between each work must be minimised.", [["not possible", "UNCERTAINTY", 3, 15]]], ["Moreover, ventilation must be increased in confined spaces.", [["ventilation", "TREATMENT", 10, 21], ["increased", "OBSERVATION_MODIFIER", 30, 39]]], ["The common contact surfaces such as tables, chairs, doorknobs, handrails, lift buttons, hoist buttons, handles and hand tools, must be sanitised regularly.", [["hand", "ANATOMY", 115, 119], ["doorknobs", "TREATMENT", 52, 61], ["handrails", "TREATMENT", 63, 72], ["common", "OBSERVATION_MODIFIER", 4, 10], ["contact surfaces", "OBSERVATION", 11, 27]]], ["Only wrapped and prepacked foods are allowed in the canteen.", [["prepacked foods", "TREATMENT", 17, 32]]], ["A special tap mechanism for water dispensers must be designed to ensure its cleanliness [44] .", [["A special tap mechanism", "TREATMENT", 0, 23], ["water dispensers", "TREATMENT", 28, 44]]], ["Furthermore, toilet facilities must be sanitised and cleaned regularly.", [["toilet facilities", "TREATMENT", 13, 30]]], ["Moreover, the hand washing facilities must be installed at appropriate places with extra supplies of soap, hand sanitiser and paper towels.", [["hand", "ANATOMY", 14, 18], ["hand", "ANATOMY", 107, 111], ["hand", "ORGANISM_SUBDIVISION", 107, 111], ["the hand washing facilities", "TREATMENT", 10, 37], ["soap", "TREATMENT", 101, 105]]], ["Sufficient rubbish bins must be provided for wastes disposal.", [["Sufficient rubbish bins", "TREATMENT", 0, 23]]], ["Furthermore, the COVID-19 preparedness and response J o u r n a l P r e -p r o o f team (CPRT) must be formed to prepare an emergency response plan (ERP) if the worker is suspected of COVID-19 infection.", [["infection", "DISEASE", 193, 202], ["the COVID", "TEST", 13, 22], ["COVID-19 infection", "PROBLEM", 184, 202], ["infection", "OBSERVATION", 193, 202]]], ["If a worker shows symptoms in the construction site, prompt action must be taken by isolating them in a dedicated room.", [["symptoms", "PROBLEM", 18, 26]]], ["Then, the construction site will be closed for disinfection.", [["the construction site", "TREATMENT", 6, 27], ["disinfection", "PROBLEM", 47, 59]]], ["All workers are required to be diagnosed to trace the COVID-19 infection.", [["infection", "DISEASE", 63, 72], ["the COVID-19 infection", "PROBLEM", 50, 72], ["infection", "OBSERVATION", 63, 72]]], ["The construction site can resume operation after being cleared by the health authority.Manufacturing, construction and machineryMachines and equipment must be sanitised and cleaned regularly.", [["operation", "TREATMENT", 33, 42], ["machineryMachines", "TREATMENT", 119, 136], ["equipment", "TREATMENT", 141, 150]]], ["Equipment sharing is not recommended to minimise COVID-19 transmission.", [["COVID", "TEST", 49, 54]]], ["The drivers of loading vehicles are recommended to remain in the vehicles, and must clean their hands when loading and unloading goods.", [["loading vehicles", "TREATMENT", 15, 31]]], ["The workers must be cross-trained and alternative sources must be identified to facilitate works that require specific skills.Health care servicesThe health care workers must clean their hands with water and soap before putting the face mask, face shield and gown on or when taking them off.", [["face", "ANATOMY", 232, 236], ["soap", "TREATMENT", 208, 212], ["the face mask", "TREATMENT", 228, 241], ["face shield", "TREATMENT", 243, 254]]], ["The reusable PPEs must be cleaned after each use and cannot be shared with other workers.", [["PPEs", "SIMPLE_CHEMICAL", 13, 17], ["The reusable PPEs", "TREATMENT", 0, 17]]], ["Meanwhile, the single use PPEs must be disposed of after each use in the biomedical waste bin.Health care servicesThe health care service providers such as the hospitals and clinics must limit the number of health care workers engaged with the patients [45] .", [["patients", "ORGANISM", 244, 252], ["patients", "SPECIES", 244, 252], ["PPEs", "TREATMENT", 26, 30]]], ["Moreover, the number of patients in health care facilities must be minimised to reduce COVID-19 transmission.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["COVID", "TEST", 87, 92]]], ["Only patients with appointments are allowed in the facilities.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["Furthermore, the patients must be punctual to their appointment time.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25]]], ["The patients must go home immediately after consultation with their physician.Health care servicesThe health care service providers should provide a dedicated place to evaluate persons with COVID-19 symptoms.", [["COVID", "DISEASE", 190, 195], ["patients", "ORGANISM", 4, 12], ["persons", "ORGANISM", 177, 184], ["patients", "SPECIES", 4, 12], ["persons", "SPECIES", 177, 184], ["symptoms", "PROBLEM", 199, 207]]], ["This can reduce the close contacts between the non-COVID-19 patients, suspected COVID-19 patients and health care workers.", [["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 89, 97]]], ["Moreover, persons with COVID-19 symptoms are advised not to visit hospitals or clinics without prior notice.", [["persons", "ORGANISM", 10, 17], ["persons", "SPECIES", 10, 17], ["symptoms", "PROBLEM", 32, 40]]], ["Furthermore, COVID-19 patients must be treated separately from other patients.", [["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 69, 77], ["COVID", "TEST", 13, 18]]], ["The dedicated wards for COVID-19 patients must comply with the WHO guidelines.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["COVID", "TEST", 24, 29]]], ["Sufficient ventilation must be provided to each COVID-19 patient (288 m 3 /hour) to avoid airborne transmission [46] .Health care servicesIf the health care facilities are overcrowded with COVID-19 patients, then the geofencing system can be used to ensure the COVID-19 patients remain at home for selfisolation and reduce the risk of the community from getting infected.", [["patient", "ORGANISM", 57, 64], ["patients", "ORGANISM", 198, 206], ["patients", "ORGANISM", 270, 278], ["patient", "SPECIES", 57, 64], ["patients", "SPECIES", 198, 206], ["patients", "SPECIES", 270, 278], ["Sufficient ventilation", "TREATMENT", 0, 22], ["the geofencing system", "TREATMENT", 213, 234], ["selfisolation", "TREATMENT", 298, 311], ["infected", "PROBLEM", 362, 370], ["infected", "OBSERVATION", 362, 370]]], ["For the high-risk group, stocking up medication is recommended to avoid frequent outings.", [["stocking up medication", "TREATMENT", 25, 47], ["frequent outings", "PROBLEM", 72, 88]]], ["Other than that, hospitals, clinics and pharmacies can deliver medications to their home.Health care servicesTemporary accommodation should be provided to the health care workers as they are not recommended to go home, to avoid transmitting COVID-19 to their family.", [["medications", "TREATMENT", 63, 74]]], ["Hence, the health authority should provide food and essentials to them.J o u r n a l P r e -p r o o fThe older person is included in the high-risk group recommended by the WHO.", [["person", "SPECIES", 111, 117]]], ["Moreover, the older person may have the pre-existing conditions which can cause the severe implications if infected with COVID-19.", [["COVID-19", "CHEMICAL", 121, 129], ["person", "SPECIES", 20, 26], ["the pre-existing conditions", "PROBLEM", 36, 63], ["COVID", "TEST", 121, 126], ["severe", "OBSERVATION_MODIFIER", 84, 90]]], ["In Sweden, 90% of the death cases were reported from the patients over 70 years of age.", [["death", "DISEASE", 22, 27], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65]]], ["Because of that, the older person must be protected from contacting the COVID-19 infection.J o u r n a l P r e -p r o o fThe temperature gun or scanner must be used to measure the body temperature of the care workers, older persons and visitors at the entrance.", [["body", "ANATOMY", 180, 184], ["infection", "DISEASE", 81, 90], ["COVID-19", "ORGANISM", 72, 80], ["body", "ORGANISM_SUBDIVISION", 180, 184], ["person", "SPECIES", 27, 33], ["persons", "SPECIES", 224, 231], ["the COVID-19 infection", "PROBLEM", 68, 90], ["The temperature gun", "TEST", 121, 140], ["infection", "OBSERVATION", 81, 90]]], ["Upon arrival at the entrance, the entire body, clothes, shoes and belongings will be sprayed with sanitizer for disinfection.", [["body", "ANATOMY", 41, 45], ["body", "ORGANISM_SUBDIVISION", 41, 45], ["belongings", "TREATMENT", 66, 76], ["sanitizer", "TREATMENT", 98, 107], ["disinfection", "TREATMENT", 112, 124]]], ["The care workers, older persons and visitors with COVID-19 symptoms will be denied entry and must seek medical attention immediately.", [["persons", "ORGANISM", 24, 31], ["persons", "SPECIES", 24, 31], ["symptoms", "PROBLEM", 59, 67]]], ["Moreover, the disposable plates, cups and cutlery are preferred to reduce object sharing between the residents.", [["the disposable plates, cups and cutlery", "TREATMENT", 10, 49]]], ["The physical contacts and activities between the older persons and care workers must be reduced.", [["persons", "ORGANISM", 55, 62], ["persons", "SPECIES", 55, 62]]], ["The care workers must wear an adequate PPE such as the apron, face shield and face mask in the care home.", [["an adequate PPE", "TREATMENT", 27, 42], ["the apron, face shield", "TREATMENT", 51, 73], ["face mask", "TREATMENT", 78, 87]]], ["Meanwhile, the older persons must wear a face mask.", [["persons", "ORGANISM", 21, 28], ["persons", "SPECIES", 21, 28], ["a face mask", "TREATMENT", 39, 50]]], ["The older persons are recommended to stay in the care home to reduce exposure to the outside community.", [["persons", "ORGANISM", 10, 17], ["persons", "SPECIES", 10, 17]]], ["If not possible, the people who live with the older persons must minimize the physical and close contacts with the outside community.", [["people", "ORGANISM", 21, 27], ["persons", "ORGANISM", 52, 59], ["people", "SPECIES", 21, 27], ["persons", "SPECIES", 52, 59], ["not possible", "UNCERTAINTY", 3, 15]]], ["Moreover, the medical services can be provided in the care home instead of at the hospital, while medication must be taken at the right time.Bodies managementThe funeral must be conducted and attended by the close relatives.", [["medication", "TREATMENT", 98, 108], ["Bodies management", "TREATMENT", 141, 158], ["right", "ANATOMY_MODIFIER", 130, 135]]], ["Moreover, the bodies must be certified free from COVID-19.", [["COVID-19", "CHEMICAL", 49, 57], ["COVID", "TEST", 49, 54]]], ["The bodies of normal death cases must be screened for COVID-19 infection by the medical practitioner and only being given to the family if free from the disease.", [["death", "DISEASE", 21, 26], ["COVID-19", "CHEMICAL", 54, 62], ["infection", "DISEASE", 63, 72], ["COVID-19 infection", "PROBLEM", 54, 72], ["the disease", "PROBLEM", 149, 160], ["normal death", "OBSERVATION", 14, 26], ["infection", "OBSERVATION", 63, 72], ["disease", "OBSERVATION", 153, 160]]], ["If the deceased is tested positive of COVID-19, then the body will be managed by the authority.", [["body", "ANATOMY", 57, 61], ["body", "ORGANISM_SUBDIVISION", 57, 61], ["COVID", "TEST", 38, 43]]], ["This is to ensure no COVID-19 related deaths are undetected and to protect those who are managing the bodies.", [["deaths", "DISEASE", 38, 44], ["COVID-19 related deaths", "PROBLEM", 21, 44]]], ["These persons can be infected from the deceased since there is an evidence that the virus can appear on the surface of the bodies [48] .ConclusionA war against COVID-19 is far from over.", [["surface", "ANATOMY", 108, 115], ["COVID-19", "CHEMICAL", 160, 168], ["COVID-19", "CHEMICAL", 160, 168], ["persons", "ORGANISM", 6, 13], ["surface", "CELLULAR_COMPONENT", 108, 115], ["COVID-19", "DNA", 160, 168], ["persons", "SPECIES", 6, 13], ["the virus", "PROBLEM", 80, 89], ["COVID", "TEST", 160, 165], ["infected", "OBSERVATION", 21, 29], ["virus", "OBSERVATION", 84, 89], ["bodies", "ANATOMY_MODIFIER", 123, 129]]], ["Therefore, it is important for us to prepare for the next waves of COVID-19 infections.", [["infections", "DISEASE", 76, 86], ["COVID-19 infections", "PROBLEM", 67, 86]]], ["The movement restriction is an effort to flatten the infection curve, but not to stop the virus entirely.", [["infection", "DISEASE", 53, 62], ["The movement restriction", "TREATMENT", 0, 24], ["the infection curve", "PROBLEM", 49, 68], ["movement restriction", "OBSERVATION", 4, 24], ["infection", "OBSERVATION", 53, 62]]], ["The social and economic sectors must be opened in phases to reduce the impact of economic recession.", [["economic recession", "PROBLEM", 81, 99], ["economic recession", "OBSERVATION", 81, 99]]], ["The community must adapt and embrace the new normal, selfregulation and self-discipline to prevent the spreading of COVID-19.", [["COVID", "TEST", 116, 121]]], ["Therefore, the social distancing and personal hygiene measures will remain in place until an effective vaccine is found.", [["personal hygiene measures", "TREATMENT", 37, 62], ["an effective vaccine", "TREATMENT", 90, 110]]]], "PMC7092830": [], "77972b166d62d99ce323d7759ab0aff521165e4d": [["Dear Editor, We have read the articles published in the Korean Journal of Radiology with great interest concerning the real-time reverse-transcriptase polymerase chain reaction (rRT-PCR) amplification of the viral deoxyribonucleic acid (DNA) and chest computed tomography (CT) results for screening or detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (1, 2) .", [["deoxyribonucleic acid", "CHEMICAL", 214, 235], ["acute respiratory syndrome coronavirus", "DISEASE", 326, 364], ["infection", "DISEASE", 380, 389], ["DNA", "CELLULAR_COMPONENT", 237, 240], ["SARS-CoV-2", "ORGANISM", 368, 378], ["severe acute respiratory syndrome coronavirus", "SPECIES", 319, 364], ["SARS-CoV-2", "SPECIES", 368, 378], ["transcriptase polymerase chain reaction", "PROBLEM", 137, 176], ["rRT-PCR", "TEST", 178, 185], ["the viral deoxyribonucleic acid", "TEST", 204, 235], ["chest computed tomography", "TEST", 246, 271], ["CT)", "TEST", 273, 276], ["screening", "TEST", 289, 298], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 315, 364], ["SARS", "TEST", 368, 372], ["infection", "PROBLEM", 380, 389], ["chest", "ANATOMY", 246, 251], ["severe", "OBSERVATION_MODIFIER", 319, 325], ["acute", "OBSERVATION_MODIFIER", 326, 331], ["respiratory syndrome", "OBSERVATION", 332, 352], ["infection", "OBSERVATION", 380, 389]]], ["We would like to share our opinions on the diagnosis of coronavirus disease 2019 or pneumonia that physicians should apply in clinical practice.", [["coronavirus disease", "DISEASE", 56, 75], ["pneumonia", "DISEASE", 84, 93], ["coronavirus", "ORGANISM", 56, 67], ["coronavirus disease", "PROBLEM", 56, 75], ["pneumonia", "PROBLEM", 84, 93], ["coronavirus disease", "OBSERVATION", 56, 75], ["pneumonia", "OBSERVATION", 84, 93]]], ["We think that patients with positive rRT-PCR and negative chest CT results are virus carriers.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["PCR", "TEST", 41, 44], ["chest CT", "TEST", 58, 66], ["virus carriers", "PROBLEM", 79, 93], ["chest", "ANATOMY", 58, 63]]]], "1f2fa602a76a8bbef2d8ed3790a41fc2ccced303": [["The VirusHuman metapneumovirus (HMPV) is a negative-strand RNA virus that replicates in the cytoplasm [1] .", [["cytoplasm", "ANATOMY", 92, 101], ["VirusHuman metapneumovirus", "DISEASE", 4, 30], ["VirusHuman metapneumovirus", "ORGANISM", 4, 30], ["HMPV", "ORGANISM", 32, 36], ["cytoplasm", "ORGANISM_SUBSTANCE", 92, 101], ["VirusHuman metapneumovirus", "SPECIES", 4, 30], ["VirusHuman metapneumovirus", "SPECIES", 4, 30], ["HMPV", "SPECIES", 32, 36], ["The VirusHuman metapneumovirus (HMPV", "TEST", 0, 36], ["strand RNA virus", "PROBLEM", 52, 68], ["metapneumovirus", "OBSERVATION", 15, 30]]], ["HMPV and avian metapneumovirus (AMPV), the closest known relative of HMPV, are members of the genus Metapneumovirus and the family Pneumoviridae [2] .", [["avian metapneumovirus", "DISEASE", 9, 30], ["HMPV", "ORGANISM", 0, 4], ["avian metapneumovirus", "ORGANISM", 9, 30], ["AMPV", "GENE_OR_GENE_PRODUCT", 32, 36], ["HMPV", "ORGANISM", 69, 73], ["avian metapneumovirus", "SPECIES", 9, 30], ["HMPV", "SPECIES", 0, 4], ["avian metapneumovirus", "SPECIES", 9, 30], ["AMPV", "SPECIES", 32, 36], ["HMPV", "SPECIES", 69, 73], ["HMPV", "PROBLEM", 0, 4], ["avian metapneumovirus (AMPV", "TREATMENT", 9, 36], ["HMPV", "PROBLEM", 69, 73], ["metapneumovirus", "OBSERVATION", 15, 30], ["HMPV", "OBSERVATION", 69, 73]]], ["HMPV shares many features with respiratory syncytial virus (RSV) of the genus Orthopneumovirus and family Pneumoviridae [3] .", [["HMPV", "DISEASE", 0, 4], ["respiratory syncytial virus", "DISEASE", 31, 58], ["HMPV", "ORGANISM", 0, 4], ["respiratory syncytial virus", "ORGANISM", 31, 58], ["RSV", "ORGANISM", 60, 63], ["respiratory syncytial virus", "SPECIES", 31, 58], ["HMPV", "SPECIES", 0, 4], ["respiratory syncytial virus", "SPECIES", 31, 58], ["RSV", "SPECIES", 60, 63], ["HMPV", "PROBLEM", 0, 4], ["respiratory syncytial virus", "PROBLEM", 31, 58], ["respiratory syncytial virus", "OBSERVATION", 31, 58]]], ["The HMPV genome is approximately 13,000 nucleotides in length.", [["nucleotides", "CHEMICAL", 40, 51], ["HMPV", "ORGANISM", 4, 8], ["HMPV genome", "DNA", 4, 15], ["HMPV", "SPECIES", 4, 8], ["The HMPV genome", "PROBLEM", 0, 15], ["HMPV genome", "OBSERVATION", 4, 15], ["approximately", "OBSERVATION_MODIFIER", 19, 32], ["13,000 nucleotides", "OBSERVATION_MODIFIER", 33, 51], ["length", "OBSERVATION_MODIFIER", 55, 61]]], ["HMPV virions contain a ribonucleocapsid core consisting of viral RNA (vRNA), nucleocapsid (N) protein, polymerase (L) protein, phosphoprotein (P), and M2-1 protein [4] .", [["HMPV", "ORGANISM", 0, 4], ["vRNA", "GENE_OR_GENE_PRODUCT", 70, 74], ["nucleocapsid (N) protein, polymerase (L) protein", "GENE_OR_GENE_PRODUCT", 77, 125], ["M2-1", "GENE_OR_GENE_PRODUCT", 151, 155], ["ribonucleocapsid core", "DNA", 23, 44], ["viral RNA", "RNA", 59, 68], ["vRNA", "PROTEIN", 70, 74], ["nucleocapsid (N) protein", "PROTEIN", 77, 101], ["polymerase (L) protein", "PROTEIN", 103, 125], ["phosphoprotein (P)", "PROTEIN", 127, 145], ["M2", "PROTEIN", 151, 153], ["1 protein", "PROTEIN", 154, 163], ["HMPV", "SPECIES", 0, 4], ["HMPV virions", "PROBLEM", 0, 12], ["viral RNA", "PROBLEM", 59, 68], ["vRNA", "TEST", 70, 74], ["nucleocapsid (N) protein", "TEST", 77, 101], ["polymerase", "TEST", 103, 113], ["protein", "TEST", 118, 125], ["phosphoprotein", "TEST", 127, 141], ["M2", "TEST", 151, 153], ["viral RNA", "OBSERVATION", 59, 68]]], ["The matrix (M) protein lines the inner face of the virion envelope.", [["inner face", "ANATOMY", 33, 43], ["matrix", "CELLULAR_COMPONENT", 4, 10], ["virion", "CELLULAR_COMPONENT", 51, 57], ["matrix (M) protein", "PROTEIN", 4, 22], ["The matrix (M) protein lines", "TREATMENT", 0, 28], ["inner", "ANATOMY_MODIFIER", 33, 38], ["face", "ANATOMY_MODIFIER", 39, 43], ["virion envelope", "OBSERVATION", 51, 66]]], ["Envelope spikes projecting from the virus include a small hydrophobic (SH) protein and the attachment (G) and fusion (F) glycoproteins.", [["fusion (F) glycoproteins", "GENE_OR_GENE_PRODUCT", 110, 134], ["small hydrophobic (SH) protein", "PROTEIN", 52, 82], ["attachment (G) and fusion (F) glycoproteins", "PROTEIN", 91, 134], ["Envelope spikes", "PROBLEM", 0, 15], ["the virus", "PROBLEM", 32, 41], ["a small hydrophobic (SH) protein", "PROBLEM", 50, 82], ["the attachment (G) and fusion (F) glycoproteins", "TREATMENT", 87, 134], ["virus", "OBSERVATION", 36, 41], ["small", "OBSERVATION_MODIFIER", 52, 57], ["hydrophobic", "OBSERVATION_MODIFIER", 58, 69]]], ["An M2-2 protein regulates RNA synthesis and supports virus growth in a hamster model [5] .", [["hamster", "ANATOMY", 71, 78], ["M2-2", "GENE_OR_GENE_PRODUCT", 3, 7], ["hamster", "ORGANISM", 71, 78], ["M2-2 protein", "PROTEIN", 3, 15], ["hamster", "SPECIES", 71, 78], ["An M2-2 protein regulates RNA synthesis", "TREATMENT", 0, 39], ["supports virus growth", "PROBLEM", 44, 65]]], ["HMPV exists as filaments and spherical particles with diameters that range from 150 to 600 nm [1] .", [["filaments", "ANATOMY", 15, 24], ["HMPV", "ORGANISM", 0, 4], ["filaments", "CELLULAR_COMPONENT", 15, 24], ["HMPV", "SPECIES", 0, 4], ["HMPV", "PROBLEM", 0, 4], ["diameters", "TEST", 54, 63], ["diameters", "OBSERVATION_MODIFIER", 54, 63]]], ["It appears morphologically similar to RSV and to members of the family Paramyxoviridae.", [["RSV", "ORGANISM", 38, 41], ["Paramyxoviridae", "GENE_OR_GENE_PRODUCT", 71, 86], ["RSV", "SPECIES", 38, 41], ["RSV", "PROBLEM", 38, 41], ["the family Paramyxoviridae", "TREATMENT", 60, 86], ["morphologically", "OBSERVATION_MODIFIER", 11, 26], ["similar", "OBSERVATION_MODIFIER", 27, 34]]], ["In fact, HMPV and RSV were previously classified as members of the Paramyxoviridae family; listings were recently changed by the International Committee on Taxonomy of Viruses (ICTV) [6] .The VirusHMPV envelope glycoproteins include the G and F proteins.", [["HMPV", "ORGANISM", 9, 13], ["RSV", "ORGANISM", 18, 21], ["VirusHMPV envelope glycoproteins", "GENE_OR_GENE_PRODUCT", 192, 224], ["G and F proteins", "GENE_OR_GENE_PRODUCT", 237, 253], ["VirusHMPV envelope glycoproteins", "PROTEIN", 192, 224], ["G and F proteins", "PROTEIN", 237, 253], ["HMPV", "SPECIES", 9, 13], ["RSV", "SPECIES", 18, 21], ["HMPV", "PROBLEM", 9, 13], ["RSV", "PROBLEM", 18, 21], ["The VirusHMPV envelope glycoproteins", "TREATMENT", 188, 224], ["the G and F proteins", "TREATMENT", 233, 253], ["HMPV", "OBSERVATION", 9, 13]]], ["The open reading frame (ORF) of G encodes a 229-236 residue glycoprotein that is unrelated in nucleotide or amino acid sequence to other pneumovirus or paramyxovirus G proteins [4] .", [["nucleotide", "CHEMICAL", 94, 104], ["amino acid", "CHEMICAL", 108, 118], ["nucleotide", "CHEMICAL", 94, 104], ["amino acid", "CHEMICAL", 108, 118], ["G", "GENE_OR_GENE_PRODUCT", 32, 33], ["amino acid", "AMINO_ACID", 108, 118], ["paramyxovirus G proteins", "GENE_OR_GENE_PRODUCT", 152, 176], ["open reading frame", "DNA", 4, 22], ["ORF", "DNA", 24, 27], ["229-236 residue glycoprotein", "PROTEIN", 44, 72], ["pneumovirus or paramyxovirus G proteins", "PROTEIN", 137, 176], ["residue glycoprotein", "PROBLEM", 52, 72], ["amino acid sequence", "TEST", 108, 127], ["other pneumovirus", "PROBLEM", 131, 148], ["paramyxovirus G proteins", "PROBLEM", 152, 176]]], ["The G protein binds heparan sulfate and other glycosaminoglycans found on airway epithelial cells in nasal and lung tissues to initiate viral entry [7, 8] .The VirusThe ORF of F encodes a 539 residue glycoprotein that shares 33%-38% amino acid identity with other pneumovirus F proteins and 10%-18% identity with paramyxovirus F proteins [4] .", [["airway epithelial cells", "ANATOMY", 74, 97], ["nasal", "ANATOMY", 101, 106], ["lung tissues", "ANATOMY", 111, 123], ["heparan sulfate", "CHEMICAL", 20, 35], ["amino acid", "CHEMICAL", 233, 243], ["amino acid", "CHEMICAL", 233, 243], ["G protein", "GENE_OR_GENE_PRODUCT", 4, 13], ["heparan sulfate", "SIMPLE_CHEMICAL", 20, 35], ["glycosaminoglycans", "SIMPLE_CHEMICAL", 46, 64], ["airway epithelial cells", "CELL", 74, 97], ["nasal", "TISSUE", 101, 106], ["lung tissues", "TISSUE", 111, 123], ["Virus", "ORGANISM", 160, 165], ["amino acid", "AMINO_ACID", 233, 243], ["pneumovirus F", "GENE_OR_GENE_PRODUCT", 264, 277], ["paramyxovirus F proteins", "GENE_OR_GENE_PRODUCT", 313, 337], ["G protein", "PROTEIN", 4, 13], ["airway epithelial cells", "CELL_TYPE", 74, 97], ["ORF", "DNA", 169, 172], ["F", "DNA", 176, 177], ["539 residue glycoprotein", "PROTEIN", 188, 212], ["pneumovirus F proteins", "PROTEIN", 264, 286], ["paramyxovirus F proteins", "PROTEIN", 313, 337], ["The G protein binds heparan sulfate", "TREATMENT", 0, 35], ["other glycosaminoglycans", "TREATMENT", 40, 64], ["airway epithelial cells in nasal and lung tissues", "PROBLEM", 74, 123], ["viral entry", "TEST", 136, 147], ["The Virus", "PROBLEM", 156, 165], ["a 539 residue glycoprotein", "TEST", 186, 212], ["amino acid identity", "TEST", 233, 252], ["proteins", "TEST", 278, 286], ["paramyxovirus F proteins", "PROBLEM", 313, 337], ["airway", "ANATOMY", 74, 80], ["epithelial cells", "OBSERVATION", 81, 97], ["nasal", "ANATOMY", 101, 106], ["lung", "ANATOMY", 111, 115]]], ["As is the case for other pneumoviruses and paramyxoviruses, the F protein is synthesized as an F0 precursor protein that is subsequently cleaved into fusion-capable F1 and F2 subunits that form a large, trimeric, mushroom-like extracellular head in addition to C-terminal transmembrane (TM) and cytoplasmic tail regions.", [["extracellular head", "ANATOMY", 227, 245], ["cytoplasmic tail regions", "ANATOMY", 295, 319], ["C-", "CHEMICAL", 261, 263], ["F protein", "GENE_OR_GENE_PRODUCT", 64, 73], ["extracellular head", "CELLULAR_COMPONENT", 227, 245], ["transmembrane", "CELLULAR_COMPONENT", 272, 285], ["cytoplasmic", "ORGANISM_SUBSTANCE", 295, 306], ["F protein", "PROTEIN", 64, 73], ["F0 precursor protein", "PROTEIN", 95, 115], ["fusion-capable F1 and F2 subunits", "PROTEIN", 150, 183], ["trimeric, mushroom-like extracellular head", "PROTEIN", 203, 245], ["C-terminal transmembrane (TM) and cytoplasmic tail regions", "PROTEIN", 261, 319], ["other pneumoviruses", "PROBLEM", 19, 38], ["paramyxoviruses", "PROBLEM", 43, 58], ["the F protein", "TEST", 60, 73], ["an F0 precursor protein", "TEST", 92, 115], ["a large, trimeric, mushroom-like extracellular head", "PROBLEM", 194, 245], ["C-terminal transmembrane (TM) and cytoplasmic tail regions", "PROBLEM", 261, 319], ["paramyxoviruses", "OBSERVATION", 43, 58], ["large", "OBSERVATION_MODIFIER", 196, 201], ["head", "ANATOMY", 241, 245], ["cytoplasmic tail", "OBSERVATION", 295, 311]]], ["High-resolution structures have been obtained for the HMPV F protein ectodomain in both prefusion and postfusion forms [9, 10] .", [["HMPV F protein ectodomain", "PROTEIN", 54, 79], ["the HMPV F protein ectodomain", "TEST", 50, 79], ["-resolution", "OBSERVATION_MODIFIER", 4, 15]]], ["These structures share many structural features common to prefusion and postfusion forms of the F proteins from RSV and paramyxoviruses [11] [12] [13] [14] .", [["F proteins", "GENE_OR_GENE_PRODUCT", 96, 106], ["RSV", "ORGANISM", 112, 115], ["[11] [12] [13] [14]", "SIMPLE_CHEMICAL", 136, 155], ["F proteins", "PROTEIN", 96, 106], ["RSV", "SPECIES", 112, 115], ["RSV", "PROBLEM", 112, 115], ["paramyxoviruses", "PROBLEM", 120, 135]]], ["After receptor binding, the F protein undergoes a dramatic change in structure that causes membrane fusion to allow virus entry.", [["membrane", "ANATOMY", 91, 99], ["membrane", "CELLULAR_COMPONENT", 91, 99], ["F protein", "PROTEIN", 28, 37], ["receptor binding", "PROBLEM", 6, 22], ["a dramatic change in structure", "PROBLEM", 48, 78], ["membrane fusion", "TREATMENT", 91, 106], ["dramatic", "OBSERVATION_MODIFIER", 50, 58], ["change", "OBSERVATION", 59, 65], ["membrane fusion", "OBSERVATION", 91, 106]]], ["Most strains of HMPV catalyze membrane fusion at neutral pH [15] while others are triggered by low pH in endosomes [16, 17] .", [["membrane", "ANATOMY", 30, 38], ["endosomes", "ANATOMY", 105, 114], ["HMPV", "ORGANISM", 16, 20], ["membrane", "CELLULAR_COMPONENT", 30, 38], ["endosomes", "CELLULAR_COMPONENT", 105, 114], ["HMPV", "SPECIES", 16, 20], ["HMPV catalyze membrane fusion", "TREATMENT", 16, 45], ["low pH in endosomes", "PROBLEM", 95, 114]]], ["In addition to membrane fusion, the F protein can also facilitate receptor binding through an Arg-Gly-Asp (RGD) motif that binds integrins [18, 19] .HMPV Discovery, Diagnoses, and PrevalenceHMPV was discovered in 2001 after isolation from dozens of young children in the Netherlands [1].", [["membrane", "ANATOMY", 15, 23], ["Arg-Gly-Asp", "CHEMICAL", 94, 105], ["Arg-Gly-Asp", "CHEMICAL", 94, 105], ["membrane", "CELLULAR_COMPONENT", 15, 23], ["F protein", "GENE_OR_GENE_PRODUCT", 36, 45], ["integrins", "GENE_OR_GENE_PRODUCT", 129, 138], ["children", "ORGANISM", 255, 263], ["F protein", "PROTEIN", 36, 45], ["Arg-Gly-Asp (RGD) motif", "PROTEIN", 94, 117], ["integrins", "PROTEIN", 129, 138], ["children", "SPECIES", 255, 263], ["HMPV", "SPECIES", 149, 153], ["membrane fusion", "TREATMENT", 15, 30], ["the F protein", "TREATMENT", 32, 45], ["receptor binding", "TREATMENT", 66, 82], ["an Arg", "TEST", 91, 97], ["Asp (RGD) motif", "TREATMENT", 102, 117], ["membrane fusion", "OBSERVATION", 15, 30]]], ["Soon after its initial identification, HMPV was found globally as an etiological agent of respiratory infections in young children and elderly adults [20] [21] [22] [23] .", [["respiratory", "ANATOMY", 90, 101], ["respiratory infections", "DISEASE", 90, 112], ["HMPV", "ORGANISM", 39, 43], ["children", "ORGANISM", 122, 130], ["children", "SPECIES", 122, 130], ["HMPV", "SPECIES", 39, 43], ["HMPV", "PROBLEM", 39, 43], ["respiratory infections", "PROBLEM", 90, 112], ["HMPV", "OBSERVATION", 39, 43], ["respiratory infections", "OBSERVATION", 90, 112]]], ["In temperate climates, HMPV epidemics tend to occur in winter and spring while in tropical climates, they are more sporadic [24] [25] [26] [27] [28] .HMPV Discovery, Diagnoses, and PrevalencePolymerase chain reaction (PCR) assays and immunofluorescence assays are often used to diagnose HMPV [29, 30] .", [["HMPV", "DISEASE", 287, 291], ["HMPV", "ORGANISM", 23, 27], ["[24] [25] [26] [27", "SIMPLE_CHEMICAL", 124, 142], ["HMPV", "ORGANISM", 287, 291], ["HMPV", "SPECIES", 23, 27], ["HMPV", "SPECIES", 150, 154], ["HMPV", "SPECIES", 287, 291], ["HMPV epidemics", "PROBLEM", 23, 37], ["HMPV", "PROBLEM", 150, 154], ["PrevalencePolymerase chain reaction", "PROBLEM", 181, 216], ["PCR) assays", "TEST", 218, 229], ["immunofluorescence assays", "TEST", 234, 259]]], ["These assays can score the viral nucleic acids and proteins of an acute infection and they may also score residual viral components after replication-competent virus has been cleared.", [["acute infection", "DISEASE", 66, 81], ["These assays", "TEST", 0, 12], ["the viral nucleic acids", "PROBLEM", 23, 46], ["an acute infection", "PROBLEM", 63, 81], ["residual viral components", "PROBLEM", 106, 131], ["competent virus", "PROBLEM", 150, 165], ["viral nucleic acids", "OBSERVATION", 27, 46], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["infection", "OBSERVATION", 72, 81], ["viral components", "OBSERVATION", 115, 131]]], ["Serum anti-viral antibodies serve as another marker of HMPV exposure, because the B cell response to HMPV is rapid and long-lasting [29, 30] .", [["Serum", "ANATOMY", 0, 5], ["B cell", "ANATOMY", 82, 88], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["HMPV", "ORGANISM", 55, 59], ["B cell", "CELL", 82, 88], ["HMPV", "ORGANISM", 101, 105], ["Serum anti-viral antibodies", "PROTEIN", 0, 27], ["HMPV", "SPECIES", 55, 59], ["HMPV", "SPECIES", 101, 105], ["Serum anti-viral antibodies", "TEST", 0, 27], ["HMPV exposure", "PROBLEM", 55, 68], ["the B cell response", "TEST", 78, 97], ["HMPV", "TEST", 101, 105]]], ["Serological findings suggest HMPV has been circulating globally in humans for decades or more before its first discovery, and that most children are first infected with HMPV before the age of five [31] [32] [33] , with nearly 100% of teenagers and adults being seropositive [29, 34] .", [["HMPV", "ORGANISM", 29, 33], ["humans", "ORGANISM", 67, 73], ["children", "ORGANISM", 136, 144], ["HMPV", "ORGANISM", 169, 173], ["humans", "SPECIES", 67, 73], ["children", "SPECIES", 136, 144], ["HMPV", "SPECIES", 29, 33], ["humans", "SPECIES", 67, 73], ["HMPV", "SPECIES", 169, 173], ["Serological findings", "TEST", 0, 20], ["HMPV", "PROBLEM", 29, 33], ["HMPV", "PROBLEM", 169, 173], ["seropositive", "TEST", 261, 273], ["suggest", "UNCERTAINTY", 21, 28], ["HMPV", "OBSERVATION", 29, 33], ["circulating", "OBSERVATION_MODIFIER", 43, 54], ["globally", "OBSERVATION_MODIFIER", 55, 63]]], ["The late discovery of HMPV was likely due to the virus's slow replication, requirement for trypsin, and minimal cytopathic effects (CPE) in many tissue culture cell lines.", [["tissue culture cell lines", "ANATOMY", 145, 170], ["HMPV", "ORGANISM", 22, 26], ["trypsin", "GENE_OR_GENE_PRODUCT", 91, 98], ["tissue culture cell lines", "CELL", 145, 170], ["trypsin", "PROTEIN", 91, 98], ["tissue culture cell lines", "CELL_LINE", 145, 170], ["HMPV", "SPECIES", 22, 26], ["HMPV", "PROBLEM", 22, 26], ["the virus", "PROBLEM", 45, 54], ["slow replication", "PROBLEM", 57, 73], ["trypsin", "TREATMENT", 91, 98], ["minimal cytopathic effects", "PROBLEM", 104, 130], ["HMPV", "OBSERVATION", 22, 26], ["likely due to", "UNCERTAINTY", 31, 44], ["minimal", "OBSERVATION_MODIFIER", 104, 111], ["cytopathic", "OBSERVATION_MODIFIER", 112, 122], ["many tissue", "OBSERVATION_MODIFIER", 140, 151], ["culture cell lines", "OBSERVATION", 152, 170]]], ["HMPV disease was often attributed to another virus such as RSV or influenza.", [["HMPV disease", "DISEASE", 0, 12], ["influenza", "DISEASE", 66, 75], ["HMPV", "ORGANISM", 0, 4], ["RSV", "ORGANISM", 59, 62], ["HMPV", "SPECIES", 0, 4], ["RSV", "SPECIES", 59, 62], ["HMPV disease", "PROBLEM", 0, 12], ["another virus", "PROBLEM", 37, 50], ["RSV", "PROBLEM", 59, 62], ["influenza", "PROBLEM", 66, 75], ["RSV", "OBSERVATION", 59, 62], ["influenza", "OBSERVATION", 66, 75]]], ["Tertiary monkey kidney epithelial cells were eventually found to support robust HMPV amplification and CPE [1].The Disease and Risk FactorsFollowing HMPV exposure, an innate cell, B cell, and T cell immune response usually develops within days and assists rapid virus clearance [29, 30] .", [["kidney epithelial cells", "ANATOMY", 16, 39], ["cell", "ANATOMY", 174, 178], ["B cell", "ANATOMY", 180, 186], ["T cell", "ANATOMY", 192, 198], ["monkey", "ORGANISM", 9, 15], ["kidney epithelial cells", "CELL", 16, 39], ["HMPV", "ORGANISM", 80, 84], ["HMPV", "ORGANISM", 149, 153], ["cell", "CELL", 174, 178], ["B cell", "CELL", 180, 186], ["T cell", "CELL", 192, 198], ["Tertiary monkey kidney epithelial cells", "CELL_TYPE", 0, 39], ["B cell", "CELL_TYPE", 180, 186], ["HMPV", "SPECIES", 80, 84], ["HMPV", "SPECIES", 149, 153], ["Tertiary monkey kidney epithelial cells", "PROBLEM", 0, 39], ["robust HMPV amplification", "PROBLEM", 73, 98], ["The Disease and Risk Factors", "PROBLEM", 111, 139], ["HMPV exposure", "PROBLEM", 149, 162], ["an innate cell", "TREATMENT", 164, 178], ["rapid virus clearance", "TEST", 256, 277], ["kidney", "ANATOMY", 16, 22], ["epithelial cells", "OBSERVATION", 23, 39], ["Disease", "OBSERVATION", 115, 122]]], ["However, HMPV can cause both upper respiratory tract (URT) and lower respiratory tract (LRT) disease, in some cases exacerbated by immune function [35, 36] .", [["upper respiratory tract", "ANATOMY", 29, 52], ["lower respiratory tract", "ANATOMY", 63, 86], ["HMPV", "DISEASE", 9, 13], ["upper respiratory tract (URT) and lower respiratory tract (LRT) disease", "DISEASE", 29, 100], ["HMPV", "ORGANISM", 9, 13], ["upper", "ORGANISM_SUBDIVISION", 29, 34], ["respiratory tract", "ORGANISM_SUBDIVISION", 35, 52], ["lower", "ORGANISM_SUBDIVISION", 63, 68], ["respiratory tract", "ORGANISM_SUBDIVISION", 69, 86], ["HMPV", "SPECIES", 9, 13], ["HMPV", "PROBLEM", 9, 13], ["both upper respiratory tract (URT) and lower respiratory tract (LRT) disease", "PROBLEM", 24, 100], ["immune function", "TEST", 131, 146], ["HMPV", "OBSERVATION", 9, 13], ["upper", "ANATOMY_MODIFIER", 29, 34], ["respiratory tract", "ANATOMY", 35, 52], ["URT", "ANATOMY", 54, 57], ["lower", "ANATOMY_MODIFIER", 63, 68], ["respiratory tract", "ANATOMY", 69, 86]]], ["LRT disease can be severe, particularly when an individual is exposed to virus for the first time.", [["LRT disease", "DISEASE", 0, 11], ["LRT disease", "PROBLEM", 0, 11], ["virus", "PROBLEM", 73, 78], ["disease", "OBSERVATION", 4, 11], ["severe", "OBSERVATION_MODIFIER", 19, 25]]], ["Outcomes can include bronchiolitis and pneumonia and can result in death [37] .The Disease and Risk FactorsAmong numerous studies of hospitalized and outpatient children worldwide, HMPV has been associated with between 6% and 40% of respiratory illnesses [30] .", [["respiratory", "ANATOMY", 233, 244], ["bronchiolitis", "DISEASE", 21, 34], ["pneumonia", "DISEASE", 39, 48], ["death", "DISEASE", 67, 72], ["HMPV", "DISEASE", 181, 185], ["respiratory illnesses", "DISEASE", 233, 254], ["children", "ORGANISM", 161, 169], ["HMPV", "ORGANISM", 181, 185], ["children", "SPECIES", 161, 169], ["HMPV", "SPECIES", 181, 185], ["bronchiolitis", "PROBLEM", 21, 34], ["pneumonia", "PROBLEM", 39, 48], ["death", "PROBLEM", 67, 72], ["The Disease and Risk Factors", "PROBLEM", 79, 107], ["HMPV", "PROBLEM", 181, 185], ["respiratory illnesses", "PROBLEM", 233, 254], ["bronchiolitis", "OBSERVATION", 21, 34], ["pneumonia", "OBSERVATION", 39, 48], ["Disease", "OBSERVATION", 83, 90]]], ["A study by Edwards et al. in the United States estimated that HMPV was responsible for annual hospitalization rates of approximately 1 per 1000 children under the age of five [33] .", [["HMPV", "ORGANISM", 62, 66], ["children", "SPECIES", 144, 152], ["HMPV", "SPECIES", 62, 66], ["A study", "TEST", 0, 7], ["HMPV", "PROBLEM", 62, 66], ["HMPV", "OBSERVATION", 62, 66]]], ["In a study by Davis et al. in the United States, hospitalizations were highest for children under the age of 2 years (approximately 2 per 1000 person years).", [["children", "ORGANISM", 83, 91], ["children", "SPECIES", 83, 91], ["person", "SPECIES", 143, 149]]], ["More than 50% of all hospitalized children had an underlying complex chronic condition such as a pulmonary disorder [38, 39] ; 18% required intensive care and 6% required mechanical ventilation.", [["pulmonary", "ANATOMY", 97, 106], ["pulmonary disorder", "DISEASE", 97, 115], ["children", "ORGANISM", 34, 42], ["pulmonary", "ORGAN", 97, 106], ["children", "SPECIES", 34, 42], ["an underlying complex chronic condition", "PROBLEM", 47, 86], ["a pulmonary disorder", "PROBLEM", 95, 115], ["intensive care", "TREATMENT", 140, 154], ["mechanical ventilation", "TREATMENT", 171, 193], ["chronic", "OBSERVATION_MODIFIER", 69, 76], ["condition", "OBSERVATION", 77, 86], ["pulmonary", "ANATOMY", 97, 106], ["mechanical ventilation", "OBSERVATION", 171, 193]]], ["In a recent study in Norway described by Moe et al. [29, 40] , up to 10% of children hospitalized with LRT disease were diagnosed with HMPV.", [["LRT disease", "DISEASE", 103, 114], ["HMPV", "DISEASE", 135, 139], ["children", "ORGANISM", 76, 84], ["HMPV", "ORGANISM", 135, 139], ["children", "SPECIES", 76, 84], ["HMPV", "SPECIES", 135, 139], ["a recent study", "TEST", 3, 17], ["LRT disease", "PROBLEM", 103, 114], ["HMPV", "PROBLEM", 135, 139], ["HMPV", "OBSERVATION", 135, 139]]], ["In this study, the most severe symptoms were observed among children between the ages of 1 and 2 years, indicating that maternal antibodies provided a degree of protection to infants.", [["children", "ORGANISM", 60, 68], ["infants", "ORGANISM", 175, 182], ["maternal antibodies", "PROTEIN", 120, 139], ["children", "SPECIES", 60, 68], ["infants", "SPECIES", 175, 182], ["this study", "TEST", 3, 13], ["the most severe symptoms", "PROBLEM", 15, 39], ["maternal antibodies", "PROBLEM", 120, 139], ["severe", "OBSERVATION_MODIFIER", 24, 30]]], ["Risk factors for serious disease included a history of premature birth or chronic airway disease.", [["airway", "ANATOMY", 82, 88], ["premature birth", "DISEASE", 55, 70], ["chronic airway disease", "DISEASE", 74, 96], ["airway", "ORGAN", 82, 88], ["serious disease", "PROBLEM", 17, 32], ["premature birth", "PROBLEM", 55, 70], ["chronic airway disease", "PROBLEM", 74, 96], ["premature", "OBSERVATION_MODIFIER", 55, 64], ["chronic", "OBSERVATION_MODIFIER", 74, 81], ["airway", "ANATOMY", 82, 88], ["disease", "OBSERVATION", 89, 96]]], ["A history of premature birth was similarly identified as a risk factor for severe HMPV disease by Pancham et al. in their study of pre-school children [41, 42] .The Disease and Risk FactorsRe-infections with HMPV are common, albeit usually mild.", [["premature birth", "DISEASE", 13, 28], ["HMPV disease", "DISEASE", 82, 94], ["FactorsRe-infections", "DISEASE", 182, 202], ["HMPV", "DISEASE", 208, 212], ["HMPV", "ORGANISM", 82, 86], ["children", "ORGANISM", 142, 150], ["HMPV", "ORGANISM", 208, 212], ["children", "SPECIES", 142, 150], ["HMPV", "SPECIES", 82, 86], ["HMPV", "SPECIES", 208, 212], ["premature birth", "PROBLEM", 13, 28], ["severe HMPV disease", "PROBLEM", 75, 94], ["The Disease", "PROBLEM", 161, 172], ["infections", "PROBLEM", 192, 202], ["HMPV", "PROBLEM", 208, 212], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["HMPV", "OBSERVATION", 82, 86], ["Disease", "OBSERVATION", 165, 172], ["infections", "OBSERVATION", 192, 202], ["mild", "OBSERVATION_MODIFIER", 240, 244]]], ["The virus threat increases when the human immune system is weakened, as in the context of hematopoietic stem cell transplantation.The Disease and Risk FactorsAged individuals comprise another vulnerable population due to their waning immune function [36, [43] [44] [45] .Treatment and Drug Discovery EffortsThere are no standard treatments for HMPV except supportive care.", [["immune system", "ANATOMY", 42, 55], ["hematopoietic stem cell", "ANATOMY", 90, 113], ["HMPV", "DISEASE", 344, 348], ["human", "ORGANISM", 36, 41], ["immune system", "ANATOMICAL_SYSTEM", 42, 55], ["hematopoietic stem cell", "CELL", 90, 113], ["HMPV", "ORGANISM", 344, 348], ["hematopoietic stem cell", "CELL_TYPE", 90, 113], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["HMPV", "SPECIES", 344, 348], ["The virus threat", "PROBLEM", 0, 16], ["hematopoietic stem cell transplantation", "TREATMENT", 90, 129], ["The Disease and Risk Factors", "PROBLEM", 130, 158], ["another vulnerable population", "PROBLEM", 184, 213], ["their waning immune function", "TEST", 221, 249], ["Treatment", "TREATMENT", 271, 280], ["standard treatments", "TREATMENT", 320, 339], ["HMPV", "PROBLEM", 344, 348], ["supportive care", "TREATMENT", 356, 371], ["virus", "OBSERVATION", 4, 9], ["weakened", "OBSERVATION", 59, 67], ["hematopoietic stem cell transplantation", "OBSERVATION", 90, 129], ["Disease", "OBSERVATION", 134, 141]]], ["Ribavirin, a nucleoside analogue, has exhibited anti-HMPV activity in laboratory studies, but its use in clinical studies has yielded conflicting results [29, 46, 47] .", [["Ribavirin", "CHEMICAL", 0, 9], ["nucleoside", "CHEMICAL", 13, 23], ["Ribavirin", "CHEMICAL", 0, 9], ["nucleoside", "CHEMICAL", 13, 23], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["nucleoside", "SIMPLE_CHEMICAL", 13, 23], ["anti-HMPV", "CANCER", 48, 57], ["Ribavirin", "TREATMENT", 0, 9], ["a nucleoside analogue", "TREATMENT", 11, 32], ["anti-HMPV activity", "PROBLEM", 48, 66], ["laboratory studies", "TEST", 70, 88], ["clinical studies", "TEST", 105, 121]]], ["The efficacy, route of administration, and dosing of ribavirin for treatments of respiratory infections have been topics of continuous debate [48] .", [["respiratory", "ANATOMY", 81, 92], ["ribavirin", "CHEMICAL", 53, 62], ["respiratory infections", "DISEASE", 81, 103], ["ribavirin", "CHEMICAL", 53, 62], ["ribavirin", "SIMPLE_CHEMICAL", 53, 62], ["administration", "TREATMENT", 23, 37], ["ribavirin", "TREATMENT", 53, 62], ["treatments", "TREATMENT", 67, 77], ["respiratory infections", "PROBLEM", 81, 103], ["respiratory", "ANATOMY", 81, 92], ["infections", "OBSERVATION", 93, 103]]], ["Other therapies are being developed to block HMPV fusion.", [["HMPV", "ORGANISM", 45, 49], ["HMPV", "SPECIES", 45, 49], ["Other therapies", "TREATMENT", 0, 15], ["block HMPV fusion", "TREATMENT", 39, 56], ["HMPV fusion", "OBSERVATION", 45, 56]]], ["For example, the peptide HRA2 (derived from a heptad repeat domain of the HMPV F protein) was shown to significantly reduce viral loads in animal studies [49] .", [["HRA2", "GENE_OR_GENE_PRODUCT", 25, 29], ["HMPV F", "GENE_OR_GENE_PRODUCT", 74, 80], ["HRA2", "PROTEIN", 25, 29], ["heptad repeat domain", "PROTEIN", 46, 66], ["HMPV F protein", "PROTEIN", 74, 88], ["the peptide HRA2", "TEST", 13, 29], ["a heptad repeat domain", "TREATMENT", 44, 66], ["the HMPV F protein", "TEST", 70, 88], ["viral loads", "PROBLEM", 124, 135], ["animal studies", "TEST", 139, 153], ["viral loads", "OBSERVATION", 124, 135]]], ["Additionally, small interfering RNAs have been used to block HMPV infections [50, 51] .", [["HMPV infections", "DISEASE", 61, 76], ["HMPV", "ORGANISM", 61, 65], ["small interfering RNAs", "RNA", 14, 36], ["HMPV", "SPECIES", 61, 65], ["small interfering RNAs", "PROBLEM", 14, 36], ["block HMPV infections", "PROBLEM", 55, 76], ["small", "OBSERVATION_MODIFIER", 14, 19], ["interfering RNAs", "OBSERVATION", 20, 36]]], ["Intravenous immune globulin (IVIG) or HMPV-specific monoclonal antibodies could potentially be used to neutralize HMPV [52] , but their benefits as treatment options for HMPV disease have not been proven.", [["IVIG", "CHEMICAL", 29, 33], ["HMPV disease", "DISEASE", 170, 182], ["Intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 11], ["immune globulin", "GENE_OR_GENE_PRODUCT", 12, 27], ["IVIG", "SIMPLE_CHEMICAL", 29, 33], ["HMPV", "ORGANISM", 38, 42], ["HMPV", "ORGANISM", 114, 118], ["HMPV", "ORGANISM", 170, 174], ["Intravenous immune globulin", "PROTEIN", 0, 27], ["IVIG", "PROTEIN", 29, 33], ["HMPV-specific monoclonal antibodies", "PROTEIN", 38, 73], ["HMPV", "SPECIES", 38, 42], ["HMPV", "SPECIES", 114, 118], ["HMPV", "SPECIES", 170, 174], ["Intravenous immune globulin (IVIG)", "TREATMENT", 0, 34], ["HMPV", "PROBLEM", 38, 42], ["specific monoclonal antibodies", "TREATMENT", 43, 73], ["treatment options", "TREATMENT", 148, 165], ["HMPV disease", "PROBLEM", 170, 182]]], ["For RSV, virus-specific antibodies have been successful as prophylaxes (particularly for vulnerable children including premature infants and infants with heart/lung disease), but not as treatment [53] [54] [55] .", [["heart", "ANATOMY", 154, 159], ["lung", "ANATOMY", 160, 164], ["heart/lung disease", "DISEASE", 154, 172], ["RSV", "ORGANISM", 4, 7], ["children", "ORGANISM", 100, 108], ["infants", "ORGANISM", 129, 136], ["infants", "ORGANISM", 141, 148], ["heart", "ORGAN", 154, 159], ["lung", "ORGAN", 160, 164], ["children", "SPECIES", 100, 108], ["infants", "SPECIES", 129, 136], ["infants", "SPECIES", 141, 148], ["RSV", "SPECIES", 4, 7], ["RSV", "PROBLEM", 4, 7], ["virus", "PROBLEM", 9, 14], ["specific antibodies", "TREATMENT", 15, 34], ["premature infants", "PROBLEM", 119, 136], ["heart/lung disease", "PROBLEM", 154, 172], ["virus", "OBSERVATION", 9, 14], ["heart", "ANATOMY", 154, 159], ["lung", "ANATOMY", 160, 164], ["disease", "OBSERVATION", 165, 172]]], ["To increase the number of treatment options, methods are now being developed to expedite the screening of anti-HMPV drug candidates [56] .", [["anti-HMPV", "CANCER", 106, 115], ["anti-HMPV", "SPECIES", 106, 115], ["treatment options", "TREATMENT", 26, 43], ["methods", "TREATMENT", 45, 52], ["the screening", "TEST", 89, 102], ["anti-HMPV drug candidates", "TREATMENT", 106, 131]]], ["Ongoing studies of HMPV protein structure/function will also assist future drug and vaccine development [57, 58] .Vaccine DevelopmentVaccination is the most effective method for control of infectious diseases.", [["infectious diseases", "DISEASE", 189, 208], ["HMPV", "ORGANISM", 19, 23], ["HMPV", "SPECIES", 19, 23], ["Ongoing studies", "TEST", 0, 15], ["HMPV protein structure", "PROBLEM", 19, 41], ["Vaccine DevelopmentVaccination", "TREATMENT", 114, 144], ["infectious diseases", "PROBLEM", 189, 208], ["infectious", "OBSERVATION", 189, 199]]], ["If the immune system is primed before a virus exposure, it can eliminate virus in the URT and avoid trafficking of virus to the lung where the greatest damage is caused.Vaccine DevelopmentSeveral HMPV vaccines have been produced and tested in pre-clinical studies [29, 30] .", [["immune system", "ANATOMY", 7, 20], ["lung", "ANATOMY", 128, 132], ["lung", "ORGAN", 128, 132], ["HMPV", "ORGANISM", 196, 200], ["HMPV", "SPECIES", 196, 200], ["a virus exposure", "TREATMENT", 38, 54], ["virus", "PROBLEM", 73, 78], ["trafficking of virus", "PROBLEM", 100, 120], ["Vaccine", "TREATMENT", 169, 176], ["HMPV vaccines", "TREATMENT", 196, 209], ["pre-clinical studies", "TEST", 243, 263], ["virus", "OBSERVATION", 115, 120], ["lung", "ANATOMY", 128, 132], ["greatest", "OBSERVATION_MODIFIER", 143, 151], ["damage", "OBSERVATION", 152, 158]]], ["These include recombinant vaccines such as vaccines based on alpha virus or bovine PIV3 [59] [60] [61] .", [["alpha virus", "ORGANISM", 61, 72], ["bovine", "ORGANISM", 76, 82], ["bovine", "SPECIES", 76, 82], ["recombinant vaccines", "TREATMENT", 14, 34], ["vaccines", "TREATMENT", 43, 51], ["alpha virus", "TREATMENT", 61, 72], ["bovine PIV3", "TREATMENT", 76, 87]]], ["Killed virus has been tested, although there is a concern that killed virus may exacerbate disease, as was the case in the 1960s when a formalin-inactivated RSV vaccine was clinically tested [62] .", [["formalin", "CHEMICAL", 136, 144], ["formalin", "CHEMICAL", 136, 144], ["Killed virus", "ORGANISM", 0, 12], ["formalin", "SIMPLE_CHEMICAL", 136, 144], ["RSV", "ORGANISM", 157, 160], ["Killed virus", "SPECIES", 0, 12], ["RSV", "SPECIES", 157, 160], ["Killed virus", "PROBLEM", 0, 12], ["killed virus", "PROBLEM", 63, 75], ["disease", "PROBLEM", 91, 98], ["a formalin-inactivated RSV vaccine", "TREATMENT", 134, 168]]], ["Protein, peptide, and virus like particle (VLP) vaccines have also been tried.", [["Protein", "TEST", 0, 7], ["peptide", "TEST", 9, 16], ["virus like particle (VLP) vaccines", "TREATMENT", 22, 56]]], ["Live-attenuated HMPV vaccines have been produced, including cold-adapted variants and viruses with mutations in the F or polymerase proteins [30] .Vaccine DevelopmentThe HMPV surface glycoproteins G and F have both been tested as vaccine antigens.", [["surface", "ANATOMY", 175, 182], ["HMPV", "ORGANISM", 16, 20], ["HMPV surface glycoproteins G", "GENE_OR_GENE_PRODUCT", 170, 198], ["F", "GENE_OR_GENE_PRODUCT", 203, 204], ["F or polymerase proteins", "PROTEIN", 116, 140], ["HMPV surface glycoproteins", "PROTEIN", 170, 196], ["G", "PROTEIN", 197, 198], ["F", "PROTEIN", 203, 204], ["vaccine antigens", "PROTEIN", 230, 246], ["HMPV", "SPECIES", 16, 20], ["HMPV", "SPECIES", 170, 174], ["HMPV vaccines", "TREATMENT", 16, 29], ["mutations", "PROBLEM", 99, 108], ["polymerase proteins", "TEST", 121, 140], ["Vaccine", "TREATMENT", 147, 154], ["The HMPV surface glycoproteins G", "TREATMENT", 166, 198]]], ["When F and G genes were individually expressed in recombinant human parainfluenza virus-type 1 (hPIV-1) constructs and tested in hamsters, the F construct exhibited better immunogenicity [63] .", [["F", "GENE_OR_GENE_PRODUCT", 5, 6], ["G", "GENE_OR_GENE_PRODUCT", 11, 12], ["recombinant", "ORGANISM", 50, 61], ["human", "ORGANISM", 62, 67], ["parainfluenza virus-type 1", "ORGANISM", 68, 94], ["hPIV-1", "ORGANISM", 96, 102], ["hamsters", "ORGANISM", 129, 137], ["F and G genes", "DNA", 5, 18], ["recombinant human parainfluenza virus-type 1 (hPIV-1) constructs", "DNA", 50, 114], ["F construct", "DNA", 143, 154], ["human", "SPECIES", 62, 67], ["parainfluenza virus-type 1", "SPECIES", 68, 94], ["hamsters", "SPECIES", 129, 137], ["human parainfluenza virus-type 1 (hPIV-1", "SPECIES", 62, 102], ["hamsters", "SPECIES", 129, 137], ["recombinant human parainfluenza virus", "PROBLEM", 50, 87]]], ["In a separate study, when a soluble G protein was expressed (ectodomain without transmembrane domain or cytoplasmic tail), it did not elicit neutralizing antibodies or protection from challenge in cotton rats [64] .", [["transmembrane", "ANATOMY", 80, 93], ["cytoplasmic tail", "ANATOMY", 104, 120], ["G", "GENE_OR_GENE_PRODUCT", 36, 37], ["cytoplasmic", "ORGANISM_SUBSTANCE", 104, 115], ["cotton rats", "ORGANISM", 197, 208], ["G protein", "PROTEIN", 36, 45], ["ectodomain", "PROTEIN", 61, 71], ["transmembrane domain", "PROTEIN", 80, 100], ["cytoplasmic tail", "PROTEIN", 104, 120], ["neutralizing antibodies", "PROTEIN", 141, 164], ["rats", "SPECIES", 204, 208], ["cotton", "SPECIES", 197, 203], ["a separate study", "TEST", 3, 19], ["a soluble G protein", "TREATMENT", 26, 45], ["neutralizing antibodies", "PROBLEM", 141, 164]]], ["In contrast, HMPV F vaccines have been produced using a variety of different vector systems and have repeatedly generated protective immune responses in preclinical animal models [59] [60] [61] .Vaccine DevelopmentSendai virus (SeV) was recently tested as a candidate vector for an HMPV F vaccine [65] .", [["HMPV F", "ORGANISM", 13, 19], ["Vaccine DevelopmentSendai virus", "ORGANISM", 195, 226], ["SeV", "ORGANISM", 228, 231], ["HMPV F", "ORGANISM", 282, 288], ["Vaccine DevelopmentSendai virus", "SPECIES", 195, 226], ["HMPV", "SPECIES", 13, 17], ["Vaccine DevelopmentSendai virus", "SPECIES", 195, 226], ["SeV", "SPECIES", 228, 231], ["HMPV", "SPECIES", 282, 286], ["HMPV F vaccines", "TREATMENT", 13, 28], ["a variety of different vector systems", "TREATMENT", 54, 91], ["an HMPV F vaccine", "TREATMENT", 279, 296]]], ["SeV is a mouse parainfluenza virus, closely related to hPIV-1.", [["parainfluenza virus", "DISEASE", 15, 34], ["SeV", "ORGANISM", 0, 3], ["mouse", "ORGANISM", 9, 14], ["parainfluenza virus", "ORGANISM", 15, 34], ["hPIV-1", "GENE_OR_GENE_PRODUCT", 55, 61], ["hPIV-1", "DNA", 55, 61], ["mouse", "SPECIES", 9, 14], ["parainfluenza virus", "SPECIES", 15, 34], ["SeV", "SPECIES", 0, 3], ["mouse parainfluenza virus", "SPECIES", 9, 34], ["hPIV-1", "SPECIES", 55, 61], ["a mouse parainfluenza virus", "PROBLEM", 7, 34], ["parainfluenza virus", "OBSERVATION", 15, 34]]], ["The recombinant was produced by inserting the HMPV F gene into the SeV backbone between F and HN genes.", [["HMPV F", "GENE_OR_GENE_PRODUCT", 46, 52], ["SeV", "ORGANISM", 67, 70], ["F", "GENE_OR_GENE_PRODUCT", 88, 89], ["HN", "GENE_OR_GENE_PRODUCT", 94, 96], ["HMPV F gene", "DNA", 46, 57], ["F and HN genes", "DNA", 88, 102], ["HN genes", "ANATOMY", 94, 102]]], ["When the vaccine was delivered intranasally to small research animals, it induced a robust immune response that was protective against an HMPV challenge.Vaccine DevelopmentHMPV vaccines have rarely progressed to clinical studies, although a live-attenuated vaccine was once tested in adults [66] .", [["HMPV", "ORGANISM", 138, 142], ["HMPV", "SPECIES", 138, 142], ["the vaccine", "TREATMENT", 5, 16], ["an HMPV challenge", "TREATMENT", 135, 152], ["Vaccine DevelopmentHMPV vaccines", "TREATMENT", 153, 185], ["clinical studies", "TEST", 212, 228], ["a live-attenuated vaccine", "TREATMENT", 239, 264], ["HMPV", "OBSERVATION", 138, 142]]], ["For any new vaccine program, there are numerous steps required to advance from vaccine concept to clinical application.", [["any new vaccine program", "TREATMENT", 4, 27], ["vaccine", "TREATMENT", 79, 86], ["clinical application", "TREATMENT", 98, 118]]], ["Steps typically include, but are not limited to: (i) vaccine design, (ii) pre-clinical vaccine testing for immunogenicity and efficacy in small and/or large animal models, (iii) preparation of pilot vaccine lots, (iv) stability testing, (v) toxicology testing, (vi) application to institutional and government regulatory boards for approval of vaccines produced with Good Manufacturing Practices (GMP) and associated clinical protocols, (vii) clinical testing of vaccines (phases I, II, III) with regulatory oversight, (viii) license application and approval, (ix) vaccine distribution to the target population using appropriate transport and storage conditions, (x) public acceptance and vaccine use, and (xi) continued vaccine monitoring for safety and efficacy.", [["GMP", "CHEMICAL", 397, 400], ["pre-clinical vaccine testing", "TEST", 74, 102], ["immunogenicity", "PROBLEM", 107, 121], ["efficacy in small and/or large animal models", "PROBLEM", 126, 170], ["pilot vaccine", "TREATMENT", 193, 206], ["toxicology testing", "TEST", 241, 259], ["approval of vaccines", "TREATMENT", 332, 352], ["clinical testing", "TEST", 443, 459], ["vaccines", "TREATMENT", 463, 471], ["vaccine", "TREATMENT", 689, 696], ["continued vaccine monitoring", "TEST", 711, 739]]], ["Lagging development of HMPV vaccines may be due, at least in part, to prioritization of other respiratory virus vaccine programs (e.g., influenza virus, RSV, coronavirus).Raising AwarenessThe threat of HMPV infection and disease continues unabated, perhaps because it is not fully recognized.", [["influenza virus, RSV, coronavirus", "DISEASE", 136, 169], ["HMPV infection", "DISEASE", 202, 216], ["HMPV", "ORGANISM", 23, 27], ["respiratory virus", "ORGANISM", 94, 111], ["influenza virus", "ORGANISM", 136, 151], ["RSV", "ORGANISM", 153, 156], ["coronavirus", "ORGANISM", 158, 169], ["HMPV", "ORGANISM", 202, 206], ["influenza virus", "SPECIES", 136, 151], ["HMPV", "SPECIES", 23, 27], ["RSV", "SPECIES", 153, 156], ["HMPV", "SPECIES", 202, 206], ["HMPV vaccines", "TREATMENT", 23, 36], ["other respiratory virus vaccine programs", "TREATMENT", 88, 128], ["influenza virus", "PROBLEM", 136, 151], ["RSV", "PROBLEM", 153, 156], ["coronavirus", "PROBLEM", 158, 169], ["HMPV infection", "PROBLEM", 202, 216], ["disease", "PROBLEM", 221, 228], ["HMPV", "OBSERVATION", 23, 27], ["threat", "OBSERVATION_MODIFIER", 192, 198], ["HMPV", "OBSERVATION_MODIFIER", 202, 206], ["infection", "OBSERVATION", 207, 216]]], ["When a respiratory viral infection occurs, it is often assumed to be due to an influenza virus infection and termed 'flu'.", [["respiratory viral infection", "DISEASE", 7, 34], ["influenza virus infection", "DISEASE", 79, 104], ["influenza virus", "ORGANISM", 79, 94], ["a respiratory viral infection", "PROBLEM", 5, 34], ["an influenza virus infection", "PROBLEM", 76, 104], ["viral", "OBSERVATION_MODIFIER", 19, 24], ["infection", "OBSERVATION", 25, 34], ["influenza", "OBSERVATION", 79, 88]]], ["Diagnostics may be available to score influenza virus and possibly RSV, but not HMPV.", [["influenza virus", "ORGANISM", 38, 53], ["RSV", "ORGANISM", 67, 70], ["HMPV", "ORGANISM", 80, 84], ["influenza virus", "SPECIES", 38, 53], ["RSV", "SPECIES", 67, 70], ["HMPV", "SPECIES", 80, 84], ["Diagnostics", "TEST", 0, 11], ["influenza virus", "PROBLEM", 38, 53], ["RSV", "PROBLEM", 67, 70], ["HMPV", "PROBLEM", 80, 84]]], ["New multiplex assays that include HMPV are cost prohibitive in many hospitals.", [["HMPV", "ORGANISM", 34, 38], ["HMPV", "SPECIES", 34, 38], ["New multiplex assays", "TEST", 0, 20], ["HMPV", "PROBLEM", 34, 38], ["HMPV", "OBSERVATION", 34, 38]]], ["Therefore, diseases caused by HMPV will go undiagnosed and unreported.", [["HMPV", "DISEASE", 30, 34], ["HMPV", "ORGANISM", 30, 34], ["HMPV", "SPECIES", 30, 34], ["diseases", "PROBLEM", 11, 19], ["HMPV", "PROBLEM", 30, 34], ["undiagnosed", "PROBLEM", 43, 54], ["HMPV", "OBSERVATION", 30, 34]]], ["Here, we recommend that efforts be increased in the HMPV field to:Raising Awareness\u2022Raising AwarenessAdvance research efforts to reveal mechanisms by which virus induces a host immune response. \u2022 Improve surveillance to measure the burden of HMPV disease. \u2022 Improve HMPV awareness among clinicians and patients.\u2022Develop a low-cost diagnostic assay for HMPV.\u2022Develop new drugs and treatment options for HMPV.\u2022Advance HMPV vaccines through clinical trials and licensure.\u2022The dedication of new funds and efforts to the conduct of vaccine clinical trials might provide the greatest benefit to the HMPV field by escorting vaccine candidates beyond the stage of pre-clinical testing.", [["HMPV disease", "DISEASE", 242, 254], ["HMPV", "DISEASE", 402, 406], ["HMPV", "ORGANISM", 242, 246], ["HMPV", "ORGANISM", 266, 270], ["patients", "ORGANISM", 302, 310], ["HMPV", "ORGANISM", 352, 356], ["HMPV", "ORGANISM", 402, 406], ["HMPV", "ORGANISM", 593, 597], ["patients", "SPECIES", 302, 310], ["HMPV", "SPECIES", 242, 246], ["HMPV", "SPECIES", 266, 270], ["HMPV", "SPECIES", 352, 356], ["HMPV", "SPECIES", 402, 406], ["HMPV", "SPECIES", 416, 420], ["HMPV", "SPECIES", 593, 597], ["surveillance", "TEST", 204, 216], ["HMPV disease", "PROBLEM", 242, 254], ["HMPV", "PROBLEM", 352, 356], ["new drugs", "TREATMENT", 366, 375], ["treatment options", "TREATMENT", 380, 397], ["HMPV", "PROBLEM", 402, 406], ["HMPV vaccines", "TREATMENT", 416, 429], ["vaccine clinical trials", "TREATMENT", 527, 550], ["the HMPV field", "TREATMENT", 589, 603], ["escorting vaccine", "TREATMENT", 607, 624], ["pre-clinical testing", "TEST", 656, 676], ["increased", "OBSERVATION_MODIFIER", 35, 44], ["HMPV disease", "OBSERVATION", 242, 254], ["HMPV", "OBSERVATION", 266, 270], ["low", "OBSERVATION_MODIFIER", 322, 325], ["new", "OBSERVATION_MODIFIER", 366, 369], ["drugs", "OBSERVATION", 370, 375]]], ["A licensed, efficacious vaccine against HMPV could then prevent a substantial number of hospitalizations among children and adults worldwide.AbbreviationsHuman metapneumovirus, HMPV; respiratory syncytial virus, RSV; parainfluenza virus type 3, PIV-3; Sendai virus, SeV; cytopathic effects, CPE; fusion protein, F; attachment glycoprotein, G; good manufacturing practices, GMP.", [["HMPV", "DISEASE", 40, 44], ["respiratory syncytial virus", "DISEASE", 183, 210], ["parainfluenza", "DISEASE", 217, 230], ["GMP", "CHEMICAL", 373, 376], ["GMP", "CHEMICAL", 373, 376], ["HMPV", "ORGANISM", 40, 44], ["children", "ORGANISM", 111, 119], ["Human metapneumovirus", "ORGANISM", 154, 175], ["HMPV; respiratory syncytial virus", "ORGANISM", 177, 210], ["RSV", "ORGANISM", 212, 215], ["parainfluenza virus type 3", "ORGANISM", 217, 243], ["PIV-3", "ORGANISM", 245, 250], ["Sendai virus", "ORGANISM", 252, 264], ["SeV", "ORGANISM", 266, 269], ["GMP", "SIMPLE_CHEMICAL", 373, 376], ["fusion protein", "PROTEIN", 296, 310], ["F", "PROTEIN", 312, 313], ["attachment glycoprotein", "PROTEIN", 315, 338], ["children", "SPECIES", 111, 119], ["Human", "SPECIES", 154, 159], ["metapneumovirus", "SPECIES", 160, 175], ["respiratory syncytial virus", "SPECIES", 183, 210], ["RSV", "SPECIES", 212, 215], ["parainfluenza virus", "SPECIES", 217, 236], ["Sendai virus", "SPECIES", 252, 264], ["HMPV", "SPECIES", 40, 44], ["Human metapneumovirus", "SPECIES", 154, 175], ["HMPV; respiratory syncytial virus", "SPECIES", 177, 210], ["RSV", "SPECIES", 212, 215], ["Sendai virus", "SPECIES", 252, 264], ["A licensed, efficacious vaccine", "TREATMENT", 0, 31], ["HMPV", "PROBLEM", 40, 44], ["Human metapneumovirus", "PROBLEM", 154, 175], ["HMPV", "PROBLEM", 177, 181], ["respiratory syncytial virus", "PROBLEM", 183, 210], ["RSV", "PROBLEM", 212, 215], ["parainfluenza virus type", "TEST", 217, 241], ["PIV", "TEST", 245, 248], ["Sendai virus", "PROBLEM", 252, 264], ["cytopathic effects", "PROBLEM", 271, 289], ["CPE", "PROBLEM", 291, 294], ["fusion protein", "PROBLEM", 296, 310], ["substantial", "OBSERVATION_MODIFIER", 66, 77], ["metapneumovirus", "OBSERVATION", 160, 175], ["respiratory syncytial", "ANATOMY", 183, 204], ["parainfluenza virus", "OBSERVATION", 217, 236]]]], "PMC7323562": [["Methodologic Overview ::: MethodsWe developed 2 modeling approaches to infer the growth rate of the outbreak in Wuhan from data from provinces other than Hubei.", [["MethodsWe", "TREATMENT", 26, 35]]], ["In the first model, the first arrival model, we computed the likelihood of the arrival times of the first known cases in provinces outside of Hubei as a function of the exponential growing population of infected persons in Wuhan before late January.", [["persons", "ORGANISM", 212, 219], ["persons", "SPECIES", 212, 219], ["infected", "OBSERVATION", 203, 211]]], ["This calculation involved using domestic travel data to compute the probability that an infected person traveled from Wuhan to a given province as a function of the unknown actual number of infected persons in Wuhan and the probability that they traveled.", [["persons", "ORGANISM", 199, 206], ["person", "SPECIES", 97, 103], ["persons", "SPECIES", 199, 206], ["This calculation", "TEST", 0, 16], ["infected", "OBSERVATION", 88, 96], ["infected", "OBSERVATION", 190, 198]]], ["The timings of the arrivals of the first infected persons in different provinces would reflect the rate of the epidemic growth in Wuhan.Methodologic Overview ::: MethodsIn the second model, the case count model, we accounted for the detection of additional persons who were infected in Wuhan and received their diagnoses in other provinces and explicitly modeled those persons by using a hybrid deterministic\u2013stochastic SEIR (susceptible-exposed-infectious-recovered) model.", [["SEIR", "CHEMICAL", 420, 424], ["persons", "ORGANISM", 50, 57], ["persons", "ORGANISM", 257, 264], ["persons", "ORGANISM", 369, 376], ["persons", "SPECIES", 50, 57], ["persons", "SPECIES", 257, 264], ["persons", "SPECIES", 369, 376], ["Methods", "TREATMENT", 162, 169], ["the case count model", "TEST", 190, 210], ["a hybrid deterministic\u2013stochastic SEIR", "TREATMENT", 386, 424]]], ["We then fitted this model to new daily case count data reported outside Hubei Province during the period before substantial transmission occurred outside of the province.Methodologic Overview ::: MethodsBy using data collected outside Hubei Province, we minimized the effect of changes in surveillance intensity.", [["surveillance intensity", "TEST", 289, 311]]], ["By the time cases were confirmed in provinces outside Hubei, all of the provinces of China had access to diagnostic kits and were engaging in active surveillance of travelers out of Wuhan (e.g., using temperatures detectors and digital data to identify infected persons [9]) as the outbreak unfolded.", [["persons", "SPECIES", 262, 269], ["diagnostic kits", "TEST", 105, 120], ["temperatures detectors", "TEST", 201, 223], ["digital data", "TEST", 228, 240], ["the outbreak unfolded", "PROBLEM", 278, 299], ["outbreak", "OBSERVATION_MODIFIER", 282, 290], ["unfolded", "OBSERVATION", 291, 299]]], ["Furthermore, the healthcare systems outside Hubei were not yet overwhelmed with cases and were actively searching for the first positive case, leading to much lower bias in the reporting in each province compared with the time series of confirmed cases in Wuhan.Individual Case Reports ::: Data ::: MethodsWe collected publicly available reports of 140 confirmed COVID-19 cases (mostly outside Hubei Province).", [["COVID", "TEST", 363, 368]]], ["These reports were published by the Chinese Centers for Disease Control and Prevention (China CDC) and provincial health commissions; accession dates were January 15\u201330, 2020 (Appendix 1 Table 1).", [["Disease Control", "TREATMENT", 56, 71]]], ["These reports include demographic information as well as epidemiologic information, including potential periods of infection, and dates of symptom onset, hospitalization, and case confirmation.", [["infection", "DISEASE", 115, 124], ["infection", "PROBLEM", 115, 124], ["symptom", "PROBLEM", 139, 146], ["case confirmation", "TEST", 175, 192], ["infection", "OBSERVATION", 115, 124]]], ["Most of the health commissions in provinces and special municipalities documented and published detailed information of the first or the first few patients with confirmed COVID-19.", [["patients", "ORGANISM", 147, 155], ["COVID-19", "DNA", 171, 179], ["patients", "SPECIES", 147, 155], ["COVID", "TEST", 171, 176]]], ["As a result, a unique feature of this dataset includes case reports of many of the first or the first few persons who were confirmed to have SARS-CoV-2 virus infection in each province, where dates of departure from Wuhan were available.Travel Data ::: Data ::: MethodsWe used the Baidu Migration server (https://qianxi.baidu.com) to estimate the number of daily travelers in and out of Wuhan (Appendix 1 Table 2).", [["SARS-CoV-2 virus infection", "DISEASE", 141, 167], ["persons", "ORGANISM", 106, 113], ["SARS-CoV-2 virus", "ORGANISM", 141, 157], ["persons", "SPECIES", 106, 113], ["CoV-2 virus", "SPECIES", 146, 157], ["SARS-CoV-2 virus", "SPECIES", 141, 157], ["SARS", "PROBLEM", 141, 145], ["CoV-2 virus infection", "PROBLEM", 146, 167], ["Methods", "TREATMENT", 262, 269], ["the Baidu Migration server", "TREATMENT", 277, 303]]], ["The server is an online platform summarizing mobile phone travel data hosted by Baidu Huiyan (https://huiyan.baidu.com).Calculations of R0 and Effect of Intervention Strategies ::: Data ::: MethodsWe considered realistic distributions for the latent and infectious periods to calculate R0.", [["Calculations of R0", "TREATMENT", 120, 138], ["Intervention Strategies", "TREATMENT", 153, 176], ["MethodsWe", "TREATMENT", 190, 199], ["infectious", "OBSERVATION_MODIFIER", 254, 264]]], ["We described the methods we used to calculate R0 and the effect of intervention strategies on the outbreak (Appendix 2).Estimating Distributions of Epidemiologic Parameters ::: ResultsWe first translated reports from documents or news reports published daily from the China CDC website and official websites of health commissions across provinces and special municipalities in China during January 15\u201330, 2020.", [["the methods", "TREATMENT", 13, 24], ["R0", "TREATMENT", 46, 48], ["intervention strategies", "TREATMENT", 67, 90]]], ["Altogether, we collected 137 individual case reports from China and 3 additional case reports from outside of China (Appendix 1 Table 1).Estimating Distributions of Epidemiologic Parameters ::: ResultsBy using this dataset, we estimated the basic parameter distributions of durations from initial exposure to symptom onset to hospitalization to discharge or death.", [["death", "DISEASE", 358, 363], ["symptom", "PROBLEM", 309, 316], ["death", "PROBLEM", 358, 363], ["Appendix", "ANATOMY", 117, 125]]], ["Our estimate of the time from initial exposure to symptom onset (i.e., the incubation period) is 4.2 days (95% CI 3.5\u20135.1 days) (Figure 1, panel A), based on 24 case reports.", [["CI", "TEST", 111, 113]]], ["One potential caveat of our estimation is that because most of the case reports we collected were from the first few persons detected in each province, this estimation might be biased toward patients with more severe symptoms if they are more likely to be detected.Estimating Distributions of Epidemiologic Parameters ::: ResultsThe time from symptom onset to hospitalization showed evidence of time dependence (Figure 1, panel B; Appendix 2 Figure 1).", [["persons", "ORGANISM", 117, 124], ["patients", "ORGANISM", 191, 199], ["persons", "SPECIES", 117, 124], ["patients", "SPECIES", 191, 199], ["more severe symptoms", "PROBLEM", 205, 225], ["symptom", "PROBLEM", 343, 350], ["time dependence", "PROBLEM", 395, 410], ["Figure", "TEST", 412, 418], ["panel B", "TEST", 422, 429], ["caveat", "OBSERVATION", 14, 20], ["Appendix", "ANATOMY", 431, 439]]], ["Before January 18, the time from symptom onset to hospitalization was 5.5 days (95% CI 4.6\u20136.6 days), whereas after January 18, the duration shortened significantly to 1.5 days (95% CI 1.2\u20131.9 days) (p<0.001 by Mann\u2013Whitney U test).", [["CI", "TEST", 84, 86], ["CI", "TEST", 182, 184], ["Mann\u2013Whitney U test", "TEST", 211, 230]]], ["The change in the distribution coincides with news reports of potential human-to-human transmission and upgrading of emergency response level to Level 1 by the China CDC.", [["human", "ORGANISM", 72, 77], ["human", "ORGANISM", 81, 86], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 81, 86], ["change", "OBSERVATION_MODIFIER", 4, 10]]], ["The emerging consensus about the risk for COVID-19 probably led to substantial behavior changes among symptomatic persons, in terms of seeking more timely medical care during this period.", [["COVID-19", "CHEMICAL", 42, 50], ["persons", "ORGANISM", 114, 121], ["persons", "SPECIES", 114, 121], ["COVID", "TEST", 42, 47], ["substantial behavior changes", "PROBLEM", 67, 95]]], ["We also found that the time from initial hospital admittance to discharge was 11.5 days (95% CI 8.0\u201317.3 days) (Figure 1, panel C) and from initial hospital admittance to death was 11.2 days (95% CI 8.7\u201314.9 days) (Figure 1, panel D).", [["death", "DISEASE", 171, 176], ["CI", "TEST", 93, 95], ["Figure", "TEST", 112, 118], ["CI", "TEST", 196, 198], ["Figure", "TEST", 215, 221]]], ["The time from symptom onset to death was estimated to be 16.1 days (95% CI 13.1\u201320.2 days).Estimating the Growth Rate of the Outbreak in Wuhan in January 2020 ::: ResultsMoving from empirical estimates of basic epidemiologic parameters to an understanding of the early growth rates of COVID-19 requires model-based inference and data.", [["death", "DISEASE", 31, 36], ["COVID-19", "DNA", 285, 293], ["symptom", "PROBLEM", 14, 21], ["death", "PROBLEM", 31, 36], ["CI", "TEST", 72, 74], ["COVID", "TEST", 285, 290], ["Growth", "OBSERVATION_MODIFIER", 106, 112]]], ["We estimated that, before the January 23 lockdown of the city, \u224840,000\u2013140,000 people in Wuhan traveled to destinations outside Hubei Province each day (Figure 2, panel B).", [["people", "ORGANISM", 79, 85], ["people", "SPECIES", 79, 85]]], ["The extensive travel before the Lunar New Year was probably an important driver of the spread of COVID-19 in China.Estimating the Growth Rate of the Outbreak in Wuhan in January 2020 ::: ResultsWe then integrated spatiotemporal domestic travel data to infer the outbreak dynamics in Wuhan by using two mathematical approaches (Appendix 2; conceptual framework depicted in Figure 3, panel A).", [["COVID-19", "CHEMICAL", 97, 105], ["COVID", "TEST", 97, 102], ["extensive", "OBSERVATION_MODIFIER", 4, 13], ["Growth", "OBSERVATION_MODIFIER", 130, 136]]], ["The first-arrival model uses a unique feature of our case report dataset whereby the dates of departure from Wuhan for many of the first persons who were confirmed with SARS-CoV-2 infection in each province were known (Appendix 1 Table 1).", [["SARS-CoV-2 infection", "DISEASE", 169, 189], ["persons", "ORGANISM", 137, 144], ["SARS-CoV-2", "ORGANISM", 169, 179], ["persons", "SPECIES", 137, 144], ["CoV-", "SPECIES", 174, 178], ["SARS", "PROBLEM", 169, 173], ["2 infection", "PROBLEM", 178, 189]]], ["We assumed an exponential growth for the total infected population I* in Wuhan, , where I* includes infected persons who are asymptomatic or symptomatic, r is the exponential growth rate, and t0 is the theoretical time of the exponential growth initiation, so that I*(t0) = 1 in the deterministic model.", [["persons", "ORGANISM", 109, 116], ["persons", "SPECIES", 109, 116], ["an exponential growth", "PROBLEM", 11, 32], ["asymptomatic", "PROBLEM", 125, 137], ["symptomatic", "PROBLEM", 141, 152], ["exponential", "OBSERVATION_MODIFIER", 14, 25], ["growth", "OBSERVATION_MODIFIER", 26, 32]]], ["We call t0 a \u201ctheoretical\u201d time in the sense that it should not be interpreted as the time of first infection in a population.", [["infection", "DISEASE", 100, 109], ["first infection", "PROBLEM", 94, 109], ["infection", "OBSERVATION", 100, 109]]], ["We should expect that t0 is later than the date of the first infection because multiple spillover events from the animal reservoir might be needed to establish sustained transmission and stochasticity might play a large role in initial dynamics before the onset of exponential growth (12\u201314).Estimating the Growth Rate of the Outbreak in Wuhan in January 2020 ::: ResultsWe used travel data for each of the provinces (Appendix 1 Table 3) and the earliest times that an infected person arrived in a province, across a total of 26 provinces (Figure 3, panel B), to infer r and t0 (Appendix 2).", [["infection", "DISEASE", 61, 70], ["person", "SPECIES", 478, 484], ["the first infection", "PROBLEM", 51, 70], ["multiple spillover events", "PROBLEM", 79, 104], ["the animal reservoir", "TREATMENT", 110, 130], ["exponential growth", "PROBLEM", 265, 283], ["infection", "OBSERVATION", 61, 70], ["spillover", "OBSERVATION", 88, 97], ["large", "OBSERVATION_MODIFIER", 214, 219], ["exponential", "OBSERVATION_MODIFIER", 265, 276], ["growth", "OBSERVATION_MODIFIER", 277, 283], ["Growth", "OBSERVATION_MODIFIER", 307, 313], ["infected", "OBSERVATION", 469, 477], ["Appendix", "ANATOMY", 579, 587]]], ["The growth rate r is estimated to be 0.29/day (95% CI 0.21\u20130.37/day), corresponding to a doubling time of 2.4 days (95% CI 1.9\u20133.3 days). t0 is estimated to be December 20, 2019 (95% CI December 11\u201326).", [["The growth rate", "TEST", 0, 15], ["CI", "TEST", 51, 53], ["CI", "TEST", 120, 122], ["growth", "OBSERVATION_MODIFIER", 4, 10]]], ["As we show later, there exist larger uncertainties in the estimation of t0.Estimating the Growth Rate of the Outbreak in Wuhan in January 2020 ::: ResultsWe further estimated that the total infected population size in Wuhan was \u22484,100 (95% CI 2,423\u20136,178) on January 18 (Appendix 2 Figure 3), which is consistent with a recently posted estimate (7).", [["larger uncertainties", "PROBLEM", 30, 50], ["the total infected population size", "PROBLEM", 180, 214], ["CI", "TEST", 240, 242], ["larger", "OBSERVATION_MODIFIER", 30, 36], ["uncertainties", "OBSERVATION", 37, 50], ["Growth", "OBSERVATION_MODIFIER", 90, 96], ["total", "OBSERVATION_MODIFIER", 184, 189], ["infected", "OBSERVATION_MODIFIER", 190, 198], ["population", "OBSERVATION_MODIFIER", 199, 209], ["size", "OBSERVATION_MODIFIER", 210, 214], ["consistent with", "UNCERTAINTY", 302, 317]]], ["The estimated number of infected persons was \u224818,700 (95% CI 7,147\u201338,663) on January 23 (i.e., the date when Wuhan started its lockdown).", [["persons", "ORGANISM", 33, 40], ["persons", "SPECIES", 33, 40], ["CI", "TEST", 58, 60], ["number", "OBSERVATION_MODIFIER", 14, 20], ["infected", "OBSERVATION_MODIFIER", 24, 32]]], ["We projected that without any control measures, the infected population would be \u2248233,400 (95% CI 38,757\u2013778,278) by the end of January.Estimating the Growth Rate of the Outbreak in Wuhan in January 2020 ::: ResultsAn alternative model, the case count approach, used daily new case counts of persons who had COVID-19 diagnosed in other provinces but who had been in Hubei Province within 14 days of becoming symptomatic.", [["persons", "ORGANISM", 292, 299], ["persons", "SPECIES", 292, 299], ["any control measures", "TREATMENT", 26, 46], ["symptomatic", "PROBLEM", 408, 419], ["infected", "OBSERVATION_MODIFIER", 52, 60], ["Growth", "OBSERVATION_MODIFIER", 151, 157], ["symptomatic", "OBSERVATION", 408, 419]]], ["This model uses data beyond the first appearance of an infected person from Wuhan but also accounts for the stochastic nature of the process by using a hybrid model.", [["person", "SPECIES", 64, 70], ["a hybrid model", "TREATMENT", 150, 164], ["infected", "OBSERVATION", 55, 63]]], ["In this model, the infected population in Wuhan was described with a deterministic model, whereas the infected persons who traveled from Wuhan to other provinces were tracked with a stochastic SEIR (susceptible-exposed-infectious-recovered) model (12).", [["SEIR", "CHEMICAL", 193, 197], ["Wuhan", "ORGANISM", 42, 47], ["persons", "ORGANISM", 111, 118], ["persons", "SPECIES", 111, 118], ["infected", "OBSERVATION_MODIFIER", 19, 27], ["population", "OBSERVATION", 28, 38]]], ["We restricted the data to the period of January 19\u201326, when new cases reported were mostly infections imported from Wuhan (i.e., indicative of the dynamics in Wuhan).", [["infections", "DISEASE", 91, 101], ["infections", "PROBLEM", 91, 101], ["infections", "OBSERVATION", 91, 101]]], ["The transitions of the infected persons from symptom onset to hospitalization and then to case confirmation were assumed to follow the distributions inferred from the case report data (Appendix 2).", [["persons", "ORGANISM", 32, 39], ["persons", "SPECIES", 32, 39]]], ["The estimated theoretical time (t0) is December 16, 2019 (95% CI December 12\u201321), and the exponential growth rate is 0.30/day (95% CI 0.26\u20130.34/day).", [["the exponential growth rate", "TEST", 86, 113], ["CI", "TEST", 131, 133], ["exponential", "OBSERVATION_MODIFIER", 90, 101], ["growth", "OBSERVATION_MODIFIER", 102, 108]]], ["These estimates are consistent with estimates in the first arrival approach (Figure 4; Appendix 2 Figure 4).Estimating the Growth Rate of the Outbreak in Wuhan in January 2020 ::: ResultsIn both models, we assumed perfect detection (i.e., of infected cases outside of Hubei Province).", [["consistent with", "UNCERTAINTY", 20, 35], ["Growth", "OBSERVATION_MODIFIER", 123, 129]]], ["To investigate the robustness of our estimates, we performed extensive sensitivity analyses to test 23 different scenarios of surveillance intensity (Appendix 2).", [["extensive sensitivity analyses", "TEST", 61, 91], ["test", "TEST", 95, 99], ["surveillance intensity", "TEST", 126, 148]]], ["First, we tested the assumption that a constant fraction of infected persons (e.g., persons with mild or no symptoms) (15) were not detected.", [["persons", "ORGANISM", 69, 76], ["persons", "ORGANISM", 84, 91], ["persons", "SPECIES", 69, 76], ["persons", "SPECIES", 84, 91], ["symptoms", "PROBLEM", 108, 116], ["infected", "OBSERVATION", 60, 68]]], ["We found that under this assumption, t0would be earlier than our estimate but the estimation of the growth rate remained the same (Appendix 1 Table 4).", [["the growth rate", "TEST", 96, 111]]], ["Second, we tested the assumption that the intensity of surveillance increases over the period of data collection, although this scenario is less likely because of the intensive surveillance implemented outside Hubei Province.", [["surveillance", "TEST", 55, 67], ["data collection", "TEST", 97, 112], ["less likely", "UNCERTAINTY", 140, 151]]], ["We found that our data in general do not support this hypothesis on the basis of corrected Akaike Information criterion scores (Appendix 1 Table 4).", [["our data", "TEST", 14, 22], ["this hypothesis", "PROBLEM", 49, 64]]], ["However, if the intensity of surveillance outside Hubei Province increased over the period of January, we would predict a lower growth rate than the estimate we just described.", [["a lower growth rate", "PROBLEM", 120, 139]]], ["For the worst-case scenario considered, we estimated the growth rate of the outbreak to be 0.21/day (Appendix 2).Other Evidence of a High Growth Rate of the Outbreak in Wuhan ::: ResultsIn addition to using 2 modeling approaches, we looked for other evidence of a high outbreak growth rate to cross-validate our estimations.", [["2 modeling approaches", "TREATMENT", 207, 228], ["a high outbreak growth rate", "PROBLEM", 262, 289], ["High", "OBSERVATION_MODIFIER", 133, 137], ["Growth", "OBSERVATION_MODIFIER", 138, 144]]], ["We found that the time series of reported deaths in Hubei, which is less subject to the biases of the confirmed case counts, is simply not consistent with a growth rate of 0.1/day (Appendix 2 Figure 5).", [["deaths", "DISEASE", 42, 48], ["a growth rate", "TEST", 155, 168], ["not consistent with", "UNCERTAINTY", 135, 154]]], ["As the infected population grows, the number of death cases will grow at the same rate but with a delayed onset corresponding to the time from infection to death.", [["death", "DISEASE", 48, 53], ["infection", "DISEASE", 143, 152], ["death", "DISEASE", 156, 161], ["a delayed onset", "PROBLEM", 96, 111], ["infection", "PROBLEM", 143, 152], ["death", "PROBLEM", 156, 161], ["infected", "OBSERVATION_MODIFIER", 7, 15], ["population", "OBSERVATION_MODIFIER", 16, 26], ["grows", "OBSERVATION_MODIFIER", 27, 32], ["infection", "OBSERVATION", 143, 152]]], ["Fitting a simple exponential growth model to the number of reported deaths in Hubei during late January 2020 yields an estimate of 0.22\u20130.27/day, which is within the 95% CI of the estimation we previously described.Other Evidence of a High Growth Rate of the Outbreak in Wuhan ::: ResultsOverall, these analyses suggest that although there exist uncertainties depending on the level of surveillance, the exponential growth rate of the outbreak is probably 0.21\u20130.3/day.", [["deaths", "DISEASE", 68, 74], ["the estimation", "TEST", 176, 190], ["these analyses", "TEST", 297, 311], ["surveillance", "TEST", 386, 398], ["the exponential growth rate", "TEST", 400, 427], ["High", "OBSERVATION_MODIFIER", 235, 239], ["Growth", "OBSERVATION_MODIFIER", 240, 246], ["exponential", "OBSERVATION_MODIFIER", 404, 415], ["growth", "OBSERVATION_MODIFIER", 416, 422]]], ["This estimation is much higher than previous reports, in which the growth rate was estimated to be 0.1\u20130.14/day (1,3\u20135).Estimating R0 ::: ResultsThe basic reproductive number, R0, is dependent on the exponential growth rate of an outbreak, as well as additional factors such as the latent period (the time from infection to infectiousness) and the infectious period (16,17), both of which cannot be estimated directly from the data.", [["infection", "DISEASE", 311, 320], ["This estimation", "TEST", 0, 15], ["the growth rate", "TEST", 63, 78], ["infection", "PROBLEM", 311, 320], ["infectiousness", "PROBLEM", 324, 338], ["much", "OBSERVATION_MODIFIER", 19, 23], ["higher", "OBSERVATION_MODIFIER", 24, 30], ["dependent", "OBSERVATION_MODIFIER", 183, 192], ["growth", "OBSERVATION_MODIFIER", 212, 218], ["latent", "OBSERVATION_MODIFIER", 282, 288], ["infectious", "OBSERVATION_MODIFIER", 348, 358]]], ["Following the approach by Wearing and Rohani (16), we found that with a high growth rate of the outbreak, R0 is in general high and the longer the latent and the infectious periods, the higher the estimated R0 (Appendix 2 Figure 6).Estimating R0 ::: ResultsTo derive realistic values of R0, we used previous estimates of serial intervals for COVID-19.", [["a high growth rate", "PROBLEM", 70, 88], ["COVID", "TEST", 342, 347], ["latent", "OBSERVATION_MODIFIER", 147, 153], ["infectious", "OBSERVATION_MODIFIER", 162, 172], ["higher", "OBSERVATION_MODIFIER", 186, 192]]], ["When infected persons are isolated after 5 days of symptoms (a probable scenario for the early outbreak in Wuhan, where the public was not aware of the virus and few interventions were implemented), the serial interval is estimated to be 8 days (Q. Bi et al., unpub. data).", [["persons", "ORGANISM", 14, 21], ["persons", "SPECIES", 14, 21], ["symptoms", "PROBLEM", 51, 59], ["the virus", "PROBLEM", 148, 157]]], ["With this serial interval, we sampled latent and infectious periods within wide biologically plausible ranges (Appendix 2) and estimated the median R0 to be 5.8 (95% CI 4.4\u20137.7) (Figure 5, panel A).", [["Appendix", "TEST", 111, 119], ["CI", "TEST", 166, 168], ["\u2013", "TEST", 172, 173], ["Figure", "TEST", 179, 185], ["infectious", "OBSERVATION_MODIFIER", 49, 59]]], ["To include a wider range of serial interval (i.e., 6\u20139 days) (Figure 5, panel A; Appendix 2 Figure 6), given the uncertainties in these estimations, we estimated that the median of estimated R0 is 5.7 (95% CI of 3.8\u20138.9) (Figure 5, panel B).", [["Figure", "TEST", 62, 68], ["Appendix", "TEST", 81, 89], ["CI", "TEST", 206, 208], ["Figure", "TEST", 222, 228]]], ["The estimated R0 can be lower if the serial interval is shorter.", [["The estimated R0", "TREATMENT", 0, 16], ["R0", "OBSERVATION", 14, 16], ["lower", "OBSERVATION_MODIFIER", 24, 29], ["shorter", "OBSERVATION_MODIFIER", 56, 63]]], ["However, recent studies reported that persons can be infectious for a long period, such as 1\u20133 weeks after symptom onset (18; R. Woelfel et al., unpub data. https://doi.org/10.1101/2020.03.05.20030502); thus, we believe that a mean serial interval shorter than 6 days is unlikely during the early outbreak in Wuhan, where infected persons were not rapidly hospitalized.Implications for Intervention Strategies ::: ResultsThe R0 values we estimated have important implications for predicting the effects of pharmaceutical and nonpharmaceutical interventions.", [["persons", "ORGANISM", 38, 45], ["persons", "ORGANISM", 331, 338], ["persons", "SPECIES", 38, 45], ["persons", "SPECIES", 331, 338], ["recent studies", "TEST", 9, 23], ["symptom onset", "PROBLEM", 107, 120], ["unpub data", "TEST", 145, 155], ["The R0 values", "TEST", 421, 434], ["pharmaceutical and nonpharmaceutical interventions", "TREATMENT", 506, 556]]], ["For example, the threshold for combined vaccine efficacy and herd immunity needed for disease extinction is calculated as 1 \u2013 1/R0.", [["herd", "ORGANISM_SUBDIVISION", 61, 65], ["combined vaccine efficacy", "TREATMENT", 31, 56], ["herd immunity", "TREATMENT", 61, 74], ["disease extinction", "PROBLEM", 86, 104]]], ["At R0 = 2.2, this threshold is only 55%.", [["this threshold", "TEST", 13, 27]]], ["But at R0 = 5.7, this threshold rises to 82% (i.e., >82% of the population has to be immune, through either vaccination or prior infection, to achieve herd immunity to stop transmission).Implications for Intervention Strategies ::: ResultsWe then evaluated the effectiveness for nonpharmaceutical interventions, such as contact tracing, quarantine, and social distancing, by using the framework by Lipsitch et al. (19) (Appendix 2).", [["infection", "DISEASE", 129, 138], ["R0", "TEST", 7, 9], ["this threshold rises", "PROBLEM", 17, 37], ["prior infection", "PROBLEM", 123, 138], ["nonpharmaceutical interventions", "TREATMENT", 279, 310], ["contact tracing", "TEST", 320, 335]]], ["We extended the framework to consider a fraction of transmission occurring from infected persons who would not be identified by surveillance and can transmit effectively (15).", [["persons", "ORGANISM", 89, 96], ["persons", "SPECIES", 89, 96]]], ["This fraction is determined by the fraction of actual asymptomatic persons and the extent of surveillance efforts to identify these persons and persons with mild-to-moderate symptoms.", [["persons", "ORGANISM", 132, 139], ["persons", "ORGANISM", 144, 151], ["persons", "SPECIES", 67, 74], ["persons", "SPECIES", 132, 139], ["persons", "SPECIES", 144, 151], ["This fraction", "TEST", 0, 13], ["mild-to-moderate symptoms", "PROBLEM", 157, 182], ["mild", "OBSERVATION_MODIFIER", 157, 161], ["-to-moderate", "OBSERVATION_MODIFIER", 161, 173]]], ["Results show that quarantine and contact tracing of symptomatic persons can be effective when the fraction of unidentified persons is low.", [["persons", "ORGANISM", 64, 71], ["persons", "ORGANISM", 123, 130], ["persons", "SPECIES", 64, 71], ["persons", "SPECIES", 123, 130], ["symptomatic persons", "PROBLEM", 52, 71], ["low", "OBSERVATION_MODIFIER", 134, 137]]], ["However, when 20% of transmission is driven by unidentified infected persons, high levels of social distancing efforts will be needed to contain the virus (Figure 6), highlighting the importance of early and effective surveillance, contact tracing, and quarantine.", [["persons", "ORGANISM", 69, 76], ["persons", "SPECIES", 69, 76], ["social distancing efforts", "TREATMENT", 93, 118], ["the virus", "PROBLEM", 145, 154], ["contact tracing", "TEST", 232, 247], ["infected", "OBSERVATION", 60, 68]]], ["Future field, laboratory, and modeling studies aimed to address the unknowns, such as the fraction of asymptomatic persons, the extent of their transmissibility depending on symptom severity, the time when persons become infectious, and the existence of superspreaders are needed to accurately predict the impact of various control strategies (20).DiscussionIn this study, we estimated several basic epidemiologic parameters, including the incubation period (4.2 days), a time dependent duration from symptom onset to hospitalization (changing from 5.5 days in early January to 1.5 days in late January outside Hubei Province), and the time from symptom onset to death (16.1 days).", [["death", "DISEASE", 663, 668], ["persons", "ORGANISM", 206, 213], ["persons", "SPECIES", 115, 122], ["persons", "SPECIES", 206, 213], ["modeling studies", "TEST", 30, 46], ["asymptomatic persons", "PROBLEM", 102, 122], ["symptom severity", "PROBLEM", 174, 190], ["infectious", "PROBLEM", 221, 231], ["superspreaders", "TREATMENT", 254, 268], ["various control strategies", "TREATMENT", 316, 342], ["this study", "TEST", 361, 371], ["infectious", "OBSERVATION", 221, 231]]], ["This finding would have important implications for forecasting epidemic trajectories and the effect on healthcare systems as well as for evaluating the effectiveness of intervention strategies.DiscussionWe found R0 is likely to be 5.7 given our current state of knowledge, with a broad 95% CI (3.8\u20138.9).", [["forecasting epidemic trajectories", "PROBLEM", 51, 84], ["intervention strategies", "TREATMENT", 169, 192], ["CI", "TEST", 290, 292]]], ["Among many factors, the lack of awareness of this new pathogen and the Lunar New Year travel and gathering in early and mid-January 2020 might or might not play a role in the high R0.", [["this new pathogen", "PROBLEM", 45, 62]]], ["A recent study based on structural analysis of the virus particles suggests SARS-CoV-2 has a much higher affinity to the receptor needed for cell entry than the 2003 SARS virus (21), providing a molecular basis for the high infectiousness of SARS-CoV-2.DiscussionHow contagious SARS-CoV-2 is in other countries remains to be seen.", [["cell", "ANATOMY", 141, 145], ["SARS", "DISEASE", 166, 170], ["SARS", "DISEASE", 242, 246], ["SARS", "DISEASE", 278, 282], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 76, 86], ["cell", "CELL", 141, 145], ["2003 SARS virus", "ORGANISM", 161, 176], ["SARS-CoV-2", "ORGANISM", 242, 252], ["SARS-CoV", "SPECIES", 76, 84], ["SARS virus", "SPECIES", 166, 176], ["SARS-CoV", "SPECIES", 242, 250], ["A recent study", "TEST", 0, 14], ["structural analysis", "TEST", 24, 43], ["the virus particles", "TEST", 47, 66], ["SARS", "PROBLEM", 76, 80], ["CoV", "TEST", 81, 84], ["cell entry", "PROBLEM", 141, 151], ["the high infectiousness of SARS", "PROBLEM", 215, 246]]], ["Given the rapid rate of spread as seen in current outbreaks in Europe, we need to be aware of the difficulty of controlling SARS-CoV-2 once it establishes sustained human-to-human transmission in a new population (20).", [["SARS", "DISEASE", 124, 128], ["human-to-human transmission", "DISEASE", 165, 192], ["SARS-CoV-2", "ORGANISM", 124, 134], ["human", "ORGANISM", 165, 170], ["human", "ORGANISM", 174, 179], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 174, 179], ["SARS-CoV", "SPECIES", 124, 132], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 174, 179], ["the rapid rate of spread", "PROBLEM", 6, 30]]], ["Our results suggest that a combination of control measures, including early and active surveillance, quarantine, and especially strong social distancing efforts, are needed to slow down or stop the spread of the virus.", [["control measures", "TREATMENT", 42, 58], ["quarantine", "TREATMENT", 101, 111], ["the virus", "PROBLEM", 208, 217], ["active", "OBSERVATION_MODIFIER", 80, 86]]], ["If these measures are not implemented early and strongly, the virus has the potential to spread rapidly and infect a large fraction of the population, overwhelming healthcare systems.", [["the virus", "PROBLEM", 58, 67], ["large", "OBSERVATION_MODIFIER", 117, 122], ["fraction", "OBSERVATION_MODIFIER", 123, 131]]], ["Fortunately, the decline in newly confirmed cases in China and South Korea in March 2020 and the stably low incidences in Taiwan, Hong Kong, and Singapore strongly suggest that the spread of the virus can be contained with early and appropriate measures.", [["the virus", "PROBLEM", 191, 200]]]]}